Immunological and toxicological studies on the benzopyrones by Lacy, Aoife
IMMUNOLOGICAL AND TOXICOLOGICAL STUDIES ON THE
BENZOPYRONES
A thesis submitted for the degree of Ph.D.
b y
Aoife Lacy B.Sc. (Hons)
April, 2004.
Based on research carried out 
at
The School of Biotechnology, 
Dublin City University, 
Dublin 9,
Ireland.
Under the supervision o f Professor Richard O’Kennedy
Declaration:
I hereby certify that this material, which 1 now submit for assessment on the programme of study 
leading to the award of Doctor of Philosophy, is entirely my own work, and has not been taken from 
the work of others, save and to the extent that such work is cited and acknowledged within the text of 
my work.
Signed
Date: ^  . % X Y )
*
This thesis is dedicated to my Mum and Dad, without their 
love and guidance I would not be where I am today.
Acknowledgements:
In the course of my studies and research, I have met extraordinary people and received 
generous help in so many ways that I will be forever grateful for all the encouragement and support. 
First and foremost, I owe a tremendous debt to my supervisor, Professor Richard O’Kennedy. I 
appreciate with much gratitude all the time and energy he invested in guiding me along the sometimes 
rocky path that was my PhD studentship. A million thanks, Richard, for all the support and advice and 
for your patience and understanding.
My time as part of the Applied Biochemistry Group has had its ups and downs and I feel 
incredibly fortunate that I was surrounded by a wonderful group of people. Someone would always 
listen to my woes and the atmosphere was always pleasant even on the most stressful days. No matter 
how busy anyone was, there was always time to listen and help out. Thanks in order of appearance to 
John, Bemie, Brian, Paul D, Stephen D, Jane, Loma, Joanne, Lynsey, Fred, Sharon, Liz and Maiy. 
Now a few special thanks. I’d like to thank Brian for all his help with the warfarin antibody. Who 
knows where I’d have ended up if I didn’t have clone 4-2-25 and all his support. Thanks to John who 
helped me with the dreaded Solution phase assays (and so much more) and for his good humour when 
it was really needed. Paul D & Stephen D, thanks with much appreciation, for your help and 
encouragement. The immunology section of my diesis wouldn’t be what it is without all you guys and 
I’m all the saner for it! Paul L, thanks for all the support over the years and especially towards the end 
where your advice and help really made a difference. Finally, to Stephen H, I really appreciate that 
you listened to all my woes and gave such sound advice. You’ve been a good friend, thanks for 
everything.
I should also mention all the staff and fellow students in the School of Biotechnology I’ve met 
along the way. My DCU experience was all the more pleasant for all their input, both intellectual and 
social. A special mention to the “Karaoke Girls” you know who you are... and why I am so grateful. 
To Bella, Grace and Paul, I owe so much... I don’t think I’d have survived the undergrad years 
without you guys.
Now, to my other life...the one outside DCU. Firstly, thanks to those who inspired me and 
helped my confidence over the years - John & Daphne and Liam. To all my friends along the way, 
Marie, Karen, Jude and Julie, thanks for the wonderful memories. My best friend Susan, you really 
have been through it all with me. Your friendship has enriched my life in so many ways. You are like 
a sister to me (& you know what that means to me) and your family, my family. I am eternally
grateful. Norcen (my 2nd mother across the road), thanks for EVERYTHING. I could write a list as 
long as this thesis and it still wouldn’t cover all you’ve done for me over the years. Now, to my actual 
family. Mum, a heartfelt thanks for listening and being there whenever I needed you throughout my 
life, which was quite often! I found out about Biotechnology in DCU thanks to you and will always be 
grateful for your inquisitive and selfless nature. To my Dad, thanks for being there. Your generous 
nature, great advice and walks out in Howth helped to ease the stress and make my life so much better. 
To Conor, thanks for caring and always showing an interest in what I’ve been up to. I couldn’t ask for 
a better big brother! You’ve all helped me become the person I am today - much love and respect. To 
the rest of my family, I want to say a big THANK YOU -  especially Beryl, Pauline, Karen, Silvana 
and Ger. It is very important that I thank some special people who have come into my life since I 
started my PhD. To Maty, we were reunited nearly four years ago now, but you’ve always had a place 
in my heart. Thank you for being part of my life and enriching it, which means so much to me. I 
couldn’t imagine life without you now. Thanks Alan for the warmth and humour, which has made 
getting to know you such a joy (I appreciate the new nickname of Dr. Doolittle!). Thanks to the rest of 
my newfound family -  it’s a great feeling to know you’re there.
Last, but definitely not least, Fai. It’s difficult to put into words how much you mean to me. 
I’ve made it to the end in one piece because of you. I am sure you’re sick of hearing it but, what would 
I do without you? Your humorous replies to that often asked question and caring nature, lifts my 
spirits. Thanks for helping me keep it together, and even if you don’t believe it, you’ve been my rock.
My acknowledgements would be complete without a quick mention to my furry friends 
Homer, Marge and Benji who never get stressed about anything -  I am working towards that 
philosophy.
“To see a thing uncoloured by one's own personal preferences and desires is to see it in its
own pristine simplicity. ”
Bruce Lee
"Research shows that you begin learning in the womb and go right on learning until the moment you 
pass on. Your brain has a capacity for learning that is virtually limitless, which makes every human a
potential genius. ”
Michael J. Gelb
v
TABLE OF CONTENTS
Declaration ii
Acknowledgements iv
Table of Contents vi
List of Figures xiii
List of T ables xvii
Abbreviations xix
Publications & Presentations xxvi
Abstract xxvii
Chapter 1: Introduction to the Benzopyrones l
1.1. Introduction 2
1.2. Occurrence 2
13. Biosynthesis 4
1.4. Pharmacokinetics 7
1.4.1. Absorption and Distribution 8
1.4.2. Metabolism 10
1.4.2.1. Metabolism in Man 11
1.4.2.2. Metabolism in Other Species 12
1.5. Toxicology 15
1.6. Applications of Coumarin and Coumarin Derivatives 16
1.6.1. Simple Coumarins 16
1.6.1.1. Industrial Uses 16
1.6.1.2. Clinical Uses 17
1.6.1.2.1. High Protein Oedema (HPO) 17
1.6.1.2.1. Chronic Infections 18
1.6.1.3. Coumarins in Cancer 18
1.6.1.3.1. Coumarin in Malignant Melanoma 19
1.6.1.3.2. Coumarin in Renal Cell Carcinoma 21
1.6.1.3.3. Coumarin in Prostate Cancer 22
1.6.1.4. Other Simple Coumarins 23
1.6.1.4.1. Cloricromene 23
1.6.1.4.2. Daphnetin 23
vi
1.6.1.4.3. Scoparone 24
1.6.1.4.1. Osthole 25
1.6.2. Applications of the Furanocou marins 25
1.6.1. Applications of the Pyranocouraarins 28
1.6.1. Applications of Other Coumarin Derivatives 28
1.7. Pyrone-Substituted Coumarins: Warfarin 29
1.7.1. Introduction to Warfarin 29
1.7.2. Pharmacology of Warfarin 31
1.7.2.1. Mechanism of Action of Coumarin Anticoagulant Drugs 31
1.7.2.2. Vitamin K Cycle 32
1.7.2.3. Vitamin K-dependent Carboxylase 33
1.7.3. Pharmacokinetics and Pharmacodynamics of Warfarin 34
1.7.3.1. Absoiption 36
1.7.3.2. Distribution & Protein Binding 36
1.7.3.3. Warfarin metabolism 37
1.7.3.3.1. Genetic Variability 40
1.7.3.4. Excretion 40
1.7.4. Warfarin Resistance 41
1.7.4.1. Hereditary Resistance 41
1.7.4.2. Acquired Resistance 42
1.7.5. Drug Interactions 42
1.7.6. Monitoring Anticoagulant Therapy 46
1.7.6.1. Prothrombin Time and INR 46
1.7.6.2. Warfarin-The ‘Rebound Phenomena’ 48
1.7.7. Clinical Uses 49
1.7.7.1. Anti-Coagulant Therapy 49
1.7.7.2. HIV-1 inhibitor 50
1.7.7.3. Anti-metastatic properties 51
1.7.7.4. IgA Nephritis 51
1.7.8. Warfarin Contraindications 52
1.8.Isoflavones 53
1.8.1. Genistein 54
1.8.1.1. Genistein and Cancer Research 55
1.9. Chapter Summary 56
vii
Chapter 2: Materials and Methods 57
2.1. Equipment
2.2. Consumable Items
2.2.1. Plastic Consumables
2.3. Reagents and Chemicals
2.4. Standard Solutions
2.5. Methods
2.5.1. Mammalian Cell Culture
2.5.1.1. Cell lines and Media Preparation
2.5.1.2. Recovery of Frozen Cells
2.5.1.3. Culture of Cells in Suspension
2.5.1.4. Culture of Adherent Cells
2.5.1.5. Cell Counts and Viability Testing
2.5.1.6. Long-term Storage of Cells
2.5.2. Solid Phase Immunoassays
2.5.2.1. ELISAs for Titration of Antibody Levels in Hybridoma Supernatants
2.5.2.2. Isotyping of Monoclonal Antibodies
2.5.2.3. Determination of Antibody Working Dilution
2.5.2.4. Determination of Optimal Conjugate Loading Density
2.5.2.5. Competitive ELISA
2.5.2.6. Affinity Analysis Using ELISA
2.5.2.7. Determination of Mouse Immunoglobulin Concentrations by 
Affinity-cap ture ELISA
2.5.3. Monoclonal Antibody Purification
2.5.3.1. Concentration of Tissue Culture Supernatant
2.5.3.2. Protein G/A Affinity Purification of Murine and Goat 
Anti-mouse Immunoglobulin
2.5.4. Toxicity Testing
2.5.4.1. Drug Preparations
2.5.4.2. In Vitro Proliferation Assays
2.5.4.3. Cytotoxicity Detection: Lactate Dehydrogenase (LDH) Assay
2.5.4.4. MTT Assay
2.5.4.5. Acid Phosphatase Assay
2.5.5. Cytosensor Microphysiometer Studies on Toxicity
2.5.5.1. Pre-experimental Preparations
58
59
59
60
61
65
65
65
65
66
66
66
67
67
67
67
68
68
68
69
69
70
70
70
71
71
71
72
73
74
76
82
2.5.5.2. Pre-experimental Preparations 76
2.5.5.2. Toxicity Studies 76
2.5.6. Cell Signalling Studies 77
2.5.6.1. ELISAs for Detecting Tyrosine Kinase Activity in Whole Cells 77
2.5.6.2. Cytosensor Studies for Detecting Tyrosine Kinase Activity 79
2.5.6.2.1. Pre-experimental Preparations 79
2.5.6.2.2. Optimisation o f EGF Stimulation 79
2.5.6.2.3. EGF-receptor Tyrosine Kinase Inhibition Studies 80
2.5.6.3. BrdU ELISA for DNA Synthesis Determination 80
2.5.7. Protein Techniques 82
2.5.7.1. BCA Protein Assay 82
2.5.7.2. Polyacrylamide Gel Electrophoresis (PAGE) 82
2.5.7.3. Staining of Gels with Coomassie Brilliant Blue 82
2.5.8. BIAcore Studies 83
2.5.8.1. Preconcentration Studies 83
2.5.8.2. Immobilisation of Drug-protein Conjugates 83
2.5.8.3. Direct Immobilisation of Drug onto the Chip Surface 83
2.5.8.4. Regeneration Studies 84
2.5.8.5. Non-specific Binding Studies 84
2.5.8.6. Competitive/Inhibition Assays 84
2.5.8.7. Solution Affinity Analysis Using BIAcore 85
2.5.8.8. Steady-state Affinity Analysis Using BIAcore 85
Chapter 3: Characterisation and Applications o f  Monoclonal
Antibodies to Warfarin 86
3.1. Introduction 87
3.1.1. Antibody Structure 87
3.1.2. Monoclonal Antibodies 90
3.1.2.1. Production of Monoclonal Antibodies Following Immunisation 91
3.1.2.1.1. Production o f Monoclonal Antibodies to Small Haptens 97
3.1.2.1.2. Clinical Applications o f Monoclonal Antibodies 98
3.1.2.1.3. Antibody Humanisation for Therapeutic Applications 99
3.1.2.1.4. Antibody Engineering 104
i x
3.1.2.1.5. Alternative Expression Systems and Novel
Antibody Constructs 105
3.1.3. Antibody Purification 108
3.1.4. Immunoassay 109
3.1.4.1 ELISA Applications 112
3.1.5. Antibody Affinity 113
3.1.6. Chapter Outline 115
3.2. Results and Discussion 115
3.2.1. Monoclonal Antibody Purification 115
3.2.2. Characterisation of Purified Antibody by SDS-PAGE 116
3.2.3. Development of a Competitive ELISA for Warfarin 118
3.2.3.1. Determination of Optimal Conjugate Loading Density and
Antibody Working Dilution 118
3.2.3.2. Antibody Concentration Determinations 120
3.2.3.2.1. Mouse IgG Determination by Antibody Capture ELISA 120
3.2.3.3. Competitive ELISAs for the Detection of Warfarin in PBS 121
3.2.3.4. Competitive ELISAs for the Detection of Warfarin in Urine 130
3.2.4. Cross-reactivity Studies 135
3.2.5. Affinity Constant Determinations 137
3.3. Conclusions 148
Chapter 4: Development o f  a BIAcore-based Inhibition Assay fo r  the
Detection o f Warfarin in Biological Matrices 151
4.1. Introduction 152
4.1.1. SPR Biosensors 152
4.1.2. BIAcore System 153
4.1.2.1. CM5 SensorChip 154
4.1.2.1.1. Dextran Activation 156
4.1.2.2. Optical System 157
4.1.2.2.1. Surface Plasmon Resonance (SPR) 157
4.1.2.3. Liquid Handling 162
4.1.2.4. BIAcore Software 163
4.1.2.5. Advantages and Limitations of BIAcore 163
4.1.3. Miniature TI-SPR Device 164
x
4.1.4. Application of SPR Technology 166
4.1.4.1. SPR Biosensors in Drug Discovery 166
4.1.4.1.1. Target Characterisation andSmall-molecule Detection 166
4.1.4.1.2. Pharmacological Applications 167
4.1.4.1.3. Proteomics 168
4.1.4.2. Biosensors in Food and Drinks Analysis 169
4.1.4.2.1. Antibiotic Detection inMilk 171
4.1.4.2.2. Pathogen Detection 172
4.1.4.3. Kinetic Studies 173
4.1.5. Analysis of Warfarin 173
4.1.5.1. Measures of Analytical Performance 178
4.1.5.2. Measurement of Low Molecular Weight Analytes using BIAcore 179
4.1.6. Chapter Outline 181
4.2. Results and Discussion 181
4.2.1. Preconcentration of Warfarin-protein Conjugates 181
4.2.2. Immobilisation of Warfarin-protein Conjugates 182
4.2.3. Development of an Inhibition Immunoassay for Warfarin 186
4.2.3.1. Regeneration Conditions 186
4.2.3.2. Assessment of Non-specific Binding 188
4.2.3.3. Determination of Working Range of Model Inhibition
Assay Range in PBS 191
4.2.3.4. Determination of Working Range of Assay in Urine 202
4.2.3.5. Cross-reactivity Studies 212
4.2.3.6. Solution Phase Steady State Affinity Determinations 213
4.2.3.7. Steady-state Affinity Determinations 218
4.3. Conclusions 222
Chapter 5: The Effects o f  Benzopyrones on the Growth, Metabolism and
Signalling Pathways o f  Human Tumour Cells 226
5.1. Introduction to Chemosensitivity Testing 227
5.1.1. Current Chemosensitivity Tests 227
5.2. Drug Discovery 230
5.2.1. In Vitro Testing 231
5.2.2. The Benzopyrones in Cancer Therapy 232
xi
5.2.2.1. In Vitro Testing of Coumarins 232
5.2.2.2. Other Coumarm Derivatives 232
5.3. Introduction to the Cytosensor Microphysiometer 233
5.3.1. Cellular Metabolism 233
5.3.2. The Cytosensor Microphysiometer Components 235
5.3.3. Measuring Acidification Rates 239
5.3.4. Applications of the Cytosensor Microphysiometer 241
5.4. Introduction to Signal Transduction and Cell Cycle Regulation 243
5.5. Components of Growth Signalling Pathways 245
5.5.1 Introduction to Phosphorylation in Signalling Pathways 245
5.5.2 Receptor Classes 245
5.5.3 Receptor Tyrosine Kinases (RTKs) and Their Substrates 246
5.5.4 Ras Activation Pathway 249
5.5.5 Role of Mitogen Activating Protein Kinase (MAPK) in Breast Cancer 251
5.5.5.1. Events Downstream of MAP Kinase 255
5.5.6. PI3-K Signal Transduction Pathway 256
5.6. Cell Cycle Regulation 258
5.6.1. Estrogens and Cell Cycle Regulation in Breast Cancer 261
5.7. Breast Cancer Research and Treatment 261
5.8. Signal Transduction Therapy 263
5.8.1. Signal Transduction Targets 263
5.8.1.1. Growth Factor Receptors 263
5.8.1.2. Ras Protein 266
5.8.1.3. Raf-1 268
5.8.1.4. Src Family of Tyrosine Kinases 268
5.81.5. MAP/ERK Kinase (MEK) 269
5.8.1.6. Extracellular Regulated Kinase (ERK) 270
5.9. Benzopyrones in Signalling Processes & Cell Cycle Regulation 270
5.10. Summary of Research Described in this Chapter 273
5.11. Results and Discussion 273
5.11.1. In Vitro Proliferation Assays 273
5.11.2. Further Chemosensitivity Testing 277
5.11.2.1. Lactate Dehydrogenase (LDH) Assay 278
5.11.2.2. MTT Assay 282
5.11.2.3. Acid Phosphatase Assay 291
xii
5.11.2.4. Cytosensor Microphysiometer 298
5.11.3. Reversibility Studies with the Cytosensor Microphysiometer 305
5.11.4. ELISA-detection of Tyrosine Phosphorylation in MCF-7 Cells 314
5.11.5. Cytosensor Microphysiometer Studies into Tyrosine Kinase Inhibition 322
5.11.6. DNA Synthesis Studies 325
5.12. Conclusions 327
Chapter 6: Overall Conclusions 334
6.1. Overall Conclusions 335
Chapter 7: References 337
Appendix 390
Appendix 1A 391
IA.1. Glossary of Terms and Definitions Commonly Employed
in Bioanalytical Validation Procedures 391
Appendix IB 393
IB.1. ‘Student’s’ t Test (For Paired Samples) 393
List of Figures
Figure 1.1: Chemical structures of Benzo-pyrone subclasses 2
Figure 1.2: Biosynthetic routes for production of coumarin & 7-hydroxycoumarin 6
Figure 1.3: Schematic representation of events of absorption, metabolism,
and excretion of drugs after their administration by various routes. 8
Figure 1.4: Metabolism of coumarin 14
Figure 1.5: Structure of Dicoumarol 30
Figure 1.6: Structure of Warfarin 30
Figure 1.7: The Vitamin K Cycle 34
Figure 1.8: Optical Enantiomers of Warfarin 35
xiii
Figure 1.9: Main metabolic pathways of warfarin in humans 39
Figure 1.10: The basic chemical structure of genistein 54
Figure 2.1: Principle of the LDH assay 73
Figure 2.2: Metabolism of MTT to a formazan salt by viable cells 74
Figure 2.3: Principle of the AP Assay 75
Figure 2.4: Basic protocol of the in vitro tyrosine kinase assay 78
Figure 2.5: Basic protocol involved in the BrdU ELISA 81
Figure 3.1: Immunoglobulin G molecule 90
Figure 3.2a: Pathways of DNA synthesis in cells 93
Figure 3.2b: Selection of hybridoma cells 94
Figure 3.2c: Resulting cells types post fusion 95
Figure 3.3: Principle of monoclonal antibody production 96
Figure 3.4: Murine, chimaeric, humanised and human antibodies 101
Figure 3.5: Diagram of scFv and Diabodies showing antigen binding sites 107
Figure 3.6: Principle of direct ELISA 111
Figure 3.7: Protein-G purified monoclonal antibody elution profile 116
Figure 3.8: SDS-PAGE Gel of Protein-G purified antibody 117
Figure 3.9: Typical titre of purified anti-warfarin monoclonal antibody 118
Figure 3.10: Determination of optimal conjugate loading density 119
Figure 3.11: Determination of monoclonal optimal working dilution 120
Figure 3.12: Mouse IgG calibration plot 121
Figure 3.13: Intra-day calibration curve for detection of warfarin in PBS 125
Figure 3.14: Intra-day linear regression curve for detection of warfarin in PBS 127
Figure 3.15: Inter-day calibration curve for detection of warfarin in PBS 129
Figure 3.16: Intra-day calibration curve for detection of warfarin in urine 132
Figure 3.17: Inter-day calibration curve for detection of warfarin in urine 134
Figure 3.18: Typical cross-reactivity plot 135
Figure 3.19: Cross-reactivity studies on anti-warfarin mAb 136
Figure 3.20: Typical Friguet Plot 138
Figure 3.21: Optimisation of Friguet assay incubation period 141
Figure 3.22: Friguet assay standard curve 142
Figure 3.23: Determination of anti-warfarin mAb dissociation constant 143
Figure 3.24: Corrected Friguet assay plot 145
Figure 3.25: Friguet plot for acenocoumarin and 6-hydroxy warfarin 146
Figure 3.26: Friguet plot for 7-hydroxy warfarin 147
xiv
Figure 4.1: Basic components of BIAcore instrument 154
Figure 4.2: Sensor chip components 155
Figure 4.3: EDC/NHS activation chemistry 156
Figure 4.4: Schematic representation of evanescent field 158
Figure 4.5: Schematic of the basis of SPR measurement 160
Figure 4.6: Schematic of the basis of SPR measurement (Ag interaction) 161
Figure 4.7: Schematic of the basis of SPR measurement (Sensogram) 162
Figure 4.8a: Cross-section of miniature Spreeta instruments 165
Figure 4.8b: Photographs of Spreeta devices 165
Figure 4.9: Schematic of ab:ag interaction at sensor chip surface 180
Figure 4.10: Preconcentration of warfarin-BSA at sensor chip surface 184
Figure 4.11: Immobilisation of warfarin-BSA at sensor chip surface 185
Figure 4.12: Regeneration profile on a warfarin-BSA sensor chip surface 189
Figure 4.13: Regeneration profile on a 4'-aminowarfarin-BSA sensor chip surface 190
Figure 4.14: Non-specific binding studies of anti-warfarin mAh to BSA/dextran 191
Figure 4.15: Overlay interaction curves for various equilibrated mAb:warfarin
Samples in HBS 193
Figure 4.16: BIAcore inhibition immunoassay intra-assay curve for anti-warfarin
mAh on immobilised warfarin-BSA sensor chip surface (HBS) 195
Figure 4.17: BIAcore inhibition immunoassay inter-assay curve for anti-warfarin
in A h on immobilised warfarin-BSA sensor chip surface (QBS) 197
Figure 4.18: BIAcore inhibition immunoassay intra-assay curve for anti-warfarin
mAh on immobilised 4'-aminowarfarin-BSA sensor chip surface (HBS) 199
Figure 4.19: BIAcore inhibition immunoassay inter-assay curve for anti-warfarin
mAb on immobilised 4'-aminowarfarin-BSA sensor chip surface (HBS) 201
Figure 4.20: BIAcore inhibition immunoassay intra-assay curve for anti-warfarin
mAb on immobilised warfarin-BSA sensor chip surface (urine) 205
Figure 4.21: BIAcore inhibition immunoassay inter-assay curve for anti-warfarin
mAb on immobilised warfarin-BSA sensor chip surface (urine) 207
Figure 4.22: BIAcore inhibition immunoassay intra-assay curve for anti-warfarin
mAb on immobilised 4'-aminowarfarin-BSA sensor chip surface (urine) 209
Figure 4.23: BIAcore inhibition immunoassay inter-assay curve for anti-warfarin
mAb on immobilised 4'-aminowarfarin-BSA sensor chip surface (urine) 211
Figure 4.24: Cross-reactivity studies on anti-warfarin mAb 213
Figure 4.25: Solution phase assay standard curve 216
xv
Figure 4.26: Solution phase calibration curve for determination of
anti-warfarin mAh dissociation constant 217
Figure 4.27: Solution phase calibration curve using bivalent model 218
Figure 4.28: Overlay interaction curves for anti-warfarin mAh over immobilised
Warfarin-BSA and BSA chip surfaces 220
Figure 4.29: Interaction curve following ‘on-line’ reference curve subtraction 221
Figure 4.30: Steady state equilibrium constant determination plot for interaction
between anti-warfarin mAb and a warfarin-immobilised chip surface 222 
Figure 5.1: Diagrammatic representation of cellular metabolism 235
Figure 5.2: Diagrammatic representation of the Cytosensor cell capsule
and sensor chamber 236
Figure 5.3: Major components of the Cytosensor Microphysiometer 237
Figure 5.4: Functions of the major components 238
Figure 5.5: Typical raw and rate data curves from cytosensor experiment 240
Figure 5.6: Schematic representation of Receptor Tyrosine Kinase sub-classes 247
Figure 5.7: EGF and receptor interaction 248
Figure 5.8: Activation/deactivation cycle of Ras protein 250
Figure 5.9: RTK - > MAP Kinase signalling pathway 251
Figure 5.10: Estrogen-activated MAP-kinase pathway 255
Figure 5.11: Events downstream of MAP Kinase 256
Figure 5.12: Cell-cycle regulation in mammalian cells 260
Figure 5.13: In vitro cell proliferation assays following exposure of
cell lines to coumarins 275
Figure 5.14: In vitro cell proliferation assays following exposure of
cell lines to coumarins 276
Figure 5.15: Control interference tests for coumarins in the LDH Assay 279
Figure 5.16: Determination of optimal cell concentration for LDH Assay 280
Figure 5.17: LDH assay results for A549 cells exposed to coumarins 281
Figure 5.18: LDH assay results for MCF-7 cells exposed to coumarins 282
Figure 5.19: Optimisation of seeding density of A549/MCF-7 cells for M IT assay 284
Figure 5.20: Interference ofbenzopyrones with the MTT salt 285
Figure 5.21: A549 MTT assay results for 7-hydroxycoumarin & warfarin 286
Figure 5.22: A549 MTT assay results for esculetin & genistein 287
Figure 5.23: MCF-7 MTT assay results for 7-hydroxycoumarin & warfarin 288
Figure 5.24: MCF-7 MTT assay results for esculetin & genistein 289
xvi
Figure 5.25: A549 AP assay results for 7-hydroxycoumarin & warfarin 293
Figure 5.26: A549 AP assay results for esculetin & genistein 294
Figure 5.27: MCF-7 AP assay results for 7-hydroxycoumarin & warfarin 295
Figure 5.28: MCF-7 AP assay results for esculetin & genistein 296
Figure 5.29: Cytosensor results for 24hr exposure to warfarin 300
Figure 5JO: Cytosensor results for 24hr exposure to esculetin 301
Figure 5.31: Cytosensor results for 24hr exposure to genistein 302
Figure 5.32: Comparison of MTT assay and Cytosensor results for
esculetin & genistein 303
Figure 5.33: Comparison of MTT assay and Cytosensor results for warfarin 304
Figure 5.34: 4hr reversibility studies with warfarin on Cytosensor 308
Figure 5.35: 24hr reversibility studies with warfarin on Cytosensor 309
Figure 5.36: 4br reversibility studies with esculetin on Cytosensor 310
Figure 5.37: 24hr reversibility studies with esculetin on Cytosensor 311
Figure 5.38: 4hr reversibility studies with genistein on Cytosensor 312
Figure 5.39: 24hr reversibility studies with genistein on Cytosensor 313
Figure 5.40: Esculetin inhibition (lhr pre-exposure) of tyrosine phosphorylation 316
Figure 5.41 : Esculetin inhibition (6hr pre-exposure) of tyrosine phosphorylation 317
Figure 5.42: Warfarin inhibition (lhr pre-exposure) of tyrosine phosphorylation 318
Figure 5.43: Warfarin inhibition (6hr pre-exposure) of tyrosine phosphorylation 319
Figure 5.44: Genistein inhibition (lhr pre-exposure) of tyrosine phosphorylation 320
Figure 5.45 : Genistein inhibition (6hr pre-exposure) of tyrosine phosphorylation 321
Figure 5.46: Effect of esculetin on MCF-7 stimulation by EGF determined on the
Cytosensor Microphysiometer 324
Figure 5.47: Effect of warfarin on MCF-7 stimulation by EGF determined on the
Cytosensor Microphysiometer 325
Figure 5.48: BrdU Assay results for MCF-7 cells exposed to benzopyrones 327
Figure 5.49: Proposed mechanism of action of esculetin in MCF-7 cells 332
List o f Tables
Table 1.1: The four main coumarin sub-types 3
Table 1.2: Extent of coumarin metabolism to 7-HC in various species 12
Table 13: Degradation half-lives of both coagulation and anti-coagulation factors 31
xvii
Table 1.4: Extent of plasma protein binding and plasma half-life 37
Table 1.5: Drug interactions 44
Table 1.6: Recommended International Normalised Ratios (INRs)
for various thromboembolic conditions 47
Table 2.1 : Equipment model used and suppliers 58
Table 2.2: Consumables used and suppliers 59
Table 23: Reagents & Chemicals used and suppliers 60
Table 2.4: Polyacrylamide gel components for protein electrophoresis 62
Table 2.5: List of cell lines and their culture media used in this work 65
Table 2.6: Seeding densities for in vitro proliferation assays 71
Table 3.1 : Functions and structural features of antibody isotypes 89
Table 32: Classification of existing therapeutic antibodies and the strategies
currently available for their production 103
Table 33: Intra-assay coefficients of variation (CV s) and percentage
accuracies data for the anti-warfarin monoclonal antibody in PBS 124
Table 3.4: Intra-assay coefficients of variation (CVs) and percentage
accuracies data for the anti-warfarin monoclonal antibody in PBS 126
Table 3.5: Inter-assay coefficients of variation (CVs) and percentage
accuracies data for the anti-warfarin monoclonal antibody in PBS 128
Table 3.6: Intra-assay coefficients of variation (CVs) and percentage
accuracies data for the anti-warfarin monoclonal antibody in urine 131
Table 3.7: Inter-assay coefficients of variation (CV s) and percentage
accuracies data for the anti-warfarin monoclonal antibody in urine 133
Table 3.8: Percentage cross-reactivity values of various benzopyroncs with
anti-warfarin mAh 137
Table 3.9: Calculation of free antibody concentrations (Friguct method) 141
Table 3.10: 'Corrected' Free Antibody Concentrations according to Stevens (1987) 145
Table 3.11: Equilibrium dissociation constants (Friguct method) 147
Table 4.1 : Summary of several available commercial biosensors in the food industry 170
Table 4.2: Techniques and detection limits for warfarin analysis 177
Table 4.3: Intra-assay CVs & percentage accuracies data for anti-warfarin
mAb on immobilised warfarin-BSA sensor chip surface (HBS) 194
Table 4.4: Inter-assay CVs & percentage accuracies data for anti-warfarin
mAb on immobilised warfarin-BSA sensor chip surface (HBS) 196
Table 4.5: Intra-assay CVs & percentage accuracies data for anti-warfarin
mAb on immobilised 4'-amino warfarin-BSA sensor chip surface (HBS) 198
Table 4.6: Inter-assay CVs & percentage accuracies data for anti-warfarin
mAb on immobilised 4'-aminowarfarin-BSA sensor chip surface (HBS) 200
Table 4.7: Intra-assay CVs & percentage accuracies data for anti-warfarin
mAb on immobilised warfarin-BSA sensor chip surface (urine) 204
Table 4.8: Inter-assay CVs & percentage accuracies data for anti-warfarin
mAb on immobilised warfarin-BSA sensor chip surface (urine) 206
Table 4.9: Intra-assay CVs & percentage accuracies data for anti-warfarin
mAh on immobilised 4'-aminowarfarin-BSA sensor chip surface (urine) 208
Table 4.10: Inter-assay CVs & percentage accuracies data for anti-warfarin
mAb on immobilised 4'-aminowarfarin-BSA sensor chip surface (urine) 210
Table 5.1 : Currently available chemosensitivity tests 229
Table 5.2: Time-scale of Drug discovery process 231
Table 53: List of research applications to-date for the
Cytosensor Microphysiometcr 242
Table 5.4: Advantages of the Cytosensor Microphysiometer 243
Table 5.5: Inhibitors of EGF-R-mediated MAP kinase pathway activation 264
Table 5.6: ICs« values determined for exposure of two cell lines to benzopyrones 277
Table 5.7: Significance of the reduction in cellular viability for MTT assay 290
Table 5.8: Significance of the reduction in cellular viability for AP assay 297
Table 5.9: Significance of difference in sensitivity between the cytosensor
microphysiometer and MTT assay 305
Table 5.10: Optimised parameters for the ELISA-based assessment
of tyrosine phosphorylation in EFF-stimulated MCF-7 cells 315
Table 5.11: Esculetin inhibition (lhr pre-exposure) of tyrosine phosphorylation 316
Table 5.12: Esculetin inhibition (6hr pre-exposure) of tyrosine phosphorylation 317
Table 5.13: Warfarin inhibition (lhr pre-exposure) of tyrosine phosphorylation 318
Table 5.14: Warfarin inhibition (6hr pre-exposure) of tyrosine phosphorylation 319
Table 5.15: Genistein inhibition (lhr pre-exposure) of tyrosine phosphorylation 320
Table 5.16: Genistein inhibition (6hr pre-exposure) of tyrosine phosphorylation 321
Abbreviations
4'-AW 4'-aminowarfarin
Ab Antibody
xix
ADME/T Absorption, distribution, metabolism, excretion and toxicity profiles
ADP Adenosine diphosphate
AFMi Aflatoxin Mi
AIDS Acquired immune deficiency syndrome
ALT Alanine aminotransferase
AMI Acute myocardial infarction
AP Acid phosphatase
AR Acquired resistance
ATP Adenosine triphosphate
ATP-TCA ATP-based tumour chemosensitivity assay
BIA Biomolecular interaction analysis
BSA Bovine serum albumin
BsDb Bispecific diabody
CD-DST Collagen gel droplet embedded culture-drug sensitivity test
CDK Cyclin-dependent kinases
CDKIs CDK inhibitors
CDR Complementarity determining regions of antibody
cNOS Constitutive nitric oxide synthase
CM carboxymethylated
CYP Cytochrome P450
CTLA-4 Cytotoxic T lymphocyte-associated antigen 4
DMEM Dulbecco’s Minimum Essential Medium
DMSO Dimethyl sulfoxide
DNA Deoxyribonucleic acid
DTT Dithiothreitol
DVT Deep vein thrombosis
e2 Estradiol
ECAR Extracellular acidification rate
EDC N-ethyl-N'-(dimethylaminopropyl)carbodiimide
EDTA Ethylene diamine tetraacetic acid
EGF Epidermal growth factor
EGF-R Epidermal growth factor receptor
ELISA Enzyme-linked immunosorbent assay
ER Estrogen receptor
ERK Extracellular regulated kinase
XX
Fab Binding region of antibody above the hinge region
Fc Constant region of antibody molecule
FCS Foetal calf serum
FDA Food and Drug Administration (U.S.)
FDH Familial dys album incmic hyperthyrox i nem ia
FGF-R Fibroblastic growth factor receptor
FPT Famesyl protein transferase
FR Framework region
FTIs Famesyl transferase inhibitors
FTS Famesylthiosalycyclic acid
5-FU 5-Fluorouracil
Fv variable binding region of antibody
FX Factor X
GAP GTPase activating protein
GC-MS Gas chromatography-mass spectrometry
GCR G-protein coupled rcceptor
GDP Guanosine diphosphate
GTP Guanosine triphosphate
Gla y-carboxyglutamate
Glu Glutamate
GN Glomerulonephritis
Grb Growth factor receptor binding protein
GRF Guanine nucleotide releasing factor
GTP Guanosine triphosphate
HAT Hypoxanthine aminopterin thymidine
HAMA Human anti-mouse antibody
MBS Hepes buffered saline
HCC Hepatocellular carcinoma
HCV Hepatitis C virus
HGPRT Hypoxanthine guanine phosphoribosyltransferase
HIV Human immunodeficiency virus
HLE Human leukocyte elastase
HPLC High performance liquid chromatography
HPO High protein oedema
HR Hereditary resistance
xxi
HRP Horseradish peroxidase
HSA Human serum albumin
HT Hypoxanthine thymidine
HV Hypervariable
i.v. Intravenous
IC50 50% Inhibitory Concentration i.e. Drug concentration causing 50% growth inhibition
IFC Integrated ^-fluidic cartridge
IFN Interferon
Ig Immunoglobulin
IgA Immunoglobulin class A
IgD Immunoglobulin class D
IgE Immunoglobulin class E
IgG Immunoglobulin class G
IgM Immunoglobulin class M
IL Interleukin
iNOS Inducible nitric oxide synthase
INR International Normalized Ratio
ISI International Sensitivity Index
Ka Association affinity constant
ka Association rate constant
Kd Dissociation affinity constant
kd Dissociation rate constant
kDa Kilodalton
LAPS Light-addressable potentiometric sensor
LDH Lactate dehydrogenase
LED Light-emitting diode
Log Logarithmic
LPS Lipopolysaccaride
mAb Monoclonal antibody
MAP Mitogen-activated protein
MDR Multi-drug resistance
MEK MAP/ERK kinase
MHC-n Major histocompatibility complex class II molecules
8-MOP 8-methoxypsoralen
mRNA Messenger RNA
MTT 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
MW Molecular weight
n Refractive index
NEAA Non-essential amino acids
NF-kB Nuclear factor-icB
NGF Nerve growth factor
NHS N-hydroxysuccinimide
NIOSH National Institute for Occupational Safety and Health
NO Nitric oxide
NSAIDs Non-steroidal anti-inflammatoiy drugs
OAT Oral Anticoagulant Therapy
2-OHC 2-hydroxycoumarin
4-OHC 4-hydroxycoumarin
7-OHC 7-hydroxycoumarin
o-HPAA o-hydroxyphenylacetic acid
o-HPLA o-hydroxyphenyllactic acid
pi Isoelectric point
p.o. peroral
PAGE Polyacrylamide gel electrophoresis
PBS Phosphate-buffered saline
PDA Photodiode array
PDGF Platelet-derived growth factor
PEG Polyethylene glycol
PG Prostaglandin
pH Log of the hydrogen ion concentration
pNPP para-Nitrophenyl phosphate
PDK Phosphatidylinositol 3-kinase
PIVKAs Proteins Induced by Vitamin K Antagonism or Absence
PKC Protein kinase C
PRB Retinoblastoma protein
PSA Prostate specific antigen
PT Protrombin time
PTB Phosphotyrosine binding domain
P-Tyr Phosphorylated tyrosine
PUVA Psoralen & UVA
xxiii
R Regression coefficient
RBD Ras binding domain
RCC Renal cell carcinoma
Req Equilibrium binding response
RI Refractive index
RIA Radioimmunoassay
Rmax Maximum binding response
RNA Ribonucleic acid
ROS Reactive oxygen species
RTK Receptor tyrosine kinase
S.D. Standard deviation
scFv Single chain Fv antibody derivative
SDS Sodium dodecyl sulphate
SE Standard error
SPR Surface plasmon resonance
TBS Tris-buffered saline
TBZ Benzimidazolecarboxylic acid
TGF Transforming growth factor
TIR Total internal reflection
TLC Thin layer chromatography
TM Transverse magnetic
TMB Tetramethyl-benzidine
TNF Tumour necrosis factor
Tris Tris(hydroxymethyl)aminomethane
TYR Tyrphostin
UV Ultraviolet
UVA Artificial long wavelength ultraviolet
VH Variable region of heavy chain
VL Variable region of light chain
VSMC Vascular smooth-muscle cells
WISN Warfarin-induced skin necrosis
WF-BSA Warfarin-BSA
%2 Chi squared (i.e. averaged squared residual per data point)
xxiv
Units
Mg microgram
(k)Da (kilo) Daltons
)il microlitre
(xM micromoles
'C degrees Celcius
AU arbitrary units
cm centimetres
g grams
h hours
K degrees Kelvin
kg kilogram
1 litre
m metre
M molar
mg milligram
min minute
ml millilitre
mm millimetres
ntn nanometre
nM nanomolar
mol molar
Pg picograms
ipm revolutions per minute
RU response units
sec, s seconds
v/v volume per unit volume
w/v weight per unit volume
Publications and Presentations
Lacy, A. & O' Kennedy, R. (2001) The application of rapid analytical systems and sensors to the 
detection of cancers and other diseases, West Indian Med. J., 50: 100-104.
Lacy, A. & O' Kennedy, R. (2004) Radioimmunoassays, In: Encyclopaedia o f  Analytical Science, 
Second Edition, In Press.
Lacy, A. & O' Kennedy, R. (2004) Studies on the coumarins and coumarin-related compounds to 
determine their therapeutic role in the treatment of cancer, Curr. Pharm. Design, In Press.
Lacy, A., Cooke, D., O’Kennedy, R. (2004) The effects of benzopyrones on the growth, metabolism 
and signalling pathways of human tumour cells, (In Preparation).
Lacy, A. & O' Kennedy, R. (Dec., 2002) Immunological and toxicological studies on the 
benzopyrones, PhD Transfer meeting, DCU.
xxvi
Abstract
The Benzopyrones are a group of compounds whose members include coumarins (e.g. esculetin, 
warfarin) and flavonoids (e.g. genistein).
An anti-warfarin monoclonal antibody (mAb) was successfully used to develop assays for the 
detection of warfarin in biological matrices. Warfarin was reproducibly detected in PBS and urine 
utilising both the enzyme-linked immunosorbent assay (ELISA) technique and BIAcore, a biosensing 
instrument. Cross reactivity studies illustrated that accnocoumarin exhibited the highest degree of 
cross reactivity with the anti-warfarin mAb, as expected, due to its high degree of structural similarity 
to warfarin. Coumarin displayed negligible cross reactivity due to its low degree of structural 
similarity to warfarin. Kinetic studies of mAb preparations yielded both dissociation constant (Kd)  and 
association constant (Ka)  values for warfarin and three structurally similar analogues. The mAb was 
successfully characterised.
Toxicological effects of four benzopyrone compounds were investigated on two carcinoma 
cell-lines (A549 and MCF-7). Three different types of 96-well microtitre assays determined that 
genistein and esculetin respectively, were the most potent inhibitors of cell proliferation and 
metabolism. These results were compared to the results from the Cytosensor microphysiometer, a 
biosensor that detects cellular metabolism. Genistein was the most potent inhibitor on cellular 
metabolism followed by esculetin. In all assays both warfarin and 7-hydroxycoumarin showed weak 
inhibition of proliferation and metabolism. Other studies performed, illustrated the ability of genistein 
and esculetin to inhibit cell proliferation by DNA synthesis suppression. Studies on tyrosine kinase 
activity in MCF-7 cells suggest that esculetin and warfarin may suppress tyrosine kinase activity, 
which in turn has an inhibitory effect on cell proliferation. Overall, the potency of growth and 
metabolic inhibition by genistein was greater than esculetin, which was far greater than warfarin.
Chapter 1 
Introduction to the Benzopyrones
i
1.1. Introduction
Coumarins owe their class name to ‘Coumarou’, the vernacular name of the tonka bean 
{Dipteryx odorata Willd., Fabaceae), from which coumarin itself was isolated in 1820 (Bruneton, 
1999). Coumarin is classified as a member of the benzopyrone family of compounds, all of which 
consist of a benzene ring joined to a pyrone ring (Ojala, 2001). The benzopyrones can be subdivided 
into the benzo-a-pyrones to which the coumarins belong and the benzo-y-pyrones, of which the 
flavonoids are principal members (Figure 1.1.).
Figure 1.1: The chemical structures o f benzopyrone subclasses, with the basic coumarin structure 
(benzo-a-pyrone) [A], andflavonoid (benzo-y-pyrones) structure [Bf.
1.2. Occurrence
There are four main coumarin sub-types: the simple coumarins, furanocoumarins, 
pyranocoumarins and the pyrone-substituted coumarins (Table 1.1). The simple coumarins (e.g. 
coumarin, 7-hydroxycoumarin and 6,7-dihydroxycoumarin), are the hydroxylated, alkoxylated and 
alkylated derivatives of the parent compound, coumarin, along with their glycosides. Furanocoumarins 
consist of a five-membered furan ring attached to the coumarin nucleus, divided into linear or angular 
types with substituents at one or both of the remaining benzoid positions. Pyranocoumarin members 
are analogous to the furanocoumarins, but contain a six-membered ring. Coumarins substituted in the 
pyrone ring include 4-hydroxycoumarin (Keating & O’Kennedy, 1997). The synthetic compound 
warfarin belongs to this coumarin subtype. By virtue of its structural simplicity coumarin has been 
assigned as head of the benzo-a-pyrones, although it is generally accepted that 7-hydroxycoumarin be 
regarded as the parent compound of the more complex coumarins (Table 1.1) (Murray et al., 1982). 
Genistein is an isoflavone and belongs to the benzo-y-pyrones. It is a natural component of soy and
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has been intensively investigated as a chemopreventitive agent, mainly against hormonally regulated 
breast and prostate cancers in animal models (Constantinou et al., 1998).
Table 1.1: The four main coumarin subtypes. The main structural features and examples o f each 
coumarin subtype are illustrated in this table.
Classification Features Examples
SIMPLE COUMARINS Hydroxylated, alkoxylated or
alkylated on benzene ring
FURANOCOUMARINS 5-membered furan ring attached
to benzene ring.
Linear or Angular
7-hydroxycoumarin
Psoralen Angelicin
PYRANOCOUMARINS „
6-membered pyran ring
attached to benzene ring.
Linear or Angular
Seselin Xanthyletin
PYRONE- 
Sll BST1TUTED 
COUMARINS
Substitution on pyrone ring, 
often at 3-C or 4-C position
Warfarin
Coumarins comprise a very large class of compounds found throughout the plant kingdom 
(Finn et al, 2002). They are found at high levels in some essential oils, particularly cinnamon bark oil 
(7000 ppm), cassia leaf oil (up to 87,300 ppm) and lavender oil. Coumarin is also found in fruits (e.g. 
bilberry, cloudberry), green tea and other foods such as chicory (Lake, 1999). Most coumarins occur 
in higher plants, with the richest sources being the Rutaceae and Umbelliferae. Although distributed
throughout all parts of the plant, the coumarins occur at the highest levels in the fruits, followed by the
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roots, stems and leaves. Environmental conditions and seasonal changes can influence the occurrence 
in diverse parts of the plant (Keating & O’Kennedy, 1997). Recently six new minor coumarins have 
been isolated from the fruits and the stem bark of Calophyllum dispar (Clusiaceae). The genus 
Calophyllum which comprises 200 species is widely distributed in the tropical rain forest where 
several species are used in folk medicine (Guilet, 2001).
Although most of the natural coumarins in existence have been isolated from the higher 
plants, some members have been discovered in microorganisms. Some important coumarin members 
have been isolated from microbial sources e.g. novobiocin and coumermycin from Streptomyces, and 
aflatoxins from Aspergillus species (Cooke et al., 1997; Cooke, 1999). The aflatoxins are a group of 
highly toxic fungal metabolites and the most commonly occurring member of the group is aflatoxin B! 
(Keating & O’Kennedy, 1997). Coumarin group antibiotics, such as novobiocin, coumermycin A] and 
clorobiocin, are potent inhibitors of DNA gyrase. These antibiotics were isolated from various 
Streptomyces species and all possess a 3-amino-4-hydroxy-coumarin moiety and a substituted 
deoxysugar; noviose, as their structural core that is essential for their biological activity. Chlorobiocin 
differs from novobiocin in that the methyl group at the C-8 of the coumarin ring is replaced by a 
chlorine atom, and the carbamoyl at the 3’ of the noviose is substituted by a 5-methyl-2- 
pyrrolcarboxyl group. Coumermycin Ai contains two of the coumarin-noviose core joined by a 3- 
methyl-2,4-dicarboxyl pyrole linker and has the same substituted noviose as in chlorobiocin (Chen & 
Walsh, 2001).
1.3. Biosynthesis
In the higher plants, coumarins are generally produced via the shikimate-chorismate 
biosynthetic pathway as a derivative of cinnamic acid, which is also a precursor of many other natural 
products such as methyl salicylate, cinnamic aldehyde and amygdalin. The shikimate-chorismate 
pathway is responsible for the formation of the aromatic amino acids (Keating & O’ Kennedy, 1997). 
This pathway is a central biosynthetic route in plants and micro-organisms. Shikimate and chorismate 
are key intermediates in the biosynthesis of the aromatic acids L-phenylanine, L-tyrosine and L- 
tryptophan (Murray et al., 1982). Shikimate is converted to chorismate through sequential 
phosphorylation, condensation and elimination reactions. Chorismate is converted to prephenate, 
which is achieved enzymatically. Aromatisation of prephenate yields phenylpyruvate that is 
transaminated to become phenylalanine. Enzymatic elimination of ammonia from phenylalanine 
produces trans-cinnamic acid, which is a precursor for the production of all coumarin species (Murray 
et al., 1982; Weinmann, 1997).
At this stage the biosynthetic pathway diverges (pathways 1 and 2 in Figure 1.2), giving rise 
to two distinct coumarin types - those which are oxygenated at carbon-7 and those that are not. In the 
latter case (pathway 1, Figure 1.2) trans-cinnamic acid is converted to coumarinyl glucoside via the 
three steps illustrated in Figure 1.2. This is the primary form in which coumarin exists. The simple 7- 
oxygenated coumarins follow a similar scheme (pathway 2, Figure 1.2). The difference being the 
initial step where trans-cinnamic acid is converted to p-coumaric acid by a /?ara-hydroxylation. P- 
coumaric acid undergoes three steps to convert to umbelliferyl glucoside (Keating & O’ Kennedy,
1997).
Details of Pathway 1 and 2 in Figure 1.2 are as follows:
Pathway 1
1. Ortho hydroxylation of /ram-cinnamic acid to /'raws-2'-hydroxycinnamic acid.
2. Glucosylation of ira«s-2'-hydroxycinnamic acid to /nms-2'-glucosyloxycinnamic.
3. Cw-isomerisation to form coumarinyl glucoside.
Pathway 2
A. Para-hydroxylation of from-cinnamic acid to /j-coumaric.
B. O/Y/îo-hydroxylation ofp-coumaric to /ra«s-2',4'-dihydroxycinnamic.
C. Glucosylation to yield frara-2'-glucosyloxy-4'-hydroxycinnamic.
D. Trarts-c/s-isomerisation to form umbelliferyl glucoside.
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Figure 1.2: Biosynthetic routes for the natural production o f coumarin and 7- hydroxycoumarin. 
Details o f the pathways are included in the text.
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1.4. Pharmacokinetics
The area of study, which elucidates the time course of drug concentration in the blood and 
tissues, is termed pharmacokinetics. It is the study of the kinetics of absorption, distribution, 
metabolism and excretion of drugs and their corresponding pharmacologic, therapeutic, or toxic 
response in animals and man (Rang & Dale, 1987). The pharmacokinetics of coumarin, including the 
excretion of various metabolites, was elucidated over many years. Coumarin is rapidly and almost 
completely metabolised with little unchanged compound excreted (Pelkonen et al., 1997).
The biological response to a drug is the result of an interaction between the drug substance 
and functionally important cell receptors or enzyme systems. The magnitude of the response is related 
to the concentration of the drug achieved at the site of its activation. This drug concentration depends 
on the dosage of the drug administered, the extent of its absorption and distribution to the site, and the 
rate and extent of its elimination from the body.
For a drug to exert its biologic effect, it must be transported by the body fluids, traverse the 
required membrane barriers, escape widespread distribution to unwanted areas, endure metabolic 
attack, penetrate in adequate concentration to the site of action, and interact in a specific fashion, 
causing an alteration of cellular function. The absorption, distribution, biotransformation 
(metabolism), and elimination of the drug from the body are dynamic processes that continue from the 
time the drug is taken until the drug has been removed from the body (Ansel et al., 1999).
A simplified diagram of this complex series of events between drug administration and its 
elimination is presented in Figure 1.3.
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Figure 1.3: Schematic representation o f events o f absorption, metabolism, and excretion o f drugs 
after their administration by various routes.
1.4.1. Absorption and Distribution
Absorption refers to the passage of a drug from its site of administration into the plasma. 
Following oral administration, coumarin is rapidly absorbed from the gastrointestinal tract and is 
distributed throughout the body (Lake, 1999). The ability of a compound to be absorbed well in the 
gastrointestinal tract following oral administration relies heavily on its physico-chemical 
characteristics.
Coumarin and 7-hydroxycoumarin are both poorly soluble in water (0.22 and 0.031 %, 
respectively). This characteristic is cause for concern with respect to their bioavailability in vivo, as 
0.3% solubility in water is considered the critical value at which the distribution of a compound limits 
its rate of absorption. However, both compounds have high partition coefficients (21.5% for coumarin 
and 10.4% for 7-hydroxycoumarin), which is considered favourable for the rapid absorption of
compounds once they are in aqueous solution. This coupled with the fact that coumarin is non-polar, 
suggests that in theory coumarin should cross lipid bilayers easily by passive diffusion (Ritschel et al., 
1981; Pelkonen et al., 1997).
In reality absorption from the gastro-intestinal tract (GIT) has been shown to be quite high, 
with most of the dose absorbed within an hour of administration. Pharmacokinetic studies in humans 
have demonstrated that coumarin is completely absorbed from the GIT after oral administration and 
extensively metabolised by the liver in the 1st pass with only between 2 and 6% reaching the systemic 
circulation intact (Lake, 1999). The low bioavailability of coumarin, in addition to its short half-life 
has brought into question its importance in vivo and it is now accepted that coumarin is a pro-drug, 
with 7-hydroxycoumarin being the compound of main therapeutic relevance. Once absorbed any 
active compound must be distributed via plasma to its target site (Rang & Dale, 1987).
At normal therapeutic plasma concentrations many drugs exist in the plasma mainly in the 
bound form. The fraction of drug that is free in aqueous solution can be as low as 1%, the remainder 
being associated with plasma protein. Ritschel et al. (1981) have shown that 35% of coumarin and 
47% of 7-hydroxycoumarin bind plasma proteins. Availability of the compounds at their target tissues 
should not be problematic since the proportions that bound were well below the accepted critical value 
of 80% binding. Once a drug is administered and drug absorption begins, the drug does not remain in 
a single body location, but rather is distributed throughout the body until its ultimate elimination 
(Ansel et al., 1999).
Coumarin has a short half-life in vivo, which is independent of the route of administration 
(1.02 hrs peroral vs 0.8 hrs intravenous) as shown by Ritschel et al., (1977). As mentioned previously, 
coumarin is rapidly metabolised to form 7-hydroxycoumarin, which quickly becomes conjugated as 
the glucuronide, such that concentrations of 7-hydroxycoumarin are always low and rarely exceed 
2.2% of the levels of 7-hydroxycoumarin-glucuronide (Ritschel et al., 1977).
The pharmacokinetics of coumarin were studied in a number of species including the rat, dog, 
gerbil, rhesus monkey and in man. Specific antibody recognition for its antigen is the basis for very 
selective and sensitive analytical methods, and has been exploited in numerous formats for the 
pharmacokinetic determination of coumarin and its derivatives. Immunoanalytical approaches have 
included ELISA-based methods for the detection of coumarin and 7-hydroxycoumarin in urine (Egan 
& O’Kennedy, 1993b). Antibody biosensors have also been employed, with either electrochemistry, or 
surface plasmon resonance (BIAcore) facilitating label-free detection of coumarin compounds in
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various matrices (Dempsey et al., 1993; Keating, 1998). Tests in animals, using radio-labelled 
coumarin, have demonstrated its distribution throughout the body to nearly all organs and tissues, and 
highlighted its accumulation in the liver and kidney. This information has proven useful in illustrating 
which species are appropriate animal models for studies on the toxicity and therapeutic relevance of 
coumarins (Lake, 1999).
1.4.2. Metabolism
Although some drugs are excreted from the body in their original form, many drugs undergo 
biotransformation prior to excretion. Biotransformation is the term used to indicate the chemical 
changes that occur with drugs within the body as they are metabolised and altered by various 
biochemical mechanisms (Ansel et al, 1999). Traditionally coumarin was viewed by pharmacologists 
as the ideal model for studying the complex metabolism of a structurally simple organic molecule, and 
as such, its metabolic fate has been extensively researched (Shilling et al., 1969; Moran et al., 1987; 
Lake, 1999). Determining the metabolic fate of coumarin is important in order to utilise the fact it is 
metabolised at several sites and to access the possible dependence of coumarin-induced toxicity on 
metabolism (Pelkonen et al., 1997).
The superfamily of cytochromes P450 (CYPs) consists of microsomal hemoproteins that 
catalyse the oxidative, peroxidative and reductive metabolism of a wide variety of endogenous and 
exogenous compounds. The CYP superfamily is divided into families and subfamilies according to 
their nucleotide sequence homology. Most biotransformations of xenobiotics (such as drugs) are 
performed by enzymes from the families CYP1, CYP2 and CYP3. The CYP2 family were examined 
using the rat, mouse and rabbit model systems. This family includes seven subfamilies in mammals. In 
humans, the most important CYPs regarding drug metabolism are CYP2A6, CYP2C9, CYP2C19, 
CYP2D6 and CYP2E1 (Taavitsainen, 2001).
Coumarin is metabolised initially by specific cytochrome P-450-linked mono-oxygenase 
enzyme (CYP2A6) system in liver microsomes, resulting in hydroxylation to form 7- 
hydroxycoumarin. After 7-hydroxylation, coumarin undergoes a phase II conjugation reaction 
resulting in a glucuronide conjugation associated with 7-hydroxycoumarin. The 7-hydroxylase activity 
is exceptionally high in human liver microsomes compared with its activity in the livers of other 
animal species. The activity of coumarin 3-hydroxylase is very high in rodent microsomes but is 
absent in human microsomes.
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Although coumarin may be metabolised by hydroxylation at all six possible positions (i.e. 
carbon atoms 3, 4, 5, 6, 7, and 8.), the most common routes of hydroxylation are at positions 7 and 3 
to yield 7-hydroxycoumarin and 3-hydroxycoumarin, respectively. Hydroxylation at carbon 3 results 
in further metabolism via ring opening, yielding two further products, o-hydroxyphenyllactic acid (o- 
HPLA) and o-hydroxyphenylacetic acid (o-HPAA) (Pelkonen et al., 1997; Lake, 1999). The 
expression of CYP enzymes (e.g. CYP2A6) varies between individuals due to genetic and 
environmental factors. These factors produce inter-individual variation in the metabolism of drugs 
such as coumarin. The frequency of poor metabolisers varies between species, races and ethnic 
groups. It has been shown that there exists large inter-species and inter-individual variability in the 
activity of these enzymes (Taavitsainen, 2001).
1.4.2.L Metabolism in Man
The metabolism of coumarin has been investigated in vivo and in vitro in a wide range of 
species including humans. Human metabolic studies usually involve oral dosage followed by urine 
collection with or without timed fractionation (Egan & O’Kennedy, 1992; Bogan et al., 1995). 
Analysis is by one of a number of techniques including spectrofluorimetry, HPLC and capillaiy 
electrophoresis (Rautio et al., 1992; Egan and O'Kennedy, 1993a; Bogan et al., 1996). Human 
metabolic studies usually involve oral dosage followed by urine collection with or without timed 
fractionation. Recent in vitro systems employed include tissue slices, hepatocytes, subcellular 
fractions, and purified and cDNA-expressed enzymes (Lake, 1999). In the majority of human subjects 
studied coumarin is extensively metabolised to 7-hydroxycoumarin. Some data for various coumarin 
dose levels and collection periods are shown in Table 1.2. The measurement of urinary 7- 
hydroxycoumarin following an oral dose of coumarin has been employed as a biomarker of human 
hepatic CYP2A6, the cytochrome P-450 (CYP) isoform which is responsible for coumarin 7 
hydroxylation in human liver (Pelkonen et al., 1997). Some individuals can metabolise a considerable 
proportion of coumarin through pathways other that 7-hydroxylation. Humans can metabolise 
coumarin by the 3,4-epoxidation and other pathways to o-HPAA (Figure 1.4.).
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Table 1.2: Extent o f coumarin metabolism to 7-HC in various species. aCoumarin administered orally 
unless otherwise statedbShilling et al. (1963). ' Egan et al. (1990).
Species Dose (mg/kg)a Collection time 
(hr)
Urinary 7-HC (% o f  
Dose)
Rat 100 890 or 120 0.4
Mouse 21. i.p. 22 25
Syrian Hamster 200 24 5
Squirrel Monkey 200 24 1
Baboon 200 24 60
Human 200mg/subject 24 b79 (range 68-92)
200mg/subject 24 c63 (range 40-97)
In humans, there are three genes in the CYP2A subfamily, however, CYP2A6 is mainly of 
greater importance, as the other two gene products (CYP2A7 and CYP2A13) are either inactive or are 
not expressed in the liver. CYP2A6 codes the enzyme catalysing coumarin 7-hydroxylation (about 
10% of total P450) (Pelkonen et al., 2000). Recently, CYP2A6 was reported to be polymorphically 
expressed in the human liver. It was shown that CYP2A6 participates in metabolism of nicotine and its 
metabolite cotinine. Some drugs and chemicals, including coumarin which is widely used as a probe 
substance for CYP2A6 both in vitro and in vivo, are also metabolised by this enzyme (Pelkonen et al.,
1998). Substrates and inhibitors currently known to be metabolised by or interfere with CYP2A6 in 
vitro and in vivo have been summarised by Pelkonen et al., (2000). Although 7-hydroxycoumarin is 
the main human metabolite, other hydroxylation pathways are important in humans and as such the 
therapeutic relevance of non-7-hydroxymetabolites should be examined rather than disregarded.
1.4.2.2. Metabolism in Other Species
Studies have examined the metabolism of coumarin and marked species differences have been 
reported. The extent of coumarin 7-hydroxylation appears to be species rather than dose dependent. 
Several species including the rat, most mouse strains, Syrian hamster, guinea pig, ferret, dog, 
marmoset and squirrel monkey appear to be poor 7-hydroxylators of coumarin excreting 5% or less of 
the administered dose of urinary 7-hydroxycoumarin. Fentem et al., (1992) have indicated that 
coumarin 3,4-epoxide is the metabolic intermediate responsible for hepatotoxicity in the rat. Certain 
mouse strains, such as DBA/2 and 129/Rr strains, which have relatively high hepatic coumarin 7-
hydroxylase activity, excrete up to 26% of an administered dose of coumarin as 7-hydroxycoumarin.
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In a study by Gangolli et al., (1974) the baboon has been reported to be an extensive 7-hydroxylator of 
coumarin with 60-66% of the dose being rapidly excreted in the urine as 7-hydroxycoumarin.
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Figure 1.4: Metabolism ofcoumarin. All biotransformations are possible, although the metabolism is 
species-specific.
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1.5. Toxicology
Since 1954, coumarin has been classified as a toxic substance by the FDA, following reports 
of its possible liver tumour-producing properties in rats (Byrden, 1996). The FDA banned its use, 
labelling as adulterated, all foods containing coumarin. Due to tests performed on rodents coumarin 
was referred to as a chemical carcinogen by NIOSH [National Institute for Occupational Safety and 
Health]. However, caution needs to be taken in extrapolating this information to human situations. 
Various tests (Ames, micronucleus) have shown that coumarin and its metabolites are non-mutagenic 
(Egan et al., 1990). Preliminary results from early studies indicated that coumarin was a toxin, but it 
was shown since, that the rat is a poor model to compare with the human for this particular metabolic 
process (Deasy, 1996). A number of studies have examined the acute, chronic and carcinogenic effects 
of coumarin in the rat and mouse. In studies involving the rat, hepatic biochemical and morphological 
changes have been examined for various periods of coumarin administration (1 week to 2 years). 
Depending on dose administered, coumarin treatment results in an increase in relative weight and 
changes in various hepatic biochemical parameters. Single oral doses of coumarin were shown to 
produce liver necrosis and increase plasma transaminase activities in DBA/2 strain mice (Lake, 1999).
In contrast, studies involving baboons, syrian hamsters and certain mice strains seem to be 
resistant to acute coumarin-induced hepatotoxicity. Species differences in coumarin-induced toxicity 
in vitro were investigated in cultured hepatocytes. These studies provide evidence for species 
differences in coumarin-induced toxicity in vitro. The relative resistance of human and cynomolgus 
monkey liver slices and/or hepatocytes to coumarin toxicity correlates with coumarin 7-hydroxylation, 
the major pathway of coumarin metabolism in these species, being a detoxification pathway of 
coumarin metabolism. However, while coumarin-7-hydroxylation pathway is a detoxification pathway 
this does not appear to be the only explanation for resistance of a species to coumarin-induced 
toxicity. In the rat coumarin-induced hepatotoxicity appears to be partially attributable to the excretion 
of coumarin metabolites in the bile. This may result in enterohepatic circulation enhancing the 
exposure of liver cells to toxic coumarin metabolites. Species such as Syrian hamster, baboon, and 
humans excrete coumarin metabolites primarily in urine. Low-level exposure to coumarin from diet 
and from fragrances used in cosmetic products would not be expected to produce any hepatotoxicity 
even in individuals with deficient 7-hydroxylase activity (Pelkonen et al., 1997, Lake, 1999).
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1.6. Applications of Coumarin and Coumarin Derivatives
The coumarins are of great interest due to their biological properties. In particular, their 
physiological, bacteriostatic and anti-tumour activity makes these compounds attractive for further 
backbone derivatisation and screening as novel therapeutic agents. Weber et a l, (1998) have shown 
that coumarin and its metabolite 7-hydroxycoumarin have antitumour activity against several human 
tumour cell lines. Both coumarin and coumarin derivatives have shown promise as potential inhibitors 
of cellular proliferation in various carcinoma cell lines (Egan et al, 1997; Cooke, 1999; Cooke & 
O’Kennedy, 1999). In addition it has been shown that 4-hydroxycoumarin and 7-hydroxycoumarin 
inhibited cell proliferation in a gastric carcinoma cell line (Budzisz et al, 2003).
1.6.1. Simple Coumarins
Coumarins and the benzopyrones are representative of a very diverse and potentially useful 
groups of drugs.
1.6.1.1. Industrial Uses
Coumarin has many uses in industiy, mainly due to its strong fragrant odour (Egan et al, 
1993). It is applied in a variety of industrial settings, the most important being the perfumery industiy. 
Coumarin is used as a fixative and enhancing agent in perfumes and is added to toilet soap and 
detergents, toothpaste, tobacco products and some alcoholic beverages. Large quantities are used in 
rubber and plastic materials and in paints and sprays to neutralise unpleasant odours. It is evident that 
coumarins are of analytical importance and are utilised as dyes, labels and derivatising agents. 
Coumarin heterocycles that are substituted in the 7-position with an amine function (azole coumarins) 
constitute an important class of fluorescent materials (Jones, 1999). Coumarin of the azole type may 
find use as fluoroprobes of the microenvironment of proteins and other biological macromolecules and 
as agents for pH sensing (Jones, 2001). The coumarin family of compounds have found widespread 
use in many analytical applications, resulting from their natural fluorescence. These compounds have 
found application as laser dyes, labelling agents and in enzyme assays where fluorescence is required 
(Cooke et al., 1997).
Work by Luo et al., (2001) involved synthesis of coumarins containing N-alkylsulfonamide 
groups built into benzoxazolyl, benzothiazolyl, or benzimidazolyl systems. These were then reacted
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with NaCN to give fluorescent red compounds. Results from a determination of the spectral properties 
and dyeing characteristics of these new dyes suggest that they are potential commercial solvent dyes. 
Ishibashi et al., (2000) have applied fluorescence techniques to the detection of OH formed on a 
photo-illuminated surface using coumarin, which readily reacts with OH to produce highly 
fluorescent products. This method has been used in radiation chemistry, sonochemistry and 
biochemistry for the detection of "OH generation in water.
1.6.1.2. Clinical Uses
Due to its biochemical properties coumarin has been proposed for use in clinical medicine. It 
was evaluated for the treatment of various clinical conditions, resulting in the employment of a variety 
of dosing regimens. Recommended doses range from 8mg for the treatment of venous constriction to 
7000mg/day in anti-neoplastic therapies.
1.6.1.2.1. High Protein Oedema (HPO)
The lymph system is responsible for drainage of interstitial fluid within human tissues. If 
excess fluid is present, as a result of injury or lymph vessel blockage, the transport capacity of the 
lymph system is compromised, and oedema (swelling of tissue) develops. There are numerous 
detrimental effects of oedemas to the patient as often there is extensive injury to blood vessels, with 
fibrin deposition and fibrosis common effects. The oedema interferes with the metabolism of the tissue 
cells and reduces oxygen transport, resulting in problematic wound healing (Casley-Smith & Casley- 
Smith, 1986). In the case of high protein oedemas (HPO), there is an accumulation of protein in the 
tissue following trauma or inflammation, with resulting permeability of the capillaries causing water 
leakage in the tissue spaces. Many disease states are associated with high protein oedemas, ranging 
from extremely severe and chronic {e.g. lymphoedema and elephantiasis) through more common and 
acute forms (e.g. bums, accidental and surgical traumas). All forms have been shown to benefit from 
benzopyrone treatment (Casley-Smith & Casley-Smith, 1997).
Coumarin and numerous other benzopyrones have been tested in high protein oedema, and all 
have been shown to successfully reduce the swelling. The objective of a recent study was to evaluate 
the oedema-protective effect of a combination vasoactive drug, coumarin/troxerutin (SB-LOT) plus 
compression stockings in patients suffering from chronic venous insufficiency after decongestion of 
the legs as recommended by the new guidelines. The study confirms the oedema-protective effect of 
SB-LOT in chronic venous insufficiency and provides a treatment option for patients who discontinue
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compression after a short time (Vanscheidt et al., 2002). In addition to laboratory-based work, Casley- 
Smiths team has been very closely involved with many clinical investigations. All trials have shown 
that coumarin either alone, or in combination with other benzopyrones, leads to both objective 
(circumference and volume), and subjective (tension, heaviness, fullness, pain) improvement, and has 
lead to the introduction of coumarin as a lymphoedema treatment in a number of western and 
developing countries.
1.6.1.2.2. Chronic Infections
In addition to its stimulatory effect on macrophages, coumarin has been shown to activate 
other cells of the immune system. Hence, coumarin has been used clinically to treat chronic infections 
such as brucellosis (Thornes, 1983). In chronic brucellosis Brucella abortis infects macrophages, thus 
eluding the immune response. When immunostimulatory drugs such as coumarin are administered, the 
symptoms of chronic brucellosis disappear. Coumarin was found by Thornes (1983) to be the most 
effective and least toxic immunostimulant. It was also effective at augmenting and maintaining IgA 
levels (normally suppressed in chronic brucellosis) and restoring delayed hypersensitivity reactions. 
These results have encouraged the use of coumarin in other chronic infections such as mononucleosis, 
mycoplasmosis, toxoplasmosis and Q fever.
A new antiplasmodial coumarin has been isolated from the roots of Toddalia asiatica. This 
finding supports the traditional use of this plant for the treatment of malaria (Oketch-Rabah, 2000).
1.6.1.3. Coumarins in Cancer
The modem era of cancer chemotherapy began in the late 1940s with the demonstration that 
the nitrogen mustards showed anti-cancer activity in malignant lymphoma. At about the same time the 
coumarins were chemically described as a group of natural compounds, present in a wide variety of 
vegetables and fruits. Over time research has indicated that the coumarins may be clinically important 
in the treatment and maintenance of cancer patients.
Anti-cancer drugs have traditionally been targeted to damage the aberrantly dividing cell by 
interrupting the cell division process (Carter et al., 1989). Reagents used include DNA intercalating 
agents {e.g. adriamycin), DNA cross-linking agents {e.g. cis-platin), topoisomerase inhibitors {e.g. 
campothecins), cytoskeleton-disrupting agents {e.g. vinblastin) and anti-metabolites {e.g. 
mercaptopurine). These drugs though effective, are cytotoxic, and thus exhibit severe side effects,
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particularly on normal proliferating tissues such as the haematopoietic system. Often combination 
therapies, whereby several cytotoxic agents are combined in the treatment regime, offer better results 
with fewer toxic side-effects, as they are carefully regulated to allow recovery of normal, but not 
malignant cells, from drug exposure (Carter et al., 1989).
Currently, chemotherapy, radiotherapy and surgery combined offer the best outcomes for 
cancer patients, and treatment combinations were successfully applied to particular cancer types, for 
example, Hodgkin’s lymphoma, testicular cancer and various leukaemias. Coumarins can be used not 
only to treat cancer but to treat the side effects caused by radiotherapy. A recent study investigated the 
efficacy of coumarin/troxerutine combination therapy for the protection of salivary glands and mucosa 
in patients undergoing head and neck radiotherapy. The results suggest that coumarin/troxerutine have 
a favourable effect in the treatment of radiogenic sialadentis and mucositis (Grotz et al, 2001).
The interest in coumarin and 7-hydroxycoumarin as anti-cancer agents, arose from reports 
(Section 1.6.1.3.1 -  1.6.1.3.3.) that these agents had achieved objective responses in some patients 
with advanced malignancies. To date, the particular mode of action of these agents in cancer cells is 
obscure, although various possibilities have been hypothesised, and these are outlined in the following 
sections. While a significant amount of research regarding the clinical applications of the 
benzopyrones has been reported it is important to emphasise that only the ‘warfarin-type’ 
anticoagulants belong to mainstream pharmacotherapy. Other types of coumarin compounds are either 
at the experimental or early clinical trial phase. Hence, additional studies on the elucidation of their 
mechanism of action are necessary to facilitate a greater understanding of these compounds if they are 
to have future clinical applications.
1.6.1.3.1. Coumarin in Malignant Melanoma
Early diagnosis of malignant melanoma facilitates surgical removal of the primary lesion and 
achieves a good prognosis. However, if the lesion progresses, the risk of recurrence becomes serious 
and represents a major challenge to the oncologist, as no satisfactory treatment for recurrent malignant 
melanoma currently exists. Studies have shown that five years after removal of the primary lesion, the 
recurrence of malignant melanoma is observed in 55-80% of high risk patients (Wcislo & Szczylik, 
2003).
Original work with coumarin derivatives in the treatment of melanoma focused on the use of 
warfarin as a maintenance therapy. This compound was known to inhibit tumour spread, and to
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stimulate granulocytes, lymphocytes and macrophages (Thornes etal., 1968). In 1980, Maat illustrated 
that the decrease in tumour metastases due to warfarin was macrophage-dependent. This data 
prompted Thornes to assess the potential application of coumarin, the parent compound of warfarin, as 
an adjuvant therapy in melanoma. Like warfarin, the in vivo actions of coumarin were known to be 
macrophage-derived. Coumarin was non-toxic and conveniently administered, it had no anti-coagulant 
activity, and a previous administration resulted in subjective improvement in cancer patients (Thornes, 
1997).
Coumarin was first compared to warfarin in a small-scale trial on patients with stage I and 
stage II melanomas after primary resection. Five patients were anti-coagulated with warfarin and six 
were given 25mg coumarin daily. During the first year, coumarin matched warfarin in its therapeutic 
effectiveness, with one patient in each group recurring (Thornes, 1993). In 1984, a placebo-controlled, 
randomised, double-blind trial (50mg coumarin alone, daily for 2 years) was established, with twenty- 
seven patients admitted. All patients were treated with standard surgical excision of the melanoma 
lesions prior to coumarin treatment. In 1987 the trial results were published, and showed 10 
recurrences in the control (N=14), but only 2 in the treated group (N=13). Since the trial termination, 
two more patients in the treated group have recurred, at two and four years (Thornes, 1997).
Only one further trial in melanoma patients has yielded results: an open trial in Australia 
found a dosage of 300mg of coumarin daily to be of no benefit to treated patients (Thornes, 1997). 
Thornes has continuously stated the importance of optimal dosing in the establishment of trials, 
believing that high doses of coumarin may inhibit rather than stimulate the immune system. Such a 
hypothesis may explain these conflicting results, but it is evident that further dosing trials are required 
to determine the real benefit of coumarin in malignant melanoma therapy. A more recent study by 
Velasco-Velazquez et al., (2003) determined the in vitro effects of 4-hydroxycoumarin (4-HC) 
employing the murine melanoma cell line B16-F10 and the non-malignant fibroblastic cell line B82. 
4-HC disorganized the actin cytoskeleton in B16-F10 cells, but not in B82 fibroblasts. Adhesion of 
tumour cells to extracellular matrix is required during the metastatic process, therefore, 4-HC might be 
useful as an adjuvant therapy for melanoma.
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1.6.1.3.2. Coumarin in Renal Cell Carcinoma
The clinical course of renal cell carcinoma (RCC) has been well documented, with long- 
lasting stable periods and rapid tumour growth its principal features. Surgeiy remains the standard care 
for patients whose tumour is confined to the kidney. However, many of these patients develop 
recurrent or metastatic disease within months, where the lungs, liver and bones are the common sites 
of secondary occurrence (Ebbinghaus et al., 1997). RCC is characterized by a lack of early warning 
signs, resulting in a high proportion of patients with metastases at the time of diagnosis or relapse 
following nephrectomy. Despite extensive investigations with many different treatment modalities, 
metastatic RCC remains a disease highly resistant to systemic therapy. The outlook for patients with 
metastatic RCC is poor, with a 5-year survival rate of less than 10% (Vuky et al., 2000).
Interest in the coumarin family of compounds stemmed from reports by Thornes, of the 
immunomodulatory activity of coumarin and its utility in malignant melanoma (Thornes, 1982). The 
clinical activity of coumarin in renal cell carcinoma patients was investigated by applying a treatment 
regime courtesy of Thornes [coumarin at lOOmg/day oral dosage, with the addition of cimetidine 4 X 
300mgs/day from day 15]. This preliminary study yielded some interesting results, with 14 objective 
results among 45 patients with metastatic RCC, and almost no toxic side effects. Validation of this 
anti-tumour activity was further demonstrated by other investigators (Dexeus et al., 1990; Kokron et 
al., 1991).
Following this success, it became clear that additional information regarding doses and 
toxicity's was required, and Marshall and colleagues implemented a phase I trial to define the 
maximally tolerated dose, and dose-limiting toxicity's of coumarin and cimetidine. 54 patients with a 
variety of advanced malignancies were admitted to this trial, with 3 patients each, given one coumarin 
dose in the range 400mg-7000mg. Coumarin was administered as a single, oral dose continuously 
during the trial, with cimetidine [4 doses of 300mg daily] added to the dosage regime on day 15. All 
coumarin doses were well tolerated, with the most common side effect of nausea attributable to the 
intense aroma of coumarin. Objective responses were observed in 7 patients, all with renal cell 
carcinoma, these responses being observed across a range of coumarin doses [600-5000mgs] 
(Marshall et al., 1991).
In vitro cytotoxic potential and mechanism of action of selected coumarins (coumarin, 7- 
hydroxycoumarin, esculetin and nitro-coumarins) using renal cell lines were investigated recently 
(Finn et al., 2002). The results obtained suggest that the nitro-coumarin (6-Nitro-7-hydroxycoumarin)
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and daphnetin (7,8-dihydroxycoumarin) examined may merit further investigation in relation to renal 
cell carcinoma.
1.6.1.3.3. Coumarin in Prostate Cancer
Prostate cancer is the most common invasive malignancy in males and is characterised by a 
very slow growth rate and a wide biological variability, especially with regard to hormonal sensitivity 
(Bosland, 1991; Agarwal, 2000). These two traits have curbed attempts at curative treatments for 
patients, as most effective chemotherapeutic drugs rely on fast growth kinetics in the tumour mass. At 
present, early detection, and removal of clinically significant tumours by surgery or radiation, has been 
the focus of therapeutic strategies. However, patient survival is dependent on métastasés where 
principal metastatic sites are regional lymph nodes and bone. Eventually, almost every prostate 
carcinoma that initially regressed on androgen deprivation will relapse into a hormonal-insensitive 
state and grow in the absence of androgen. Evidently, better therapeutic approaches to control both 
métastasés and hormone-insensitive prostate carcinomas are required.
Coumarin had previously appeared to exert immunomodulating effects in other cancers, 
hence, a small-scale study to test the efficacy of coumarin in prostate cancer was set up (Marshall et 
al., 1990). 14 patients received a single oral dose of lOOmg coumarin daily continuously during the 
trial, with 300mg of cimetidine 4 times daily added to the regime from day 15 onwards. Both drugs 
were continued until disease progression was observed. No objective responses were observed, but a 
significant subjective improvement in bone pain was noted in patients, which prompted further 
studies. A phase I trial involving 40 patients with metastatic, hormone-naïve or hormone-refractory 
prostatic cancer was conducted (Mohler et al., 1992). Participants were administered 3g of coumarin 
daily, and evaluated for toxicity and anti-tumour responses. 3 partial responses occurred, all in­
patients with low tumour loads. One responder remained with 3 responsive bone métastasés and stable 
prostate specific antigen (PSA) levels for 7 years following the trial. Myers et al., (1994) examined the 
effects of various concentrations (0-500 (ig/ml) of coumarin on the proliferation of two renal cell 
carcinoma cell lines (786-0 and A-498) and two malignant prostatic cell lines (DU 145 and LNCaP). 
After 5 days of treatment, coumarin inhibited the growth of the four cell lines. The LNCaP prostatic 
cell line was most sensitive to the inhibitory effects of coumarin.
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1.6.1.4. Other Simple Coumarins
1.6.1.4.1. Cloricromene
Cloricromene is a coumarin derivative (8-monochloro-3-P-diethylaminoethyl-4-methyl-7- 
ethoxy-carbonylmethoxy coumarin) with beneficial effects on splanchnic, hemorrhagic and endotoxic 
shock. The drug is semi-synthetic with anti-platelet and anti-leukocyte properties, it inhibits tumour 
necrosis factor-a (TNF-a) and prevents the expression of inducible nitric oxide synthase fiNOS 
protein] (Zingarelli et al., 1993; Maltese & Bucolo, 2002). Previous work has shown that cloricromene 
modifies several granulocyte as well as monocyte/macrophage functions, which explains at least in 
part its protective action in ischemia (Zatta & Bevilacqua., 1999). It decreases superoxide anion 
production, inhibits chemotaxis of polymorphonuclear cells, reduces levels of platelet-activating 
factor, and leukotriene B4 and decreases the release of arachidonic acid by interfering with 
phospholipase A2 activation. Cloricromene decreases myocardial infarct size after ischemic- 
reperfusion injury in vivo, and it has been suggested that this is due to inhibition of TNF-a. It was 
established that cloricromene inhibts lipopolysaccharide-induced cellular oxidative activity, which is 
important for nuclear factor-KB (NF-kB) activation. Cloricromene interferes with early signal 
transduction pathway triggered by lipopolysaccaride (Corsini et al., 2001). A rapid and simple method 
was developed for the simultaneous separation and quantification of cloricromene and its active 
metabolite cloricromene acid, in rabbit aqueous humor. The assay provided good reproducibility and 
accuracy for both analytes and proved suitable for pharmacokinetic studies of cloricromene (Maltese 
& Bucolo, 2002).
1.6.1.4.2 Daphne tin
Aerial parts of Daphne oleoides are used to treat rheumatoid arthritis and lumbago in Turkish 
folk medicine. 17 compounds were isolated and their structures were elucidated. Daphnetin showed 
potent in vitro inhibitory activity on inflammatory cytokines such as interlukin-1 and TNF-a (Ullah et 
al., 1999; Yeilada et al, 2001). Protein kinases play key roles in the control of cell proliferation, 
differentiation and metabolism. The effect of coumarin and its derivatives, including daphnetin, 
esculin, 2-hydroxycoumarin (2-OH-coumarin), 4-hydroxycoumarin (4-OH-coumarin) and 7- 
hydroxycoumarin, on the activity of protein kinases was investigated by Yang and co-workers (1999). 
Only daphnetin was reported to be a protein kinase inhibitor. This compound inhibited tyrosine 
specific protein kinase, EGF-R and serine/threonine-specific protein kinases, including cAMP- 
dependent protein kinase (PKA) and protein kinase C in vitro. The structural comparison of daphnetin
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with coumarin and other coumarin derivatives suggests that the hydroxylation at C8 may be required 
for daphnetin to act as a protein tyrosine kinase inhibitor. Recently two new coumarin glycosides 
along with two known coumarin glycosides, daphnetin glucoside and daphnin were isolated from the 
aerial parts of Cruciata taurica. It is possible that these new compounds will have important clinical 
applications (De Rosa et al., 2002).
1.6.1.4.3. Scoparone
Scoparone (6,7-dimethoxycoumarin), is a known anti-asthmatic coumarin derivative extracted 
from the traditional Chinese herb Artemisia capillaries herba. Broncial asthma is a chronic 
inflammatory disease of the airways with obscure etiologies. It has been documented that elevations in 
intracellular calcium ion concentration is the main reason for contraction of the bronchi and increased 
sensitivity to bronchi sensitizers. Scoparone has been reported to directly reduce intracellular calcium 
ion concentrations in isolated guinea-pig tracheal smooth muscle. These in vivo and in vitro 
pharmacological experiments indicate that scoparone exerts strong anti-asthma action, along with both 
prophylactic and therapeutic properties for the treatment of asthma (Liu et al., 2002). In order to 
elucidate the clinical effects of scoparone, it is necessary to clarify its pharmacokinetics, especially 
species-specific differences in pharmacokinetics among various animal models, and then to compare 
this data to those from human studies. Therefore, the pharmacokinetics of scoparone was determined 
in rabbit plasma by HPLC. Distribution and elimination of this compound in rabbit plasma were both 
relatively rapid. These results indicate that scoparone could be easily administered by spray inhalers 
with few associated side effects expected (Fang et al., 2003).
in organ transplantation, the ischemic injury during cold preservation is a most challenging 
problem, especially in liver transplantation. Scoparone antioxidant effects can be utilised in cold- 
preserved hepatocytes where it is used as an additive to preservation solutions or as an agent given to 
the recipient to reduce ischemic injury (Cho et al., 2000). Scoparone has other important therapeutic 
properties which include its ability to act as a vasodilator on rat aortic rings precontracted with 
phenylephrine (Huang et al., 1992). It was reported to exhibit immunosuppressive effects on human 
peripheral blood mononuclear cells (IL-1, IL-2 production and IL-2 receptor expression were reduced 
in presence of scoparone). Immunosuppressive effect may be due to inhibition of protein tyrosine 
kinase and release of arachidonic acid metabolites. Differential oxidation of scoparone can be used as 
a sensitive indicator for distinguishing between different cytochrome P450 isoforms. Regioselective 7- 
demethylation of scoparone is regularly employed as an indicator of Phenobarbital-like induction of
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rat liver cytochrome P450 isoform CYP2B1, e.g. by the antiepileptic drug phenytoin (Meyer et al, 
2001).
1.6.1.4.4. Osthole
Osthole (7-methoxy-8-[3-methylpent-2-enyl] coumarin), is a coumarin compound isolated 
from medicinal plants, such as Cnidium monnieri and Angelica pubescens. It possess a variety of 
pharmacological and biochemical properties, and is considered to have potential therapeutic 
applications (Okamoto et al., 2003). It has both anti-inflammatoiy and analgesic activities and has 
been reported to inhibit platelet aggregation and suppresses thromboxane formation and breakdown of 
phosphoinositides (Wu et al, 2002). Osthole also exhibits vasorelaxant action by elevation of cGMP 
levels of vascular smooth muscle and inhibition of calcium influx (Ko et al, 1992; Tsai et al., 1996). 
It has also been reported to have an antiproliferative effect on vascular smooth muscle cells. The 
antiproliferative effect occurs at the early Gi phase of the cell cycle and is due to the increase in cyclic 
AMP and cyclic GMP contents. Abnormal VSMC proliferation is a major component of vascular 
disease, including atherosclerosis, vein graft occlusion and re-stenosis following angioplasty. An 
important therapeutic aim is to inhibit VSMC proliferation without interfering with endothelial repairs 
(Guh et al., 1996).
Fas ligand is a major inducer of apoptosis, and Fas-mediated apoptosis is involved in the 
development of various diseases such as hepatitis. Fas and Fas ligand are expressed in the livers of 
hepatitis C virus (HCV)-induced chronic hepatitis. This Fas system plays a major role in the 
development of apoptosis in virus-induced chronic hepatitis. Recently, it has been indicated that 
normalisation of alanine aminotransferase (ALT) prevents the development of hepatocellular 
carcinoma (HCC) in HCV-induced chronic hepatitis. Thus, inhibition of Fas-mediated liver injury 
leads to preventing the development of HCC in virus-induced hepatitis. The effect of osthole on 
hepatitis induced by anti-Fas antibody in mice was studied. Pretreatment of mice with osthole 
prevented the elevation of plasma ALT caused by anti-Fas antibody. The results indicated that osthole 
prevented anti-Fas antibody-induced hepatitis by inhibiting the Fas-mediated apoptotic pathway 
(Okamoto et al., 2003).
1.6.2. Applications o f the Furanocoumarins
As stated in Section 1.2. there are four main coumarin subtypes the simple coumarins, 
furanocoumarins, pyranocoumarins and pyrone-substituted coumarins. The furanocoumarins are a
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therapeutically important subtype as they have various significant clinical applications. The 
furanocoumarins consist of a 5-membered iuran ring attached to a benzene ring. Two of the most 
important and well known furanocoumarins are Psoralen (Linear) and Angelicin (Angular). The terms 
linear and angular refer to the orientation of the furan ring with respect to the coumarin nucleus 
(Keating & O’Kennedy, 1997).
The linear furanocoumarins (or psoralens) are naturally occurring plant biosynthetic 
metabolites that have been used since ancient times in skin photochemotherapy to treat a number of 
skin disorders including mycosis fungoides, psoriasis and vitiligo (Diawara el al., 1997). Most 
psoralens have strong absorption bands in the range 200-350 nm, with lower absorbances towards the 
visible region of the spectrum. Their planar aromatic structure and hydrophobic nature facilitate their 
intercalation with DNA bases. Purified 8-methoxypsoralen (8-MOP) has been used for over 50 years 
for treatment of vitiligo. It was determined that artificial long wavelength ultraviolet (UVA) radiation 
was the most efficient for activating 8-MOP. This photochemotherapy became known as PUVA 
(psoralen & UVA). The therapy met with unprecedented success from the outset, leaving little 
perceived need to understand the underlying science. However, in recent years there has been a new 
found interest in the basic aspects of psoralen photobiology and molecular mechanistic events 
contributing to therapeutic responses as well as to the development of skin cancers in PUVA patients 
(Bethea et al., 1999).
Psoralens have recently found application in the regulation of human cervical carcinoma cell 
proliferation in conjunction with anti-sense technology (Murakami et al., 2001). Oligonucleotides and 
their analogs have been used to inhibit protein biosynthesis by suppressing the gene expression in a 
sequence specific manner. The method is called antisense strategy and has been applied to gene 
therapy for incurable diseases such as cancers and viral infections. Among various reports regarding 
antisense technology, many have presented clear evidence that the antisense mechanism participated 
in the regulation of cell growth. Some of the antiproliferative effects of oligo(nucleoside 
phosphorothioate)s (S-oligo) may be attributed to the interaction of S-oligo with certain proteins such 
as growth factors. Upon UVA irradiation psoralen derivatives have the ability to crosslink covalently 
with pyrimidine bases (e.g. thymine and uracil). As psoralen derivatives can inactivate gene 
expression via cross-linking, they were conjugated with oligonucleotides to reinforce antisense effects. 
During in vitro experiments psoralen-conjugated S-oligos have shown resistance to nucleases and, 
therefore, have exhibited significant inhibitory effects upon UVA irradiation. Psoralen-conjugated S- 
oligos (Ps-S-oligo) were prepared and used to inhibit the proliferation of human cervical carcinoma 
cells. Upon UVA irradiation of Ps-S-oligo treated cells, Ps-S-oligo complementary to the initiation
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codon region (Ps-P-As) of human papillomavirus (HPV)18-E6*-mRNA of human cervical carcinoma 
cells significantly inhibited proliferation. The E6* protein is tightly correlated with the transformation 
of human cervical cells and, therefore, its suppression may regulate cellular proliferation. The 
psoralen-conjugated antisense DNA has significant potential to regulate gene expression, which may 
provide useful information to explore novel gene regulating agents (Murakami et al., 2001).
Angelicin is a naturally occurring furanocoumarin that shows anti-fungal activity. A broad 
range of opportunistic pathogenic fungi are making their appearance in the medical scene. Candida is 
now ranked at the third most common causative agent of blood stream infections in most hospitals. 
There are many anti-fungal compounds of plant origin. These compounds can be constitutive and are 
present in plant tissues most of the time or they can be induced so that they are produced only in 
special circumstances such as infection. Coumarins can be classified in the latter group. Anti-fungal 
activities of the synthesised coumarins and angelicin derivatives have been reported against Candida 
albicans, Cryptococcus neoformans, Saccharomyces cerevisiae and Aspergillus niger. The 
development of azoles has transformed the treatment of many fungal infections, however, treatment 
can often necessitate application of highly toxic drugs such as amphotericin B. Therefore, it is 
desirable to develop natural antifungals with low toxic side effects. Toxicity of several coumarins was 
evaluated against KB cells derived from human carcinoma of the nasopharynx. Angelicin and several 
potent antifungals were found to be non-toxic in this assay (Sardari et al., 1999).
Nitric oxide (NO) is synthesised from 1-arginine by constitutive and inducible nitric oxide 
synthase (cNOS and iNOS) in numerous mammalian cells and tissues. Inducible NOS is an important 
pharmaceutical target in inflammatory and mutagenesis research. Therefore, inhibition of NO 
production by iNOS may have potential therapeutic value when related to inflammation and septic 
shock. NO is known to cause mutagenesis and deamination of DNA bases, and to play an important 
role in the formation of carcinogenic N-nitroso compounds in vivo. Chronic inflammation of the colon 
increases the risk of colorectal cancer in rats. On the basis of this evidence, iNOS inhibition has 
become a new approach for cancer chemoprevention. Various naturally occurring furanocoumarins 
such as angelicin, pimpinellin and sphondin have shown iNOS inhibition in lipopolysaccharide- 
activated macrophage cells (Wang et al., 2000).
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1.6.3. Applications o f the Pyranocoumarins
Plant materials have a long histoiy of being successfully used in the treatment of cancer, both 
as chemotherapeutic agents and as complementary treatments. The pyrano-coumarin compound ( ± )-
3-angeloyl-4-acetoxy-cis-khel-lactone was isolated from Radix peucedani, a herb well-known for the 
treatment of respiratory diseases and pulmonary hypertension. Resistance of cancer cells to 
chemotherapeutic agents remains one of the major obstacles in achieving an effective treatment for 
cancer. The molecular mechanism of multi-drug resistance (MDR) in cancer cells may involve over­
expression of membrane drug efflux pumps, p53 mutations, and up-regulation of bcl-2, DNA repair or 
cellular detoxification enzymes. P-glycoprotein is over-expressed in various MDR cell lines and 
functions as an ATP-dependent drug efflux pump that rapidly extrudes anti-tumour drugs from target 
cancer cells, which prevents the drugs from exerting their cytotoxic effects. ( ± )-3-angeloyl-4- 
acetoxy-cis-khel-lactone is a P-glycoprotein inhibitor and studies were recently performed to 
determine its effect on MDR cell lines. Work by Wu and co-workers (2003) demonstrated that this 
pyranocoumarin causes apoptotic cell death for drug sensitive KB-3-1 and multidrug resistant KB-V1 
cancer cell lines. Strong synergistic interactions were demonstrated when the pyranocoumarin was 
combined with common anti-tumour drugs such as vincristine, doxorubicin and paclitaxel. The results 
suggest that pyranocoumarins could be a potential MDR reversing agent (Wu et al., 2003). Some 
pyranocoumarins isolated from Calaphyllum species have been shown to inhibit HI V-l replication and 
cytopathicity through their interaction with HIV-1 reverse transcriptase. Pyranocoumarins may 
provide a new class of anti-HIV compounds (Dharmaratne et al., 1998).
1.6.4. Applications o f Other Coumarin Derivatives
Synthesis of many 4-(aryloxymethyl) coumarins and 3-heteroaryl-coumarins as anti-microbial 
and anti-inflammatory agents were recently reported by Ghate and colleagues (2003). Vanillins have 
been found to exhibit anti-microbial properties. It was therefore, of interest to react 4-(bromomethyl)- 
coumarins with vanillins to obtain the corresponding ethers. The ethers were then converted to the 
corresponding 4-(2-benzo[b]-furanyl) coumarins by intramolecular aldol condensation. Eight 
compounds were screened for their anti-inflammatoiy activity. 5,6-benzo-4,2-benzo[b]-furanyl 
coumarin was the most active anti-inflammatory compound among those tested (Ghate et al., 2003).
Serine proteases play an important role in numerous physiological processes and are also 
involved in pathological states. Among these proteases, human leukocyte elastase (HLE) has the 
ability to degrade various structural proteins and has been implicated as a causative factor in
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emphysema, chronic bronchitis, acute respiratory distress syndrome, cystic fibrosis and arthritis. 
Thrombosis is one of the leading single cause of morbidity and mortality in developed countries. The 
most widely studied target for antithrombotic intervention has been the serine protease thrombin. A 
new series of coumarins have been developed which target serine proteases such as HLE and 
thrombin. 6-Chloromethylcoumarin derivatives are known serine protease inhibitors. Mass 
spectrometry was used to confirm a previously postulated inhibition mechanism for these coumarin 
derivatives. The results demonstrated that the serine protease inhibition resulted from a nucleophilic 
attack on the intracyclic carbonyl group (Pochet et al., 2003).
The 4-(l-piperazinyl)coumarins were evaluated in vitro to determine their inhibitory 
properties towards human platelet aggregation induced in platelet-rich plasma by ADP, collagen or the 
calcium ionophore A23187. The results indicated that these coumarin derivatives showed high activity 
as in vitro anti-platelet agents (Roma et al., 2003).
Atherosclerotic cardiovascular disease is the leading cause of death in developed countries. 
Current therapies mostly focus on lowering LDL-cholesteroI (a risk factor) and statins used for this 
purpose are quite effective and safe. However, most patients still experience adverse coronary events 
despite statin therapy. Coumarins are known to have anti-oxidant potential and it was demonstrated 
that a 2-ethoxy-3-propanoic acid coumarin derivative can lower blood glucose levels in animal 
models. Coumarin derivatives of different heterocycles were designed based on cyclisation of 2- 
ethoxy-3-phenylpropanoic acid and 2-benzylmalonic acid as novel lipid-lowering agents and their 
preliminary in vivo screening indicates one of the novel coumarin derivatives has moderate 
triglyceride-lowering activity (Madhavan et al., 2003).
1.7. Pyrone-Substituted Coumarins: Warfarin
The previous sections in this introduction deal with the simple coumarins, pyranocoumarins 
and furanocoumarins. However, a significant amount of work was carried out on warfarin, a pyrone- 
substituted coumarin (Chapter 3 & 5). It has anti-coagulant properties, which will be described 
separately from the other coumarins.
1.7.1. Introduction to Warfarin
The emergence of warfarin as a drug of therapeutic potential can be attributed to the work of
Karl Paul Link and his team at the University of Wisconsin during the late 1930's and early 1940's.
29
Previous to their work observations by Schofield in Canada and Roderick in North Dakota indicated 
that a haemorrhagic disorder affecting cattle was caused by the consumption of spoiled sweet clover 
hay from the Melitotus alba or the M. officinalis family.
When sweet clover hay spoils in the curing process it is easy for it to become contaminated 
with moulds because of its succulent stems. Pénicillium nigricans, P.jensi and Aspergillus metabolise 
coumarin present into dicoumarol. In 1933 work began in the laboratory of K.P. Link to isolate the 
unknown agent causing the disease in cattle. After extensive research, an elaborate extraction scheme 
was developed whereby the anti-coagulant was crystallised by Campbell in 1939 and identified by 
Heubner as 3,3'-inethylbis-4-hydroxycoumarin or dicoumarol (Figure 1.5.). More than 100 related 
structural compounds of dicoumarol were synthesised in order to find the portion that contains the 
highest anti-coagulant potency.
Figure 1.5: Structure o f Dicoumarol (3,3'-methylenebis-4-hydroxycoumarin)
Work of Stahmann concluded that the minimal structural requirements for anti-coagulant 
activity were an intact 4-hydroxycoumarin residue with the 3-position substituted by a carbon residue 
or H-atom, whilst maximum anti-coagulant activity requires 4-hydroxycoumarin with the 3-position 
containing a keto group in a 1,5-spatial relationship with respect to the 4-hydroxycoumarin group. 
Warfarin (3-[acetonylbenzyl]-4-hydroxycoumarin) was subsequently synthesised by Ikawa in 1944, 
with the name warfarin arising out as a combination of the letters from Wisconsin Alumni Research 
Foundation and coumarin (Figure 1.6.).
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oFigure 1.6: Structure o f Warfarin (3-(a-acetonylbenzyl)-4-hydroxycoumarin)
1.7.2. Pharmacology o f Warfarin
1.7.2.1. Mechanism o f  Action o f  Coumarin Anticoagulant Drugs
Warfarin, a coumarin derivative, produces an anticoagulant effect by interfering with the 
cyclic interconversion of vitamin K and its 2,3 epoxide (vitamin K epoxide). Vitamin K is a cofactor 
for the carboxylation of glutamate residues (Glu) to y-carboxyglutamate (Gla) on the N-terminal 
regions of vitamin K-dependent proteins in the presence of vitamin K and molecular oxygen. These 
proteins, which include the coagulation factors II, VII, IX, and X, require y-carboxylation by the 
vitamin K conversion cycle. Warfarin induces hepatic production of partially decarboxylated proteins 
with reduced coagulant activity (Hirsh et al., 2003). The epoxidation reaction occurs in conjuction 
with the carboxylase reaction, where the active form of vitamin K is converted to vitamin K 2,3- 
epoxide, which is in turn converted back to the quinone form by vitamin K] epoxide reductase to 
complete the vitamin K cycle (Suttie, 1993). Due to the fact warfarin does not affect the activity of 
previously synthesised and circulating coagulation factors, depletion of these mature factors through 
normal catabolism must occur before the anticoagulant effects of warfarin are observed. Each factor 
varies in its degradation half-life (Table 1.3.), and this results in the requirement of 3-4 days therapy 
before a complete response to warfarin is observed. Warfarin is completely absorbed after oral 
administration and then is highly bound to albumin in the plasma. An inverse relation between the 
albumin and free warfarin levels is one reason why postoperative or acutely ill patients require lower 
doses of warfarin (Gage et al., 2000). Warfarin also interferes with the carboxylation of Gla proteins 
synthesised in bone. Although these effects contribute to foetal bone abnormalities when mothers are
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treated with warfarin during pregnancy, there is no evidence that warfarin directly affects bone 
metabolism when administered to children or adults (Hirsh et al., 2003).
Table 1.3: Degradation half-lives o f both coagulation and anti-coagulation factors.
Coagulation/Anticoagulation Factors Degradation Half-Life (Hrs)
Coagulation Factor II 60
Coagulation Factor VII 4-6
Coagulation Factor IX 24
Coagulation Factor X 48-72
Anticoagulant Protein C 8
Anticoagulant Protein S 30
1.7.2.2. Vitamin K  Cycle
A combination of dietaiy intake and microbiological synthesis in the gut provides the vitamin 
K requirement of mammals and phylloquinone is the most active source to meet the vitamin K 
requirements in humans. O’Reilly (1976) outlined the major factors necessary to prevent vitamin K 
deficiency as: (a) normal dietary intake of the vitamin (b) the presence of bile in the intestine (c) a 
normal absorptive surface in the liver and (d) a normal liver.
The direct link between vitamin K and blood coagulation was first established by Heinrik 
Dam whilst studying the dietary effects of chickens fed a ‘lipid-free’ diet. Dam (1929) discovered that 
the blood of chickens maintained on such a diet was devoid of clotting activity. However, when 
cereals were replaced back into the diet, the coagulation status of the chickens returned to normal. 
Vitamin K (phylloquinone, 2-methyl-3-phythyl-l,4-naphtoquinone) was identified as the agent 
necessary to cure the clotting defect in the chickens. The haemorrhagic condition was initially 
believed to be solely due to the depletion of the concentration of prothrombin (factor II). However, it 
was later discovered that the levels of factors VII, IX and X were also depleted and these proteins 
subsequently became known as the Vitamin K-dependent clotting factors (Suttie, 1993). A unique 
feature of the vitamin K-dependent proteins is the y-carboxyglutamate residues (Gla) formed during 
post-translational modification of these proteins (Section 1.7.2.1. and Figure 1.4).
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1.7.2.3. Vitamin K-dependent Carboxylase
The enzyme responsible for the post-translational modification of the glutamic residues on 
precursor clotting factors to y-carboxyglutamate residues, necessary for the clotting ability of clotting 
factors is the vitamin K-dependent carboxylase (Berkner, 2000). The carboxylation reaction requires 
molecular oxygen, carbon dioxide and vitamin K as a cofactor. The hydroquinone form of vitamin K 
(vitamin KH2) is reduced to the epoxide form of the vitamin (vitamin K 2,3-epoxide) in conjunction 
with the carboxylation reaction. Vitamin K 2,3-epoxide is then recycled to the quinone form of the 
vitamin by a vitamin K-epoxide reductase. Elevated levels of the epoxide form of the vitamin can be 
found in the plasma of orally anticoagulated patients (Nakamura et al., 1994). The quinone form of the 
vitamin is subsequently reduced back to the hydroquinone form of the vitamin by a vitamin K 
reductase (Figure 1.7.) to complete the vitamin K cycle.
Oral anticoagulants exert their anticoagulant effect by inhibiting the cyclic inter-conversion of 
vitamin K, by inhibition of the epoxide- and vitamin K-reductases leading to a depletion of the 
hydroquinone (i.e. active) form of the vitamin. By inhibiting this regeneration of the epoxide form of 
the vitamin back to the hydroquinone form, partially carboxylated forms of the vitamin K-dependent 
clotting factors of varying Gla content are secreted; and pools of these partially carboxylated forms of 
prothrombin have been isolated and studied (Malhotra et al., 1981; 1985; Takamiya & Yoshioka,
1996). A decrease in the number of Gla residues on the prothrombin molecule from 10 to 9 was found 
to result in a 30% decrease in coagulant activity, whilst a decrease to below 6 Gla residues reduces the 
coagulant activity by almost 95%.
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Figure 1.7: The vitamin K cycle and its link to carboxylation o f glutamate residues on vitamin In­
dependent coagulation proteins. Vitamin K obtained from food sources is reduced to vitamin KH2 by a 
warfarin-resistant vitamin K reductase. Vitamin KH2 is then oxidised to vitamin K epoxide (vitamin 
KO) in a reaction that is coupled to carboxylation o f glutamic acid residues on coagulation factors. 
This carboxylation step renders the coagulation factors II, VII, IX  and X  and the anticoagulant factors 
protein C and S functionally active. Vitamin KO is then reduced to vitamin K in a reaction catalysed 
by vitamin KO reductase. By inhibiting vitamin KO reductase, warfarin blocks the formation o f 
vitamin K and vitamin KH2, thereby removing the substrate (vitamin KH2) for the carboxylation of 
glutamic acids.
1.7.3. Pharmacokinetics and Pharmacodynamics o f Warfarin
Warfarin is a widely prescribed oral anticoagulant which is available in the form of a racemic 
mixture consisting of equal amounts of R-and S-warfarin (Figure 1.8.) and displays both 
stereoselective metabolism and pharmacologic potency. The asymmetric carbon at position 9 of 
warfarin gives rise to these two entantiomers which are differentially metabolised, a process termed 
stereoselective metabolism. Different forms of P450 enzymes (Section 1.7.3.3.) catalyse metabolism 
of warfarin at different sites, and this process is referred to as regioselective metabolism (Kaminsky & 
Zhang, 1997). The S-enantiomer of warfarin is approximately three to five times as potent as the R- 
enantiomer and has a shorter half-life of elimination. Enantiomers have the same chemical 
composition, but are mirror images of each other. Both enantiomers are extensively metabolised in the 
body, and their metabolism involves highly stereospecific pathways catalysed by the cytochrome P450 
system (Gage et al., 2000; Linder, 2001; Zhou & Chan, 2002).
The relationship between the dose of warfarin and the response is influenced by genetic and 
environmental factors, including common mutations in the gene coding for cytochrome P450 the 
hepatic enzyme responsible for oxidative metabolism of the warfarin S-isomer. Several genetic 
polymorphisms in this enzyme have been described that are associated with lower dose requirements 
and higher bleeding complication rates compared with the wild-type enzyme CYP2C9* (Hirsh et al., 
2003). The pharmacodynamic effect of warfarin is measured using the prothrombin time or the INR. 
The INR is calculated by dividing the patient’s prothrombin time by the mean of the normal 
prothrombin time and then raising this ratio to an exponent, the international sensitivity index. That 
index reflects the sensitivity of the thromboplastin reagent to warfarin-induced changes in the levels of 
the clotting factors (Gage et al., 2000).
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1.7.3.1. Absorption
Warfarin is rapidly absorbed from the gastrointestinal tract, has high bioavailablilty, and 
reaches maximal blood concentrations in healthy volunteers 90 minutes after oral administration. 
Racemic warfarin has a half-life of 36-42 hours, circulates bound to plasma proteins (mainly albumin), 
and accumulates in the liver, where the 2  enantiomers are metabolically transformed by different 
pathways.
1.7.3.2. Distribution & Protein Binding
Following absorption the drug is highly protein bound (>99%), leaving only a small portion of 
free active drug circulating in the plasma (Table 1.4.). The binding of warfarin and its analogues to 
human serum albumin have been extensively studied (Ferrer etal. 1998; Bertucci et al., 1999; Dockal 
et al., 1999). Human serum albumin is composed of three structurally similar globular domains, HSA 
I, HSA II and HSA III (Dockal et al., 1999). The primary warfarin-binding site was found to be 
located on domain II with a secondary binding site was found on domain I. Bertucci et al. (1999) 
demonstrated that the (S)-enantiomer has a higher affinity for HSA using competitive displacement 
studies. This high degree of protein binding predisposes warfarin to a range of possible drug 
interactions, which can have a dramatic effect on the degree of anticoagulation achieved (Section
1.7.5.). A recent study investigated the effect of familial dysalbuminemic hyperthyroxinemia (FDH) 
on warfarin pharmacokinetics. Warfarin was selected as a model compound to study FDH human 
serum albumin (HSA)/drug interactions since it binds to the HSA subdomain IIA and its 
pharmacokinetics are significantly influenced by HSA binding. The findings of this study indicated 
that FDH patients had elevated serum free warfarin concentrations which resulted in about a 5-fold 
reduction in the serum half-life of the drug (Petersen et al., 2000).
36
Table 1.4: Extent o f Plasma protein Binding and Plasma Half-Life
Oral Anticoagulant Plasma Half-life (ti/2) (hrs) Protein Binding (%)
R-Warfarin 35-58 99
S-Warfarin 24-33 99
R-Acenocoumarol 8 - 1 0 99
S-Acenocoumarol 0.5-1.0 99
Phenprocoumon 72-120 99
Dicoumarol 24-96 99
Ethyl biscoumate 2-5 90
1.7.3.3. Warfarin Metabolism
Inter-patient variability in warfarin sensitivity appears to be linked to inherited differences in 
metabolic capacity (Loebstein et al., 2001; Tabrizi et al., 2002). Warfarin is essentially catalysed by a 
series of Cytochrome P450 enzymes to a series of hydroxylated metabolites (Kaminsky & Zhang,
1997). A series of carbonyl reductases in the endoplasmic reticulum and cytosol reduce the carbonyl 
side chain to yield diastereomeric alcohols (Herman & Thijssen, 1989) (Figure 1.9). The S enantiomer 
(possessing the predominant anticoagulant effect) is oxidised by a cytochrome P450 enzyme in the 
liver (CYP2C9) and then excreted in the bile, while the R enantiomer is metabolised by a different 
enzyme to an inactive alcohol that is excreted in the urine. Both enantiomers block the regeneration of 
the reduced form of vitamin K. By interfering with the vitamin K-dependent carboxylation of 
glutamate residues on the procoagulant forms of the clotting factors, warfarin inhibits the formation of 
several functional clotting factors (II, VII, Ix, and X) (Gage etal., 2000).
The principal metabolism of warfarin in humans is catalysed by a variety of cytochromes 
P450 (P450 or CYP specific forms) to a series of monohydroxylated metabolites. The P450 enzymes 
belonging to the CYP2C subfamily have been shown to constitute the major forms of P450 in 
mammalian livers and play important roles in the oxidation of clinically used drugs. CYP2C9 is one of 
the major CYP2C gene products that catalyses oxidation of a variety of clinically used drugs such as 
torsemide, diazepam and warfarin in human liver microsomes. In vitro experiments have shown that 
the formation of the two main metabolites of S-warfarin, S-7-hydroxywarfarin and S-6 - 
hydroxywarfarin, is catalysed primarily by CYP2C9 (Ragueneau-Majlessi et al, 2001), whereas R- 
warfarin 7-hydroxylation appears to be catalysed by several P450 enzymes such as CYP1A2 and 
CYP3A4. (Kaminsky & Zhang, 1997; Yamazaki & Shimada, 1997).
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Early studies involving warfarin metabolism identified the hydroxywarfarins, namely 6 - and 
7-hydroxywarfarin, and the warfarin diastereomeric alcohols, as the primary metabolites of warfarin 
(Lewis & Trager, 1970). Studies using human microsomes and recombinant P450’s have extensively 
probed the regio- and stereoselectivity of warfarin (Takahashi etal., 1997). Zhang etal. (1995) probed 
the (R)- warfarin metabolism using two isozymes (CYP4501A1 and CYP4501A2), and found that 
(R)- warfarin 6 -hydroxylation rates could be used as markers of hepatic P4501A2, whilst 6 - 
hydroxylation/8 -hydroxylation rates could be used as markers for P4501A1. These particular isozymes 
were shown to be of particular importance because of their ability to bioactivate chemical carcinogens. 
The predominant human P450 catalysing S-warfarin metabolism is CYP2C9. Since this P450 also 
catalyses the metabolism for numerous drugs, the potential for warfarin-drug interactions is substantial 
(Section 1.7.5.). Both CYP1A2 and CYP3A4 are the major contributors to R-warfarin metabolism. 
Like CYP2C9, both of these enzymes catalyse the metabolism of various drugs. Therefore, there is a 
potential for R-warfarin and drug interactions (Kaminsky & Zhang, 1997).
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Figure 1.9: Main metabolic pathways o f warfarin in humans
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1.7.3.3.1. Genetic Variability
A high affinity hepatic S-warfarin 7-hydroxylase ascribed to cytochrome P4502C9 is 
responsible for both regioselective and stereoselective metabolism of S-warfarin. The cytochrome 
P4502C9 is encoded by the CYP2C9 gene. This gene exhibits structural polymorphism leading to two 
gene variants (alleles) which encode qualitatively different proteins with differing catalytic activities 
with respect to the 7-hydroxylation of S-warfarin. Studies performed to date strongly support a role for 
CYP2C9 polymorphism in the etiology of warfarin hypersensitivity. More in depth studies which 
include identification of all relevant CYP2C9 alleles and ratios are needed to strengthen the 
relationship between CYP2C9 genetics and warfarin maintenance dose requirements (Linder, 2001).
A recent study investigated population differences in the metabolic activity of cytochrome 
P450 (CYP) 2C9 between genotypically matched Caucasian and Japanese patients by using the 
unbound oral clearance of S-warfarin as an in vivo phenotypic trait measure. The findings of this study 
indicate that population differences in the frequencies of known variant CYP2C9 alleles account only 
in part for the variability observed in in vivo CYP2C9 activity in different populations. CYP2C9 
genetic polymorphisms (e.g. allelic variants 2C9*2 and 2C9*3) markedly influence warfarin dose 
requirements and metabolic clearance of the S-warfarin enantiomer, although nongenetic factors may 
also contribute to their large interindividual variability (Scordo et al., 2002). Further studies are 
required to identify currently unknown factors (e.g. transcriptional regulation) responsible for the large 
intrapopulation and interpopulation variability in CYP2C9 activity (Loebstein et al., 2001; Takahashi 
et al., 2003). CYP2C9 appears to be the predominant route of warfarin elimination, but alternative 
metabolic pathways and other genetic variants may potentially influence the response to warfarin 
therapy. Polymorphisms of the CYP2C9 subfamily are common, are associated with significant 
reductions in warfarin dose and may partially account for inter-patient variability in warfarin 
sensitivity. When interactions between genetic factors and other variables that influence warfarin 
effect are more completely understood, CYP analysis may prove useful for guiding warfarin 
prescription, particularly at the onset of therapy (Tabrizi et al, 2002).
1.7.3.4. Excretion
Elimination of warfarin is primarily related to alterations in the degree of drug-protein 
binding, which affects the plasma concentration of circulating free drug available for metabolism. The 
major metabolites of warfarin (6 - and 7-hydroxywarfarin) and the two diasteromeric warfarin alcohols 
are eliminated in the urine with less than 2 % of the administered dose excreted as warfarin. The rate
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of elimination shows high interindividual variability with plasma half-lives ranging from 20-60 hours 
(Palaretti & Legnani, 1996).
1.7.4. Warfarin Resistance
Resistance to warfarin has been defined as: “the inability of Oral Anticoagulant Therapy 
(OAT) to bring the Prothrombin Time (PT) down to adequate levels of anticoagulation when 
administered at a dose near or equivalent to the normally recommended doses” (LeFrere et ah, 1987). 
In order to simplify understanding of warfarin resistance in this section, it shall be described as either 
hereditary resistance (HR), or acquired resistance (AR).
1.7.4.1. Hereditary Resistance
Hereditary resistance is believed to be caused by an abnormal receptor with an increased 
affinity for vitamin K and a reduced affinity for the coumarins. This form of resistance was first 
described over 30 years ago with the inability of patient to attain the desired degree of anticoagulation 
even with greater than 20 times the normal therapeutic concentration (O' Reilly, 1964). Other family 
members were tested and their response was similar to that of the patient. It was postulated then (O’ 
Reilly, 1964), that HR is an autosomal dominant characteristic. Warrier and coworkers (1986) 
reported that the resistance was not absolute and could be overcome with large doses of the drug, 
suggesting an altered affinity of the enzyme or hepatic receptor for warfarin.
Two potential forms of hereditaiy warfarin resistance were reported in man. One mechanism 
appears to be a pharmacokinetic mechanism where the clearance of (S)-warfarin was increased 4-fold 
compared to control subjects. A second mechanism for hereditaiy warfarin resistance appears to be 
dependent upon pharmacodynamic mechanism of the drug action. This form of resistance is 
characterised by the relatively high doses of warfarin required to achieve therapeutic effect, normal 
warfarin pharmacokinetics, extremely high warfarin concentrations in blood, normal concentrations 
and half-lives of blood clotting proteins and the pattern of inheritance that of a monogenetic dominant 
trait. Although a considerable amount of progress was made in identifying genetic mechanisms 
contributing to variability in the response to warfarin, several questions remain to be answered in 
order to raise the level of knowledge to the point where this information can be routinely applied to 
patient care (Linder, 2001).
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/. 7.4.2. Acquired Resistance
Several cases of warfarin resistance associated with intra-venous lipid administration have 
also been documented (Lutomski et al., 1987; MacLaren et al., 1997). The use of heparin therapy was 
recommended for patients receiving lipid emulsions in order to overcome this complication. The 
precise mechanism of this particular interaction is not fully understood and was suggested to be due to 
enhanced binding of warfarin to albumin, or a result of enhanced clotting factor production.
The literature contains one report of warfarin resistance in a patient due to malabsorption 
(Talstad et al., 1994). The case study involves a patient who after two years of satisfactory 
anti coagulation therapy with warfarin experienced selective malabsorption of warfarin. At this stage of 
warfarin therapy the dosage required was now 5 times the initial prescribed dosage. The reported 
malabsorption was not due to drug interactions or gastrointestinal disease. Enhanced clearance of 
warfarin has been reported and found to be due to an intrinsically high oral clearance of the more 
active S enantiomer (Hallak et al., 1993).
Chu et al. (1996) described the first reported naturally occurring mutation in the propeptide 
sequence of Factor IX that directly affects the carboxylation by y-glutamyl carboxylase. A patient 
whose PT was in the desired therapeutic range was admitted to hospital with bleeding complications. 
It was subsequently found that the patients Factor IX activity was <1% on warfarin therapy, but 
returned to normal levels when warfarin therapy was terminated. A mutation predicting a substitution 
of an Ala- residue to a Thr-residue at position 10 in the pro-peptide region of Factor IX was found. 
Ala-residues at position 10 in vitamin K-dependent proteins are highly conserved and, therefore, likely 
to be important in the binding of the carboxylase for y-carboxylation. This in turn results in a reduced 
affinity of the carboxylase for the Factor IX precursor and demonstrates a previously unreported 
mechanism of warfarin ‘sensitivity’. Bentley et al. (1986) produced a dosage-algorithm from a study 
of well-controlled patients, in order to aid the physician in the diagnosis of patients with an abnormal 
response to warfarin. The study provides two algorithms that can help the physician identify the 
causes of the abnormal warfarin response and dose accordingly.
1 .7.5. Drug Interactions
Many potentially fatal diseases can be completely cured by modem treatments. However, the 
number of patients suffering from particular chronic diseases has been increasing (Makino et al., 
2001). The potential for pharmacokinetic drug interactions is of concern with any new drag,
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particularly if given for chronic diseases such as epilepsy and cardiovascular conditions, as patients 
are likely to receive concomitant therapy for other underlying disorders. Since modem drugs do not 
cure chronic diseases but prevent further deterioration associated with them, patients must take drugs 
for extended periods of time. This increases the chances of interaction with other drugs as shown in 
Table 1.5.
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Table 1.5: Drug Interactions. List o f drugs that either inhibit the metabolism o f warfarin 
(i.e. increase the warfarin effect) or induce the metabolism o f warfarin (i.e. decrease the 
warfarin effect).
Increase in Warfarin Effect Decrease in Warfarin Effect
CNS DRUGS • Tricyclic CNS DRUGS •  barbiturates
antidepressants •  carbamazepine
(TCAs) •  phenytoin
• Selective
serotonin reuptake
inhibitors (SSRIs)
AN TIBACTE RIALS • cotrimoxazole ANTIBACTERIALS •  rifampicin
• isoniazid
• metronidazole
ANTI­ • indinavir ALCOHOLS •  ethanol
RETROVIRALS • ritonavir
• saquinavir
CARDIOVASCULAR • amiodarone
• quinidine
• verapamil
ANTIFUNGALS • miconazole
• fluconazole
• itraconazole
ANTILIPIDAEMICS • clofibrate
• gemfibrozil
• statins
GASTRO­ • cimetidine
INTESTINAL • omeprazole
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The anticoagulant response to warfarin is influenced both by pharmacokinetic factors, 
including drug interactions that affect its absorption or metabolic clearance, and by pharmacodynamic 
factors, which alter the haemostatic response to given concentrations of the drugs. Other drugs may 
influence the pharmacokinetics of warfarin by reducing the gastrointestinal absorption or disrupting 
metabolic clearance. For example, the anticoagulant effect of warfarin is reduced by cholestyramine, 
which impairs its absorption, and is potentiated by drugs that inhibit warfarin clearance. Inhibition of 
S-warfarin metabolism is more important clinically because this enantiomer is 3-5 times more potent 
than the R-isomer as a vitamin K antagonist. Phenylbutazone, sulfinpyrazone, metronidazole, and 
trimethoprim-sulfamethoxazole inhibit clearance of S-warfarin, and each potentiates the effect the 
effect of warfarin on the prothrombin time. In contrast, drugs such as cimetidine and omperazole, 
which inhibit clearance of the R-isomer, potentiate the PT only modestly in patients treated with 
warfarin. Amiodarone inhibits the metabolic clearance of both S- and R-enantiomers and potentiates 
warfarin anticoagulation. Drugs such as aspirin, NSAIDs, penicillins (in high doses), and moxolactam 
increase the risk of warfarin-associated bleeding by inhibiting platelet function. Of these aspirin is the 
most important because of its widespread use and prolonged effect. Aspirin and NSAIDs can produce 
gastric erosions that increase the risk of upper gastrointestinal bleeding.
The anticoagulant effect is inhibited by drugs like barbiturates, carbamazepine and rifampicin, 
which increase hepatic clearance. Chronic alcohol consumption has a similar potential to increase the 
clearance of warfarin, but ingestion of even relatively large amounts of wine has little influence on PT 
in subjects treated with warfarin.
With the increasing use of orally active fluropyrimidine prodrugs such as capecitabine and 5- 
Fluorouracil (5-FU) in the treatment of colorectal, breast and other cancers, the potential for drug 
interactions will increase. 5-FU is a pyramidine analog that is widely used in the treatment of a variety 
of solid tumours. The cytotoxicity of 5-FU is mainly attributed to the formation of fluoro- 
deoxyuridine-monophosphate that inhibits thymidylate synthetase, as well as to the incorporation of 
the drug into ribonucleic acid. It was postulated that 5-FU interferes with the synthesis of hepatic 
cytochrome CYP2C9, leading to impaired metabolism of warfarin (Zhou & Chan, 2002). Capecitabine 
is an oral prodrug of 5-FU and hence it is likely that the interaction with warfarin occurs by the same 
mechanism. Interacting drugs affecting the metabolism of warfarin in a stereoselective manner could 
result in marked differences in modifying the anticoagulant response to warfarin (Buyck et al., 2003).
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1.7.6. Monitoring Anticoagulant Therapy
1.7.6.1. Protrombin Time and INR
The start of anti-coagulant treatment is a critical period, as the hemorrhagic risk lies mainly in 
the induction phase. Warfarin has a narrow therapeutic index, so even a modest change in dose- 
response can lead to either thrombosis or haemorrhage. There is a great inter- and intraindividual 
pharmacokinetic and pharmacodynamic variability. It is therefore, difficult to predict the correct 
induction dose and obtain a more rapid and accurate individualisation of the dose of warfarin (Bertola 
et al, 2003). The risk of bleeding with warfarin can be markedly reduced without affecting efficacy by 
using a low intensity therapeutic range. The prothrombin time (PT) assay is the most common test 
used to monitor oral anticoagulant therapy. The PT responds to reduction of 3 of the 4 vitamin In­
dependent procoagulant clotting factors (II, VII, and X) that are reduced by warfarin at a rate 
proportionate to their respective half-lives (Table 1.3.).
The PT assay is performed by adding a mixture of calcium and thromboplastin to citrated 
plasma. The term “thromboplastin” refers to a tissue factor/phospholipid-containing extract, usually 
from brain, lung, or placenta, which promotes the activation of factor X by factor VII. Warfarin- 
induced responsiveness of a given thromboplastin to reduction in clotting factors reflects its potential 
for factor X activation. A responsive or sensitive thromboplastin produces a greater prolongation of 
the PT for a given reduction in the plasma concentrations of these factors (Hirsh, 1995). Thus, during 
the first few days of warfarin therapy, the PT reflects mainly the reduction of factor VU, the half-life 
of which is ~ 6  hours. Subsequently, reduction of factors X and II contributes to prolongation of the 
PT. PT monitoring of warfarin treatment is veiy imprecise when expressed as a PT ratio (calculated as 
a simple ratio of the patient’s plasma value over that of normal control plasma) because 
thromboplastins can vary markedly in their responsiveness to warfarin (Hirsh et al., 2003).
It was noticed that the PT would vary from laboratory to laboratory and even with the same 
analyser from time to time. The problem was traced to varying sensitivities of the materials used to 
perform the test. A mathematical formula was devised to take this variance into account (Table 1.6.). 
This is called the International Normalized Ratio or INR. If the patient INR is in the desired range 
there is a greater chance of avoiding a clot with the least chance of developing major bleeding. Major 
bleeding is usually defined as needing two units of blood or more. However, it is not a veiy good 
predictor of who will have minor bleeding. It measures clotting time, so it is not a good indicator of 
some other factors in the blood. The INR calibration model, adopted in 1982, is now used to
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standardise reporting by converting the PT ratio measured with the local thromboplastin into an INR 
calculated as follows:
INR = (patient PT/mean normal PT) IS1
Log INR = ISI(log observed PT ratio),
Where ISI denotes the International Sensitivity Index of the thromboplastin used at the local 
laboratory to perform the PT measurement. The ISI reflects the responsiveness of a given 
thromboplastin to reduction of the vitamin K-dependent coagulation factors. The more responsive the 
reagent, the lower the ISI value (Hirsh et al., 2003). In a patient who is starting warfarin for the first 
time, no demographic or clinical information reliably predicts the steady-state dose that will achieve a 
given INR. The mean steady-state dose is 4 to 5 mg per day, but warfarin doses range from 0.5 to 
more than 50 mg per day (Gage et al., 2000).
Table 1.6: Recommended International Normalised Ratios (INRs) for various thromboembolic 
conditions.
INDICATION PT RATIO RECOMMENDED INR
Acute Myocardial Infarction 1.3-1.5 2.0-3.0
Atrial Fibrillation 1.3-1.5 2.0-3.0
PE Treatment 1.3-1.5 2.0-3.0
Mechanical Prosthetic Valves 1 .5-2.0 3.0-4.5
Venous Thrombosis 1.3-1.5 2.0-3.0
Tissue Heart Valves 1.3-1.5 2.0-3.0
Valvular Heart Disease 1.3-1.5 2.0-3.0
Systemic embolism prevention 1.3-1.5 2.0-3.0
It takes an average of almost 2 weeks to achieve a steady-state INR response. This long delay 
arises from warfarin’s long half-life of accumulation, the time required for functional clotting factors 
to fall to low levels, and the time required to establish the correct daily dose empirically (Gage et al.,
2000). Information concerning patient sensitivity during the first 24 h of treatment could allow the 
practitioner to adapt the dose according to the patient’s individual requirement as early as the second 
intake of warfarin. This early adaptation will improve the monitoring of oral anticoagulation in elderly
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patients by reducing the risk of over or under anticoagulation and by shortening the time required to 
reach the correct maintenance dosage.
1.7.6.2. Warfarin-The ‘ReboundPhenomena’
The expression ‘rebound-phenomena’ is used to describe a hypercoagulable state that exists 
following withdrawal of warfarin treatment. The first reported effects of ‘rebound phenomenon’ in 
patients following cessation of warfarin treatment was reported by Cosgriff & Stuart (1953). 
Withdrawal of warfarin therapy commonly results in the low-grade activation of the coagulation 
system, although the degree of activation is transient in most cases. However, higher levels of 
activation were observed for certain individuals predisposing them to an increased incidence of 
thrombotic complications (Palaretti & Legnani, 1996).
Two theories may explain the nature of the increased levels of blood coagulation and 
thrombin generation following warfarin withdrawal. The first explanation is that the reduced 
prothrombin levels during warfarin therapy balance the levels of increased coagulation, and when 
anticoagulant therapy is withdrawn the activation of coagulation is no longer ‘counterbalanced’ by the 
oral anticoagulant effect. This ‘catching up’ effect of the procoagulant factors was first described by 
Wright (1960) and later by Hirsh (1982). The second explanation describes how an actual ‘rebound 
phenomena’ may actually occur following cessation of warfarin therapy. The levels of Factor VII (has 
a role in thrombotic events) and Factor IX showed recovery times of 2 days (Schofield et al., 1987). 
The return to normal levels of the anticoagulant proteins C and S was slower creating an imbalance 
between pro- and anticoagulant factors which may lead to activation of blood coagulation (Palaretti 
and Legnani, 1996). It was shown that the degree of hypercoagulability is more marked when 
discontinuation of warfarin is immediate rather than gradual. When anticoagulants are phased out 
gradually, the differences between the procoagulant and anticoagulant proteins are less marked 
reducing the likelihood of blood activation and the possibility of the ‘rebound phenomenon’.
Recent studies on the risk of warfarin withdrawal due to impending surgical procedures 
indicate that the risk of bleeding is outweighed by the risk of serious thromboembolic events. Aside 
from anecdotal reports, there is little data available on the risk of thrombotic complications in patients 
in whom use of warfarin and aspirin is discontinued before cutaneous operation. It was reported that 
thrombotic events included strokes, cerebral and pulmonary embolism, myocardial infarction, 
transient ischemic attack and deep vein thrombosis (DVT). Since there are no reports of severe 
hemorrhagic complications during continued use of warfarin before surgery it is recommended not to
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discontinue warfarin therapy due to surgery (Kovich & Otley, 2003). Chronic anticoagulation therapy 
with warfarin is not uncommon in the elderly population of patients requiring cataract surgery. 
Preoperative cessation of anticoagulant therapy carries a significant risk of thromboembolic events 
and is particularly hazardous for certain patients, such as those with artificial heart valves. Several 
studies document the safety of cataract surgery in patients treated with warfarin. In summary, cataract 
surgery can be safely performed without discontinuing anticoagulation medication and without 
exposing patients at risk for systemic and life-threatening complications (Rotenstreich et al., 2001).
For dental extractions, patients who have been taking warfarin are at an increased risk of 
perioperative thromboembolism if the drug is stopped but may be at an increased risk of bleeding if 
continued. In addition, several antibiotics that are prescribed as prophylaxis during dental extraction 
against bacterial endocarditis may increase the effects of warfarin and the risk of bleeding. However, a 
study has shown that continuation of warfarin after dental extractions showed no evidence of 
increased clinically important bleeding. Since there are serious risks associated with stopping 
warfarin, the practice of routinely discontinuing it before dental extractions should be reconsidered 
(Evans et al., 2002).
1.7.7. Clinical Uses
Warfarin is the therapeutic of choice for treatment of a variety of thromboembolic disorders, 
including atrial fibrillation, deep vein thrombosis and threatened stroke. The dosage required to 
achieve the desired therapeutic effect varies up to 120-fold (5 - 80mg/ml) between individuals (Linder,
2001). The clinical effectiveness of oral anticoagulants was established by well-designed clinical trials 
in a variety of disease conditions. Oral anticoagulants are effective for primary and secondary 
prevention of venous thromboembolism, for prevention of systemic embolism in patients with 
prosthetic heart valves or atrial fibrillation, for prevention of acute myocardial infarction (AMI) in 
patients with peripheral arterial disease and in men otherwise at high risk, and for prevention of stroke, 
recurrent infarction, or death in patients with AMI (Hirsh et al., 2003). Brief descriptions of several 
alternative applications of warfarin are described below.
1.7.7.1. Anti-Coagulant Therapy
In vivo, the coumarin anti-coagulants act by blocking the synthesis of four blood factor 
proteins essential to the blood clotting process. The factors (Factor II, VII, IX and X) are necessary 
components of the prothrombin complex, and vitamin K is essential for their correct post-translational
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modification. It is known that warfarin and other coumarin anti-coagulants interfere with this vitamin 
K-dependent process, by inhibiting the formation of vitamin K from its precursor (Vitamin K 
epoxide). This interference causes abnormal processing of blood factors, leading to accumulation of 
abnormal prothrombin proteins called PIVKAs (Proteins Induced by Vitamin K Antagonism or 
Absence), with a resultant depression of clotting activity.
The coumarin anti-coagulants are thus employed therapeutically to depress blood clotting. 
They have been applied in the treatment of venous thromboembolism, acute myocardial infarction and 
threatened stroke. Warfarin (also known as coumadin) is particularly extensively used in the clinical 
treatment of all thromboembolic disorders. Indeed it is the ninth most widely prescribed drug in the
1.7.7.2. HIV-1 Inhibitor
The urgent requirement for suitable therapeutic agents to arrest the development of the AIDS 
epidemic has led to considerable progress in recent years in the field of drug development against 
HIV. The anti-HIV activity of drugs and immunomodulating substances such as warfarin, cimetidine, 
levamisole and gramicidin may be used in a cocktail drug combination for HIV therapy (Bourinbaiar 
& Jirathitikal, 2003). Warfarin has shown promising results as a potent HIV inhibitor in vitro. A single 
dose of warfarin exhibited a specific inhibition of HIV replication in lymphocytes (Bourinbaiar et al., 
1993). Tummino et al. (1994) showed that warfarin inhibits the HIV retroviral protease in a 
competitive manner in the micromolar concentration range.
Retroviruses are known to share structural epitope domains with host-cell proteins (i.e., 
molecular mimicry). Molecular mimicry has been suggested as a fundamental mechanism underlying 
the pathogenicity of autoimmune disease. Tishkoff and co-workers have identified regions of sequence 
similarity shared between plasma-derived blood-clotting factor X (FX), major histocompatibility 
complex class II molecules (MHC-II), and human immunodeficiency virus-1 envelope glycoprotein 
120 (HIV-1 env gp 120) that may possibly act as shared epitopes. FX zymogen could be the initial 
requirement for activation of viral envelope glycoprotein-fusegenic activity and may play a key role in 
host protease-dependent viral tropism. It is a vitamin K-dependent trypsin-like serine protease that 
may interrupt host viral tropism by down-modulation of vitamin K action using specific vitamin K 
antagonists, such as warfarin. Kinetic analysis in vitro supports warfarin as a competitive inhibitor of 
HIV-1 protease (Tishkoff et al., 2000).
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1.7.7.3. Anti-metastatic Properties
Metastasis involves several distinct steps, including one in which the tumour cell, after entry 
into the bloodstream, comes to rest in a capillary located at the distant site where a metastatic tumour 
will ultimately form. Components of the blood-clotting pathway may contribute to metastasis by 
trapping cells in capillaries or by facilitating adherence of cells to capillary walls. Conceivably, 
anticoagulants could interfere with this step in the metastatic process (Hejna et al., 1999). Warfarin 
has shown particularly promising results in the treatment of SCCL (Small Cell Carcinoma Lung) a 
tumour cell type that is characterised by a coagulation associated pathway (Aisner et al., 1992; Maurer 
et al, 1997; Fitzpatrick, 2001). Studies by Mousa (2002) have shown that anticoagulation with 
commonly used agents such as unfractionated heparin and warfarin (Coumadin) prevent tumour 
formation by limiting the ability of tumour cells to be retained in the pulmonaiy microvasculature. 
Other anti-coagulants have shown promise in cancer treatment. Among drugs available for testing, 
aprotinin and low molecular weight heparin have particular appeal. The former blocks a pathway of 
tumour cell growth, invasion and metastasis while the latter blocks growth factor activity, 
angiogenesis, and other tumour growth mechanisms as well as coagulation activation (Zacharski, 
2002).
Recent studies suggest that anticoagulant drugs and cimetidine therapy in malignancy may 
improve cancer survival and inhibit the metastatic process. A study investigated and compared the 
effects of anticoagulant drugs (e.g. warfarin and heparin), cimetidine and a combination of cimetidine 
with anticoagulants on adhesion of highly invasive breast cancer cell lines BT-549 and MDA-MB-231 
in vitro. A high anti-adhesion effect was observed with cimetidine and warfarin. Anticoagulants such 
as warfarin can decrease adhesion and tumour angiogenesis. Application of cimetidine and 
anticoagulant drugs intensifies the anti-adhesion effect together with other anti-metastatic effects 
(Bobek et al., 2003). There is now considerable evidence that the blood coagulation system plays an 
important role in the biology of malignant tumours. This evidence was derived from a combination of 
clinical, biochemical, histological, and pharmacological observations that point to the possibility of 
favourably affecting the course of malignant disease with agents that interfere with blood coagulation 
pathways (Mousa, 2002).
1.7.7.4. Ig A Nephritis
Human glomerulonephritis (GN) remain one of the most important causes of end-stage kidney 
disease worldwide. Although there is no cure for this type of kidney disease, the current therapeutic
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measures serve to retard the progression to end stage renal failure. Dipyridamole (well-known 
vasodilator) and low dose warfarin was found to be successful in retarding progression to end-stage 
renal failure in patients with Ig A nephritis (Leim, 2001).
1.7.8. Warfarin Contraindications
Although the most common side effect associated with the use of warfarin is bleeding, other 
nonhemorrhagic side effects including skin necrosis have been reported. Deleterious effects on bone 
are also suggested by warfarin’s ability to induce embryopathy when administered to women during 
their first trimester of pregnancy (Simon et al., 2002).
The first reports of a possible connection between the drug and skin damage were by Flood et 
al who described a migratory thrombophlebitis in 1943 and Verhagen who was the first to describe 
skin necrosis in 1954. Warfarin-induced skin necrosis occurs in 0.01-0.1% of warfarin-treated patients 
(Ad-El et al., 2000). To date approximately 300 cases have been reported worldwide. This rare but 
dramatic complication of warfarin therapy is characterised by rapidly developing skin and 
subcutaneous tissue death that usually occurs 3-10 days after the initiation of warfarin therapy. Skin 
necrosis may mimic the clinical findings of fulminant purpura, breast cancer, necrotising fascitis, 
microembolisation and decubitis ulcers (Babu & McIntyre, 2001; Kurtoglu et al, 2001). There are 
also several adverse skin manifestations associated with the use of anticoagulants, ranging from 
purpura, haemorrhagic necrosis to maculopapular vesicular urticarial eruptions (Zimbelman et al, 
2000; Roche-Nagle et al., 2003). A few cases of warfarin-induced skin necrosis are found in the 
orthopaedic literature where warfarin can induce skin necrosis after total hip arthroplasty (Clark & 
Bremner, 2002). Warfarin-induced skin necrosis (WISN) is often associated with large initial loading 
dose of warfarin. It is thought to be due to a rapid elimination of protein C (a natural anticoagulant) 
compared with other vitamin K-dependent clotting factors. WISN is mainly seen in middle aged, peri- 
menopausal, and obese women (Roche-Nagle et al., 2003). Therefore, it is recommended to introduce 
warfarin gradually, especially in middle-aged, obese women treated for venous thromboembolism in 
order to avoid this serious and at times life-threatening complication (Lennox et al., 2001).
Warfarin provides effective protection against thromboembolism, but its use in pregnancy is 
associated with an augmented rate of abortion and the risk of warfarin-induced embryopathy. The risk 
of maternal thromboembolic events is heightened during pregnancy because of the patient’s 
hypercoagulable state, which is characterised by increased levels of clotting factors and of fibrinogen 
and platelet adhesiveness (Vitale et al., 1999; Brooks et al, 2002; Vitale et al., 2002). Following
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numerous reports on adverse pregnancy outcomes related to oral anticoagulants, the manufacturers 
have contraindicated their use during pregnancy since the late 1970s. Warfarin therapy during 
pregnancy has been implicated in two major adverse effects. Warfarin embryopathy was attributed to 
the inhibiting effect of warfarin on vitamin K reductase activity. Vitamin K is involved in the 
carboxylation of two essential components of bone and cartilage development. The effect of warfarin 
on embryonic calcium desposition and subsequent bone formation and growth in a critical period of 
embryological ossification (6-9 weeks’ gestation) results in stippled calcification, extremity 
shortening, vertebral abnormalities, and nasal hypoplasia. The other adverse effect results from 
warfarin over-anticoagulation of the foetus. Since warfarin readily crosses the placenta, 
anticoagulation may occur any time during pregnancy and may cause haemorrhage in every foetal 
organ. In patients with mechanical prosthetic heart valves, long-term anticoagulation is mandatory to 
prevent thromboembolic phenomena. In a recent retrospective Multicenter survey, the Working Group 
on Valve Disease of the European Society of Cardiology concluded that heparin is neither effective 
nor safe for long-term use during pregnancy in patients with mechanical heart valve, bringing an 
increased risk of both thromboembolism and bleeding to mother and foetus. There is a close 
dependency between warfarin dosage and foetal complications. Patients whose warfarin dose was 
greater than 5mg per day had a significantly higher number of foetal complications in comparison to 
patients on less than 5mg per day. Recently protocols of low intensity anticoagulation with coumarin 
derivatives and studies suggesting that foetal adverse effects of anticoagulation might be dose- 
dependent led to the American Heart Association to recommend low dose warfarin administration 
from the first trimester to the 35th week of pregnancy (Cotrufo et al., 2002).
Other uncommon adverse reactions that occur with warfarin administration include 
agranulocytosis, alopecia, anaphylactoid reactions, anorexia, cold intolerance, diarrhoea, dizziness, 
elevated hepatic enzymes, exfoliative dermatitis, headache, hepatitis, jaundice, leukopenia, nausea 
and/or vomiting.
1.8. Isoflavones
For many years now, isoflavones have been investigated by clinicians, pharmacologists and 
plant physiologists. Isoflavones have exceptionally interesting, multidirectional therapeutic properties 
and the biological activity of these substances is conditioned by the location of the phenyl ring near 
the third carbon of the benzo-y-pyrone. Hence, these compounds, in addition to antiflammatory, 
antimycotic and radical scavenging properties, also exhibit both estrogenic and anti-estrogenic effects 
(Luczkiewicz & Glod, 2003). Genistein (4,5,7-trihydroxyisoflavone) is a natural isoflavone
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phytoestrogen present in soybean (Figure 1.10). In the gastrointestinal tract, the p-glucoside 
conjugates of soy are converted by the natural gut microflora into free genistein and other related 
isoflavones, which are present in circulating blood, accumulate in tissue and are excreted in urine of 
people who consume high amounts of soy in their diet. Studies have revealed that individuals who 
consume a traditional diet high in soy products have a low incidence of certain types of cancer, such as 
breast, prostatic and colon cancer (Fioravanti et al., 1998). Genistein has been shown to inhibit cancer 
cell proliferation in vitro and this effect may be attributed to the fact that it is a known tyrosine kinase 
inhibitor (Section 4.9). Therefore, this compound was chosen to determine its effect on two cell lines 
in vitro (Chapter 5.). The following section gives background details on this therapeutically important 
compound.
Figure 1.10: The basic chemical structure o f genistein. It belongs to the benzo-y-pyrone subclass.
1.8.1. Genistein
Although genistein belongs to the benzopyrones is not classed as a coumarin (benzo-a- 
pyrone). It is a flavonoid and belongs to the benzo-y-pyrones. Genistein is a phytoestrogen, which 
belongs to the 'isoflavone' class of compounds. These diphenolic compounds structurally resemble 
estradiol (E2) and were shown to have weak estrogenic activity (Tanos, 2002).
Reports about environmental estrogens, or xenoestrogens, have been widespread in the last
few years. There are important distinctions between estrogenic compounds of industrial origin and
those that come from plants. Compounds such as insecticide DDT and industrial PCBs were
implicated by some researchers in causing estrogen-dependent cancers in exposed populations. Unlike
some industrial xenoestrogens, which tend to bioaccumulate in adipose tissue and persist in the body
for years, phytoestrogens are readily metabolised and spend relatively little time in the body. The
timing of exposure, repeated exposures and levels of exposure to phytoestrogens are important.
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The two major classes of phytoestrogens that have captured the most scientific attention are 
isoflavones and lignans. Diet rich in natural anti-estrogenic substances such as isoflavones has been 
considered as one of the main reasons for significantly lower incidence of breast cancer in China, 
Japan, and South East Asia. Soybeans are a particularly abundant source of isoflavones such as 
genistein and daidzein (Barrett, 1996).
1.8.1.2. Genistein and Cancer Research
Genistein has been shown to inhibit cancer cell proliferation in vitro. This effect was 
attributed to inhibition of several key enzymes, especially tyrosine kinase, which plays a critical role 
in cell proliferation and transformation. Tyrosine kinase is also associated with oncogene expression 
in breast cancer. Breast cancer is one of the most frequently diagnosed malignancies in women, and its 
incidence is increasing in industrialised nations. Tanos et al., (2002) have investigated the effect of 
genistein on human dysplastic and malignant epithelial breast cell lines, expressing low and high 
metastatic potentials. They discovered that genistein has a significant in vitro inhibitory effect on the 
growth rate of dysplastic (fibrocystic cells) and cancerous breast cells. The results obtained, illustrate 
that genistein has not only anti-proliferative effect on cancer cells but also on pathological (non- 
malignant) cells. In vitro studies show that genistein also exhibited a synergistic additive effect when 
cancer cells were exposed to a genistein and tamoxifen treatment. These results indicate the potential 
of genistein administration alone or in combination with tamoxifen for the treatment of breast cancer 
(Tanos, 2 0 0 2 ).
A separate study has shown that genistein treatment has a role in triggering cell death and 
promotes cell cycle arrest on y-irradiated K562 myeloid leukaemia cells (Papazisis et al, 2000). 
Genistein structurally resembles estradiol (E2) and demonstrates weak estrogenic activity in several 
studies (Fioravanti et al, 1998; Ratna, 2002; Tanos et al., 2002). In humans, this compound appears to 
have both estrogenic and anti-estrogenic effects, depending on the concentrations of circulating 
endogenous estrogens and estrogen receptor (ER). Genistein binds to the estrogen receptor with an 
affinity approximately 1 0 0 -fold lower than that of estradiol, resulting in enhanced proliferation 
activity. The estrogen agonistic activity in the absence of estrogen may account for the beneficial 
effects of genistein against atherosclerosis, coronary artery disease, osteoporosis and post-menopausal 
manifestations of hot flushes. The protective effect of genistein against other forms of hormone- 
dependent cancers, such as prostate cancer, may be due to similar mechanisms (Ratna, 2002).
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1.9. Chapter Summary
In this chapter the coumarin family of compounds were reviewed, as a prelude to the work 
described in this thesis. The occurrence, biosynthesis and pharmacokinetics of coumarins were 
described. Particular focus was given to the metabolism and toxicology of the parent compound, 
coumarin, with the importance of coumarin metabolites addressed. Many of these metabolites, and 
other coumarin derivatives are very important, both clinically and industrially, and the uses of 
coumarins in these settings were summarised. A review of the use of benzopyrones in cancer therapy, 
the focus of chapter 5 was given. Since warfarin is the main focus of chapters 3 and 4, and is also of 
importance in chapter 5, its origins and uses were described in detail. Finally, the isoflavones are 
described with emphasis on genistein, as it is relevant to the work described in chapter 5 and facilitates 
understanding of the clinical importance of this compound and its potential benefits for use in cancer 
patients.
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Chapter 2 
Materials & Methods
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2.1. Equipment
Table 2.1: Equipment model used and suppliers.
Class Model Source
Cytosensor® Cytosensor single unit (4) Molecular Devices
M icrophysiometer Serial No: C04706
BIAcore™ BIAcore™ 3000 BIACORE AB
Centrifuges Heraeus Christ Labofuge 6000 Heraeus Instruments Inc.
Biofuge A Microcentrifuge Heraeus Instruments Inc.
Sorvall refrigerated centrifuge Du Pont Instruments
C 0 2 Tissue culture EG 115 IR Heraeus Instruments Inc./Jouan
incubator
Microscope Nikon Diaphot inverted microscope Micron Optical Co. Ltd.
pH meter 3015 pH meter Jenway Ltd.
Rocker Platform Stuart Platform Shaker STR6 Lennox
Protein Electrophoresis Atto dual minislab system AE-6450 Atto Corp.
Apparatus
Spectrophotometers U.V.-160A Shimadzu Corp.
Spectrophotometer
Titertek Multiscan plate reader Medical Supply Company
Sonicator & Waterbath RM6  Lauda waterbath A.G.B. Scientific Ltd.
Laminar Flow Unit Holten 2448K laminar air flow unit Holten Laminar A/S
Millipore Filtration Millipore Filtration Device A.G.B. Scientific Ltd.
Apparatus
Ultrafiltration Cell Stirred Cell 8400 Amicon Inc.
Full Addresses:
AGB: Dublin Industrial Estate, Dublin 11, Ireland.
Amicon Inc.: Beverly, Massachusetts 01915, U.S.A.
Atto Corp.: 2-3 Hongo 7-Chrome, Bunkyo-Kui, Tokyo 113, Japan.
BIACORE AB: St. Albans, Hertfordshire AL13AW, England.
Molecular Devices: Unit 6 , Raleigh Court, Rutherford Way, Crawley, West Sussex, England. 
Du Pont Instruments: Instrument Products Division, Newtown, Connecticut 06470, U.S.A. 
Heraeus Instruments Inc.: 111-a Corporate Boulevard, Sth Plainfield, New Jersey 07080,U.S.A. 
Holten Laminar A/S: Gydevang 17, DK 3450 Allerod, Denmark.
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Jenway Ltd.: Gransmore Green, Felsted Dunmow, Essex, CM6  3LB, England. 
Lennox: P.O Box 212A, John F. Kennedy Dr., Naas Rd., Dublin 12, Ireland. 
Medical Supply Company: Damastown, Mulhuddart, Dublin 15, Ireland. 
Nikon Corporation: 2-3 Marunouchi 3-chome, Chiyoda-ku, Tokyo, Japan. 
Pharmacia Biosensor: St. Albans, Hertfordshire AL1 3AW, England. 
Shimadzu Corp.: 1 Nishinokyo-Kuwabaracho, Nakagyo-ku, Kyoto 604, Japan.
2.2. Consumable Items
2.2.1. Plastic Consumables
Table 2.2: Consumables used and suppliers
Class Item Source
Plastics Eppendorf tubes, sterile universal 
containers and gilson tips
Sarstedt Ltd.
Cytosensor capsules/ 
Reference Electrode kit
Biosciences
Nunc Maxisorp plates Nunc
Tissue Culture plastic-ware Coming Costar
Miscellaneous CM5 Chips Pharmacia Biosensor
Nanosep™ Ultrafiltration 
membranes
Amicon Inc.
Milipore 0.2 pm filters A.G.B. Scientific Ltd.
Full Addresses:
AGB: Dublin Industrial Estate, Dublin 11, Ireland.
Coming Costar: High Wycombe, Buckinghamshire HP 13 6 EQ, England. 
Biosciences: 3, Charlemont Terrace, Dunlaoire, Co. Dublin, Ireland. 
Nunc: P.O. Box 280-Kamstrup DK, Roskilde, Denmark.
Sarstedt Ltd.: Sinnottstown Lane, Drinagh, Co. Wexford.
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2.3. Reagents and Chemicals
All chemicals were reagent grade and were purchased through Sigma Aldrich Company Ltd, 
(Airton Road, Tallaght, Dublin 24.) except as noted below.
Table 2.3: Reagents & Chemicals used and suppliers:
Class Chemical Supplier
Chemicals Acencoumarin (Sintrom®) Ciba-Geigy
Biochemical & 
Immunological 
Reagents
Anti-phosphotyrosine monoclonal antibody Promega
Alkaline phosphatase-labelled antibodies Southern Biotechnology 
Ltd.
Phosphate buffered Saline tablets Oxoid Ltd.
BCA Kit Pierce
MTT, LDH and BrdU Kits Roche
Tissue culture MCF-7 cells N.C.T.C.C.
Dulbecco's modification of Eagles medium Gibco BRL
Foetal calf serum Gibco BRL
HEPES Gibco BRL
Tiypsin Gibco BRL
L-glutamine Gibco BRL
Non-essential amino acids Gibco BRL
Phosphate-buffered saline tablets Oxoid
Sodium pyruvate Gibco BRL
Full Addresses:
Ciba-Geigy: CH-4002 Basle, Switzerland.
Gibco BRL: Trident House, Renfrew Rd., Paisley PA4 9RF, Scotland. 
N.C.T.C.C.: National Cell and Tissue Culture Centre, DCU, Dublin 9, Ireland. 
Oxoid: Basingstoke, Hampshire, England.
Pierce: 3747 North Meridian Road, PO box 117, Rockford, IL 61105, U.S.A.
60
Promega Corporation: 2800 Woods Hollow Road, Madison, WI 53711, U.S.A 
Roche Diagnostics Ltd: Bell Lane, Lewes, East Sussex BN7 1LG, United Kingdom 
Southern Biotechnology: 160A Oxmoor Boulevard, Birmingham, Alabama 35209, U.S.A.
2.4. Standard Solutions
Phosphate Buffered Saline (PBS-l):
One tablet was dissolved per 100 mis o f distilled water according to the manufacturer’s 
instructions. When dissolved, the tablets prepare Dulbecco’s A PBS which contains 10 mM 
phosphate buffer and 0.14 M NaCl, pH 7.2-7.4 (referred to in text as PBS-l).
Phosphate Buffered Saline 2 (PBS-2):
PBS-l was prepared as described above, with 0.3 M NaCl added (referred to in text as PBS- 
2).
Wash Buffer:
PBS-l containing 0.05% (v/v) Tween-20.
Diluent Buffer:
PBS-l containing 0.05% (v/v) Tween-20 and 5% (v/v) FCS.
HBS Buffer:
Hepes Buffered Saline (HBS):
Hepes buffered saline (BIACORE running buffer) containing 50 mM NaCl, 10 mM HEPES, 
3.4 mM EDTA and 0.05% (v/v) Tween-20 was prepared by dissolving 8.76 g o f NaCl, 2.56 g 
of HEPES, 1.27 g o f E.D.T.A. and 500 |^ 1 o f Tween 20 in 800ml o f distilled water. The pH of 
the solution was then adjusted to pH 7.4 by the addition of 2M NaOH. The final volume was 
then made up to 1,000 ml in a volumetric flask. The solution was filtered through a Milipore 
0.2 ¡j,m filter and degassed prior to use.
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SDS-PAGE (Sodium Dodecyl Sulphate-PolyAcrylamide Gel Electrophoresis) solutions:
Stock Solutions:
(A) 30% (w/v) acrylamide containing 0.8% (w/v) bis-acrylamide.
(B) 1.5 M Tris-HCl, pH 8.8, containing 0.4% (w/v) SDS.
(C) 0.5 M Tris-HCl, pH 6.8, containing 0.4% (w/v) SDS.
(D) 10% (w/v) ammonium persulphate.
Table 2.4: The quantities o f stock solutions required for the preparation of resolving and
stacking gel used for polyacrylamide gel electrophoresis.
Solution Resolving Gel Stacking Gel
Acrylamide (A) 3.3. ml 0.83 ml
Distilled Water 4.17 ml 2.9 ml
Resolving Gel 
Buffer (B)
2.5 ml ------
Stacking Gel 
Buffer (C)
------- 1.25 ml
Ammonium 
Persulphate (D)
100 nl 25 |il
TEMED 10 (J.1 5 (J.1
62
Coomassie Blue Stain Solution
Coomassie Blue R-250 1.25 g
Methanol 227 ml
dH20  227 ml
Glacial acetic acid 46 ml
The components were dissolved, mixed thoroughly, filtered through Whatman paper 
grade number 1, and stored at room temperature (R.T.) in a dark bottle.
Destain Solution
Methanol 150 ml
Glacial acetic acid 50 ml
dH20  300 ml
The above components were mixed, thoroughly, and stored at R.T.
Electrophoresis Buffer
Tris. HC1 3.00 g
Glycine 14.40 g
SDS 1.00 g
The components were dissolved in 1L o f dH^O, and stored at R.T.
Sample Buffer
1M Tris.HCl (pH 6.8) 0.60 ml
50% (v/v) Glycerol 5.00 ml
10% (w/v) SDS 2.00 ml
2-ME (2-Mercaptoethanol) 0.50 ml
1% (w/v) Bromophenol blue 0.90 ml
The components were thoroughly mixed together, and stored at -20°C.
Acrylamide Stock Solution (A)
Acrylamide 29.20 g
Bisacrylamide 0.80 g
The components were dissolved in 100ml dH20, and stored in the dark at 4°C.
63
4X Resolving Gel Buffer (B)
2M Tris-HCI (pH 8.8) 75.0 ml
10% (w/v) SDS 4.0 ml
dH20 21.0 ml
The components were thoroughly mixed together, and stored at 4°C.
4X Stacking gel Buffer (C)
1M Tris.Cl (pH 6.8) 50.0 ml
10% (w/v) SDS 4.0 ml
dH20  46.0 ml
The components were thoroughly mixed together, and stored at 4°C.
Ammonium Persulphate Solution (D)
Ammonium persulphate 0.10 g
dH20  1.00 ml
The components were mixed thoroughly and stored at R.T.
Electrophoresis buffer
Tris 3.10 g
Glycine 14.40 g
Methanol 200.0 ml
The components were dissolved in 1,000 ml o f dH20 , and stored at R.T.
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2.5. Methods
2.5.1. Mammalian Cell Culture
All mammalian cell cultures were grown in a humidified 5% C0 2 atmosphere, at 37°C. All 
cell counts were made using a Neubauer Counting Chamber. Viable cell counts were obtained by 
mixing cells, with a 1/5 volume of a commercial 0.4% (w/v) isotonic Trypan blue solution. Dead cells 
were stained blue. The viable cell count was carried out within 5 mins of the addition of Trypan blue. 
Cells were visualised with a phase contrast microscope. All cells were pelleted by centrifugation and 
all centrifugations were at 2 0 0 0  rpm for 1 0  min. unless otherwise stated.
2.5.1.1. Cell Lines and Media Preparation
The cell lines used in the experimental work and their appropriate culture media are outlined 
in Table 2.5. In all cases, the culture medium was supplemented with FCS (at either 5 or 10% (v/v) as 
outlined in Table 2.5.), L-glutamine (2mM), HEPES (lmM) and gentamycin (5|ig/ml). Sodium 
pyruvate (lmM) and non-essential amino acids (1% (v/v)) were also used to supplement the MCF-7 
media.
Table 2.5: List o f cell lines and their culture media used throughout this work.
Cell Line ATTCNo. Description Culture Medium
MCF-7 HTB 22 Human Caucasian Breast Carcinoma DMEM. S io
A549 CCL 185 Human Caucasian Lung Carcinoma DMEM.S5
Clone 4.2.25 NA Murine Hybridoma(Balb/C-Sp2) DMEM.Ss
2.5.1.2. Recovery o f  Frozen Cells
Cells were recovered from liquid nitrogen by thawing rapidly at 37°C and transferring to a 
sterile universal tube containing lOmls of DMEM.S10 [DMEM containing 10% (v/v) Foetal Calf 
Serum (FCS)]. The cells were centrifuged at 2000 rpm for 10 mins, resuspended in fresh medium, 
transferred to culture flasks, and incubated at 37°C in a humid 5% C0 2 incubator.
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2.5.I.3. Culture o f Cells in Suspension
4.2.25. hybridoma cells (derived from fusion of mouse spleenocytes to Sp2/0 cells ATTC No. 
CRL 1581) were maintained in DMEM.S10. The cells were subcultured, using a split ratio of 1:4, at 
approximately 70% confluency. For subculturing, the cells were flushed off the surface of the flask 
using a Pasteur pipette, collected and centrifuged at 2,000 rpm. The pellet was then resuspended in 4 
ml of fresh culture medium. 1 ml of the resuspended pellet was then transferred to T-75 flasks 
containing 14 ml of fresh DMEM
2.5.1.4. Culture o f  Adherent Cells
The two other cell lines used (A549 and MCF-7) in the experiments were adherent cell lines. 
All cells were strongly adherent and required trypsinisation for harvesting prior to subculturing or 
experimental usage.
For trypsinisation the medium was decanted and 1 ml of trypsinising solution (Gibco 0.025% 
(w/v) trypsin with 0.02% (w/v) EDTA in 0.1M PBS, pH 7.4) was used to rinse the flask, thus 
removing residual FCS which contains a trypsin-inhibitory activity. After this volume was decanted a 
further 4mls of the trypsinising solution was added to the flask and the flask was incubated at 37°C 
until all the cells had detached from the flask surface. 6mls of DMEM.S10 was added to this cell 
suspension, which was then transferred to a sterile universal tube and centrifuged at 2000 rpm for 10 
mins. The cells were resuspended in culture medium and seeded at 1 X 106 cells/ml, using 15mls of 
DMEM per 75cm2 culture flask.
2.5.1.5. Cell Counts and Viability Testing
Trypan Blue was used routinely to determine cell numbers and viabilities. 20|xl of Trypan 
Blue stain (Sigma, 0.25% (w/v)) was mixed with IOOjj.1 of cell suspension and allowed to incubate for 
3 mins. A sample of this mixture was loaded onto the counting chamber of an improved Neubauer 
Haemocytometer slide, and cell numbers and viabilities were determined. Viable cells excluded the 
dye and remained white, while dead cells stained blue. In all cases the minimum number of cells 
counted was 200.
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2.5.1.6. Long-Term Storage o f Cells
Cells required for long-term storage were frozen in liquid nitrogen. Harvested cells were 
pelleted and resuspended in freezing medium (90% FCS, 10% DMSO, (v/v)) to a concentration of 1 X 
106 cells/ml. 1ml aliquots were then transferred to sterile cryotubes, and lowered slowly (over a 3 hour 
period) into the gas phase, before being eventually immersed in liquid nitrogen.
2.5.2. Solid Phase Immunoassays
2.5.2.1. ELISAs for Titration o f  Antibody Levels in Hybridoma Supernatants
100 jaI of a solution of 50 |i,g/ml warfarin-BSA conjugate prepared in PBS-1, was added to all 
of the wells of a Nunc maxisorp plate, and incubated at room temperature overnight. Wells were 
washed with 5 x 200 (j.1 of wash buffer, and 100 |xl of a 5% (v/v) solution of FCS in PBS-1 was added 
to each well, and incubated for 90 minutes at 37°C. This was to ‘block’ any remaining adsorption sites 
on the plastic surface. Wells were then washed out with 5 x 200 jxl of wash buffer. 100 (j.1 of test 
sample (i.e. the appropriate dilution of hybridoma supernatant) was added to the wells of the plate. 
Samples were diluted (serial doubling dilutions including neat sample) in PBS-1 containing 0.05% 
(v/v) Tween-20 and 5% (v/v) FCS. Samples were incubated for 90 minutes at 37°C.
Wells were washed with 5 x 200 p.1 of wash buffer, 100 fxl of secondary antibody (alkaline 
phosphatase conjugated to a goat anti-mouse antibody), diluted as required in diluent buffer, was 
added to each well and incubated for 90 minutes at 37°C. Wells were washed with 5 x 200 pi of wash 
buffer, and 100 pi of substrate was added per well. The substrate used was para-nitrophenyl phosphate 
(pNPP) provided in tablet form (final concentration 25mM), and dissolved in the required volume of 
dH20  immediately before use, according to the manufacturer’s instructions. Substrate was left to 
develop in the dark at room temperature, or overnight at 4°C. Absorbance readings were read at 405 
nm using a Titertek plate reader.
2.5.2.2. Isotyping o f  Monoclonal Antibodies
ELISA plates were coated and blocked as described in section 2.5.2.1. 100 (J.1 of hybridoma 
supernatant was then added to each well of the coated plate. Alkaline-phosphatase-labelled goat anti­
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mouse immunoglobulin subtypes were then added to the wells and the ELISA developed as described 
in section 2.5.2.1. Wells giving positive results defined the monoclonal antibody isotype.
2.5.23. Determination o f  Antibody Working Dilution
ELISA plates were coated and blocked as described in section 2.5.2.1. Serial dilutions of 
purified monoclonal antibody were then prepared in diluent buffer, starting dilutions at 1/10. Sixteen 
serial dilutions were then prepared by doubling dilution in diluent buffer. 100 pi of test sample was 
then added to the wells of the plate in triplicate, and incubated at 37°C for 90 minutes.
Wells were then washed with 5 x 200 pi of wash buffer, and lOOpI of the appropriate 
secondary antibody (i.e. alkaline phosphatase conjugated to a goat anti-mouse antibody) prepared in 
diluent buffer was added to each well, and the plate incubated at 37°C for 90 minutes. Wells were then 
washed with 5 x 200 pi of wash buffer and 100 pi of substrate (pNPP) was added per well. The plate 
was developed at room temperature in the dark or overnight at 4°C. Absorbance was measured at 405 
nm using a Titertek plate reader. The antibody dilution that gave half the maximum absorbance was 
chosen. For the 4.2.25 monoclonal antibody producing clone supernatant, a 1/800 dilution of antibody 
was used in ELISA.
2.5.2.4. Determination o f  Optimal Conjugate Loading Density
Warfarin-BSA conjugate was prepared in PBS-1 at various concentrations, namely, 100, 50, 
25, 12.5, 6.25, 3.125 and 0 pg/ml. A 50pg/ml solution of BSA control was also prepared in PBS-1 as a 
control. lOOpl of the respective conjugate concentration was used to coat two rows of a Nunc 
Maxisorp immunoplates overnight at room temperature. The ELISA was developed as per section
2.5.2.3. The optimal conjugate loading density was defined as that coating density that gave the widest 
linear working range over the greatest range of antibody dilutions used.
2.5.2.5. Competitive ELISA
Nunc Maxisorp plates were coated and blocked as described in section 2.5.2.1. Serial dilutions 
of warfarin ranging in concentration from 7.81 -1000 ng/ml were prepared in diluent buffer. 50 pi of 
each drug concentration was then added to the wells of a coated microtitre plate, and 50 pi of purified 
antibody at 2 x working dilution was added to the wells of the plate. The plate was then developed as
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described in section 2.5.2.1. Absorbance values were then measured at 405 nm using a Titertek plate 
reader. Absorbance values at each antigen concentration were then divided by the absorbance 
measured in the presence of zero antigen concentration to give normalised absorbance readings. A plot 
of the normalised absorbance reading versus antigen concentration (ng/ml) was used to construct the 
calibration curve.
2.5.2.6. Affinity Analysis Using ELISA
The method of Friguet et al. (1985) was employed. Briefly, the day before the ELISA 
analysis, a series of antibody-antigen mixtures were prepared in eppendorf tubes and placed on a 
rocking platform at room temperature overnight, and allowed to reach equilibrium. These solutions 
each contained a constant but unknown concentration of antibody. This concentration was nominally 
referred to as “1”. The antibody:antigen solutions each contained a constant concentration of antibody, 
and varying but known concentrations of antigen ([A]). Additionally, serial doubling dilutions of 
antibody were prepared from that antibody dilution given the nominal antibody concentration of “1”. 
These dilutions were used to construct a standard curve of nominal antibody concentration versus 
absorbance at 405 nm. The following morning, the nominal concentration of free antibody in each 
solution was determined by ELISA, as per section 2.5.2.1. Absorbance readings at 405nm values were 
related to nominal concentration values, by reference to the constructed standard curve of nominal 
antibody concentration versus absorbance at 405 nm. The fraction of total antibody, bound by antigen 
(v), was calculated for each antigen concentration. The slope of a plot of 1/v versus 1/[A] (Klotz plot) 
defined the dissociation constant for the interaction.
2.5.2.7. Determination o f  Mouse Immunoglobulin Concentrations by Affmity- 
Capture ELISA
Goat anti-mouse immunoglobulin which was previously affinity-purified (according to section
2.5.3.2.), was diluted to a final concentration of 1 pg/ml in PBS-1, and 100 pi added to the wells of an 
ELISA plate and allowed to coat overnight at room temperature. The plate was then blocked as 
described in section 2.5.2.1. Dilutions of mouse IgG of known concentration ranging from 3.90-1000 
ng/ml were prepared in diluent buffer. Dilutions of purified antibody ranged from 1/10 to 1/10,000 and 
were also prepared in diluent buffer. 100 pi of the solutions containing mouse IgG of known 
concentration and the dilutions of purified antibody were added to the wells of the ELISA plate in 
triplicate. The ELISA was developed as described in section 2.5.2.1. using a goat anti-mouse alkaline 
phosphatase-labelled secondary antibody. A calibration curve of absorbance at 405 nm versus log of
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mouse IgG concentration allowed for the determination of the mouse IgG concentration in the affinity- 
purified and hybridoma supernatants.
2.5.3. Monoclonal Antibody Purification
2.5.3.1. Concentration o f  Tissue Culture Supernatant
200 ml of conditioned supernatant from the 4.2.25 hybridoma cell line was collected over a 
period of time as described in section 2.5.1.3. Sodium azide was added to a final concentration of 
0.02% (w/v) to the supernatants to prevent microbial growth, and stored at 4°C until required. The 
supernatant was concentrated 10-fold to a final volume of 20 ml, using a stirred ultrafiltration cell with 
a 76 mm diaflo ultrafilter membrane, with a molecular weight cut-off of 100,000 daltons, and the 
concentrate stored at 4°C until required.
2.5.3.2. Protein G/A Affinity Purification o f  Murine and Goat Anti-Mouse 
Immunoglobulin
lml of a suspension of immobilised protein G (immobilised on Sepharose 4B) (stored in PBS- 
1 containing 20% (v/v) ethanol) was equilibrated in a column with 20ml of PBS-1. 10 ml of 
concentrated hybridoma supernatant, or, 2 ml of goat serum containing anti-mouse immunoglobulin 
was passed through the column, the eluate collected and passed through the column a second time. 25 
ml of wash buffer was passed through the column and, subsequently, the retained protein was eluted 
with 0.1 M glycine-HCl buffer (pH 2.5). 850 pi fractions of eluate were collected in eppendorf tubes 
containing 150 pi of Tris-HCl (pH 8.5). Tris-HCl was used to neutralise the pH of the fractions 
collected so that the mAb present would not denature. The absorbance of each fraction was measured, 
at 280 nm. Those fractions containing significant protein were pooled, dialysed against PBS-2 and 
stored at -20°C until required for further use.
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2.5.4. Toxicity Testing
2.5.4.1. Drug Preparations
Drug solutions (benzopyrones) were prepared fresh for each experiment. Stock solutions of all 
drugs were made in DMSO, from which all required drug dilutions were made into culture medium, in 
such a way that the final concentration of solvent exposed to cells was always less than 0.1% (v/v). In 
all experiments, control cells were exposed to 0.1 % (v/v) DMSO in culture medium.
2.5.4.2. In Vitro Proliferation Assays
Cells were seeded into 25cm2 flasks at the appropriate density (see Table 2.6.) and allowed to 
adhere for 6 hours, prior to addition of the drug of interest (warfarin, genistein and esculetin) at the 
desired concentration. Incubation of cells with drugs was continued for 96 hours, after which the cell 
number and viability was determined using Trypan Blue as outlined in section 2.5.1.5. All 
experiments were carried out in duplicate on at least three separate occasions. The increase in cell 
number for drug-treated cells was expressed as a percentage of the increase for untreated control cells, 
and growth curves were constructed from this data.
Table 2.6: Seeding Densities for In Vitro Proliferation Assays.
Cell Lines Seeding Density
A549 1 X105 cells/flask
MCF-7 2.5 XI05 cells/flask
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2.5.4.3. Cytotoxicity Detection: Lactate Dehydrogenase (LDH) Assay
This assay is based on the cleavage of a tetrazolium salt when LDH is present in the culture 
supernatant. The principle of the LDH assay is illustrated in Figure 2.1. Cells were seeded at 5 X 104 
cells/well in sterile 96 well plates, allowed to adhere (over 24hrs.) and exposed to drug concentrations 
(range 0-250pg/ml) for 24 hours at 37°C. Each drug concentration was tested in 5 separate wells (in 
duplicate), with each experiment repeated on at least three separate occasions.
Immediately prior to testing supernatants, LDH reaction mix was prepared from the kit 
components as follows: 250pl of catalyst solution (Diaphorase/NAD+ mixture) was mixed with
11.25mls of dye solution (iodotetrazolium chloride (INT) and sodium lactate). Test supernatants were 
prepared by centrifugation of the cells in their 96 well plates at 250g for 10 mins. From each well, 
1 OOpl of supernatant was transferred to a second 96 well plate, lOOjil of LDH reaction mix was added, 
and the plates were incubated for 30 minutes at room temperature. Absorbances at 492nm were 
determined on a Titertek plate reader, with a reference wavelength of 620nm. The absorbances 
obtained were compared to that of cells exposed to a 1% (v/v) Triton X-100 solution (maximal LDH 
release).
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Figure 2.1: Principle o f the LDH Assay. In the 1st step, released lactate dehydrogenase (LDH) 
reduces NAD+ to NADH + i t  by oxidation o f lactate to pyruvate. In the 2nd enzymatic reaction 2 H  
are transferred from NADH + i t  to the yellow tétrazolium salt INT (2-[4-idophenyl]-3-[4- 
nitrophenylJ-5-phenyltetrazolium chloride) by a catalyst (diaphorase).
2.S.4.4. M TTAssay
This non-radioactive colourimetric assay system is a modification of that first described by 
Mosmann et al. (1983), and involves the use of a tétrazolium salt, MTT (3-[4,5-dimethylthia2:ol-2-yI]- 
2,5-diphenyltetrazolium bromide). In metabolically active cells, this yellow MTT salt is cleaved to 
form purple formazan crystals, and as such can be used to assess the cellular metabolism and viability 
as shown in Figure 2.2.
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Figure 2.2: Metabolisation o f MTT to a formazan salt by viable cells.
Cells were seeded at 5 X 105 cells/well into sterile 96 well plates, and allowed to adhere prior 
to the addition of lOOp.1 of the appropriate drug solution (concentration range: 0-500pg/ml). 
Incubation with drug was continued for 24 hours. Following this time period, lOpl of MTT [3-[4,5- 
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide] labelling reagent (5mg/ml in 0.1 M PBS) was 
added to each well, and the plates were incubated at 37°C for 4 hours to allow for formazan crystal 
formation. lOOp.1 of solubilisation buffer (10% (w/v) SDS in 0.01M HC1) was added to dissolve the 
crystals overnight. The following morning the absorbance at 560nm was read on a Titertek Twinplus 
plate-reader. Drug-treated cells were compared to untreated control cells. Each drug concentration was 
tested in 7 separate wells in a randomised manner and each experiment was repeated on at least three 
separate occasions.
2.S.4.5. Acid Phosphatase Assay
Acid phosphatase activity is correlated with membrane integrity and cell viability. The 
principle of the assay is based on the conversion of p-nitrophenyl phosphate (p-NPP) to a yellow 
compound called p-nitrophenol that can be quantified simply by measuring absorbance of light at 
405nm as shown in Figure 2.3. Acid phosphatase activity is an accurate indicator of cell number 
because the amount of enzyme remains relatively constant in most cell types.
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Figure 2.3: This assay utilises the fact that viable cells have acid phosphatase activity and non-viable 
cells do not. Therefore, when detergent (in buffer) lyses viable cells the acid phosphatase acts on 
substrate pNPP also in buffer. This phosphatase-catalysed reaction changes pNPP to p-nitrophenol 
and inorganic phosphate. In the second part o f the reaction NaOH is added to end the phosphatase 
assay after the two-hour incubation step. The hydroxide reacts with the p-nitrophenol to remove the 
phenolic proton and p-nitrophenolate is formed, which is a yellow coloured compound absorbing at 
405 nm.
Cells were seeded at 1 X 103 cells/well into sterile 96 well plates, and allowed to adhere over­
night prior to the addition of lOOpl of the appropriate drug solution (concentration range: 0- 
500pg/ml). Incubation with drug was continued for 96 hours. Following this time period, cell-culture 
media was poured off, and wells were washed with PBS. A substrate containing buffer (lOmM p-NPP, 
0.1% (v/v) Triton X in 0.1M sodium acetate, pH 5.5) was prepared and lOOpl was added to each well. 
The plates were then incubated at 37 °C for 2 hours. After incubation the reaction was stopped by 
adding 50pi of 1.0M NaOH solution to each well. The absorbance at 405nm was read on a Titertek 
Twinplus plate-reader. Drug-treated cells were compared to untreated control cells. Each drug 
concentration was tested in 6 separate wells and each experiment was repeated on at least three 
separate occasions.
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2.5.5. Cytosensor Microphysiometer Studies on Toxicity
2.5.5.1. Pre-Experimental Preparations
On the day prior to the experiment MCF-7 cells were seeded into transwell cell capsules at a 
density of 2.5 X 105 cells/capsule in DMEM.Sio and allowed to adhere overnight.
On the day of the experiment, running media was prepared from stock liquid 10X DMEM, as 
a IX DMEM solution with a low buffering capacity i.e. without HEPES or sodium bicarbonate. 
Sodium chloride was added at 0.044M to compensate for the osmolarity as a result of the absence of 
sodium bicarbonate. Other supplements included L-glutamine (2mM), gentamycin (5pg/ml) and FCS 
(0.5% (v/v)). After all these additions, the pH was adjusted to 7.35 with 1M NaOH, and the media was 
filter-sterilised (0.22|_im) using a Millipore apparatus. This media was heated to 37 °C prior to use.
2.5.5.2. Toxicity Studies
On the day of the experiment the cells were assembled onto the Cytosensor 
Microphysiometer, and running medium (37°C) was passed over them at a 50% flow-rate (~ 
lOOpl/min). The cells were allowed to stabilise on the instrument for 3-4 hours. A pump cycle of 4 
minutes duration was used with the acidification rate being measured in the final 30 secs of this 4- 
minute cycle. Once a steady base-line acidification rate was obtained the cells were exposed to drugs 
(Warfarin and esculetin) in the concentration range 0-100pg/ml (final concentrations in running 
medium) for 24 hours. The acidification rate was measured and recorded every 4 mins during this 
exposure period.
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2.5.6. Cell Signalling Studies
2.5.6.1, ELISA for Detecting Tyrosine Kinase Activity in Whole Cells
This ELISA was developed as a modification (optimise conditions for use with different cell 
line) of a method published by Cooke, (1999). Sterile 96 well plates were seeded with MCF-7 cells at 
a density of 5 X 104 cells/well and allowed to adhere for 6 hours in DMEM.S10. The cells were then 
subjected to a 16hr period of serum-depletion. Following this serum-free period, each well (containing 
MCF-7 cells) was stimulated with 100ng/ml EGF for 15 minutes at 37°C. The medium was 
immediately removed and the wells were washed with ice-cold PBS containing lOOfxM sodium 
orthovanadate, after which the cells were fixed with methanol for 10 minutes at -20°C. Figure 2.4 
illustrates the basic steps involved in this assay.
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Figure 2.4: Diagram outlining the basic protocol involved in the ELISA for the dectection
o f tyrosine kinase activity in MCF-7 cells.
200|il of blocking solution (10% (v/v) FCS, 0.2% (v/v) Tween-20, lOOpM sodium 
orthovanadate in Tris Buffered Saline, TBS, [lOmM Tris-HCl, pH 8.0, 150mMNaCl]) was added per 
well and the plates were incubated at 37°C for 1.5 hours. After incubation, the blocking solution was 
removed and the plate was washed once with TBS containing 0.1% (v/v) Tween-20. lOOpl of primary 
antibody (anti-phosphotyrosine, dilution of 1/750 in TBS containing 10% (v/v) FCS, 0.1% (v/v) 
Tween-20) was added per well. The plates were incubated for 1 hour at 37°C.
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Following incubation the plates were washed five times with TBS containing 0.1% (v/v) 
Tween-20, and twice with TBS. Anti-mouse IgG-alkaline phosphatase conjugate was diluted 1/2000 
in TBS containing 10% (v/v) FCS, 0.1% (v/v) Tween-20. lOOpl of this solution was added per well 
and incubation was carried out at 37°C for 1 hour. Following incubation the plates were washed five 
times with TBS containing 0.1% (v/v) Tween-20 and twice with TBS. lOOpl of pNPP was added per 
well with colour development for 45 minutes before the absorbance at 405nm was measured.
To determine the effect of the benzopyrones on tyrosine phosphorylation, the ELISA was 
performed as outlined above, with cells being pre-exposed to drug solutions (in the concentration 
range O-lOOpg/ml), for 1 or 6 hours (as appropriate) prior to EGF stimulation. Controls were used 
which were positive tyrosine kinase inhibitors (Genistein, 1 hour and 6 hour exposure). In all 
experiments, increases in absorbances (405nm) in stimulated cells compared to unstimulated cells 
were determined. Absorbance increases for drug-treated cells were normalised versus untreated 
control cells. Inhibition of tyrosine kinase activity was demonstrated if the absorbance increase for the 
drug-treated cells was diminished compared to the absorbance increase for control cells.
2.5.6.2. Cytosensor Studies for Detecting Tyrosine Kinase Activity
2.5.6.2.I. Pre-experimental Preparations
On the day prior to the experiment, MCF-7 cells were seeded into transwell cell capsules at a 
density of 2.5 X 105 cells/capsule in DMEM.S10 and allowed to adhere for 6 hrs. Serum-free medium 
was then used to replace the culture medium and the cells were serum-starved for 16 hours. Running 
media was prepared from stock liquid 10X DMEM, as a IX DMEM solution with a low buffering 
capacity i.e. without HEPES or sodium bicarbonate. Sodium chloride was added at 0.044M to 
compensate for the osmolarity as a result of the absence of sodium bicarbonate. Other supplements 
included L-glutamine (2mM), gentamycin (5pg/ml) and BSA (1 mg/ml). After all these additions the 
pH was adjusted to 7.35 with 1M NaOH, and the media was filter-sterilised (0.22pm) using a 
Millipore apparatus. The media was heated to 37 °C prior to use.
2.5.6.2.2 Optimisation o f  EGF Stimulation
On the day of the experiment the cells were assembled into the Cytosensor Microphysiometer 
and running medium (37°C) was passed over them at a 60% flow-rate (~120pl/min). The cells were 
allowed to stabilise on the instrument for 3-4 hours. A pump cycle of 2 minute duration was used, with
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the acidification rate being measured in the final 30 secs of this 2 minute cycle. Once a steady base­
line acidification rate was obtained, the cells were exposed to various concentrations of EGF in the 
range (O-lOOng/ml). By carrying out these experiments in triplicate, it was determined that the 
maximal response was obtained at 200ng/ml of EGF and this was used in all subsequent experiments 
(Section 2.5.6.2.3.)
2.5.6.2.3. EGF-Receptor Tyrosine Kinase Inhibition Studies
The passing of EGF (200ng/ml) over MCF-7 cells on the Cytosensor Microphysiometer was 
shown from experiments in Chapter 4 to cause a substantial (~ 20%) increase in the acidification rate 
of the cells. This increase was mainly due to the activation of the receptor-associated tyrosine kinase 
(on EGF binding to the receptor), and could be blocked by pre-exposure of the cells to the tyrosine 
kinase inhibitor, genistein.
In order to determine if the benzopyrones could inhibit the activation of the EGF-RTK the 
cells were pre-exposed to warfarin (0-20^g/ml) or esculetin (0-20^g/ml) for either 1 or 6 hours prior 
to the EGF stimulation (200ng/ml). In all the cytosensor (tyrosine kinase inhibition) experiments 
genistein was used as the positive control.
2.5.63. BrdU ELISA forDNA Synthesis Determination
The BrdU ELISA is designed as a precise, simple and fast colorimetric alternative to 
determine DNA synthesis in viable cells by measurement of pyramidine analogue, 5-bromo-2’- 
deoxyuridine (BrdU) incorporation during DNA synthesis in actively proliferating cells. After its 
incorporation into newly synthesised DNA, BrdU is detected by ELISA. This is achieved with the help 
of a murine monoclonal antibody conjugated with peroxidase. This monoclonal antibody recognises 
and binds to BrdU incorporated into the DNA of proliferating cells and is known as Anti-BrdU-POD. 
When the substrate solution, tetramethyl-benzidine (TMB) is added it reacts with the anti-BrdU-POD 
to give a colour change which can be detected using a plate reader set at the appropriate wavelength 
(Figure 2.5.).
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Figure 2.5: Diagram outlining the basic protocol involved in the BrdU ELISA.
MCF-7 cells were seeded at 5 x 105 cells/well (100|xl/well) into sterile 96 well plates, and 
allowed to adhere over night (37°C, C 02 incubator) prior to the addition of lOOpl of the appropriate 
drug solution (concentration range: 0-100|ig/ml) and final volume was 200j.il/well. Incubation with 
drug was continued for 24 hours. Following this time period 20(il/well of BrdU labelling solution was 
added to each well (final concentration: 10|_iM BrdU). The cells were then reincubated for an 
additional 2 hours at 37°C. After this time the labelling medium was removed by tapping off, 
200f.il/well of FixDenat solution (cell fixing solution) was added to each well and the microtitre plate 
was incubated for 30 mins at room temperature. The FixDenat solution was then removed from each 
well by flicking off and tapping plates. lOOfd of anti-BrdU-POD working solution was added to each 
well except the wells reserved as background controls. The microtitre plates were then incubated for 
90 mins at room temperature. The antibody conjugate was removed by flicking off and rinsing the
wells three times with 200jJ/well wash solution (PBS). This wash solution was removed by tapping 
and 1 OOfil of substrate solution (TMB) was added to each well. Finally, microtitre plates were 
incubated at room temperature until colour development was sufficient for photometric detection (5- 
30 mins) at 370nm.
2.5.7. Protein Techniques
2.5.7.1. BCA Protein Assay
The BCA assay was used to detect protein quantitatively and was obtained commercially as a 
kit from Pierce, Rockford IL. In this assay, Cu2+ reacts with protein under alkaline conditions to give 
Cu+, which reacts with BCA to give a coloured product. Two separate reagents are supplied as part of 
the kit: Reagent A, an alkaline bicarbonate buffer, and Reagent B, a 4% (w/v) copper sulphate 
solution. The working solution was prepared fresh each time by combining 50 parts of Reagent A to 1 
part Reagent B. Protein standards in the range 0-1 mg/ml were prepared in 0.1 M PBS, pH 7.4.
For the assay lOfxl of sample or standard was placed in the well of a 96-well plate. 200p.l of 
the BCA working solution was added and the plate was gently swirled to ensure mixing of the 
solutions. The plate was then incubated at 37°C for 30 mins, before the absorbance of each well at 
560nm was determined on a Titertek Twinplus plate-reader. All standards and samples were 
determined in triplicate. The absorbances of the standard solutions were used to construct a standard
curve from which the protein concentration of the samples could be determined.
2.5.7.2. Polyacrylamide Gel Electrophoresis (PAGE)
Polyacrylamide gel electrophoresis (PAGE) was carried out using the discontinuous system, 
in the presence of sodium dodecyl sulphate (SDS), as described by Laemmli (1970). 8% (w/v) 
resolving and 4% (w/v) stacking gels were normally used and prepared from the following stock 
solutions as outlined in Table 2.4.
2.5.7.3. Staining o f Gels with Coomassie Brilliant Blue
Gels were stained with Coomassie staining solution for visualisation of protein bands. Gels
were stained for 1 hour in 0.2% (w/v) Coomassie Brilliant Blue in methanol:acetic acid:distilled water 
(3:1:6). Gels were destained overnight in methanol:acetic acid:distilled water (3:1:6).
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2.5.8. BIAcore Studies
2.5.8.1. Preconcentration Studies
The BIAcore™ with CM5 chips, was used for all ‘real-time’ analyses. For a detailed 
description of the theory and practice of this instrument, the reader is referred to Jonnson et al. (1991) 
and Chapter 5 of this thesis. For preconcentration studies, warfarin-BSA was dissolved at a 
concentration of 50 pg/ml in 10 mM sodium acetate buffer, at a range of pH values between 3.8-5.5. 
These were passed, sequentially, over an underivatised chip surface, and that pH giving the greatest 
mass (measured in terms of response units (RU)) pre-concentrated at the surface of the chip, was used 
for subsequent warfarin-BSA immobilisation procedures.
2.5.8.2. Immobilisation of Drug-Protein Conjugates
The chip surface was activated, by passing 35 p.1 of a solution containing 0.05 M NHS and 0.2 
M EDC in ultra-pure (UP) H20, over the chip surface at a flow rate of 5 pl/min. 35 jxl of a solution of 
warfarin-BSA in 10 mM acetate buffer, pH 4.8, was passed over the surface at a flow rate of 5 (il/inin. 
Unreacted NHS groups were ‘capped’ by passing 35 (xl of a 1 M ethanolamine (pH 8.5) solution over 
the surface at a flow rate of 5 p.l/min.
2.5.8.3. Direct Immobilisation o f Drug on to the Chip Surface
Direct immobilisation of drug directly onto the chip surface, was performed manually outside
the BIAcore instrument. The chip was first allowed to equilibrate to room temperature. 40 p,l of HBS
buffer (Section 2.4.) was added to the sensor chip well and left for 5 minutes (in order to prime the
chip surface). This solution was then removed using lint-free adsorbent paper, without the paper
touching the dextran matrix. Equal volumes of 0.4 M EDC and 0.1 M NHS were then mixed, and 40
fil of the resulting solution, containing 0.05 M NHS and 0.2 M EDC in UPH20, was added to the chip
well and left for 15 minutes. The EDC/NHS was then removed using adsorbent paper. 4'-
aminowarfarin, at a concentration of 50 jig/ml in 10m M sodium acetate buffer, pH 5.5, was then
added to the chip well and allowed to react for 20 minutes. The chip was then blocked by adding 40 |xl
of a 1.0 M ethanolamine (pH 8.5) solution to the chip well and left for 20 minutes. The chip was then
extensively washed with distilled water and dried under nitrogen. The chip could then be stored in
HBS or in a desiccator for use with subsequent assays (1-2 months).
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2.5.8.4. Regeneration Studies
To assess the stability of the immobilised drug-protein conjugates or directly immobilised 
drug surfaces, a known concentration of antibody was passed over the chip surface and the surface 
regenerated with mild acid/base solution (10-25 mM HC1 was usually sufficient to dissociate the 
complex). This cycle of binding and regeneration was usually completed for greater than 50 cycles, 
and the binding signal measured to assess the stability and suitability of the immobilised surface for 
assay purposes.
2.5.8.5. Non-Specific Binding Studies
Bovine serum albumin (BSA) (-8000 RU) was immobilised on one of the flow cell surfaces 
of a sensor chip. A separate flow cell surface was left blank (no compound immobilised) and allocated 
as the dextran surface for non-specific binding studies. Purified monoclonal antibody solutions, and 
hybridoma supernatants at the requisite dilution (i.e. 1/100 dilution) were passed over the blank CM- 
dextran and BSA-immobilised sensor chip surfaces. The degree of non-specific binding of the 
monoclonal antibody to both the dextran layer and the immobilised BSA portion of the drug-protein 
conjugate was determined from the sensogram data which evaluated the amount of antibody bound (in 
RU) to either surface.
2. S. 8.6. Competitive/Inhibition Assays'
Warfarin was prepared at a series of concentrations ranging from 0.03-5,000 ng/ml by serial 
dilution, using Hepes Buffered Saline (HBS), pH 7.4 as diluent (Section 2.4). Antibody was then 
mixed with the various antigen concentrations using the BIAcore autosampler. The antibody:antigen 
mixture was allowed to equilibrate for a specified time interval (normally 5-10 minutes). The 
equilibrium mixtures were then passed sequentially, in random order, over the chip surface at 10 
(0,1/min for 4 minutes, and the chip surface regenerated between cycles by pulses of the appropriate 
regeneration solution for each antibody type. The amount of bound antibody following injection of the 
antibody:antigen mix was measured in terms of response units (R). The respective responses (R), were 
then divided by the response measured for the antibody.antigen mixture containing zero antigen (R0), 
to give normalised binding responses (R/R0). A plot of antigen concentration ng/ml versus normalised 
binding responses (R/Ro) could then be used to construct the calibration plot using BIAevaluation 3.1 
software.
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2. S. 8.7. Solution Affinity Analysis Using Biacore
Warfarin-BSA (13,000 RU) was immobilised using the conventional EDC/NHS coupling 
chemistry. Serial dilutions of Protein G-purified anti-warfarin monoclonal antibodies of known 
concentration were passed over the immobilised surface, and a calibration curve was constructed of 
mass bound measured in terms of response units, versus antibody concentration (nM). A known 
concentration of antibody was then incubated with varying concentrations of warfarin (nM), and 
allowed to reach equilibrium overnight. The equilibrium samples were then sequentially passed over 
the immobilised surface and the binding response calculated. The response values measured were used 
to calculate the amount o f‘free antibody’ in the equilibrium mixtures, from the constructed calibration 
curve. A graph was then constructed of drug concentration (nM) versus ‘free antibody concentration’ 
(nM), and using the solution phase interaction models in BIAevaluation 3.1 software, the overall 
affinity constant could be determined.
2.5.8.8. Steady State Affinity Analysis Using Biacore
Warfarin-BSA (-1200 RU) and BSA (-1500 RU) were immobilised on separate flow cell 
surfaces of a sensor chip. Serial dilutions of purified monoclonal antibodies to warfarin of known 
concentration, were then sequentially passed over the chip surfaces using ‘on-line’ reference curve 
subtraction. A graph was then constructed of the equilibrium binding response (Req) measured versus 
antibody concentration (nM). Using the steady-state interaction model in BIAevaluation 3.1 software, 
the affinity constant could then be calculated for the interaction.
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Chapter 3
Characterisation and Applications of 
Monoclonal Antibodies to Warfarin
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3.1. Introduction
Antibodies are serum-proteins called immunoglobulins that are produced by B-lymphocytes in 
response to a foreign substance (i.e. antigen). Antibodies may be raised to almost all classes of 
substances including, proteins, polysaccharides, nucleic acids and complex particles (e.g. pollens, 
infectious agents and cells). They typically exhibit high binding affinities for the target antigen and 
mediate many biological effector functions as part of the humoral immune system. Those most 
commonly produced and used for analytical applications have been either entire or partial antibodies 
of the subclass immunoglobulin G (IgG) (Jefferis & Deverill, 1992).
3.1.1. Antibody Structure
An illustration of a typical antibody, an immunoglobulin G (IgG) molecule, is shown in 
Figure 3.1. An antibody is a Y-shaped molecule that possesses two identical antigen-binding sites. 
Each binding site is formed from two polypeptide chains, one heavy (H) chain (50 kDa) and one light 
(L) chain (25 kDa) that are coupled together by a disulphide bridge. The heavy chain consists of four 
domains named from the binding site as VH, CH1, CH2, and CH3. C stands for constant domain 
(Crowther, 1995). The variable region is composed of the variable heavy (Vh) and variable light (VL) 
domains, which demonstrate amino acid variability between antibodies. The variable region is further 
subdivided into hypervariable (HV) and framework (FR) regions (Steward, 1984). Hypervariable 
regions have a high ratio of different amino acids in a given position, relative to the most common 
amino acid in that position. Within light and heavy chains, three hypervariable regions exist -  HV 1, 2 
and 3. Four FR regions, which have more stable amino acids sequences, separate the HV regions. The 
HV regions directly contact a portion of the antigen's surface. For this reason, HV regions are also 
sometimes referred to as complementarity determining regions (CDRs). The FR regions form a beta- 
sheet structure, which serves as a scaffold to hold the HV regions in position to contact the antigen. 
The CDRs differ in length and sequence between different antibodies and are mainly responsible for 
the specificity (recognition) and affinity (binding) of the antibodies to their target markers. Proteolytic 
digestion of antibodies releases different fragments termed Fv (Fragment variable), Fab (Fragment 
antigen binding) and Fc (Fragment crystallisation). Antibody engineering can join the separate 
segments of the heavy and light chains in the Fv with a flexible peptide linker to form a single-chain 
Fv (scFv).
X-ray crystallographic studies have established that six CDRs form the strongest contacts 
with the antigen and define the antibody binding properties. The CDRs from both VHand VL domains
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associate in three-dimensional space to form the antigen-binding site (idiotype). The CDR region can 
be further sub-divided into three different regions (i.e. CDR1, CDR2 and CDR3) of about 10 amino 
acid residues in length between which lies more conserved sequences known as the framework 
residues. When the heavy and light chains are created, the variable (V) region is formed and the CDR 
sequences are exposed, forming a cleft that serves as the antigen-binding pocket. It is the precise 
amino acid sequence, shape and positioning of this cleft or pocket resulting from the combination of 
the six CDR sequences which form hypervariable loops that confers the particular antibody 
specificity. Furthermore, studies indicate that the VH region plays a greater role in antigen-binding 
than the Vl region (Davies, 1994a).
There are five main classes of antibody (isotypes) that have been resolved, which differ in the 
structure of their heavy chains (Table 3.1). The basic four-chain model holds for all antibody isotypes 
with specific heavy chains for each class, y for IgG, |j. for IgM, 8 for IgD, a  for IgA and e for IgE 
(Cahill et al, 1995; Bengten et al., 2000). The light chains are serologically divided into k  and X 
chains, although these are similar in each isotype class. In addition, each antibody isotype is 
segregated into sub-classes such as IgGj and IgG2a (Jefferis & Deverill, 1992). Antibody function is 
largely determined by the specificity and affinity of the antigen-binding site and by the heavy chain 
isotype.
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Table 3.1: Functions and Structural Features o f Antibody Isotypes
Characteristic IgG IgM IgD IgA IgE
Molecular
Weight
150 kDa 950 kDa 175 kDa 165 kDa 
(monomeric) 
390 kDa 
(secretory)
190 kDa
Subunits 1 5 1 1 ,2  or more 1
Heavy chain 4 5 4 4 5
domains
Heavy chain r 5 a E
Light chain KorÀ Kor A. K or X Kor X k  or X
Molecular Y2K2, (¿2*2, S2k2, ( a 2K 2)  1,2,3 or 4 s2k2,
Formula l i h fx2A,2 82^ 2 (a 2A.2) 1,2,3 or 4 s2A,2
Subclasses IgG,, IgG2, 
IgG3 & IgG4
none none IgAi & IgA2 none
Valency 2 5/10 2 4 2
Concentration 8-16 mg/ml 0.5-2 mg/ml 40 ng/ml 1-4 mg/ml 0.4 ng/ml
in serum
Half-life IgG„ 2 & 4: 
23 days 
IgG3: 8 days
5 days 3 days 6  days 2.5 days
Polymer unit Monomer Monomer
(membrane)
Pentamer
(secreted)
Monomer Monomer, 
dimer, trimer 
& tetramer
Monomer
Function • Main serum • First to be • Primarily a cell • Chief Ig • Triggers
antibody in produced in surface receptor component of inflammatory
secondary a primary • expression external reactions via specific
response response varies during secretions receptors on mast
• ability to • low affinity B cell (e.g. saliva, cells and basophils
bind many 
cell types 
and to fix 
complement 
(varies with 
subclass)
but high 
avidity to 
multivalent 
antigens 
• complement 
fixation
differentiation sweat, tears) • elicits effector 
responses to some 
gut parasites
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Figure 3.1: Illustration o f an immunoglobulin G molecule. The molecule is composed offour peptide 
chains that fold into domains, which are stabilised by disulphide bonds. Interchain disulphide bridges 
connect the heavy and light chains; there are also intrachain disulphide bonds that form loops within 
the chain. Both antigen-binding sites are formed by association o f the variable region of the heavy 
chain (VH) with the variable region o f the light chain (Vj) and the amino acid residues that form the 
binding contacts with the antigen are located in the CDR regions. The CDR regions confer specificity 
to the particular antibody-binding site, and exhibit high amino acid sequence variability. 
Carbohydrate residues are commonly located along the constant domains but the biological role o f 
these residues is uncertain.
3.1.2. Monoclonal Antibodies
Traditionally, all antibody sera were purified from whole blood extracted from an animal that 
had undergone an immunisation procedure against the target antigen. These polyclonal antibody 
preparations are composed of many antibody isotopes with specificities for a range of epitopes located
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on the antigen surface. This heterogeneity limited the application of polyclonal antibodies in many 
areas.
In 1975, César Milstein and Georges Köhler at the Medical Research Council's (MRC) 
Laboratory of Molecular Biology (LMB) in Cambridge (UK) worked out a way to produce “custom- 
built” antibodies in vitro with relative ease (Köhler & Milstein, 1975). Monoclonal antibodies (mAbs), 
derived from the progeny of a single immune cell, were pure and available in potentially unlimited 
quantities. Since then mAbs have become essential reagents for both highly specific protein detection 
and the characterisation of protein structure and function. The combined properties of hybridoma 
immortality and the exquisite specificity of the monoclonal antibody (mAb) produced have been 
readily exploited for the creation of standardised reagents for diagnostic assays and, more recently, 
novel therapeutic agents (Bruce et al, 2002).
3.1.2.1. Production o f Monoclonal Antibodies Following Immunisation
In order to produce monoclonal antibodies, an animal such as a mouse or rat is initially 
immunised with the antigen of interest. The serum response of the animal is directly monitored for 
antibody production to the antigen. When an adequately high serum titre is attained the animal is 
sacrificed and the spleencocytes are harvested for cell fusion procedures (Sikora & Smedley, 1984). A 
variety of myeloma cell lines are commercially available as suitable fusion partners and the most 
frequently employed include X63-Ag8.653 and Sp2/0-Agl4 cell lines, which were produced from a 
myeloma cell line developed following the injection of mineral oil into the peritoneal cavity of mice 
(Delves, 1995). Kohler and Milstein (1975) developed a method, by which spleen lymphocytes were 
activated in vivo and then fused to myeloma cells using polyethylene glycol (PEG), yielding 
hybridoma cells. Even though the initial report by Köhler & Milstein used Sendai virus as the fiisogen, 
almost all researchers subsequently used PEG to induce cell fusion and procedures are well 
established for fusing cells with PEG (Gefter et al., 1977; Herzenberg et al., 1978). Once spleenocytes 
are fused with myeloma cells it is necessary to eliminate unfused cells as not all myeloma cells will 
have fused with spleenocytes to form hybridomas and remain growing healthily in an unfused state. 
This is accomplished by utilising a myeloma cell line deficient in the enzyme responsible for 
incorporation of hypoxanthine into DNA. Cells can synthesize DNA in two ways, either by de novo 
synthesis or via the ‘salvage’ pathway using exogenous sources of preformed bases as summarised in 
Figure 3.2a. If myeloma cells are grown in the presence of a purine analogue, for example 8- 
azaguanine or 6-thioguanine, the hypoxanthine guanine phosphoribosyltransferase (HGPRT) enzyme 
catalyses the incorporation of the purine analogue into DNA where it interferes with normal protein
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synthesis and so the cells die. Gene coding for the HGPRT enzyme is on the X chromosome, so only a 
single copy per cell is expressed. Cells will arise that are deficient in the HGPRT gene and therefore 
do not incorporate the purine analogue, i.e. HGPRT-deficient cells which are unable to utilise 
hypoxanthine and therefore, can only synthesise ribonucleotides by de novo synthesis (Figure 3.2b). A 
selective medium containing Hypoxanthine, Aminopterin, and Thymidine (HAT medium) is used. 
Aminopterin (analogue of folic acid) binds folic acid reductase and blocks the coenzymes required for 
de novo synthesis DNA. To grow in this medium a cell must make DNA via the ‘salvage’ pathway. If 
HGPRT-deficient myeloma cells are fused with normal spleenocyte cells and then placed in HAT 
medium, only the hybrids between myelomas and normal cells will grow (myeloma cell provides 
immortality; spleenocyte provides the HGPRT enzyme -  Figure 3.2c) The hybridoma cells are a 
permanent cell line and have the ability to grow in culture and to secrete a defined antibody. The 
secreted antibodies can then be screened for binding to antigen by enzyme-linked immunosorbent 
assay (ELISA). Those hybridoma cells secreting antibody that binds to antigen are cloned by limiting 
dilution to yield one cell per well. Therefore, all resulting cells are derived from a single parent cell 
(Sikora& Smedley, 1984).
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De novo synthesis Salvage pathway
Figure 3.2a: Pathways o f DNA synthesis in cells. Most cells can make DNA either by de novo 
synthesis or via the ‘salvage’pathway, using an endogenous or exogenous source o f preformed bases 
(Hay & Westwood, 2002).
t
Supply of key enzymes HGPRT and 
TEC from normal spleenocyte 
fusing with mutant myeloma 
allows synthesis of pyrimidines and 
purines from hypoxanthine (H) 
and thymidine (T) present in HAT medium
Figure 3.2b: In order to select cells which are solely the result o f fusion with a normal antibody- 
forming cell with a myeloma cell, de novo DNA synthesis is partially stopped with aminopterin A. This 
reagent blocks the enzyme dihydrofolate reductase, while the ‘salvage’ pathway is blocked by 
preselecting for the myeloma cells that can survive in the presence o f the lethal purine analogues, 8- 
aza or 6-thioguanine. These cells lack the key salvage pathway enzymes: hypoxanthine guanine 
phosphoribosyltransferase (HPGRT) and thymidine kinase (TK). These enzymes are then supplied by 
the normal antibody-forming partner cell (Hay & Westwood, 2002).
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Figure 3.2c: The myeloma ‘parent’ is HGPRT-deficient and so is unable to grow in HAT medium. 
HAT contains either the folic acid analogue aminopterin or the amination inhibitor, azaserine, which 
block de novo synthesis. Since these cells cannot use hypoxanthine they die. Hybrid cells grow out 
from HAT medium because DNA from the normal partner provides the information to synthesize 
HGPRT and the myeloma cell DNA provides the 'message ’ for unrestricted proliferation (Hay & 
Westwood, 2002).
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3.1.2.1.1. Production o f  Monoclonal Antibodies to Small Haptens
The ability of a particular molecule to provoke an immune response is known as 
immunogenicity and is dependent upon a variety of factors such as molecular weight, chemical 
composition and ‘foreignness’. Substances with a molecular weight of approximately 100,000 Da are 
the best immunogens, while molecules with a molecular mass of less than 1,000 Da (haptens) do not 
usually cause antibody production (Kuby, 1997). The prospect of raising mAbs with high affinity for 
the target antigen is greatly reduced for haptens with a molecular weight of <1000 Da and mAbs to 
such small haptens can only be generated using the hapten conjugated to a carrier molecule. One of 
the potential problems is that a hapten alone is too small to cross-link lymphocyte cell-surface 
receptors and so will not stimulate B-cell differentiation to plasma cells and antibody production. The 
B-cell response to antigen, in the majority of cases, requires co-operation by T-cells. Again because of 
its small size, the hapten cannot stimulate two lymphocytes simultaneously. This may be overcome by 
hapten conjugated to an immunogenic protein. The T-cells will recognise this protein, or carrier 
molecule, and so co-operate with B cells to produce anti-hapten antibody (anti-carrier antibody is also 
produced) (Hay & Westwood, 2002). The most frequently used carriers are highly immunogenic 
proteins (e.g. Bovine Serum Albumin [BSA]; 67kDa, Ovalbumin; 45kDa), but lipid bilayers, polymers 
(e.g. dextran), and synthetic organic molecules have also been used (Hermanson, 1996). Carriers must 
be inherently immunogenic, possess suitable functional groups for covalent linkage and be non-toxic 
in vivo.
Fasciglione et al., (1996) recognised three crucial aspects for the production of conjugates 
(e.g. warfarin-BSA). These consist of the hapten conjugation method employed, the choice of carrier 
molecule and the amount of neodeterminants introduced. The conjugation method should enhance the 
specific antibody response to the hapten. It was determined that the choice of carrier protein 
specifically modulates the serum titre and affinity of clones generated. Hydrophobic haptens are 
capable of modifying the tertiary structure of carrier proteins and become hidden in the core of 
protein, thereby limiting the interaction with the immune response and serum response generated. 
Hence, it was suggested that specific hydrophilic carriers such as poly-L-lysine and sepharose be used 
for small hydrophobic haptens (Fasciglione et al, 1996). Hapten-protein conjugates can be utilised at 
the screening stage of antibody production. When screening for the presence of specific antibody it is 
necessary to use a conjugate containing a different protein moiety than the immunogen to minimise 
false positive results. This finding is supported by reports of difficulties associated with the selection 
of antibodies to small molecular weight haptens during screening procedures, resulting in the selection 
of antibodies sharing a combined drug-protein epitope (Danilova, 1994; Keating, 1998; Killard, 1998).
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The use of conjugates employing different coupling chemistries and carrier protein homology than 
those used for immunisation procedures is thus strongly recommended. Danilova (1994) suggested 
that, when dealing with very small haptens, the conjugate used for screening should possess a different 
carrier molecule and coupling chemistry than that used for immunisation.
There are a variety of coupling chemistries available for coupling proteins to small molecules 
such as warfarin. The choice of coupling chemistry employed is generally selected as a result of the 
chemical residues available for coupling and whether or not spacer molecules need be employed to 
distance the molecule from the carrier protein. Many aromatic ring systems contain active hydrogens, 
which can easily be displaced by attacking electrophilic groups. Diazonium groups are particularly 
reactive with these active hydrogens, and are a useful means of attachment for molecules with few 
available functional groups (Hermanson, 1996). Amino groups on phenolic compounds can be 
converted to diazonium groups by reaction with sodium nitrite in acidic conditions. The diazonium 
group reacts rapidly with the aromatic ring of tyrosine and histidine residues on protein molecules. 
Fitzpatrick (2001) used this conjugation procedure for the coupling of (4'-AW) 4'-aminowarfarin to 
various proteins (i.e. thyroglobulin, keyhole limpet haemocyanin (KLH), bovine serum albumin 
(BSA) and ovalbumin). Drug-protein conjugates containing diazonium bonds yield highly coloured 
complexes that are also extremely stable. Examples of haptens to which mAb were raised against 
include 5-benzimidazolecarboxylic acid (TBZ) a broad-spectrum anthelmintic and O, Odiethyl 0 (5 - 
carboxy-2-flurophenyl) phosphorothioate a conserved structure of organophosphorus pesticides (Jang 
et al., 2002; Moran et al., 2002). A recent application of using mAbs to detect haptens concerns the 
development of an immunochemical rapid test for multiresidue analysis of antimicrobial drugs in milk 
using a hapten-glucose oxidase conjugate (Strasser et al., 2003).
3.1.2.1.2. Clinical Applications o f  Monoclonal Antibodies
Monoclonal antibodies have become the cornerstone of most diagnostic kits, immunoaffinity 
procedures and are extensively used for the detection of a wide variety of target antigens ranging from 
pesticides, illicit drugs and toxins to blood markers (Markowska, 2003). Their use in the monitoring of 
environmental (e.g. pesticides, pollutants) and food (e.g. growth promoters) residues were recently 
reviewed (Fitzpatrick et al., 2000). Monoclonal antibodies have become an extraordinarily important 
resource for medical research, diagnosis and therapy. However, the design of a therapeutic strategy 
requires consideration of certain factors including short- and long-term side-effects as well as benefits 
of monoclonal antibody use. Particular attention needs to be paid to deciding which therapeutic effect 
is most desirable and how it is expected that the antibody may produce that effect (Waldmann, 1989).
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Over a century ago, Paul Ehrlich proposed that antibodies could be used as “magic bullets” to target 
and destroy human diseases. This vision is still being pursued today for many kinds of therapy, such as 
in the treatment of malignancies, where a “toxic payload” (such as a radioactive element or a plant 
toxin) attached to the antibody can be accurately delivered to the target. This confers potential 
suitability for homing in on and killing cancer cells, infectious diseases (bacteria, viruses and their 
toxins) as well as modulating the immune system by binding and inhibiting or enhancing its regulatory 
molecules and thus curing autoimmune and inflammatory diseases.
The impact of mAbs in the treatment of human tumours has greatly increased in recent years 
(Bestagno et al., 2003). Lin and co-workers (2003) investigated the effects of an anti-basic fibroblast 
growth factor mAb (bFGF-mAb) on the proliferation, invasion and angiogenesis of ovarian cancer. 
They determined that the bFGF-mAb was capable of inhibiting the in vitro proliferation of SKOV3 
human ovarian cancer cells in a concentration dependent manner. Thus, this mAb shows promise in 
the biological treatment of ovarian cancer. Other forms of cancer such as small cell lung cancer 
(SCLC), B-cell non-Hodgkin’s lymphoma and renal cancer have shown promising results following 
monoclonal antibody treatment, in clinical trials (Coleman et al., 2003; Heidenreich et al., 2003; 
Shepherd, 2003).
Some applications of monoclonal antibody therapy have already met with success. 
Abciximab, a Fab monoclonal antibody fragment that blocks the platelet glycoprotein Ilb/UIa 
receptor, is increasingly used as an adjunct to coronary intervention. A clinical study has confirmed 
that abciximab remains clinically efficacious when readministered as an adjunct to percutaneous 
coronary intervention. However, concomitant heparin administration must be carefully monitored and 
warfarin therapy should be avoided. Reduced dosing may be necessary when abciximab is 
readministered within days of the initial administration (Madan & Tcheng, 2000).
3.1.2.1.3. Antibody Humanisation fo r  Therapeutic Applications
The development of mAbs has had a considerable impact on the area of clinical diagnostics, 
but the expected success in the area of human therapy to date has not been fully realised (Clark, 2000). 
Although the first mAb to be approved as a human therapeutic was a murine antibody (OKT3) it was 
generally not well tolerated and certain problems were initially encountered with the use of these 
monoclonal antibodies. They did not always trigger the requisite effector function, and had a short 
life-span in vivo, due to the fact the antibodies often elicited a HAMA (Human anti-Mouse Antibody) 
response. The HAMA response resulted in the increased clearance of the antibody from the circulation
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thereby negating the therapeutic potential. Murine antibodies also possess the potential to be highly 
immunogenic in humans (Jaffers el al., 1986; Kellermann & Green, 2002). In order to circumvent this 
response it was necessary to minimise the non-human sequence of the mAbs (Figure 3.4.). This was 
achieved by constructing chimaeric antibodies where the mouse variable regions were joined to human 
constant regions (Boulianne et al., 1984). This technology was advanced by humanisation, which led 
to the successes of infliximab (anti-tumour necrosis factor a) and trastuzumab (anti-human epidermal 
growth factor 2). Chimaerisation solved some of the initial problems associated with murine mAbs: as 
it allowed for increased half-life in the circulatory system through interaction with the Brambell 
receptor (FcRn), which protects the IgG from catabolism thereby recycling it back to the serum pool 
(Ghetie & Ward, 2000); and the ability to recruit effector cells such as complement and cytotoxic cells 
(Glennie & Johnson, 2000; Rader et al., 2003). Infliximab is a promising agent for the treatment of 
Hidradenitis suppurativa (HS) a chronic disease characterized by significant morbidity. The initial 
findings suggest that infliximab is associated with objective and subjective improvement in HS. 
Further controlled studies of the efficacy of infliximab and its effect on the course of the disease are 
warranted (Sullivan et al., 2003)
Research into the use of chimaeric Fab fragments for radioimmunoscintigraphy has shown 
promise due to the fact that the chimaeric fragments half-life is longer than intact mAb and can 
accumulate rapidly in tumours thus helping in the early diagnosis of pancreatic carcinoma (Otsuji et 
al., 2003). A chimaeric and complementary-determining region (CDR) grafted monoclonal antibody 
(mAb) was generated by Forero and co-workers (2003) to help reduce the immunogenicity problem in 
radioimmunotherapy with monoclonal antibodies. However, humanization has prolonged the 
circulation of radiolabeled antibodies, resulting in an increased normal tissue exposure to radioactivity 
and greater dose-limiting bone marrow suppression. To overcome this problem, a tumour-associated 
glycoprotein (TAG)-72-specific CDR grafted mAb with C(H)2 domain deletion (DeltaC(H)2) was 
developed from the mAb CC49. Preliminary studies were preformed with metastatic colorectal 
carcinoma patients. These studies support the further clinical investigation of this agent in phase I 
trials by intravenous and intraperitoneal routes. Although there are many promising applications of 
chimaeric and humanised antibodies, there are some drawbacks. Chimaeric antibodies may still be 
considered immunogenic, and humanisation requires sophisticated molecular biological techniques 
and may sacrifice the affinity and potency of the original antibody.
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Figure 3.4: This diagram illustrates the concept o f mouse, chimaeric, humanised and human 
antibodies (Blue = murine, Red =human).
Although display technologies using systems such as phage, ribosomes or yeast can be 
powerful tools to generate human antibodies (Table 3.2.), optimising such antibodies for high affinity 
and potency can be labour intensive. Two strategies have evolved, which utilise recombinant antibody 
technology through the expression of naive variable regions expressed on the surface of bacteriophage 
and the use of transgenic mice (Vaughan et al., 1998). The rationale behind mice transgenic for human 
immunoglobulin loci is to harness the natural recombination and affinity maturation machinery to 
generate human antibodies of wide diversity and high affinity.
The evolution of transgenic mouse technologies was first marked by the report of a transgenic 
mouse containing a predominantly human IgH minilocus, permitting the expression of IgM antibodies 
with human n chains, but containing mouse light chains (Bruggermann et al., 1989). The 
XenoMouse™ strains of transgenic mice were the first engineered mice to include a majority of both 
the human VH and V k  repertoire. The mice immunoglobulin genes were replaced with human Ig 
genes on YAC (Yeast Artificial Chromosomes) transgenes, which carry the majority of the human 
variable repertoire as well as the possibility of undergoing class-switching from IgM to IgG and 
efficient affinity maturation, Xenomouse™ strains of mice recognise human antigens as foreign, and 
are capable of producing antibodies with sub-nanomolar affinities (Mendez et al., 1997). Due to the 
fact that the YAC transgenes are integrated into a mouse chromosome, they offer superior genetic 
stability. Currently, five fully human antibodies from the XenoMouse™ strains have been used in 
clinical trials (Green, 1999; Galka et al., 2000). The first transgenic-mouse-derived fully humanised 
antibody entered clinical trials in 1998 (Yang et al., 1999a). Since then other mAbs have followed 
including antibodies against epidermal growth factor, CD4, CTLA-4 (cytotoxic T lymphocyte-
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associated antigen 4) CD69, and several cancer-specific target antigens (Tistravik et al., 1999; Yang et 
al, 1999b; Molina et al., 2003). XenoMouse™ antibodies are also adaptable to production directly 
from hybridomas, transgenic plants or recombinant cell lines with many in preclinical and early 
clinical testing stages at the present time. Laboratory and initial clinical studies suggest that 
epratuzumab, a humanized anti-CD22 monoclonal antibody, may have anti-lymphoma activity in both 
unlabeled and radiolabeled forms. Efforts are underway to establish the utility of epratuzumab as a 
treatment for B-cell malignancies, through single agent and combination regimens, to define the 
optimal settings for its clinical application (Coleman et al., 2003).
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Table 3.2: Classification o f existing therapeutic antibodies and the strategies currently available for 
their production.
Antibody Type Description
MURINE These have been used therapeutically and the first inAb to be FDA
MONOCLONAL approved was OKT3 a mouse IgG2a (1986). These mAbs tend to provoke
ANTIBODIES: strong (HAMA) immune responses, which restricts their usefulness for 
repeated application in the same patient.
CHIMAERIC The whole of the variable regions of a mouse or rat antibody are expressed
ANTIBODIES: along with human constant regions. This provides the antibody with 
human effector functions and also reduces immunogenicity (HAMA) 
caused by the murine Fc region.
HUMANISED An alternative to chimaeric antibodies where only the complimentarity
ANTIBODIES: determining regions from the rodent antibody V-regions are combined 
with framework regions from human V-regions. These antibodies should 
be more ‘human-like’ than chimaeric and, thus, less immunogenic than 
chimaeric antibodies.
HUMAN ANTIBODIES Some antibodies have been rescued from immune human donors using
FROM IMMUNE either EBV transformation of B-cells or by PCR cloning and phage
DONORS: display. By definition these antibodies are completely human in origin.
FULLY HUMAN Synthetic phage libraries created which utilising randomized combinations
ANTIBODIES FROM of synthetic human antibody V-regions. By selection on antigen fully
PHAGE LIBRARIES: humanised abs can be made where it is assumed the V-regions are very 
‘human-like’ in nature.
FULLY HUMAN Transgenic mice have been created which have a repertoire of human
ANTIBODIES FROM immunoglobulin germline gene, segments. These mice when immunised
TRANSGENIC MICE: thus make human-like antibodies.
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3.1.2.1.4. Antibody Engineering
In the late eighties initial steps in antibody engineering revolutionized the technology of 
antibody production, particularly in the area of immunotherapy and diagnostics and is reviewed by 
Kramer & Hock, (2003). Recombinant DNA technology and antibody engineering have 
supplemented, and in some instances, replaced hybriboma technology in the production of ‘tailor- 
made’ antibodies of high affinity to any particular antigen (Hoogenboom & Chames, 2000; Hudson & 
Souriau, 2001). With the advent of this technology, antibody genes can be amplified and selected 
using phage display and in addition, cell surface and cell free display systems. An advantageous 
feature of these display systems is the linking of the phenotype (binding specificity) and genotype 
(antibody V regions) of the antibodies during selection, thus allowing simple co-selection of the 
desired antibodies and their encoding genes based on the binding characteristics of the displayed 
antibodies (Yau et al., 2003). Phage display involves cloning DNA into bacteriophage genome as a 
fusion to one of phage coat proteins. Following expression the antibody fragments are presented on 
the surface of the phage with the encoding DNA residing within the phage. The phage display library 
can then be panned by selection of phage with specific binding affinity towards a particular 
immobilised target ligand. The affinity of the antibodies created was reported to be proportional to the 
size of the antibody library (Sblattero & Bradbury, 2000).
Recombinant antibody libraries can be constructed from naïve or immunised donors, and also 
from synthetic libraries. Immunised donors are previously enriched for specific immunoglobulin, with 
some undergoing affinity maturation. The affinity of the selected antibodies is frequently not 
adequately elevated and may necessitate in vitro affinity maturation to produce antibodies of suitable 
affinity (Hemminki et al., 1998). This can be achieved in a variety of ways from the use of mutator 
strains, the use of error prone PCR (Harayama, 1998), chain or oligonucleotide-directed mutagenesis 
shuffling (Jirholt et al., 1998). The introduction of diversity into the V genes allows for the creation of 
a ‘mature’ secondary library from which higher affinity variants may be selected. BIAcore-based 
selection procedures allows for the selection of particular variants with respect to specific affinity and 
kinetic rate constants (Duenas et al., 1996). High affinity antibodies may be selected from naïve 
libraries that are particularly useful for selection of human antibodies (Hoogenboom et al., 1998).
ScFvs with femtomolar association constants, the highest yet reported for monovalent ligands 
have been produced using a similar approach of ‘molecular breeding’ involving repeated cycles of 
affinity mutagenesis (Boder et al., 2000). The potential applications of such higher affinity variants 
with association constants 1000 fold greater than possible by in vivo maturation, is particularly
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interesting for developing areas such as immunotherapy and tumour targeting. scFv antibodies have 
recently been directed towards several pathogenic targets such as the highly infectious Brucella 
melitensis (Hayhurst et al., 2003). A recombinant scFv antibody to the exotoxin from Burkholderia 
pseudomallei was constructed by phage display and exhibited good specificity towards the exotoxin 
(Su et al., 2003). Antibodies from phage and ribosome display libraries have found application in 
microarray technology (He & Taussig, 2001; Tomlinson & Holt, 2001) and may prove useful for 
studying protein-protein interactions and proteomics (Haab et al., 2001; Kodadek, 2001).
3.1.2.1.5. Alternative Expression Systems and Novel Antibody Constructs
A variety of expression systems are available for the production of antibodies and antibody 
fragments, including the use of bacteria, yeast, plants, insect cells and mammalian cells. Each one has 
advantages and limitations with respect to ease of production and the glycosylation pattern of 
antibodies recorded. Two potentially relatively low cost antibody expressions systems are described. 
The concept of using plants as heterlogous expression hosts for recombinant antibodies is more than a 
decade old (Hiatt et al., 1989). It was reported that genetically engineered tobacco plants were capable 
of synthesising correctly folded immunoglobulin heavy and light chains. Plants represent an 
inexpensive, efficient and safe alternative to traditional systems used for the commercial-scale 
synthesis of recombinant antibodies (Nolke et al., 2003). Therefore, it is not surprising that a variety 
of ‘plantibodies’ have since been constructed, three of which are currently in use as 
immunotherapeutic products for the treatment of caries and cancer (Larrick et al., 1998). Plantibodies 
offer several advantages as potential protein sources and they represent a viable alternative to 
prokaryotic and mammalian expression systems. Advantages include the production of antibodies on 
an agricultural low-cost scale, and potential increased safety as plants do not serve as human pathogen 
hosts (e.g. HIV, prions). Contemporary applications in agronomic research include 
immunomodulation of physiological processes and engineering of antibody-mediated resistance to 
pathogen infection (Stoger et al., 2003). The most advanced application, however, is the utilisation of 
plants as bioreactors to produce antibodies required for medical use or industrial processes (Fischer & 
Emans, 2000; Daniell et al., 2001; Larrick & Thomas, 2001).
One of the challenges created by the biotechnology revolution is the development of methods 
for the cost-effective large-scale production of highly purified proteins. Recent developments indicate 
that expression of recombinant proteins in the milk of transgenic animals may be suited for the 
production of complex polypeptides (Pollock et al., 1999). Expression vectors containing the gene 
encoding the specific protein fused to milk specific regulatory genes can be introduced by
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microinjection into embryo cells. Following a period of in vitro culture the embryos can be transferred 
to pseudopregnant animals and development to full term (Little et al., 2000). Following integration 
into the germline, the mammary gland specific transgene is transmitted in Mendelian fashion and, if 
expressed, will become a dominant genetic characteristic inherited by offspring of the mammalian 
originator. The identified animals can then be bred or induced to lactate. Dairy goats were shown to be 
excellent animals for the production of transgenic milk, capable of producing between 1 and 5 g/1 of 
recombinant antibody (Pollock et al., 1999). The efficiency of microinjection has limited the 
development of this technology as the integration into the genome of specific transgenes is typically 
low, 0.1% in cattle to 5% in mice. The antibodies can be separated from the majority of milk proteins 
by standard dairy procedures to relatively pure antibody (-60%), which can be further, purified by 
traditional chromatography procedures (e.g. Ion exchange, Protein A/G chromatography). A variety of 
antibodies have been produced in the milk of transgenic animals, and in particular cases been shown to 
be produced at levels 160,000 fold times those recorded in cell culture systems whilst retaining all 
biological activity (Newton et al., 1999).
A scFv (single chain variable fragment) antibody contains a synthetic amino acid linker 
peptide (usually a glycine-serine repeat linker), which acts to stabilise the antibody fragment without 
interfering with the domain association. Diabodies are recombinant, dimeric, antibody-based 
molecules (55-60kDa) composed of two non-covalently associated single-chain antibody fragments 
(scFv) that bind to an antigen in a divalent manner (Aubrey et al., 2003). The construction of scFv 
fragment, with a short linker (5-10 amino acid residues) between the variable heavy and light domains, 
permits interchain, but not intrachain, pairing of the variable domains (Lu et al., 2003). Careful 
selection of the linker length dictates the size (kDa), and thus the valency of the scFv multimer formed 
(Hudson & Kortt, 1999). Reducing the linker length below 3 residues forces the scFv to form 
triabodies (90 kDa) or tetramers (120 kDa). As a result of the increase in valency, scFv multimers 
exhibit veiy high avidity and reduced off rates as a result of multiple binding and re-binding when one 
Fv dissociates (Pluckthhun & Pack, 1997). In BIAcore studies conducted, Iliades et a/.,(1997) found 
that the trimers produced from a scFv exhibited an approximate 4-fold apparent slower off-rate 
compared to the monomeric unit.
The association of two diverse scFv molecules from different parent IgG will result in the 
formation of bispecific diabodies (Hollinger et al., 1993), which have been successfully used for 
ELISA, immunohistochemistry and immunoblotting procedures (Kontermann et al., 1997).
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Figure 3.5: Schematic diagram o f scFv and diabodies showing antigen binding sites. When joined by 
a peptide linker (L) at least 12 residues long scFv’s are predominantly monomeric, diabodies 
(~60Kda) are formed by selecting linkers between 3 and 12 residues. Reducing the linker length below 
3 residues can force scFv into triabodies (~90 kDa) and tetramers (-120 kDa).
The use of diabodies has gained increasing interest particularly in the areas of immunotherapy 
and tumour imaging (Arndt & Krauss 2003; Kipriyanov, 2003). The reduced size of diabodies 
compared to whole Ig for tumour targeting has the advantage of increased tumour penetration and 
faster clearance rates in vivo. To target NK cells against non-Hodgkin's lymphoma, Kipriyanov et al., 
(2002) constructed a bispecific diabody (BsDb) with reactivity against both human CD 19 and FcyRIII 
(CD 16). It was able to induce specific lysis of tumour cells in the presence of isolated human NK cells 
and the results obtained demonstrated the synergistic effect of small recombinant bispecific molecules 
recruiting different populations of human effector cells to the same tumour target. Bispecific diabodies 
have also been shown to induce cytotoxic and ‘vaccine effects’ in vivo (van Spriel et al., 2000), and a 
number are currently under trial for the treatment of various cancer cell types. Two bispecific 
diabodies (BS1.5 and BS1.5H) were produced and tested as potential agents for pretargeted delivery 
of radiolabelled bivalent haptens to tumours expressing carcinoembryonic antigen. These results 
indicate that both diabodies are promising candidates for use in a variety of pretargeting applications, 
including tumour therapy with radionucleotides and drugs (Rossi et al, 2003).
The combination of genetic engineering and advanced selection techniques has led to the 
development of a novel range of protein ligands, ‘affibodies’ (affinity ligands). Despite their small 
size and simple structure, these proteins have been shown to possess binding features similar to
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antibody variable domains in that selective binding with high affinity can be achieved towards various 
target molecules (Hansson et al., 1999; Ronnmark et al., 2002). Knottins, are a small group of small 
disulphide-bonded proteins capable of binding to target molecules. Smith and colleagues (1998) 
created knottin scaffolds with binding capacities in the micromolar range for target antigens such as 
alkaline phosphatase. Nord et a l,(1997) have also created ‘affibodies’, in which 13 surface-located 
positions of the 58 amino acid three-helix bundle protein Z, and a one-domain analogue of 
staphylococcal protein A, have been targeted for random mutagenesis during library constructions 
(Andersson et al., 2003). This affibody was revealed to be exceptionally stable to pH extremes and 
harsh regeneration conditions and thus potentially useful in areas such as affinity purification (Nord et 
al, 2000). The potential for improving binding affinity has also been exploited through the use of in 
vitro affinity maturation strategies, such as a-helix shuffling strategy employed by Gunneriusson et 
a l,(1999) which resulted in a 20-30-fold increase in functional affinity.
3.1.3. Antibody Purification
Immunoglobulins are relatively robust molecules capable of maintaining biological activity 
following exposure to extremes of pH for short periods of time, and storage for relatively long periods 
at -20“C. It is widely accepted that purified antibodies are superior to crude animal antisera, cell 
culture supernatant and cell lysates in ELISA, Western blot analyses, and immunohistochemical 
staining (Sun et al., 2003). Affinity purification is a crucial step in obtaining antibodies from the 
antiserum of animals immunised with a peptide antigen conjugated to a carrier protein. Protein A and 
G may be used for the isolation of IgG. Protein G is a 30 kDa bacterial cell wall protein isolated from 
the group G streptococci, and binds to immunoglobulin molecules primarily through their Fc regions. 
Protein G binds with a higher affinity to particular immunoglobulin molecules such as mouse IgG] 
that do not bind particularly well to Protein A. Protein A is a 42 kDa cell wall component of several 
strains of Staphylococcal aureus and binds specifically to the Fc region of immunoglobulin molecules. 
Protein A and G can be easily coupled to sepharose to produce solid supports with high 
immunoglobulin capacity, exhibiting low degrees of non-specific binding. Following application of 
the crude antibody preparation to such column supports and subsequent washing to remove non- 
specifically bound protein, the bound antibody can be eluted by exposure to high/low pH solutions. 
Recent developments include the generation of an affinity column for antibody purification by semi­
synthetic intein-mediated protein ligation and an chromatographic procedure utilising a thermally 
responsive poly(N-isopropylacrylamide)-dextran derivative conjugate (Anastase-Ravion et al., 2001; 
Sun et al., 2003).
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3.1.4. Immunoassay
Immunoassays with high accuracy and specificity that are inexpensive, fast and convenient to 
perform are always advantageous (Yau et al., 2003). One of the most commonly employed techniques 
for measuring antibody-hapten interactions, is the use of ELISA, which is now far more commonly 
employed than radioimmunoassay techniques, primarily as a result of the hazardous nature and 
disposal of radioimmunoassay reagents. Immunoassays are classified into one of two types, 
heterogeneous or homogenous. In heterogeneous assays the antigen-antibody complex is separated 
from free antigen and antibody, while in homogenous assays, no such physical separation occurs. 
ELISA is a good example of a heterogeneous assay (Watanabe et al., 2000; Webb & Hall, 2001).
Enzyme immunoassays can be further classified as competitive and non-competitive. A wide 
variety of ELISA formats are possible. However, a competitive ELISA format is described in the 
context of the assay format utilised for the detection and development of a competitive immunoassay 
for warfarin (Figure 3.6). The hapten of interest that is covalently coupled to a protein (e.g. warfarin- 
BSA), is added to the wells of a 96-well immunoplate, and binds to the immunoplate predominantly 
through hydrophobic interactions. Loosely bound protein is then removed by washing with a solution 
containing detergent. A blocking agent (e.g. 5% FCS in PBS-1) is then added to the wells to ‘block’ 
any remaining available adsorption sites on the surface of the plate. The use of such blocking agents is 
necessary to ensure that no non-specific binding of either primary or secondary-labelled antibody to 
the wells of the plate occurs. A solution containing a limiting constant amount of monoclonal 
antibody and varying known concentrations of antigen (warfarin) are then applied to the wells of the 
immunoplate, and incubated for a specified time interval. Competition then occurs between free 
warfarin in solution and warfarin-BSA immobilised to the immunoplate for binding to the anti­
warfarin monoclonal antibody. The contents of the well are then removed and the plate washed to 
remove any non-specific antibody. The presence of antigen-specific antibody (i.e. monoclonal anti­
warfarin antibodies) in the wells of the immunoplate can then be determined using a species-specific 
secondary enzyme-labelled antibody for the primary antibody (e.g. alkaline phosphatase-labelled goat 
anti-mouse immunoglobulin). The substrate for the enzyme is added and a coloured product is formed, 
which can be measured spectrophotometrically at the appropriate wavelength.
In such assay formats as the concentration of free antigen (i.e. warfarin) in solution increases, 
less antibody is available to bind to the solid-phase immobilised antigen (i.e. warfarin BSA). 
Consequently, an inverse relationship exists between the intensity of the coloured solution formed and 
the concentration of free antigen in solution. In this way, the concentration of warfarin in unknown
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solutions can be determined by reference to a suitable standard curve. The sensitivity of such 
competitive ELISA formats can be optimised using the appropriate dilution of antibody preparation 
and immobilised conjugate. However, the ultimate sensitivity of all immunoassay procedures is 
primarily a factor of the intrinsic affinity of the antibody preparation for the particular antigen (Yau et 
al, 2003).
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Figure 3.6: Schematic o f the principle o f direct ELISA. Warfarin-BSA is used to ‘coat’ the wells o f a 
96-well immunoplate and sticks to the y-irradiated plate primarily by hydrophobic interactions [A]. 
The wells o f the immunoplate are then blocked with a suitable blocking solution (e.g. 5% (v/v) F.C.S. 
solution in PBS-1) to block any remaining absorption sites on the plate [B]. The antibody-containing 
samples are then added to the wells o f the immunoplate, and, following a suitable incubation step, 
washed (i. e. wash buffer section 2.3.) to remove non-specific protein [C]. A species-specific secondary 
enzyme-labelled antibody is then added to the wells o f the immunoplate and incubated for a suitable 
period o f time [D], The wells are washed extensively again, and substrate added to the wells o f the 
plate. In the presence o f enzyme (i. e. the enzyme-labelled secondary antibody) a coloured product is 
formed and its absorbance can then be measured spectrophotometrically at the appropriate 
wavelength for the substrate [.EJ.
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3.1.4.1. ELISA Applications
ELISA is very versatile and as a result was applied to a variety of sectors including the food 
industry and drug screening for the pharmaceutical industry.
Regarding the food industry ELISA is very useful for the detection and quantification of many 
contaminants (e.g. toxins) and pathogenic organisms such as Salmonella and E. coli. A study was 
undertaken by Sarimehmetoglu and co-workers in the University of Ankara, Turkey (2004) in order to 
determine the presence and levels of aflatoxin Mi (AFMi) in cheeses. AFMi is a hepatic carcinogenic 
metabolite found in the milk of lactating animals that consume aflatoxin Bj. A total of 400 cheese 
samples were used as the study material. The competitive ELISA determined 110 out of 400 samples 
contained levels of AFM, that exceeded the legal limit established. In an attempt to develop a standard 
for ELISA-PCR detection of Shiga toxin producing E. coli 0157, six published PCR tests were 
evaluated in a comparative study on a panel of 277 bacterial strains isolated from foods, animals and 
humans. Since its recognition in 1982, enterohaemorrhagic E. coli 0157 is recognised as an important 
human pathogen predominantly associated with haemorrhagic colitis and the more serious severe 
complications of haemolytic uraemic syndrome. It causes high morbidity and mortality especially 
among the young and elderly (Fach et al., 2003).
Another significant area of ELISA application is drug screening with several recent 
developments highlighting the importance of ELISA in this sector. ELISA in microtitre plate format is 
widely used for high throughput screening of chemicals and drugs for their effects on various 
biological activities (Svojanosky et al, 1999; Itoh et al, 1999; Elian, 2003). These assays make it 
possible to rapidly evaluate a large number of compounds and can be readily adapted for automatic 
manipulations. Cell-based ELISAs are especially valuable as they reflect the ability of drugs to 
permeate cell membrane and to affect cellular targets and functions. Apoptosis plays an important role 
in human disease and drugs, which stimulate or inhibit apoptotic cell death, may have valuable clinical 
applications. Thus, specific and sensitive screening procedures are required to select drugs affecting 
apoptosis. Based on this requirement a solid-phase ELISA was developed for the specific and sensitive 
detection of apoptotic cells. The assay involved the binding of cells to microtitre plates. The attached 
cells were then treated with formamide to denature DNA in apoptotic cells, which is followed by 
staining of the denatured DNA with a mixture of anti-ssDNA mAb and peroxidase-conjugated anti­
mouse IgM. Two human carcinoma cell lines (leukaemic cells and breast carcinoma cells) treated with 
drugs (e.g. etoposide, cisplatin and staurosporine), were examined using this assay format. It was 
determined from these assays that the absence of an apoptotic signal in the breast cancer cells treated
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with cytotoxic concentrations of cisplatin that this drug kills cells by non-apoptotic mechanisms, 
whereas apoptosis was the dominant mechanism of cell-death caused by staurosporine. This illustrates 
the potential of this assay format to provide a foundation for high-throughput screening of drugs based 
on their ability to induce or suppress apoptosis (Frankfurt & Krishan, 2001).
In order to successfully screen drugs in a variety of applications it is important to develop 
ELISAs capable of detecting the target drug in a various biological matrices (e.g. blood, urine, saliva), 
especially if the drug has clinical or therapeutic significance in both animals and humans. An 
important example involves recent developments utilising a competitive ELISA format for the 
quantification of plasma and intracellular levels of the HIV protease inhibitor, ritonavir. Successful 
HIV treatment is critically dependent on drug potency, viral susceptibility and plasma drug levels. 
However, serum pharmacokinetics of this inhibitor revealed large inter-individual variations caused by 
low or variable oral bioavailablity of current formulations and by extensive cytochrome P450 
metabolism. Therefore, a simple and sensitive analytical method for the routine determination of 
serum and intracellular levels of ritonavir is likely to represent a useful clinical tool. A convenient 
one-step competitive ELISA was developed by Akeb and colleagues (2002) for measuring plasma and 
intracellular ritonavir levels in HIV patients. Anti-ritonavir polyclonal antibodies were raised in 
rabbits using a ritonavir-KLH conjugate as immunogen. This assay format accurately and specifically 
detected 3-4ng/ml of ritonavir in plasma and intracellular drug levels in the peripheral blood 
mononuclear cells of patients undergoing ritonavir therapy.
ELISAs are becoming very popular within the forensic toxicology community because of their 
relative ease to perform, potential for automation, the small sample size requirement, lack of 
radioisotopes, and their ability for use with blood and urine specimens. Clonazepam is a 
benzodiazepine derivative approved for use as an anticonvulsant in 1975. However, in recent years it 
is used in drug-facilitated assaults and for this reason it is important to be able to detect clonazepam 
and 7-aminoclonazepam in whole blood and urine for use as evidence in such cases (Elian, 2003).
3.1.5. Antibody Affinity
The net interaction between an antibody’s antigen binding site and the corresponding antigen 
epitope dictates the affinity of the interaction between the two molecules. Merging of the antigen 
binding site with antigen can be investigated thermodynamically. To measure the affinity of a single 
antigen binding site, it is necessary to use a monovalent antigen, or even a single isolated antigenic 
determinant (a hapten). Due to the fact that the non-covalent bonds between antibody and epitope are
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dissociable, the overall binding of antibody and antigen must be reversible. Therefore the Law of Mass 
Action can be applied to the reaction and the equilibrium constant KA can be determined. This is the 
affinity constant.
Antigen-Antibody reactions are reversible Applying the Law of Mass Action
Ab Ag AbAg
Y  + •  £  Y
Equilibrium constant of affinity,
is given by:
M M  r y
[•]
(1)
All antigen-antibody reactions are reversible. The Law of Mass Action can therefore be 
applied, and the antibody affinity (given by the equilibrium constant KA) can be calculated. (Square 
brackets refer to the concentrations of the reactants).
Antibody avidity indicates the overall strength of interaction between antibody and antigen 
and is dependent upon the number of antigen binding sites with which it makes contact. If an antibody 
has more than one antigen binding site (in the case of IgG two and in the case of IgM five) then these 
multivalent molecules will be more likely to lock tightly onto their target antigen (Sikora & Smedley, 
1984). In addition, antigen can also be monovalent (e.g. hapten) or multivalent (e.g. microorganism). 
The strength with which a multivalent antibody binds a multivalent antigen is termed avidity, to 
differentiate it from the affinity of a single antigenic determinant for an individual combining site. The 
avidity of an antibody for its antigen is dependent on the affinities of the individual combining sites 
for the determinants on the antigen. It is greater than the sum of these affinities if both antigen-binding 
sites can combine with the target antigen. This is because all of the antigen-antibody bonds must be 
broken simultaneously before the antigen and antibody dissociate. In normal physiological situations 
avidity is likely to be more relevant than affinity, as naturally occurring antigens are multivalent. 
However, the precise measurement of hapten-antibody affinity is more likely to give an insight into 
the immunochemical nature of the antigen-antibody reaction.
Measurements of antibody affinity relate to equilibrium conditions. Affinity indicates the 
tendency of the antibodies to form stable complexes with the antigen. However, for many biological
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activities of antibodies, it is possible that the kinetics of the reaction may also be significant. Kinetics 
measures the forward rate (on-rate) constant or association constant ka and the reverse rate (off-rate) 
or dissociation constant kd. At equilibrium, the ratio of the two constants gives the equilibrium 
constant, or affinity of the antibody.
The affinity of the interaction between an antibody and antigen is the net result of the 
intermolecular forces between the two molecules, and four types of such intermolecular forces have 
been identified. They include hydrogen bonding, ionic interactions, ‘van der Waals’ forces and 
hydrophobic interactions. Hydrogen bonding involves the interaction of a H-atom covalently linked to 
an electronegative atom with the unshared electron pair of another electronegative atom. Ionic 
interactions are the result of the attraction between oppositely charged groups and consequently can be 
disrupted by changes in salt concentration or pH. Hydrophobic interactions involve the association of 
non-polar (hydrophobic) residues in aqueous environments. ‘Van der Waals’ forces are the result of 
interactions between electron clouds of neighbouring molecules as two polar groups come in close 
contact. This results in the induction of oscillating dipoles between the two molecules resulting in a 
net attractive force. The strength of these particular forces is only effective over short distances, which 
can usually be disrupted by high ionic strength or extremes of pH (Fitzpatrick, 2001).
3.1.6. Chapter Outline
This chapter outlines the characterisation and application of anti-warfarin monoclonal 
antibody (mAb) produced and purified from clone 4.2.25. Optimisation of ELISA using this mAb was 
performed in phosphate buffered saline (PBS) and in urine. Cross reactivity studies investigated the 
specificity of the mAb to compounds that were structurally similar to warfarin (e.g. acenocoumarin). 
Finally, kinetic studies involving a method developed by Friguet et al., (1985) were utilised to 
determine the dissociation constant (KD) of the mAb to warfarin and its analogues.
3.2. Results and Discussion
3.2.1. Monoclonal Antibody Purification
200mls of ‘spent’ hybridoma supernatant from clone 4.2.25 was concentrated using an 
Amicon™ filtration device as described in section 2.5.3.1. The concentrate was then passed through a 
Protein G column as described in section 2.5.3.2. The fractions were then assayed at 280nm, using a
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spectrophotometer, and the fractions containing protein were pooled and dialysed against 3-4 changes 
of PBS-2.
2 4 6 8 10 12
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Figure 3.7: Elution profile o f monoclonal 4.2.25 following purification on a Protein G column. 20 ml 
o f concentrated ‘spent’ hybridoma supernatant was applied to the lml Protein G column, which was 
then washed with two column volumes o f wash buffer. 0.1 M  Glycine-HC I (pH 2.5) was then applied 
to the column and 850 /£ extracts were collected in eppendorf tubes containing 150 pi o f 1 M  Tris- 
HCl (pH 8.0). The samples were then measured for protein content by recording absorbance 280 nm, 
and those fractions (i.e. fractions 1-6) containing immunoglobulin were pooled and dialysed against 
several changes o f PBS-2 at 4°C.
3.2.2. Characterisation o f  Purified Antibody by SDS-PAGE
The purity of the protein G-purified anti-warfarin monoclonal antibody was assessed by 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) as described in Section
2.5.7.2. and Table 2.4. SDS-PAGE allows the separation of proteins according to their size. Figure 
3.8. depicts the SDS-PAGE gel of the purified anti-warfarin monoclonal antibody with molecular 
weight bands at 50 kDa and 25kDa. These bands represent the heavy (50kDa) and light (25kDa) 
chains of the antibody.
116
SOkDa
 ►
20 kDa
 ►
1 2 3 4 5
Figure 3.8: SDS-PAGE gel o f the protein-G purified anti-warfarin monoclonal antibody.
Lane [1] contains Sigma Marker wide range M. W 6,5kDa-205kDa
Lane [2] shows purified heavy (50KDa) and light (25kDa) chains o f
anti-WF mAb. Lane [3] shows purified heavy (50kDa) and light (.25kDa) chains o f
anti-WF mAb. Lane [5] shows anti-WF mAb in supernatant before purification. Lane
[6] shows anti-WF mAb in supernatant before purification.
Once the purity of the monoclonal antibody was established the purified antibody fractions 
were then assayed for antibody activity as described in section 2.5.2.3. Titres of the hybridoma 
supernatant following concentration, and after affinity purification are shown in Figure 3.9. Both SDS- 
PAGE and antibody titre results confirm the mAb is well purified and binds warfarin.
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Figure 3.9: Typical antibody titre for clone 4.2.25 from 'spent' hybridoma supernatant and affinity- 
purified antibody sample were greater than 1/50,000 and 1/100,000, respectively. Results shown are 
the mean o f triplicate measurements +S.D.
3.2.3. Development o f  a Competitive ELISA for Warfarin
A competitive ELISA was developed for the detection of warfarin in solution using a 
warfarin-BSA conjugate and the protein G-purified mAb.
3.2.3.1 Determination o f  Optimal Conjugate Loading Density and Antibody 
Working Dilution
Utilising too high a conjugate loading density (i.e. solid-phase form of immobilised antigen) 
will shift the binding equilibrium in favour of binding to the ELISA plate and cause reduced 
sensitivity to free antigen in solution (i.e. the desired detectable analyte). Similarly, utilising too high 
an antibody concentration, will require high concentrations of free antigen in solution to inhibit 
antibody binding to the ELISA plate, and therefore result in decreased assay sensitivity. It is essential, 
therefore, to optimise both the concentration of the solid-phase antigen and the concentration of 
antibody (i.e. the working dilution of antibody) to be used for competitive ELISA techniques.
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A checkerboard ELISA was carried out as described in section 2.5.2.4. in order to determine 
optimal conjugate loading density. A concentration range of warfarin-BSA from 0-100  pg/ml was 
prepared in PBS-1 and applied to a 96-well microtitre plate. Dilutions of purified mAb from 1/100 to 
1/100,000 were prepared and added to the plate. The optimal conjugate loading density was defined as 
that conjugate coating density (pg/ml) that gave the widest linear detection range over the range of 
antibody dilutions used. The optimal warfarin-BSA coating concentration was found to be 50 ng/ml, 
as shown in Figure 3.10.
The optimal dilution of antibody to be used in competitive ELISA experiments was 
determined by setting up a standard curve of serial doubling dilutions of purified mAb as described in 
section 2.5.2.3. using the optimal warfarin-BSA conjugate loading density. The optimal working 
dilution of mAb for competitive ELISA was taken from the linear portion of the dilution curve, where 
there is greatest change in absorbance for similar change in antibody dilution. The optimal working 
dilution of purified mAb was determined to be a 1/800 dilution (Figure 3.11.).
0 1 * i i i
10 100 1000 10000 100000
1/Antibody Dilution
Figure 3.10: Determination o f optimal conjugate loading density. Wells o f an immunoplate were 
coated with varying concentrations o f conjugate ranging from 0 -100 /Jg/ml. Serial doubling dilutions 
o f mAb were then added to the wells o f the plate as described in section 2.5.2.4. The conjugate loading 
density that gave the widest linear detection range over the antibody dilution series was used, and 50 
fig/ml was chosen as the optimal conjugate loading density. The results shown are the average of 
duplicate results.
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Figure 3.11: Determination o f mAb optimal working dilution. The working dilution o f mAb for 
competitive ELISA was taken from the linear portion o f the sigmoidal mAb dilution curve, where the 
greatest change in absorbance for a similar change in antibody dilution occurs. A 1/800 working 
dilution was determined from the above curve.
3.23.2. Antibody Concentration Determinations
Affinity-based techniques such as ELISA and other biosensor-based techniques provide a 
unique means of determining the biologically active concentration of antibody, unlike spectroscopic 
techniques that provide total protein concentrations, and consequently inaccurate thermodynamic 
constants. Concentration of purified mAb was determined using a well-based ELISA capture system 
employing purified polyclonal anti-mouse immunoglobulin (M6149) as the capture antibody as 
described in section 2.5.2.7.
3.2.3.2.1. Mouse IgG Determination by Antibody Capture ELISA
Goat anti-mouse immunoglobulin (M6149) was initially purified on a Protein-G sepharose 
column as described in section 2.5.3.2. The concentration of protein in the purified fraction was 
estimated by means of UV absorbance at 280 nm (1 mg/ml IgG O.D.280 mn ~ 1.35) (Hudson & Hay, 
1988). The wells of an ELISA microtitre plate were coated with a solution containing approximately
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1 |ig/ml goat anti-mouse immunoglobulin (M6149) in PBS-1, and blocked as described in section
2.5.2.1. Serial dilutions of murine IgG of known concentration ranging from 3.90-1000 ng/ml were 
prepared in blocking buffer. Dilutions of protein G purified mAb ranging from 1/10 to 1/10,000, were 
prepared. The known concentrations of murine IgG and the dilutions of purified mAb were then added 
to the wells of the microtitre plate and the ELISA was then developed as described in section 2.5.2.1. 
The concentration of antibody in the purified antibody fraction was calculated by constructing a 
standard curve of the log of mouse immunoglobulin concentration versus absorbance at 405 nm. A 
spline calibration plot was constructed using BIAevaluation 3.1 software™. From the results from the 
spline calibration plot (Figure 3.12.) concentration of antibody in the affinity-purified fraction for 
clone 4.2.25. was calculated to be approximately 32.97 pg/ml.
Figure 3.12. Mouse IgG calibration plot constructed using BIAevaluation™ software. A spline is 
fitted to the data set for non-linear plots, allowing for calculation o f the mouse IgG in protein G 
purified fraction. Each point on the curve is the mean o f three replicates.
3.2.3.3. Competitive ELISA fo r  the Detection o f  Warfarin in PBS
Protein G affinity-purified monoclonal antibody from clone 4.2.25. was used in a competitive 
ELISA format for the detection of warfarin in solution as described in section 2.5.2.5. Immunoassays 
are generally best modelled using a four-parameter fit equation, of the form:
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Where Rm
Rlo
Cone
Ai
Response at infinite concentration 
Response at zero concentration 
Analyte Concentration (M)
Fitting constant 
Fitting constant
Four-parameter equations of the form above were fitted to the data sets obtained for 
immunoassays curves using BIAevaluation 3.1 software. Such calibration curves also allowed for the 
determination of unknown values from the constructed plot. In this way it was possible to calculate the 
degree of precision of analytical measurements at different concentrations points relative to the fitted 
four-parameter equation.
Fitting a four-parameter curve to the data set as opposed to utilising the straight-line portion of 
the sigmoidal plot conventionally obtained with ELISAs, greatly extends the working range of the plot 
at the asymptotes of the curve for both ends of the concentration range employed. 4-parameter curves 
were fitted to the data obtained using BIAevaluation software™. A comparison of the extended 
working range obtained can be observed in Table 3.4 and 3.5 and Figures 3.13 and 3.14, which 
illustrates that the working range of the ELISA was extended with no significant effect on the degree 
of assay precision.
In order to measure the accuracy of the immunoassay, intra-day variability studies were 
performed. Five sets of warfarin standards ranging from 1.95 - 500 ng/ml were prepared, and assayed 
on the same day and their means plotted. These absorbance values (A) were then divided by the 
absorbance measurement in the presence of zero antigen concentration (A0) to give normalised 
absorbance values (A/A0). A calibration plot of the mean normalised absorbance value versus warfarin 
concentration in ng/ml was then constructed using BIAevaluation software™ (Figure 3.13). From the 
calibration curve it was possible to calculate the mean, standard deviation, coefficient of variation and 
precision for intra-assay measurements. The coefficient of variation (CV’s) were determined to assess 
the precision of the analytical method, expressing standard deviation as a percentage function of the 
mean. These values ranged from 1.05 - 7.29 % indicating the assay had a high degree of precision and 
the results are shown in Table 3.3.
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To measure the intermediate precision (precision of repeated measurements, taking into 
account sources of variation such as runs, days and reagents), inter-day assay variability studies were 
performed with the anti-warfarin monoclonal antibody. Five sets of warfarin standard ranging from 
3.91 - 500 ng/ml were prepared, and assayed five times over five days. A separate calibration curve 
plotting normalised values (A/A0) versus concentration values (ng/ml) was then constructed for each 
assay curve. The normalised values from each curve for each concentration determination were then 
back-calculated using the calibration curve and BIAevaluation software. The mean back-calculated 
concentration from each of the calibration curves was then used to calculate the mean, standard 
deviation and coefficient of variation for the inter-assay curve. The CVs were determined and ranged 
from 3.16 - 8.62 %. The percentage accuracies of the curve (Figure 3.15) were good (Table 3.5) 
especially in the linear range of the assay (96-102 %), which indicates that the curve provides an 
accurate representation of the sigmoidal relationship between the measured response and the logarithm 
of concentration observed for the immunoassay. Residual plots for the calibration curves are included 
for each calibration curve, which illustrate the ‘goodness of the fit’ of the applied 4-parameter 
equations (Figure 3.13 & 3.15). The residual plots also illustrate the precision profile of the calibration 
curves over the assayed concentration range and illustrate that the 4-parameter equation demonstrates 
no bias over the assayed concentration range, unlike linear plots (Figure 3.14) which have a tendency 
to demonstrate increased bias at the extremities of the linear plot (Findlay et al, 2000).
123
Table 3.3: Intra-day Assay coefficients o f variation (CVs) and percentage accuracies data for the anti­
warfarin monoclonal antibody in PBS. Coefficients o f variance (a quantitative measure of precision) 
were calculated utilising the equation % CV = (S.D./Mean) x 100, where the standard deviation (S.D.) 
is computed from replicate (5 replicates) analyses within a single validation run. Percentage accuracy 
is the difference between the actual warfarin concentration (A WC) of the prepared warfarin standards 
and the mean back calculated warfarin concentration (MBCW) value obtained from the 4-parameter 
calibration curve: (AWC/MBCW) x 100
Actual Warfarin 
Concentration 
(ng/ml)
Mean Back Calculated 
Warfarin Concentration 
from calibration curve 
(ng/ml)
%CV % Accuracies
500.00 646.90 6.19 77.29
250.00 245.65 6.17 101.77
125.00 105.21 6.37 118.81
62.50 65.24 7.29 95.80
31.20 32.50 4.06 96.00
15.60 15.59 1.05 100.06
7.81 7.52 2.19 103.86
3.91 4.00 3.63 97.75
1.95 1.91 3.05 102.09
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Figure 3.13: Intra-day Assay calibration curve for the detection o f warfarin in PBS utilising an anti­
warfarin mAb. A 4-parameter equation was fitted to the data set using BlAevaluation 3.1. software. 
The intraday means and coefficients o f variation are tabulated in Table 3.3. Each point on the curve is 
the mean offive replicate measurements analysed within a single validation run. Residual plots for the 
calibration curves are included for each calibration curve, which illustrate the 'goodness o f the fit' of 
the applied 4-parameter equations and supports the % accuracy findings.
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Table 3.4: Intra-day Assay coefficients o f variation (CVs) and percentage accuracies data for the anti- 
warfarin monoclonal antibody in PBS (using linear regression). Coefficients o f variance (a 
quantitative measure o f precision) were calculated utilising the equation % CV = (S.D./Mean) x 100, 
where the standard deviation (S.D.) is computed from replicate (5 replicates) analyses within a single 
validation run. Percentage accuracy is the difference between the actual warfarin concentration 
(AWC) of the prepared warfarin standards and the mean back calculated warfarin concentration 
(MBCW) value obtained from the 4-parameter calibration curve: (AWC/MBCW) x 100
Actual Warfarin 
Concentration 
(ng/ml)
Mean Back Calculated 
Warfarin Concentration 
(ng/ml)
%CV % Accuracies
31.20 29.37 4.06 106.23
15.60 16.96 1.05 91.98
7.81 7.83 2.19 99.74
3.91 3.90 3.63 100.26
1.95 1.91 3.05 102.09
126
W arfarin C on centration  ( n g /m l)
Figure 3.14: Intra-day Assay curve:
Linear regression analysis was applied to the data set giving the line o f  best fit, from which 
the intra-assay mean, coejficient o f  variation and precision were calculated and shown in the 
above table. Each point on the curve is the mean o f  (n=5) replicate measurements carried out 
on a single day ±  standard deviation.
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Table 3.5: Inter-day Assay coefficients o f variation (CVs) and percentage accuracies data for the anti­
warfarin monoclonal antibody in PBS. Coefficients o f variance (a quantitative measure o f precision) 
were calculated utilising the equation % CV = (S.D./Mean) x 100, where the standard deviation (S.D.) 
is computed from replicate (5 replicates) analyses over 5 validation runs on 5 separate days. 
Percentage accuracy is the difference between the actual warfarin concentration (AWC) o f the 
prepared warfarin standards and the mean back calculated warfarin concentration (MBCW) value 
obtained from the 4-parameter calibration curve: (AWC/MBCW) x 100.
Actual Warfarin 
Concentration
(ng/ml)
Mean Back Calculated 
Warfarin Concentration 
from calibration curve 
(ng/ml)
%CV % Accuracies
500.00 499.95 3.78 100.01
250.00 243 3.86 102.88
125.00 129.97 5.17 96.18
62.50 61.10 4.42 102.30
31.25 31.26 3.16 99.97
15.63 15.53 7.92 100.64
7.81 8.42 7.11 92.76
3.91 4.07 8.62 96.07
128
1 -r
0.9 -■ 
0.8 -■ 
0.7 -■
o 0.6 -■
<  0.4 -•
0.3 -■
0.2 - ■  
0.1 - ■  
0 - 
1
’S
■INw
£
0.01 
0 : 
-0.01
- 0.02
1 10 100 
W arfarin C oncentration  n g /m l
1000
Figure 3.15: Inter-day Assay calibration curve for the detection o f warfarin in PBS utilising an anti- 
warfarin mAb. A 4-parameter equation was fitted to the data set using BIAevaluation 3.1 software. 
The interday means and coefficients o f variation are tabulated in Table 3.5. Each point on the curve is 
the mean o f five replicate measurements analysed over five days. Residual plots for the calibration 
curves are included for each calibration curve, which illustrate the 'goodness o f the fit' o f the applied 
4-parameter equations and supports the % accuracy findings.
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3.2.3.4. Competitive ELISA for the Detection o f Warfarin in Urine
Quantitative determination of mAb in urine samples was also investigated. The ionic 
composition of urine can vary considerably from sample to sample. To compensate for the potential of 
great inter-individual variability in the salt composition of urine, the mAb sample was prepared in 
PBS of twice the normal ionic strength. Warfarin samples ranged approximately from 3 - 500ng/ml. 
These samples were spiked into control urine and assayed for the presence of free drug with mAb.
To carry out intra-day assay variability studies in urine, five sets of warfarin standards ranging 
from 3.91 - 500 ng/ml were prepared, and assayed on the same day and their means plotted. These 
absorbance values (A) were then divided by the absorbance measurement in the presence of zero 
antigen concentration (A0) to give normalised absorbance values (A/A0). A calibration plot of the 
mean normalised absorbance value versus warfarin concentration in ng/ml was then constructed using 
BlAevaluation software™. From the calibration curve it was possible to calculate the mean, standard 
deviation, coefficient of variation and precision for intra-assay measurements. The CVs were 
determined to assess the precision of the analytical method, expressing standard deviation as a 
percentage function of the mean. These values ranged from 3.47 - 15.41 % as shown in Table 3.6, 
where it can be seen that there was a much greater degree of variance in comparison to PBS assays 
(Table 3.3). This is due to the undefined nature of urine, however this assay is still reproducible as the 
results show in Figure 3.16 and Table 3.6.
To carry out inter-day assay variability studies, 5 sets of warfarin standard ranging from 3.91 - 
500 ng/ml were prepared, and assayed five times over five days. A separate calibration curve plotting 
normalised values (A/Ao) versus concentration values (ng/ml) was then constructed for each assay 
curve. The normalised values from each curve for each concentration determination were then back- 
calculated using the calibration curve and BlAevaluation software. The mean back-calculated 
concentration from each of the calibration curves was then used to calculate the mean, standard 
deviation and coefficient of variation for the inter-assay curve. The CVs were determined and ranged 
from 3.63 - 17.16 %. Again there was a greater degree of variance than the PBS assays however, this 
assay is still reproducible and the results are shown in Figure 3.16 and Table 3.7. The percentage 
accuracies of the curve (Figure 3.17) were good (Table 3.7) especially in the linear range of the assay 
(99-102 %), which indicates that the curve provides an accurate representation of the sigmoidal 
relationship between the measured response and the logarithm of concentration observed for the 
immunoassay. Residual plots for the calibration curves are included for each calibration curve, which 
illustrate the ‘goodness of the fit’ of the applied 4-parameter equations.
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Table 3.6: Intra-day Assay coefficients o f variation (CVs) and percentage accuracies data for the anti- 
warfarin monoclonal antibody in urine. Coefficients o f variance (a quantitative measure ofprecision) 
were calculated utilising the equation % CV= (S.D./Mean) x 100, where the standard deviation (S.D.) 
is computed from replicate (5 replicates) analyses within a single validation run. Percentage accuracy 
is the difference between the actual warfarin concentration (A WC) o f the prepared warfarin standards 
and the mean back calculated warfarin concentration (MBCW) value obtained from the 4-parameter 
calibration curve: (AWC/MBCW) x 100.
Actual Warfarin 
Concentration 
(ng/ml)
Mean Back Calculated 
Warfarin Concentration 
from calibration curve 
(ng/ml)
%CV % Accuracies
500.00 496.98 15.41 100.61
250.00 255.70 15.19 97.77
125.00 120.91 13.63 103.38
62.50 63.46 11.28 98.49
31.25 32.37 11.04 96.54
15.63 14.74 4.83 106.04
7.81 7.58 4.94 103.03
3.91 4.25 3.47 92.00
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Figure 3.16: Intra-day Assay calibration curve for the detection o f warfarin in urine utilising an anti­
warfarin mAb. A 4-parameter equation was fitted to the data set using BIAevaluation 3.1. software. 
The intraday means and coefficients o f variation are tabulated in Table 3.6. Each point on the curve is 
the mean offive replicate measurements analysed within a single validation run. Residual plots for the 
calibration curves are included for each calibration curve, which illustrate the 'goodness o f the fit' o f 
the applied 4-parameter equations and supports the % accuracy findings.
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Table 3.7: Inter-day Assay coefficients o f variation (CVs) and percentage accuracies data for the anti­
warfarin monoclonal antibody in urine. Coefficients o f variance (a quantitative measure o f precision) 
were calculated utilising the equation % CV = (S.D./Mean) x 100, where the standard deviation (S.D.) 
is computed from replicate (5 replicates) analyses over 5 validation runs on 5 separate days. 
Percentage accuracy is the difference between the actual warfarin concentration (AWC) o f the 
prepared warfarin standards and the mean back calculated warfarin concentration (MBCW) value 
obtained from the 4-parameter calibration curve: (AWC/MBCW) x 100.
Actual Warfarin 
Concentration 
(ng/ml)
Mean Back Calculated 
Warfarin Concentration 
from calibration curve 
(ng/ml)
%CV % Accuracies
500.00 499.29 17.16 100.14
250.00 251.44 13.69 99.43
125.00 123.04 9.12 101.59
62.50 64.54 9.01 96.84
31.25 29.99 5.63 104.20
15.63 16.01 4.46 97.63
7.82 7.67 8.28 101.96
3.91 3.99 3.63 97.99
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Figure 3.17: Inter-day Assay calibration curve for the detection o f warfarin in urine utilising an anti­
warfarin mAb. A 4-parameter equation was fitted to the data set using BIAevaluation 3.1 software. 
The interday means and coefficients o f variation are tabulated in Table 3.7. Each point on the curve is 
the mean o f five replicate measurements analysed over five days. Residual plots for the calibration 
curves are included for each calibration curve, which illustrate the 'goodness o f the f i t ’ o f the applied 
4-parameter equations and supports the % accuracy findings.
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3.2.4. Cross-Reactivity Studies
Cross-reactivity may be defined as a measure of the antibody response to structurally related 
molecules, as a result of shared epitopes (Findlay et al., 2000). Given the unique specifity of 
antibodies, one of the first steps in immunoassay design is the assessment of reactivity towards 
structurally related molecules that share such common epitopes (Davies, 1994b). Cross-reactivity can 
be assessed by setting up serial dilutions of the competing antigen in parallel with similar dilutions of 
the specific antigen as described in section 2.5.2.5. Cross-reactivity can be defined as the point where 
the reduction in signal recorded in the presence of a particular analyte concentration (Ax) gives a 50% 
reduction in the signal in the presence of zero analyte (A0) (i.e. Ax/A0=50%). This concentration value 
at 50% inhibition (EC50) can then be expressed as a percentage of the analyte giving the same decrease 
in signal (Figure 3.18).
Therefore,
% Cross-re activity = Concentration of analyte giving 50% decrease in signal z,] „
—  —  " “  — r j  X  1 0 0 / y
Concentration of the cross-reactant giving 50% decrease in signal
100 1000 
Drug Concentration (ng/ml)
10000
Figure 3.18: Typical plot illustrating the potential cross reactivity o f a particular antibody 
preparation towards a structurally related compound using the ratio o f concentrations o f each 
compound that gives 50% inhibition. (The % cross reactivity is calculated by expressing the antigen 
concentration, Z¡, as a percentage o f the cross reactant concentration, Z2.).
The nitro-group on the parent molecule (4-hydroxycoumarin) was chosen as the point of 
attachment for two particular reasons. Firstly, it provided a convenient means of conjugation.
Secondly, as the major human metabolites of warfarin involve hydroxylations of the 4- 
hydroxycoumarin ring structure and carbon side chain of the molecule, it was believed that 
conjugation via the phenyl substituent would confer a greater degree of specificity to the antibodies 
produced against warfarin.
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Figure 3.19: Cross-reactivity studies o f monoclonal antibodies. Cross-reactivity studies were carried 
out on the Protein-G- purified anti-warfarin monoclonal antibodies, as described in section 2.5.2.5., 
to structurally related warfarin derivatives. The antibody demonstrated little or no reactivity towards 
coumarin-based molecules (e.g. 7-HC, 4-HC, Coumarin) suggesting that the presence o f the carbonyl 
group and possibly the phenyl ring are also required for antibody recognition.
The results from the cross-reactivity study are shown in Figure 3.19 and Table 3.8. The cross­
reactivity of the purified monoclonal antibody demonstrated the highest degree of cross-reactivity 
(18.18%) towards acenocoumarin, as expected given that the two compounds are essentially identical
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except for the presence of the nitro group. Since this particular region does not confer any antibody 
specificity being the point of conjugation, this would explain the similar affinity of the monoclonal 
antibody preparation to acenocoumarin. The monoclonal antibody showed cross-reactivity of 
approximately 8 and 1 % towards 6- and 7-hydroxywarfarin, respectively. Cross reactivity studies were 
also carried out using 4-hydroxycoumarin (which comprises half of the molecule), coumarin, 7- 
hydroxycoumarin, and 7-hydroxycoumarin-4-acetic acid. Cross-reactivities towards these particular 
compounds in each case was negligible and typically of the order of < 0.001%.
Table 3.8: Cross-Reactivity o f protein G-purified anti-warfarin monoclonal antibody
Compound % Cross Reactivity
Warfarin 100.00
Acenocoumarin 18.18
6-Hydroxywarfarin 8.33
7-Hydroxywarfarin 1.00
7-Hydroxycoumarin 0.09
4-Hydroxycoumarin 0.09
Coumarin 0.09
7-Hydroxycoumarin-4-acetic acid 0.09
3.2.5. Affinity Constant Determinations
An ELISA-based approach originally published by Friguet et al., (1985) was used to measure 
the affinity of the anti-warfarin mAb to warfarin and structurally related analogues by calculation of 
the dissociation constant (KD) of antibody:antigen mixtures at equilibrium in solution. An unknown 
but constant concentration of mAb is incubated with known varying concentrations of the antigen of 
interest. The antibody:antigen mixtures are allowed to attain equilibrium and the ‘bound’concentration 
of antibody (V) can be can then be calculated by indirect ELISA as described in section 2.5.2.6. by the 
expression:
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y _ A q  ~ A l
A0 (3)
Where A0 = Absorbance in the absence of antigen 
Ai = Absorbance in the presence of antigen
The concentration of bound antibody can be related to the antigen concentration by the following 
equation:
± - ^  + 1 (4)V Ag
A plot of 1/(V) versus l/[Ag] will thus yield a straight line graph with a y-intercept of 1, with 
the slope of the regression line (KD), describing the overall equilibrium constant for the antibody: 
antigen interaction at equilibrium.
l/[Ag]
Figure 3.20: Typical plot obtained using the method o f Friguet et al., (1985). A plot o f the
reciprocal o f bound antibody (1/V) versus the reciprocal o f antigen concentration 
(l/[Ag]) should yield a straight line plot with a y-intercept o f 1 and whose slope 
defined the dissociation constant for the particular antibody: antigen interaction at 
equilibrium.
Two points must be addressed if this technique is to be used correctly to obtain reliable 
dissociation constants. The first prerequisite is to demonstrate the correlation between ‘free’ (i.e. 
unbound) antibody concentration in solution and enzymatic activity, and adding various dilutions of
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antibody to antigen-coated wells of an ELISA plate as described in section 2.5.2.6. and constructing a 
calibration plot of nominal antibody concentration versus absorbance. A straight line plot similar to 
that in Figure 3.22. of ‘nominal’ antibody concentration (i.e. 1/dilution factor) versus enzymatic 
activity at 405 nm is attained, demonstrating the linear correlation between antibody concentration and 
enzymatic activity. This calibration plot can then be used to calculate the concentration of antigen 
bound antibody at equilibrium in the antibody: antigen mixtures.
The ‘free’ antibody concentration, i, following incubation with the antigen can be related to 
absorbance by the following equation:
i _ A
¡o A0 (5)
Where A0 = absorbance in the absence of antigen.
A = absorbance in the presence of antigen.
i„ = total antibody concentration.
The second prerequisite is that no readjustment of the antibody:antigen equilibrium mixture 
should occur during the incubation in the antigen-coated wells. This can be demonstrated 
experimentally by placing serial dilutions of antibody into the wells of an antigen-coated ELISA plate 
for a specified time interval. The contents of these wells can then be transferred into adjacent antigen- 
coated wells on the ELISA plate for a similar incubation period. An overlay of the plots for the 
developed ELISA of wells 1 and 2, as shown in Figure 3.21, should demonstrate no significant 
decrease in the antibody bound in the second set of wells. This implies that the amount of antibody 
bound by the solid phase antigen is negligible compared to the amount of antibody in solution, and is 
therefore unlikely to cause any significant displacement of the antibody:antigen mixture at 
equilibrium. The fraction of antibody retained by the first set of wells, / ,  can be calculated by the 
following equation:
Al(c ) -A 2(c)
Ai(c) f6)
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Where
/  = fraction of antibody retained
A,(c) /  A2 ( c )  = enzymatic activities in the first and second set of wells, respectively,
(i.e. absorbance measurements) 
c = initial concentration of antibody
The antigen concentration was shown to have the greatest effect on the solid phase disruption 
of fluid phase equilibrium in affinity assays (Friguet et al., 1985; Seligman, 1994). Reducing the 
incubation period in the antigen-coated wells also minimises the disruption of the fluid phase 
equilibrium. The optimal incubation period for clone 4.2.25 on the 96-well microtitre plate was 
typically of the order of 15-20 minutes. The value of/calculated for clone 4.2.25, was approximately 
= 0.03, demonstrating that the amount of bound antibody is negligible compared to overall antibody 
concentration. By calculating the amount of unbound antibody at equilibrium by reference to the 
antibody concentration calibration plot, the amount of ligand-bound antibody (V), can thus be 
estimated and used to calculate the overall affinity constant.
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Table 3.9: Calculation o f free antibody concentrations.
The nominal concentrations o f antibody were calculated by reference to the constructed antibody 
standard curve and substituting the value obtained into equation 4. The value for the bound antibody 
was calculated to yield the values o f 1/V. from which a plot o f l/[Ag] versus 1/V was constructed, 
whose slope (KD) defined the dissociation constant KD of the overall reaction.
[Warfarin]
mol/1
1/[Warfarin] 
1/mol
l/[Ag]
Abs at 405nm Nominal
Antibody
concentration
NC
1/V
1.62 e'6 616000 0.072 0.126 1.085
8.12 e 7 1232000 0.101 0.165 1.115
4.06 e '7 2464000 0.304 0.435 1.469
2.03 e'7 4920000 0.432 0.606 1.373
5.07 e 8 19680000 0.647 0.892 1.610
I
<DU
•eoCO
3
1/Dilution Factor Nominal Antibody Concentration 
Figure 3.21: The value for f  (equation 6), represents the small amount o f antibody that is captured in 
the ELISA and should represent a small fraction o f the total free antibody. The above figure shows 
that for the anti-warfarin antibody, negligible readjustment occurred for the determination o f the 
affinity constant by the Friguet method.
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Nominal Antibody Concentration
Figure 3.22: A standard curve o f nominal antibody concentration versus Absorbance at 405 nm was 
constructed as described in section 2.5.2.6. The highest antibody concentration used was given the 
nominal antibody concentration o f '1' and serial doubling dilutions up to 1/256 dilution were prepared 
from this, o f nominal concentration o f0.5, 0.25, 0.125, 0.0625, 0.03125, 0.0156, 0.0078 and 0.0039, 
respectively. The antibody dilutions were then applied to the microtitre plated for a predetermined 
incubation period to ensure that there would be minimal disturbance o f the fluid phase equilibrium of 
the antibody:antigen mixture as described in equation 6. A linear plot o f nominal antibody 
concentration versus absorbance at 405 nm was used to construct the antibody standard curve to 
determine the bound fraction o f antibody present at equilibrium in the equilibrium mixtures. The 
results shown are the mean o f triplicate measurements + standard deviation.
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Figure 3.23: Determination o f the equilibrium dissociation constant for the interaction between 
warfarin and clone 4.2.25 by the method o f Friguet et al., (1985). The nominal unbound antibody 
concentrations were calculated using the standard curve constructed in Figure 3.22, and equation 
(3.3) from which the values o f 1/V were subsequently determined at the respective antigen 
concentrations as shown in Table 3.9. The calculated equilibrium dissociation constant for the 
interaction between warfarin and monoclonal antibody 4.2.25 was calculated to be 6.0 x 10'8 M.
However, an antibody (e.g. anti-warfarin antibody), whether monovalently bound or 
completely non-bound to its specific antigen in solution, will still be able to bind to the coated wells of 
an ELISA plate. The concentration of antibody complex measured at equilibrium (Friguet method) 
does not take into account the fact that monovalently bound antibodies may also bind to the plate 
(Bobrovnik, 2003). The apparent binding constant measured will therefore not equal that of the 
corresponding antibody Fab fragments. Stevens (1987) developed a ‘correction factor’ based on the 
binomial distribution theory to provide the ‘correct’ concentration of liganded antibody binding sites 
to allow for the calculation of the ‘correct’ thermodynamic constant. Stevens (1987) postulated that if 
the probability that a Fab binding site is bound is taken as, z, then the probability that the binding site 
is free can then be interpreted as 1-z. For the case of an intact IgG molecule, the following 
relationships can be used to describe the three populations of antibody fractions existing within the 
equilibrium complex:
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Completely Unbound: (1-z2)
Monovalently bound: 2z (1-z)
Bivalently bound: z2 (7)
On the basis of binomial distribution, assuming that the binding of one Fab does not preclude 
the binding of a second Fab (which is the case for small haptens, not necessarily true for larger 
molecular weight haptens due to steric hindrance factors (Quinn & O’Kennedy, 2001)), of the three 
antibody populations present at equilibrium, only the bivalently bound antibody, (z2), is incapable of 
binding to the ELISA plate. The fraction of free antibody assayed by ELISA (m) is therefore equal to 
1-z2.
m = \ - z 2 (8)
and
z = Vl -  m (9)
represents the corrected fraction of liganded binding sites in terms of the apparent free IgG. The 
method of Friguet et al.,{ 1985) measures the ‘bound’ fraction of unbound IgG (V), using the 
relationship:
V — ~
A o (10)
It can be seen, therefore, that as the concentration in equation (7) represents the bivalently 
bound antibody fraction, the corrected fraction of occupied antibody binding sites at any antigen 
concentration is given by:
z = 4 V  (11)
Stevens (1987) found that overall association constants were overestimated by a factor of at 
least 2, with the level of error inversely proportional to the level of binding site occupancy. By 
substituting the corrected value of liganded binding sites a more ‘realistic’ value of association 
constants is determined which takes into account the bivalent nature of the antibody giving association 
constants for whole IgG that closely mirror those for Fab fragments (Bobrovnik, 2003).
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Table 3.10: 'Corrected' Free Antibody Concentrations according to Stevens (1987).
[Warfarin]
mol/1
1/[Warfarin] 
1/mol
l/[Ag]
Nominal
Antibody
concentration
NC
1/V Corrected Free 
Antibody 
concentration 
l/z=(l/V)m
1.623 e'° 616000 0.126 1.085 1.042
8.12 e'7 1232000 0.165 1.115 1.056
4.06 e 7 2464000 0.435 1.469 1.172
2.03 e 7 4920000 0.606 1.373 1.269
5.07 e'8 19680000 0.892 1.610 1.503
Figure 3.24: Friguet assay for warfarin clone 4.2.25 using 'corrected' IgG concentrations described 
by Stevens (1987) to account for bivalency o f IgG. The corrected overall dissociation constant (KD = 
2.0 x 10'8M) indicates that there is a 3 fold increase in estimation o f overall affinity constant 
compared to the 'uncorrected'IgG concentration shown in Figure 3.22 ( KD = 6.0 x 10'SM).
It could be argued that the method of Friguet et al., (1985) only works particularly well for 
high affinity antibodies, as the incubation step in ELISA must be sufficiently short not to perturb the 
antibody:antigen equilibrium complex. For low affinity antibodies (high off rates) such a condition
145
can be difficult to achieve in practice. Friguet assays for the anti-warfarin antibody with particular 
antigens are shown in Figures 3.25 and 3.26 and overall affinities shown in Table 3.11.
i / M
Figure 3.25: Friguet affinity determinations o f equilibrium dissociation constants for the interaction 
between clone 4.2.25 and antigens acenocoumarin (Top) and 6-hydroxywarfarin (Bottom).
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l/[Ag]
Figure 3.26: Friguet affinity determination o f equilibrium dissociation constant for the interaction
between clone 4.2.25 and antigen 7-hydroxywarfarin.
Table 3.11: Equilibrium dissociation constants ( K„ ) determined using the method o f Friguet et
al., (1985) for the interaction between warfarin and mAb from clone 4.2.25. The 
affinity o f the mAb to structurally related molecules o f warfarin was also measured, 
and the equilibrium dissociation constants determined are tabulated below.
Antigen Clone 4.2.25
(M)
Warfarin 2.0 x I O'8
Acenocoumarin 4.0 x 10-7 -
6-hydroxywarfarin 6.0 x 10'°
7-hydroxywarfar in 2.0 x 10‘b
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3.3. Conclusions
The results presented in this chapter describe the development and validation of an 
competitive immunoassay for the detection of warfarin in biological samples. This was accomplished 
by utilising an anti-warfarin mAb, which was purified (Section 3.2.1) and characterised (Section 3.2.2) 
prior to assay development. The purity of the mAb was assayed by SDS-PAGE analysis (Figure 3.8). 
Purified mAb was initially utilised in the development of a model competitive assay for the detection 
of warfarin in PBS. In order to determine the optimal warfarin coating concentration (Figure 3.10) and 
optimal working dilution (Figure 3.11), a checkerboard ELISA was performed as described in Section
3.2.3. Varying dilutions (0-100 ng/ml) were coated on a microtitre plate and the optimal conjugate 
loading density was determined to be 50 pg/ml, which correlates well with previous findings, by 
Fitzpatrick (2001). The optimal working dilution of antibody was determined from the standard curve 
(Figure 3.11) to be a 1/800 dilution. For all immunoassay calibration plots the use of a 4-parameter 
function in BIAevaluation™ software was adopted which fitted an advanced smoothed curved cubic 
polynomial to the data set. Immunoassay curves are inherently non-linear in origin and adopt a 
familiar sigmoidal bell shaped curve on log-linear plots. The fitting of a linear plot (Figure 3.14) to the 
data set ignores the inherent shape of the plot, with the resulting ‘linear’ plot showing a greatly 
reduced dynamic range with reduced precision at both the upper and lower ends of the calibration set. 
Fitting 4-parameter equations to immunoassay curves offers a much more realistic fitting of the data 
set, and can increase the detection range by 4-fold at both ends of the linear range increasing the 
dynamic range considerably with no significant effect on the degree of assay precision or 
performance.
A competitive ELISA was developed as described in Section 2.5.2.5. and 3.2.3.3. and a four-
parameter equation fitted to the data using BIAevaluation 3.1 software. Intra- and Inter-day studies
were performed in order to determine the accuracy and precision of repeated measurements of both
assays. The coefficient of variance values of each assay provide a quantitative measure of precision of
the analytical method. The inter- and intra-assay variation for the competitive ELISA in PBS were
typically of the order of 3-8%, and demonstrated the accuracy and reproducibility of the technique.
This compares well to intra- and inter-day CV’s for a radio-immunoassay (RIA) developed for the
detection of small hapten coumestrol, which ranged from 2-9% (Lapcik et al., 2003). These values are
well within the current recommended guidelines for immunoassay calibrations, that suggest that
tolerance limits of 20% be applied to immunoassay curves with respect to assay precision (Findlay et
al., 2000). The percentage accuracies values obtained in the linear part of the inter-day plot (Figure
3.15) indicate the fitted four-parameter curves provide an accurate representation of the sigmoidal
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relationship between the measured response and the logarithm of concentration observed for the 
immunoassay. The assay results compare well to previous studies by Fitzpatrick (2001) involving the 
detection of warfarin in PBS using an anti-warfarin monoclonal antibody. The working range of the 
assay was similar to the present assay (Section 3.2.3.3.) working range (3.91-500 ng/ml). The CV’s 
determined by Fitzpatrick for the intra- and inter-day variability studies ranged from 1.0-9.10% and 
4.07-14.37%, respectively. The percentage accuracies for intra- and inter-day curves ranged from 
91.05-109.79% and 95.64-102.09%, respectively. In the work presented in this chapter the CV’s for 
the intra- and inter-day studies ranged from 1.05-7.29% and 3.16-8.62%, respectively. The intra- and 
inter-day % accuracies ranged from 96-102%.
In order to assess the feasibility of detecting warfarin in a biological matrix, samples of urine 
were acquired and spiked with known concentrations of warfarin. It was evident from the intra- and 
inter-day variation studies in Section 3.2.3.3 that the anti-warfarin mAb was suitable for use in the 
development of a competitive ELISA for the detection of warfarin in complex biological matrices. 
Standards of warfarin ranging from 3.9 -  500^g/ml were prepared in urine and mixed with purified 
mAb (1/800 dilution). The inter- and intra-assay variation for the competitive ELISA in urine were 
typically of the order of 3 -  17%. Although there is a higher degree of variation due to the undefined 
nature and sample variation of urine, these values are still within the recommended limit of 20%. This 
immunoassay format is a suitable complement to the instrumental methods (i.e. High performance 
liquid chromatography [HPLC], Gas chromatography-mass spectrometry [GC-MS] and BIAcore) 
especially for screening purposes, for samples with low concentrations of analyte and for small 
volume samples such as body fluids, cell and tissue culture supernatants (Maurer & Arlt, 1998; 
Lombardi et al., 2003; Anfossi et al., 2004).
One of the initial steps in designing an immunoassay is the assessment of reactivity towards 
structurally similar molecules. The cross-reactivity studies carried out demonstrated that the anti­
warfarin mAb shared a common epitope between the 4-hydroxycoumarin ring structure and the 
carbonyl substituent. As Table 3.8 illustrates, acenocoumarin shows the highest degree of cross­
reactivity (18%) due to its structural similarities to warfarin. Both 6-hydroxywarfarin and 7- 
hydroxywarfarin show varying degrees of cross-reactivity (8% & 1%) with the anti-warfarin mAb. 
Previous cross reactivity studies by Fitzpatrick (2001) involving polyclonal antibodies showed that 
these type of antibodies have much higher cross reactivities with regard to acenocoumarin (98%), 6- 
hydroxywarfarin (28%) and 7-hydroxywarfarin (3%). However like the anti-warfarin monoclonal 
antibody the polyclonal antibody showed negligible cross reactivity with the other compounds tested 
(7-hydroxycoumarin, 4-hydroxycoumarin, coumarin and 7-hydroxycoumarin-4-acetic acid).
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Fitzpatrick utilised a Hyperchem® molecular modelling software package in order to analyse the 3 
dimensional structure models of warfarin and its metabolites (e.g. 6-and 7-hydroxywarfarin). The 
models indicated that the 4-hydroxycoumarin residue and the carbonyl side chain appear to lie along 
the same plane, orthogonal to the phenyl substituent (i.e. the point of conjugation). It can be postulated 
therefore that the majority of the antibody-binding site is directed against the 4-hydroxycoumarin ring 
structure and carbonyl side-chain. Consequently, substitutions (e.g. hydroxylations to the coumarin 
ring) could lead to differing specificities of antibody binding pocket for the antigen, as the 
‘complementarity’ of the binding domain is disturbed. In this context, the hydroxylation at position-7 
of the 4-hydroxycoumarin ring could be expected in the context of a polyclonal antibody population, 
to have a more marked effect on the antibody affinity given the suggested epitope region, than a 
hydroxylation at position 6 of the 4-hydroxycoumarin residue, which would concur with the 
experimental observations noted. The fact that the degree of cross-reactivity towards the coumarin and 
its hydroxylated metabolites is negligible implies that the antibodies require both the coumarin ring 
structure and the presence of the carbonyl side chain for antibody recognition.
The final section of this chapter deals with the measurement of the affinity of anti-warfarin 
mAb to warfarin and structurally related analogues by calculation of the dissociation constant (KD) of 
antibody:antigen mixtures at equilibrium in solution. The method of Friguet el al. (1985) was used to 
assess the overall dissociation constants for the anti-warfarin mAb to warfarin and structurally related 
analogues. The affinity profile of the monoclonals produced measured by the equilibrium dissociation 
constants, was generally of the order: warfarin > acenocoumarin > 7-Hydroxy warfarin > 6- 
hydroxywarfarin. These results suggest that the majority of the antibodies were directed against an 
epitope on the coumarin portion of the molecule. This implies that the monoclonal antibody produced 
from clone 4-2-25 was directed against a combined epitope near the 4-hydroxycoumarin residue and 
the branched keto substituent at position 3 part of the coumarin molecule. This also explains why there 
was a reasonably high degree of affinity of the mAb for the hydroxylated metabolites. The 
dissociation constants determined by the method of Friguet et al. (1985) demonstrate the method to be 
an accurate means of determining equilibrium affinity constants.
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Chapter 4
Development of a BIAcore-based 
Inhibition Assay for the Detection of 
Warfarin in Biological Matrices
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4.1. Introduction
Biosensors are analytical devices composed of a recognition element of biological origin, a 
physico-chemical transducer and the processing unit. The biological element is capable of sensing the 
presence, activity or concentration of a chemical analyte in solution. The sensing takes place either as 
a binding event or a biocatalytical event. These interactions produce a measurable change in a solution 
property, which the transducer converts into a quantifiable electrical signal (D'Orazio, 2003). The 
biological component of the biosensor is composed of two distinct groups: catalytic (e.g. enzymes, 
micro-organisms, and tissues) and non-catalytic (e.g. antibodies, receptors and nucleic acids) (Griffiths 
& Hall, 1993). A promising area of development in biospecific interaction analysis (B1A) is the use of 
biosensors to detect and measure interactions in ‘real-time’ (Jonsson et al., 1991; Liedberg & 
Lundstrom, 1993). Biosensors can be segregated into four fundamental groups, depending on the 
process of signal transduction (e.g. optical, electrochemical and thermal sensing) (Goepel, 1991; 
Seyhi, 1994; Goepel & Heiduschka, 1995). Biosensors based on the optical phenomenon of surface 
plasmon resonance (SPR) are among the most versatile of those processes (Williams & Addona, 
2000). Biosensor technology is moving towards miniaturised, chip-based, microarrays capable of 
multi-analyte detection in order to achieve inexpensive, portable, robust and easy to use analytical 
systems (Ekins, 1998; de Wildt et al., 2000).
4.1.1. SPR Biosensors
Surface plasmon resonance biosensors allow the label free detection of biomolecular 
interactions in ‘real-time’ and have become well established as laboratory tools in the 
biopharmaceutical industry. (Myszka & Rich, 2000). In receptor-driven drug discovery, crude tissue 
extracts and cell homogenates are screened for potential ligands of orphan receptors, an approach 
termed ‘ligand-fishing’ that can identify possible interacting pairs of molecules and target agents 
(Cooper, 2003). SPR instruments offer a unique means of monitoring reaction kinetics and 
determining equilibrium constants and also allow for the determination of active analyte 
concentrations (Zhu et al., 2000; Schindler et al., 2002; Ahmad et al., 2003). SPR systems can also be 
used to detect pathogens such as Escherichia coli 0157:H7 in biological matrices (Kai et al., 2000), 
and were successfully used as analytical tools in the food and drink industries (Gaudin et al., 2001; 
Mello & Kubota, 2002; Leonard et al., 2003, McCamey et al., 2003).
There are a number of SPR-based devices currently commercially available including the
BIAcore range of instruments (BIAcore AB). Affinity Sensors manufactures the IAsys line of
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instruments, which is a cuvette-based system utilising evanescent-wave technology (Bertucci & 
Cimitan, 2003). Windsor Scientific Limited markets the IBIS system, which can be configured as a 
flow- or cuvette-based system. Nippon Laser & Electronics Lab developed the SPR-CELLIA system 
and Texas Instruments latest SPR device (Spreeta 2000) can be configured for a variety of applications 
(Myszka & Rich, 2000). However, since the research described in this thesis involves the use of the 
BIAcore 3000, the mode of operation and the principle of SPR are described in the context of the 
BIAcore range of instruments. The mode of operation of the miniaturised SPR device is briefly 
explained (Section 4.1.3.).
4.1.2. BIAcore System
Pharmacia Biosensor was created in 1984 as a separate company within Pharmacia, to develop 
biosensing technology. In 1990 they introduced their first commercial biosensor (BIAcore) system to 
the market (Robinson, 1995). BIAcore is a fully automated instrument that monitors biomolecular 
interactions and includes sample handling equipment that performs the biomolecular interactions, SPR 
analysis, and the regeneration of the sensor surface. Three features of BIAcore are essential for a 
complete system for real-time BIA:
1. Sensor chip and optical system, responsible for generation and detection of the SPR signal
2. Integrated micro-fluidic cartridge, for optimal transport of samples to the sensor surface
3. Autosampler for unattended handling of long series of analyses.
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Figure 4.1: Basic components o f BIAcore(m) instrument: (1) optical detection system; (2) sensor 
chip; (3) integrated microfluidic cartridge (IFC); (4) connector block; (5) autosampler; (6) eluent 
pump; (7) autosampler pump; (8) waste bottle; (9) buffer bottle.
The entire system is controlled by a microprocessor, enabling development of programs to run 
multiple samples simultaneously without intervention. Since the introduction of the first BIAcore 
system, BIAcore AB have introduced more instruments to target specific areas of the biosensor 
market. These instruments include BLAlite™ (1994), BIAcore X™ (1996), BIAquadrant™, BIAcore 
S51 and BIAcore J (2001) and these systems offer varying degrees of automation and parameter 
specifications (Leonard et al., 2003). Several generations of the original BIAcore were developed, 
(BIAcore 1000, 2000 and 3000) which are enhanced versions of the original.
4.1.2.1. CM5 Sensor Chip
One of the most essential features of an SPR biosensor is the interface between the sensor 
surface and the immobilised ligand (Myszka & Rich, 2000). BIAcore technology utilises a sensor chip 
that consists of a glass slide coated on one side with a thin gold film, to which a matrix of 
carboxymethylated dextran is covalently attached. The gold film is essential for the generation of an 
SPR signal at a convenient combination of reflectance angle and light wavelength, and is in addition 
chemically inert to solvents and solutes used in biochemical interactions. The dextran layer comprises 
the outermost layer of the chip surface and is a linear polymer of glucose units modified by 
carboxymethylation (Lofas & Johnsson, 1990). Dextran exhibits very low non-specific adsorption of 
biomolecules and therefore provides a very favourable matrix for biomolecular interactions 
(O’Shannessy et al., 1992). There are several reasons why dextran facilitates biomolecular interactions 
and they are as follows:
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1. Covalent immobilisation of biomolecules.
2. Surface binding capacity is increased.
3. Hydrophillic surface environment is provided, which is favourable for most interactions of
biological interest.
4. Surface is provided with a low degree of non-specific binding.
The sensor chip forms one wall of the micro-fluidic cell. The dextran surface of the chip 
makes contact with the solution being examined. There are four independent flow cells on the sensor 
chip surface. Therefore each chip can be utilised for up to four separate series of measurements 
(Sjolander & Urbanicky, 1991).
Figure 4.2: Sensor chip components. The sensor chip surface consists o f three layers ([4] glass, [3] 
thin gold film and [1] dextran surface). The dextran layer is bonded to the gold film through an inert 
[2] linker layer.
1 5 5
4.1.2.1.1. Dextran Activation
For carboxymethylated dextran to be useful for immobilisation reactions, the carboxyl group 
must first be activated so that it can participate in covalent binding. Generally this involves activation 
of the surface by derivatisation with N-hydroysuccinimide (NHS), mediated by N-ethyl-N’- 
(dimethylaminopropyl) carbodiimide (EDC) according to the reaction scheme illustrated in Figure 4.3. 
(Nuzzo & Allara, 1983; Bain et al., 1989). Typically, 30-40% of the carboxyl groups on the dextran 
are converted to reactive NHS esters (which are receptive toward primary amino functions) and 
reducing the activation contact period is the simplest method for regulating the yield of immobilised 
ligand. Many biomolecules have uncharged amino groups available for interaction with NHS esters to 
yield a covalent immobilisation to the dextran layer. For those biomolecules that do not possess amino 
groups it is possible to add this functionality or to react the biomolecules using different coupling 
strategies (e.g. thiol coupling) (Lofas et al., 1991). The reaction works best between pH 6 and 9, whilst 
the efficiency of the reaction decreases rapidly below pH 4.5.
Figure 4.3: Activation chemistry o f the carboxymethylated dextran surface with N-hydroysuccinimide 
/  N-ethyl-N'-(dimethylaminopropyl) carbodiimide (NHS/EDC). Protein at a pH  lower than its 
isoelectric point is injected over the surface following EDC-mediated NHS derivatisation. Unreacted 
sites are capped with ethanolamine.
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4.1.2.2. Optical System
In BIAcore, the optical phenomenon used for detection is SPR and the light source is a high- 
efficiency near-infrared light-emitting diode (LED). The polarised light from the LED (760nm) is 
focused onto the gold film giving a fixed range of incident angles. The SPR response is monitored by 
a fixed array of light-sensitive diodes covering the whole beam of reflected light.
4.1.2.2.1. Surface Plasmon Resonance (SPR)
SPR is a unique optical surface sensing technique involving an electron charge density wave 
phenomenon that arises at the surface of a metallic film when light is reflected at the film under 
specific conditions. In order to describe SPR it is useful to begin with the phenomenon of total internal 
reflection (TIR), which occurs at an interface between non-absorbing media. When light is incident on 
two media of different refractive index (e.g. glass and water), a portion of the light coming from the 
medium of higher refractive index is refracted and the remainder of the light is reflected (Figure 4.5.). 
When the angle of incident light is greater than the critical angle of incidence, the light is totally 
internally reflected and no light is refracted across the interface between the two surfaces of different 
refractive index. Under conditions of total internal reflection (TIR), the incident light leaks an 
electrical field intensity (a distance of approximately one wavelength) called an evanescent field wave 
into the low refractive index medium. The amplitude of this evanescent wave decays exponentially 
with the distance travelled from the interface into the lower dense medium (Figure 4.4). The 
penetration depth of the evanescent field wave is usually defined as the distance over which the wave 
decays to 1/e, or about 37%, of its maximum intensity.
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Figure 4.4: [A] SPR is excited by p-polarised totally internally reflected (TIR) light at a glass/metal 
film interface. The evanescent field, E, is a non-transverse wave that has components in all spatial 
orientations. The incident p-polarised light is focused into a wedge-shaped beam providing a 
continuous interval o f light wave vectors kx. The wavevector o f the plasmon wave, k,p depends on the 
refractive indices o f the conductor nt and the sample medium n2. 0 refers to the angle o f incidence. 
[B] Relative evanescent electric field amplitude versus distance to solid/solution interface (nm). The 
continuous line represents the SPR-evanescent wave (gold film), whereas the dashed blue line 
represents non-absorbing TIR (no gold film). Adapted from BIAcore manual.
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In BIAcore the TIR-interface between the glass and water layer is coated with a thin layer of a 
suitable conducting material (e.g. gold, silver). The p-polarised component of the evanescent wave can 
be transferred to the metal layer, causing the electrons to resonate, which results in the generation of a 
surface plasmon wave. This resonance effect occurs when there is a match between the energy of the 
surface electrons and the energy of the incident light photons. By measuring the amount of light 
reflected by the metal surface the coupling of energy between the evanescent wave and surface 
electrons can be observed. All the light is reflected at most wavelengths, except for the SPR angle 
where most of the light is absorbed, which can be observed by a decrease in the intensity of the 
reflected light measured. As the wavelength of light and the properties of the metal film are constant, 
SPR can be used to probe the refractive index of the aqueous layer adjacent to the gold layer. 
Biomolecular interactions occurring at the sensor surface change the solute concentration and thus the 
refractive index within the evanescent wave penetration range (Figure 4.6.). The displacement of the 
SPR angle as result of biological interactions occurring at the chip surface is measured in ‘real-time’ 
and interpolated as a sensogram (Figure 4.7.).
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Figure 4.5: Schematic depicting typical BIAcore SPR measurements. In the example illustrated, 
antibody (V) is immobilised at the gold sensor chip surface using conventional coupling chemistries 
(e.g. EDC/NHS). Plane polarised light is emitted from a high efficiency light emitting diode and is 
focused onto the gold chip surface in the shape o f a wedge shaped beam by means o f a glass prism 
under conditions o f total internal reflection. The reflected light is then measured by a two-dimensional 
photo-diode array. Under conditions o f total internal reflection at a metal-coated interface an 
electromagnetic portion o f the light known as the evanescent wave penetrates into the medium of 
lower refractive index. Buffer is passed over the surface and the dip in reflected light intensity (grey 
line) recorded at angle (I). The angle at which SPR occurs is dependent on a number o f factors 
including the refractive index o f the layer adjacent to the metal film. SPR can thus be used to probe 
and monitor the interactions occurring at the chip-surface in ‘real-time ’.
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Figure 4.6: Antigen ( • )  is then injected over the antibody-immobilised chip surface. Binding of 
antigen to immobilised antibody causes an increase in the mass bound at the sensor chip surface and 
a subsequent change in the refractive index at the sensor chip surface, causing a shift (0) in the 
resonant angle o f the reflected light (i.e. from angle I  to angle II). The shift in the resonant angle is 
proportional to the change in the mass o f analyte bound at the sensor chip surface.
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Figure 4.7: A plot o f the change in the resonant angle (0) measured in 'real-time ’following antibody: 
antigen binding versus time, is interpolated by the instrument software to generate the characteristic 
SPR response curve (Sensogram). The change in the SPR angle is converted to arbitrary response 
units by the instrument software. The response signal measured is proportional to the concentration of 
bound analyte. A change o f approximately 1 kRU corresponds to a mass change in surface protein 
concentration of approximately 1 ng/mm2. Before injecting antigen, the baseline response should be 
stable. Response increase during association phase represents complex formation in real-time. 
Equilibrium is achieved when an equal number of antigen molecules associate with and dissociate 
from the surface simultaneously. To monitor dissociation, the instrument automatically switches back 
to running bujfer and information regarding the stability o f the complex is collected. The surface is 
washed and any remaining complexes can be dissociated from the surface. Following regeneration, 
the binding response should return to the starting baseline position. (I & II = SPR angle; Figure 4.5 
&4.6)
4.1.2.3. Liquid Handling
Samples, reagents and buffers are supplied to the sensor chip surface through a precision 
liquid handling system. There are three main components that comprise this system. Firstly, stepper 
motor-driven syringe pumps are utilised and designed to deliver smooth pulse-free flow. One pump 
maintains continuous flow over the chip surface, while the other pump is utilised for injection of 
samples and reagents via the autosampler. The autosampler is responsible for sample handling and is 
designed to take defined volumes of liquid from specified sample positions and deliver them to other 
positions for mixing or into the micro-fluidic cartridge. Finally, the integrated |>fluidic cartridge (IFC) 
controls the delivery of liquid to the sensor chip surface. It consists of a series of precision-cast
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channels in a hard polymer plate, forming sample loops and flow channels for buffer and sample 
delivery. Operation of the whole IFC, including choice of sample loop and valve actuation, is 
automatically controlled through the instrument software.
4.1.2.4. BIAcore Software
Operation of BIAcore is controlled from a separate personal computer running BIAlogue 
software under Microsoft Windows. This program provides the user interface for the entire system, 
from pump control and sample injection to data collection and evaluation. The SPR signal (Section
4.1.2.2.1.) is expressed in resonance units (RU) and plotted against time in a sensorgram (Figure 4.7). 
The sensorgram is displayed directly on the computer screen in real-time as the analysis progresses. 
This data can be saved and evaluated (e.g. kinetics studies) with the help of BIAevaluation software.
4.1.2.5. Advantages and Limitations o f  BIAcore
In comparison to many other interaction technologies, SPR-based biosensors such as BIAcore 
exhibit several distinct advantages for characterising real-time BIA. Following the interactions as they 
happen, can yield valuable diagnostic information and provide rapid, quantitative kinetic data useful 
for pilot experiments to establish conditions for automated analyses. There are no labelling 
requirements, which results in minimal interference with the interaction being studied. Regeneration 
of the surface is normally included in the automatic analysis method, and the system can be 
programmed for unattended analysis of 1000 samples or more. The flexibility of BIAcore allows for 
the immobilisation of a wide range of biomolecules and the amount of materials required for 
immobilisation of ligands and regeneration solutions are minimal. In relation to assay performance, it 
is vital that the amount of complex (e.g. antibodyrantigen) at equilibrium can be measured in the 
presence of unbound reactant, without disturbing the reaction equilibrium (Homola et al., 1999; 
Myszka & Rich, 2000). The feature of multi-channel analysis, means that the interactions can be 
monitored over different immobilised ligand sensor surfaces, and provide direct comparison. It is 
advantageous to the user that BIAcore comes as a complete integrated system, which includes the 
processing unit, sensor chip, controlling computer and software for data collection and analysis.
Although the advantages of using BIAcore are numerous there are some limitations to its 
application, which should be noted. The initial cost of setting up BIAcore technology can be quite 
high and routine servicing is required to keep it running at optimal performance. Other drawbacks, 
which limit its applications, include the limited life-time of the biological components and
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practicability in handling (Mello & Kubota, 2002). Biosensors, in general, offer an exciting alternative 
to conventional methods of analysis in various research areas. However, the sensitivity of each sensor 
system depends on improvements in several aspects including the biological elements, flow-cell 
design, transducer sensitivity, miniaturisation and antibody design and production. Future biosensor 
developments will evolve into highly sensitive, inexpensive devices, routinely used both in the field 
and the laboratoiy in a wide variety of applications ranging from rapid detection systems for the food 
industry to therapeutical analysis of biological matrices.
4.1.3. Miniature TI-SPR Device
The first mass-produced Spreeta device was introduced in 1999 by Texas Instruments. Their 
goal was to move SPR applications from high-cost systems to low-cost, portable electronic systems 
designed for field-work. This fully integrated miniature SPR sensor contains a light emitting diode 
(LED), polariser, thermistor (to allow for correction due to temperature fluctuations) and two 128 
silicon photo diode arrays housed in an epoxy resin moulding which was designed in the form of the 
Kretschmann geometry prism (Figure 4.8a.).It measures approximately 3 cm x 1.5 cm x 4 cm and 
provides electrical connections using a 16-pin DIP connector device. Mirrored surfaces are thermally 
evaporated onto the internal surfaces of the device except for the SPR sensing portion of the device. 
The wedge shaped beam reflects off the SPR sensing layer and is reflected onto the PDA array by 
means of a mirror. The SPR minimum can then be measured in ‘real-time’ following dedicated signal 
processing (Kukanskis et al., 1999). In 2001, Texas Instruments began production of the newest 
Spreeta device, the Spreeta 2000. This device is smaller than the original Spreeta (1.5 cm x 0.7 cm x 3 
cm) and interfaces using a miniature 10-pin card-edge connector (Figure 4.8.b).
The Spreeta 2000 sensor consists of a plastic prism moulded to a microelectronic circuit 
contained on a printed circuit board (PCB) (Figure 4.8.a). The circuit contains an infrared LED (830 
nm peak wavelength), a 128-pixel linear diode array detector, and a non-volatile memory chip for 
recording identification and calibration information. The LED emits a diverging beam that passes 
through a polariser and strikes an elliptical region of the sensor surface at a range of angles above the 
critical angle. The sensor surface is formed by a glass chip coated with a thin layer of gold (produces 
the SPR effect) and epoxied to the plastic prism. The thin layer of gold produces the SPR effect. For 
certain angles of incidence, part of the energy of the traverse-magnetic (TM) polarised incident light 
joins into a surface plasma wave travelling along the interface between the gold layer and the analyte. 
The loss of this energy is observed as a sharp attenuation of reflectivity. The angles at which this 
occurs vary with the surface refractive index (RI) of the analyte. Hence, it is possible to measure the
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surface R1 by measuring the reflection spectrum. The light reflected from the Spreeta 2000 sensor 
surface then reflects from the sensor’s top mirror and back down onto the PCB. A fraction of this light 
strikes the diode array detector and each detector pixel collects this light that strikes the sensor surface 
at different angles. From this a reflectivity versus angle spectrum may be obtained by reading the 
detector array (Chinowsky et al., 2003).
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Figure 4.8(a): Cross-section o f miniature Spreeta and Spreeta 2000 instruments, illustrating the 
components o f the sensor. Mass changes are related to changes in the resonant angle and position o f 
the reflectance minima, which can be detected using a dedicated software package in ‘real-time ’.
Figure 4.8 (b): Photograph o f original Spreeta and enhanced Spreeta 2000 device (Chinowsky et al., 
2003).
Spreeta technology appeals to a broad market base including medical diagnostics (in 
hospitals/physician’s office), environmental monitoring and the food and drinks industries (Elkind et 
al., 1999; Homola et al., 1999; Leonard et al., 2003).
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4.1.4. Application ofSPR Technology
Biosensors are increasingly becoming practical and they can be tailored to match individual 
analytical demands for almost any target molecule or compound that interacts specifically with a 
biological system (Scouten et al., 1995). Surface plasmon resonance biosensors are amenable to 
characterising unmodified biopharmaceuticals, studying the interaction of drug candidates with 
macromolecular targets and identifying binding partners during ligand fishing experiments (Hoyer- 
Hansen et al., 2000; Myszka & Rich, 2000). There is an increasing number of potential applications of 
SPR technology driving forward the development of novel sensor devices such as miniaturised 
portable formats, thus making SPR instruments progressively more important in modern biophysical 
analytical laboratories.
4.1.4.1. SPR Biosensors in Drug Discovery
Pharmaceutical companies are always searching for technologies that will lower development 
costs and decrease the lead-time to market. The average costs of developing a small molecular weight 
drug was estimated to be approximately $800 million dollars with a lead-time to market of 
approximately 12-15 years. Biopharmaceuticals costs are less expensive ($200 million) with a 
development time of between 5-7 years (Hensley & Myszka, 2000). SPR biosensors can be 
implemented in many stages of the drug discovery process to increase throughput and lower costs, 
while generating a wealth of new information about drug candidates.
4.1.4.1.1. Target Characterisation and Small-molecule Detection
The use of SPR-based instruments is gaining increasing momentum in the area of 
biopharmaceutical discovery and characterisation of biomolecules. These instruments can monitor 
directly a particular molecule’s binding activity and determine kinetic and thermodynamic parameters 
of receptor-ligand interactions (e.g. immobilisation conditions and sample concentrations). SPR 
biosensors provide a rapid and reliable method to assess the quality of molecules that are destined for 
further applications. Utilising these biosensors can enhance drug-screening methodologies where only 
functional targets will enter the screening phase of drug discovery. Recent improvements in SPR- 
based biosensor design, have made it possible to routinely detect the binding of low-molecular-mass 
analytes (<500 Da).
166
Recent research has demonstrated the applicability of SPR in characterising both high- and 
low-affinity small-molecule interactions. Kampranis et al. (1999) measured the kinetics of wild-type 
and mutant DNA gyrases binding to a number of anti-bacterial agents, including coumarin and 
cyclothialidine drugs (Molecular Weight < 700 Da). The study of these high-affinity drug-protein 
interactions (KD = l-150nM) allowed the identification of the particular gyrase residues that were 
responsible for drug binding. An excellent example of using SPR biosensors in small molecule 
screening was reported by Markgren et al. (1998, 2000). This group developed a rapid and informative 
assay to screen and rank a panel of HIV-1 inhibitors binding to HIV proteinase. Identification of the 
proteinase-binding compounds and their relative binding capabilities enabled ranking of the inhibitors 
based on their association and dissociation rates.
4.1.4.1.2. Pharmacological Applications
SPR biosensors can play an equally significant role in the general pharmacological assessment 
of drug candidates in addition to the benefits of characterising specific drug-target interactions. Novel 
biosensor applications are being developed for the predictive profiling of important pharmacokinetic 
parameters of target molecules in terms of their individual absorption, distribution, metabolism, 
excretion and toxicity (ADME/T) profiles (Cooper, 2003). Routine ADME applications are being 
developed for SPR biosensors to determine the binding tendency of compounds to carrier plasma 
proteins (e.g. serum albumin), their ability to pass through membranes and their role in signal 
transduction (e.g. cytochrome P450). Myszka and co-workers (2000) demonstrated the potential of 
SPR technology to collect high-resolution binding data on small molecules interacting with human 
serum albumin (HSA). They injected a series of warfarin samples over a sensor chip coated with a 
HSA surface. By utilising the kinetics software available with the system they were able to determine 
that HSA binds warfarin with an affinity of 17 (xM and this value correlates well with values measured 
by traditional equilibrium assays. A more recent study detected differences in binding of enantiomeric 
drug compounds to immobilised albumins where warfarin was a control drug. The results indicated 
slight differences in binding patterns of the enantiomers to human and rat albumin (Ahmad et al., 
2003). In a similar assay, Frostell-Karlsson et al. (2000) investigated the interactions of a panel of 19 
drug compounds with immobilised HSA. They demonstrated the possibility of ranking the panel of 
drugs as high, intermediate or low HSA binders using single drug concentrations.
Two new chips constructs (referred to as HPA and LI) released by BIACORE have made it 
possible to construct stable membrane surfaces within the flow cell. A comprehension of the intestinal 
absorption profile of new drug candidates is of importance for screening, especially in order to
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differentiate between drugs that demonstrate low, medium or high absorption. As the majority of 
drugs are administered orally, the fraction of drug absorbed from the intestine is of substantial 
significance. In vivo studies of drug absorption are complicated to perform and the necessity for 
suitable in vitro models is increasing. Danelian et al. (2000) investigated the direct interaction of a 
panel of 27 drugs by mimicking drug adsorption to the human intestine through immobilisation of 
liposomes on a L1 chip surface and monitoring the binding response of the drugs as they flowed over 
the surface. The results correlated well with previously reported oral absorption data, and allowed for 
the classification of the compounds absorbed by the transcellular route into low, medium and high 
membrane permeability based on the measured responses. Applications are also being developed to 
characterise the activation of metabolic pathways such as cytochrome P450.
4.1.4.1.3. Proteomics
Proteomics can be defined as the qualitative and quantitative comparison of proteomes 
(PROTEin complement to a genOME) under different conditions to further unravel biological 
processes (Williams & Addona, 2000). SPR biosensors serve two main purposes in proteome analysis: 
[1] as a sensitive instrument to confirm detection and quantify direct binding of ligand from cell 
lysates and conditioned media and [2] to act as micropurification devices capable of recovery of 
sufficient quantities of analyte for subsequent analysis and characterisation. Attention has thus been 
focused on identifying new ligand-receptor pairs and the characterisation of protein-protein 
interactions. The SPR biosensor has the ability to detect and quantify analytes from complex fluids, 
cell lysates and conditioned media, which makes this technology a logical method for orphan ligand 
screening. This form of screening termed ‘ligand-fishing’ involves the process by which ‘orphan 
receptors’ are screened against multitudes of compounds, cells and tissue extracts to identify alleged 
targets. Furthermore, performing biosensor experiments in tandem with mass spectroscopy provides 
immediate molecular weight identification of the analytes that bind to the immobilised receptor.
A relatively new analytical platform combining BIA and mass spectrometry (MS) is referred 
to as BIA-MS. It is an integration of a surface plasmon resonance biosensor for real-time interaction 
analysis and mass spectrometry for the subsequent identification of interacting molecules (Natsume et 
al., 2001). Traditional methods involving BIA require purification steps that are both time- and labour- 
intensive and case by case strategy is often needed. BIA-MS was developed to address these 
unfavourable conditions as biomolecules detected and captured on the sensor chip can now be 
analysed and identified by MS. To gain more flexibility and sensitivity in terms of choice of analytical 
procedure Sonksen and colleagues (1998) reported an novel microrecovery procedure for combined
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BIAcore-Maldi-MS analysis that allows for elution of bound analytes in as little as 4|xl of eluant. Mass 
spectrometry offers several advantages such as specificity, sensitivity and rapidity over the majority of 
protein identification techniques, which rely on proteolytic digestion of separated proteins and 
subsequent analysis of proteins by PAGE. Nelson et al. (1997a) performed MS analysis of analytes 
bound directly to the sensor chip surface, and also coupled MS with the use of the SPR probe 
instrument whose relatively large surface area allows for greater quantities of analytes to be recovered, 
and also given the exposed nature of the sensor surface collection and elution of analytes is also 
simplified (Nelson et al., 1997b). Although biological applications of BIA-MS are still limited, the 
research described in this section indicates that it may be used to characterise both stable and transient 
interactions with relatively fast dissociation rates. It may also be utilised in crude protein mixtures to 
identify novel molecules and simultaneously monitor the interactions taking place (Natsume et al., 
2003).
4.I.4.2. Biosensors in Food and Drinks Analysis
Application of biosensor technology in the food and drinks industry looks promising as this 
industry needs suitable analytical methods for process and quality control. Biosensors offer advantages 
as alternatives to conventional methods due to their inherent specificity, simplicity and quick response 
and can provide important information about the physical and chemical characteristics of food (Mello 
& Kubota, 2002). In the food industry, the quality of a product is evaluated through periodic chemical 
(chromatography, spectrophotometry, titration, and electrophoresis) and microbial analysis. 
Conventional techniques for the detection and identification of micro-organisms mainly rely on 
specific microbiological and biochemical identification (e.g. enrichment methods, nucleic acid-based 
assays, immunological detection assays). Although these methods can be inexpensive, sensitive and 
yield reliable quantitative and qualitative information on the number and nature of the micro­
organisms tested, they are greatly restricted by the time it takes to complete the assay (standard 
enrichment assays vary between 3-7 days). Commercial biosensors are available in several forms, such 
as autoanalysers, manual laboratory instruments and portable (hand-held) devices. A list of 
commercially available biosensors is specified in Table 4.1. The food industry is vast, but its profit 
margins are low and competition is intense. Although the rapid detection of pathogens, pesticides, 
micro-organisms and toxins is an attractive area for biosensor application within this industry, 
investment in modem, expensive analytical methods is not always feasible. Drawbacks that need to be 
addressed include the limited lifetime of the biological components, mass production as well as ease 
of use. (Mello & Kubota, 2002).
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Table 4.1: Summary o f several available commercial biosensors in the food industry. In spite o f much 
biosensor research in food analysis, only a few systems are commercially available. Very few 
biosensors are presently used in the food industry for on-line analysis, although in principle they 
could be combined with flow-injection analysis for on-line monitoring o f raw-materials, product 
quality and, possibly, the manufacturing process. Biosensors have found application in the analysis o f 
glucose and other carbohydrates or alcohols. BIAcore and several other devices are applied 
commercially for bacterial detection.
Company (Location) Biosensor Device Compounds Analysed
DANVERS (USA) Apec glucose analyser Glucose
EPPENDORF (GERMANY) ESAT 6660 Glucose 
Analyser
Glucose
SOLEA-TACUSSEL
(FRANCE)
Glucoprocesseur Glucose
YELLOW SPRINGS 
INSTRUMENTS (USA)
ISI Analysers Glucose, lactose, L-lactate, 
ethanol, methanol, glutamate 
and choline.
TOYO JOZO BIOSENSORS 
(JAPAN)
Models: PM-1000 & PM 
1000DC (online), M100 and 
AS200
Glucose, lactate, L-amino 
acids, cholesterol, 
tryglicerides, glycerine, 
ascorbic acid and alcohol.
BIACORE AB (SWEDEN) BIAcore Bacteria, pantotheinic acid, 
folic acid, biotin, vitamin B2 
and B 12.
BIOTRACE (UK) Unilite Bacteria
BIOSENSORI SPA (ITALY) Midas Pro Bacteria
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Detection of contaminants is a very active area of research since spoilage of foods by toxins 
(e.g. domoic acid in mussels, terodotoxin in fish), viruses (e.g. hepatitis A) or micro-organisms (e.g. 
Escherichia coli, Salmonella, Listeria) is a serious concern (Luong et al., 1997). Detection utilising 
antibodies is perhaps the only technology that has been successfully employed for the detection of 
cells, spores, viruses and toxins. During the past decade, with the emergence of hybridoma techniques 
(Section 3.1.2.1.) and the development of recombinant antibody phage display technology, 
immunological detection of microbial contamination has become more specific, reproducible, 
sensitive and reliable. Biosensors offer the potential of detecting pathogens in ‘real-time’ but, 
unfortunately still require the time-consuming pre-enrichment step in order to detect low numbers of 
pathogens in food and water. Methods are available to reduce assay time and include microwave 
digestion, evaporation, acidic or alkaline hydrolysis and filtration.
Successful detection of micro-organisms requires optimisation of several parameters including 
antibody availability, immobilisation strategies, sample preparation and assay design (Kaclikova et al., 
2001; Quinn & O’Kennedy, 2001; Leonard et al., 2003). BIAcore is utilised in the development of 
competitive and inhibitive immunoassays. With this system, either hapten (inhibitive) or antibody 
(competitive) is immobilised onto the sensor chip surface. In some cases immobilisation of hapten can 
prove difficult depending on the available functional groups. Hence, in some assays (referred to as an 
inhibition assay), hapten-protein conjugates (e.g. warfarin-BSA) are immobilised onto the surface. 
Free hapten standards are prepared and premixed with antibody. After an appropriate incubation time, 
the mixture is passed over the hapten-protein conjugate immobilised surface. The hapten in solution 
inhibits the binding of antibody to the immobilised hapten on the surface and the amount of antibody 
binding to the surface is inversely proportional to the amount of free hapten in solution. A competitive 
assay involves the immobilisation of antibody on the chip surface. A mixture of standard samples and 
high molecular mass hapten-conjugates is then passed over the surface allowing both to compete for 
the binding site on the antibody. These immunoassay results are then used in the construction of a 
standard curve and unknown concentrations determined from such a curve (Dillon et al., 2003). The 
following section describes recent biosensor applications within the food industry and other areas for 
drug and pathogen detection.
4.1.4.2.1. Antibiotic Detection in Milk
Several biosensor-based immunoassays were developed for the detection of antibiotics in 
milk. Penicillins and other beta-lactam antibiotics constitute the antimicrobial drugs most frequently 
tested for in quality assurance programs for milk worldwide. They are used in veterinary medicine in
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the treatment of septicaemia, urinary and pulmonary infections. The presence of penicillin residues in 
food of animal origin (milk, meat) can have several drawbacks including the reduction of 
hypersensitivity reactions and antibiotic resistance in the consumer. Gaudin and colleagues (2001) 
successfully developed a BlAcore-based immunoassay for screening penicillin residues in milk. This 
assay format involved the use of a commercial antibody directed against ampicillin, which had a much 
higher affinity for the open beta-lactam ring structure. A different approach was developed by 
Gustavsson and co-workers (2002) that involved a BIAcore inhibition assay for penicillin detection. A 
microbial receptor protein with carboxypeptidase activity was used as the detection molecule. One 
advantage of using this receptor protein over antibodies that are more commonly used is that only the 
active, intact beta-lactam structure is recognised, whereas most antibodies detect both active and 
inactive forms.
Other antibiotics of concern to the food industry are the aminoglycosides. These are broad 
spectrum antibiotics most commonly used in veterinary drug medicine in the treatment of infections 
caused by aerobic Gram-negative bacteria such as mastitis. The BIAcore 3000 biosensor was used in 
combination with a mixture of four specific antibodies to form a competitive inhibition assay for 
simultaneous detection of five relevant aminoglycosides in reconstituted skimmed milk (Haasnoot et 
al., 2003a). Other molecules such as antibacterials (e.g. sulfonamides, nicarbazin) and hormones can 
be detected in milk and a range of other biological matrices including serum and liver samples (Gillis 
et al., 2002; Crooks et al, 2003; Haasnoot et al., 2003b; McCamey et al, 2003).
4.1.4.2.2. Pathogen Detection
Salmonella is of major significance as a pathogenic micro-organism in food-boume infections 
in humans, causing mild to severe clinical effects (e.g. temperature, gastroenteritis). Therefore, 
detecting the presence of this bacterial species is quite apparent in prevention and treatment of 
infection (e.g. in Salmonella eradication programs for food-producing animals). The BIAcore 3000 
was used to detect serum antibodies in chickens having current or recent Salmonella infections. The 
assay format involved the immobilisation of three well-defined flagellar recombinant DNA antigens 
(expressed in E. coli) onto the surface of the sensor chip. Sera from different batches of chicken with 
or without infection was passed over the surface in order to detect anti -salmonella antibodies. The 
sensitivity, specificity, precision and reproducibility obtained suggested that this approach could be 
used for detecting past or present infection with a range of pathogens in animals (Jongerius- 
Gortemaker et al., 2002). A different approach to Salmonella detection was taken by Bokken et al., 
(2003). In this study BIAcore was used to detect Salmonella through antibodies reacting with
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Salmonella group A, B, D and E. Anti -Salmonella antibodies were immobilised to the chip surface 
and bacteria was injected over the surface and allowed to bind. Although further work is required to 
cover the detection of all relevant Salmonella serovars in food-producing animals and food products, 
this work demonstrates the merits of this alternative biosensor approach in terms of automation, 
sensitivity (serovars detected at 1 x 107 CFU/ml), simple handling and limited hands-on time.
A method was developed by Kai and co-workers (2000) for the rapid detection of pathogenic 
E. coli in human stool samples. Another area of significant interest that involves the testing of human 
samples is the detection of illicit drug residues. Different assay formats were utilised for the detection 
of morphine-3-glucuronide (M3G, the main metabolite of heroin and morphine). Polyclonal antibodies 
and recombinant antibodies were produced for the development of BIAcore inhibition assay for the 
detection of M3G in biological matrices (Brennan et al., 2003; Dillon et al., 2003).
4.1.4.3. Kinetic Studies
BIAcore is generally used for two main types of biomolecular studies, which involve 
concentration analysis (Zhu et al., 2000) and kinetic determinations (Deprez et al., 2002). Affinity and 
rate constants are frequently measured using the BIAcore instrument with a high degree of accuracy. 
The basis of kinetic interaction is described in greater detail in Section 4.2.3.6. The concentration and 
kinetic determinations possible with BIAcore are impressive considering that no labelling of the 
biomolecules is performed. Some recent applications include enzyme kinetic assays, the examination 
of the kinetic mechanism of MAP kinase and the kinetic analysis of estrogen receptor homo-and 
heterodimerisation in vitro (Stocklein et al., 2000; Schindler et al., 2002; Usami et al., 2002; Jisa & 
Jungbauer, 2003).
4.1.5. Analysis o f  Warfarin
Currently there is an extensive assortment of sensitive analytical methods available for the 
quantitative determination of warfarin and it’s metabolites in animal and human biological samples, 
which avail of various means of detection ranging from chromatography to phosphorescence-based 
measurements (Table 4.2.). The majority of techniques available require extensive sample pre­
treatment (i.e. protein precipitation, liquid-liquid/ solid phase extraction, evaporation and 
reconstitution) to determine the plasma concentration levels of warfarin. Analysis of warfarin is not a 
new phenomenon and several of the earliest techniques for detection of warfarin in plasma were 
primarily based on thin-layer chromatography (TLC) of radiolabelled ligands followed by scintillation
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counting (Lewis & Träger, 1970). Cook et al. (1979) developed a stereoselective radioimmunoassay 
(RIA) for the enantiomers of warfarin in rat-dosed subjects. The analytical procedure was based on a 
displacement radioimmunoassay (RIA) incorporating the use of tritium- labelled warfarin.
High-performance liquid chromatography (HPLC) development significantly advanced drug 
molecules research, allowing for precise determination of their pharmacokinetic profiles without the 
use of radiolabelled ligands. HPLC analysis of warfarin is predominantly carried out by reverse-phase 
HPLC, which employs the use of a suitable polar mobile phase and a non-polar stationary phase, 
typically employing hydrophobic C18 or C8 carbon chains. A number of investigators have employed 
the use of derivatisation schemes to enhance the detectability of warfarin by ultraviolet and 
fluorescence detection methods and to allow for resolution of warfarin enantiomers (Banfield & 
Rowland, 1984). Recent advances in column chromatography have allowed for the development of 
various columns incorporating ß-cyclodextrin molecules capable of enantiomeric resolution of the 
warfarin enantiomers (Ring & Bostick, 2000). In the 2003 spring meeting of the South-Western 
Association of Toxicologists (USA) the determination of warfarin in post-mortem specimens by liquid 
chromatography (LC) and mass spectroscopy (MS) was discussed. A recent medical examiner case 
involving a suspected overdose of an anticoagulant prompted the development of an assay for warfarin 
in biological specimens. Warfarin and p-chloro-warfarin, as the internal standard, were isolated from 
acidified post-mortem fluid and tissue homogenate by extraction with n-butyl chloride. The n-butyl 
chloride fraction was extracted into base, acidified, extracted back into n-butyl chloride and 
evaporated to dryness. The residue was reconstituted in mobile phase for analysis by LC/MS. 
Warfarin concentrations were determined from heart blood (1.3 mg/L), vitreous humor (0.02 mg/L), 
and liver (1.1 mg/kg).
The pharmacokinetic profile of warfarin in man was extensively reviewed (King et al., 1995). 
Cai et al. (1994) studied the pharmacokinetic profile of 12 stroke patients on warfarin therapy by 
developing a simplified method for direct determination of warfarin enantiomers by high-pressure 
liquid chromatography with fluorescence detection. This method involved solid phase extraction of 
warfarin in plasma, precolumn derivatization to form diastereoisomeric esters, and post-column 
reaction to discriminate each enantiomer separately. Ultrafiltration was employed in the separation of 
unbound warfarin enantiomers. The limits of detection routinely attainable by the many published 
chromatographic publications are often unable to accurately determine the levels of free plasma 
concentrations of warfarin in patient samples, which in the majority of cases are at least an order of 
magnitude outside the desired quantification limits. De Orsi and co-workers (1998) developed a 
method utilising HPLC for the determination of warfarin and acenocoumarin in raw materials and
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pharmaceuticals. The current trend in anticoagulant therapy is towards lower intensity treatment 
(Lodwick, 1999). Consequently, there is a need to develop newer more sensitive analytical techniques 
capable of detecting lower concentrations of warfarin in biological fluids, for the accurate 
determination of the physiologically free fraction of warfarin in plasma (Fitzpatrick, 2001).
‘Warfarin-like’ anticoagulants were routinely used as rodenticides, where repeated ingestion 
of the rodenticide results in death by haemorrhage. The determination of such residues is often 
important in cases of accidental ingestion by non-target animals. A particular study of interest, 
involved the investigation of drug binding sites on chicken albumin using site selective fluorescent 
probes (warfarin and dansylsarcosine). Overall, the results suggest that chicken albumin, like 
mammalian albumins, has discrete binding sites for warfarin and dansylsarcosine (Rajaian et al, 
1997). Anticoagulant residues are not usually present in the stomachs of poisoned animals and the 
liver is usually the most useful material for diagnostic analysis, where residues are normally present in 
the affected animals at concentrations below 1 fxg/g. Jones (1996) described a method for the detection 
of the same rodenticides in animal liver tissues using gel-permeation chromatography (GPC) as a 
clean-up procedure followed by post-column reaction with fluorescent detection. The reported limit of 
detection for warfarin was 0.010 pg/g and 0.002 |ig/g for each of the other rodenticides.
Capitân-Vallvey et al. (1999) described a novel phosphorescence-based assay for the 
determination of warfarin in plasma and water samples using solid-phase room-temperature 
transmitted phosphorescence. Samples were spotted on Whatman No. 4 filter paper, together with 
iodide and NaOH solutions, after which they were dried and the transmitted phosphorescence intensity 
measured at 467 nm using two quartz plates to avoid the quenching effect produced by oxygen. A 
linear range of detection of warfarin between 300 and 4,000ng/ml was reported, with a lower limit of 
detection of 80 ng/ml. Some other recent warfarin analysis methodologies include site directed 
mutagenesis. A defined set of five recombinant proteins comprising combinations of domains and/or 
subdomains of the HSA N-terminal were prepared and utilised to determine the essential structural 
elements for the formation of the warfarin binding site on HSA. Affinity constants for binding to 
warfarin were estimated by fluorescence titration experiments and found to be highest for HSA- DOM
I-II and HSA, followed by HSA-DOM IB-II, HSA-DOM II, and HSA-DOM I- IIA. In addition, 
ultraviolet difference spectroscopy and induced circular dichroism experiments indicated that the 
primary warfarin binding site is centered in subdomain IIA (Dockal et al., 2000). Using a similar 
method Watanbe et al., (2001) determined the conformational stability and warfarin-binding 
properties of HSA using recombinant mutants and fluorescence spectroscopy. Recently, Petersen and 
colleagues (2002) examined the binding of warfarin to human serum albumin (HSA) mutants
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(K195M, K199M, F211V, W2I4L, R218M, R222M, H242V, and R257M). Warfarin bound to human 
serum albumin (HSA), exhibits an intrinsic fluorescence that is approximately 10-fold greater than the 
corresponding signal for warfarin in aqueous solution. This property of the warfarm/HSA complex has 
been widely used to determine the dissociation constant for the interaction. In the present study, such a 
technique was used to show that specific substitutions in subdomain IIA altered the affinity of f ISA 
for warfarin.
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Table 4.2: Techniques and detection limits for warfarin analysis
Detection Method Limits o f  Detection/ 
Quantitation (ng/ml)
Reference
Thin Layer Chromatography (Primarily Qualitative detection Breckenridge & Orme (1973)
(TLC) limits not reported)
Radioim m unoassay (RIA) L.O.D pg range Cook etal. (1979)
Phosphorescence 300-4,000 ng/ml Capitán-Vallvey et al. (1999)
Capillary Electrophoresis 
H PLC -T otal:
200-20,000 ng/ml Gareil et al. (1993)
Fluorescence- L.O. D .« 0.2 ng/ml Lee etal. (1981)
1-100 ng/ml (free) Steyn et al. (1986)
500-10,000 ng/ml (total) Steyn et al. (1986)
6.0-450 ng/ml King et al. (1995)
Ultraviolet- 40-800 ng/ml Fasco et al. (1977)
100-5,000 ng/ml De Vries et al. (1982)
HPLC-Enantiomeric:
100-1000 ng/ml Chan & Woo (1988)
Fluorescence- 25-2500 ng/ml Boppana et al. (2002)
Ultra violet- L.O. D. « 20 ng/ml De Vries & Schmitz-Kummer 
(1993)
L.O.D.as 20 ng/ml Takahasi et al. (1997)
SPR based Immunoassay
12.5-2500 ng/ml Ring & Bostick (2000)
Monoclonal: 0.5-500 ng/ml Fitzpatrick & O’ Kennedy
Polyclonal: 10-2000 ng/ml (2001)
Amperometric biosensor 1,500 ng/ml-150 (Xg/m l Hutt et al. (1994)
Gas-chromatography M ass L.O. D. «2 ng/ml Bush etal. (1983)
Spectrometry (GC-M S) L.O. D. »10 ng/ml Kunze et al. (1996)
L.O.D. w 25 ng/ml Maurer & Arlt (1998)
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4.1.5.1. Measures o f Analytical Performance
When developing a new analytical assay procedure, various parameters of analytical 
significance must be considered. Findlay et al. (2000) recently outlined particular issues regarding the 
bioanalytical validation of immunoassay procedures. Bruno (1998) addressed the growing need for 
validation of immunoassays performed on BIAcore instruments, and described the relevant validation 
parameters according to current ICH guidelines (International Congress of Harmonisation).
Immunoassays rely on the antibody-antigen interaction for the specific analyte measurement, 
and the constructed calibration plot is inherently sigmoidal in shape and best fitted with a four- 
parameter logistical fit. The working range of immunoassays is as a result slightly limited when 
compared to chromatographic procedures. Also, depending on the source of the antibody preparation 
(i.e. polyclonal or monoclonal), there can be significant variation in reagent variability, although the 
development of monoclonal and recombinant techniques has obviated the majority of these 
difficulties. The sample throughput of immunoassays is significantly better than chromatographic 
techniques, which can also involve extensive sample pre-treatment and derivatisation steps. Given the 
recent advances in genetic engineering, the possibility of producing antibodies and fragments thereof 
with enhanced affinities (KD«10'I5M) (Boder et al., 2000), has advanced the possibility of determining 
even lower analyte concentrations in complex matrices without the need for extensive sample pre­
treatment. Similarly, with the use of such antibody libraries and the unique specificity of the 
antibodies, common biosensor detection formats can be used for the analysis of a wide range of 
analytes, without the need for developing individual chromatographic assay separation techniques.
Findlay et al. (2000) suggested that the previously published minimum acceptable limits of 
accuracy at 15% (20% at the lower limit of quantitation (LLOQ)) should be increased to 20% (25% at 
the LLOQ). Wong et al. (1997) described the validation of an immunoassay for the detection of the 
concentrations of antibody in mouse serum. The main parameters addressed for the validation of the 
biosensor assay included: precision, accuracy, linearity, stability of the immobilised ligand, specificity 
and sensitivity. The stability of the immobilised ligand is an additional parameter that requires 
validation in the development of biosensor assays, unlike ELISAs. This must be determined prior to 
sample analysis through monitoring the binding capacity of the immobilised ligand by a series of 
consecutive binding-regeneration cycles. Depending on the nature of the immobilised ligand, the 
binding capacity may be drastically reduced by repeated regeneration exposure to mild acidic and 
basic pulses and/or the combined use of organic solvents (e.g. particularly for immobilised antibody 
molecules). Wong et al. (1997) suggested the use of independent positive controls to monitor the
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ligand surface-binding capacity, and to continue with the use of the immobilised surface when the 
binding capacity for the positive controls remains within 20% of the original measured binding 
response value.
4.1.5.2. Measurement o f Low Molecular Weight Analytes using BIAcore
Immunoassays are generally the method of choice for the detection of larger macromolecules 
and biomarkers. However, with recent developments in biosensor and antibody technology that has 
allowed for the standardisation of reagents, the use of immunoassays is continually growing for the 
measurement of smaller molecular weight molecules such as warfarin. For the detection of small 
molecular weight analytes, the most commonly employed assay format is the inhibition-based assay 
whereby an equilibrium drug-antibody mixture is passed over the derivatised chip surface (Section 
4.2.3.3)
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Figure 4.9: Schematic o f the antibody:antigen interaction occurring at the sensor chip surface. 
Equilibrated mixtures o f antibody and antigen are injected over a functionalised sensor chip surface 
([A] warfarin-BSA, [B] 4'-aminowarfarin). The amount o f antibody available to bind to the chip 
surface will be ‘inhibited’ by the free warfarin concentration in solution (i.e. the greater the free 
analyte concentration in solution, the less free antibody available for binding to the chip surface).
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4.1.6. Chapter Outline
The development of a biosensor-based immunoassay for the detection of warfarin in 
biological matrices is described. An anti-warfarin mAb was used to develop the inhibition-based SPR 
immunoassay, and a schematic of the interaction occurring at the sensor surface is shown in Figure 
4.9. The ability of the assay to measure free warfarin concentrations in urine were also assessed. 
Analytical issues regarding the accuracy, precision and robustness of the various immunoassays were 
investigated.
4.2. Results and Discussion
4.2.1. Preconcentration o f Warfarin-protein Conjugates
For the successful immobilisation of drug-protein conjugates at the sensor chip surface it is 
essential to maximise the interaction between the carboxymethylated dextran (CM-dextran) surface 
and the target drug-protein molecule, in this instance warfarin-BSA. Electrostatic preconcentration of 
warfarin-BSA onto the sensor surface is a crucial step in the immobilisation process and relies on 
electrostatic interaction between unmodified carboxyl groups on the sensor surface and positive 
charges on the conjugate. This interaction is primarily influenced by the pH and ionic strength of the 
buffer. At pH values greater than 7, the CM-dextran surface has a net negative charge. Proteins at pH 
values below their isoelectric point (pi) will have a net positive charge and thus, have the ability to be 
electrostatically attracted to the chip surface. Therefore in order for electrostatic preconcentration to 
occur, it is necessary to use a buffer with pH below the pi of warfarin-BSA. Low ionic strength 
buffers (e.g. 10 mM acetate buffer) are employed for protein immobilisation procedures as they favour 
such electrostatic attractions between the dextran layer and the protein of interest. This 
‘preconcentration’ step is an effective way of maximising the potential interaction between the 
warfarin-BSA conjugate and the CM-dextran layer for subsequent immobilisation, and increasing the 
potential yield of immobilised ligand.
A solution of 50 |!g/ml warfarin-BSA was prepared in 10 mM acetate buffer and transferred 
into eppendorf tubes. The pH of each warfarin-BSA solution was adjusted to the desired pH value by 
the dropwise addition of a 10% (v/v) solution of acetic acid. Each solution was passed sequentially 
over an underivatised sensor chip surface at 10 (il/min for a period of 3 minutes as described in section
2.4.8.1. The differing degree of preconcentration can be measured by the response prior to the end of
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the injection for each protein solution at the various pH values. Following injection, the flow of 
running buffer over the chip surface is usually sufficient to dissociate the electrostatic attraction 
between the protein and CM-dextran surface (Figure 4.10). The degree of preconcentration illustrates 
a significant increase at pH values below 5. From these preconcentration experiments, it was possible 
to determine that the optimal pH for warfarin-BSA immobilisation procedures, was pH 4.65 in 10 mM 
acetate buffer.
4.2.2. Immobilisation o f Warfarin-protein Conjugates
Ligand immobilisation in BIAcore analysis involves the sequence of surface activation, ligand 
preconcentration/immobilisation and surface deactivation. In order for the CM-Dextran to be useful 
for immobilisation reactions, the carboxyl group must first be activated so that it can participate in 
covalent binding. There are different methods for accomplishing this but the most commonly 
employed strategy is the use of EDC (N-ethyl-N'-(dimethylaminopropyl)carbodiimide) and NHS (N- 
hydroxysuccinimide) chemistry. These reaction procedures and their underlying chemistries are 
described in section 4.1.2.1.1. and the accompanying Figure 4.3. Optimal pH reaction conditions are 
between pH 6 and 9, whilst the efficiency of the reaction decreases rapidly below pH 4.5. Hapten- 
protein conjugates are frequently characterised by low isoelectric points, which can make sufficient 
levels of surface immobilisation complicated when conventional EDC/NHS chemistry is applied. 
When this occurs, the pH chosen for immobilisation procedures is often a compromise between the 
effective preconcentration pH and a pH level at which EDC/NHS chemistry works well. Therefore, 
the pH selected for immobilisation procedures may not always be the pH at which the most effective 
preconcentration occurred. After immobilisation of warfarin-BSA, unreacted NHS-esters remaining on 
the sensor surface need to be deactivated. A high ethanolamine concentration ensures that the 
deactivation or ‘capping’ is effective. Deactivation was achieved by treatment with 1 M ethanolamine 
hydrochloride (pH 8.5), which also served to remove non-covalently bound protein by reducing the 
electrostatic attraction between the protein and CM-dextran surface.
For immobilisation of warfarin-BSA the procedure was carried out as described in Section
2.5.8.2. Immobilisation of the drug 4'-aminowarfarin directly onto the chip surface was carried out as 
described in section 2.5.8.3., direct immobilisation of drug was performed external to the BIAcore 
instrument due to the relatively high concentration of DMSO (5-10%) in the coupling buffer. 
Following surface deactivation, the chip surface was pulsed with two 30 second pulses of 30 mM HC1, 
which ensured complete removal of non-covalently bound protein. A typical immobilisation strategy 
for the coupling of warfarin-BSA to the sensor chip surface is demonstrated in Figure 4,11. Routinely,
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it was possible to attain surface immobilisation of greater than 10,000 response units (RU) of 
warfarin-BSA. Immobilisation of 4'-aminowarfarin directly to the chip surface resulted in 
approximately »200 RU bound to the chip surface. The molecular weight ratio between 4- 
aminowaffarin and warfarin-BSA (i.e. 318 Da to 84 kDa), represents a significantly large increase in 
epitope concentration at the sensor chip surface, and is reflected in the 20-fold dilution of antibody 
required with directly immobilised warfarin surfaces compared to warfarin-conjugate surfaces.
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Figure 4.10: Preconcentration o f warfarin-BSA onto a CM-dextran chip surface. Solutions o f 50
pg/ml o f warfarin-BSA in 10 mM acetate buffer at various pH increments were passed 
over an unactivated CM-dextran surface at 10 pl/min for a period o f 3 minutes. The 
low ionic strength o f the buffer used favours the electrostatic attraction between the 
negatively charged dextran layer and the positively charged protein (i.e. below 
isoelectric point). The degree o f ‘preconcentration ’ was measured from the response 
prior to the end o f each sample injection. The ionic strength o f running buffer (150 
mM NaCl) was sufficient to dissociate the electrostatically attracted conjugate from 
the chip surface. The optimal pH  for immobilisation o f warfarin-BSA onto a CM- 
dextran chip surface was calculated to be pH  4.65, and all subsequent immobilisation 
procedures o f warfarin-BSA were thus prepared in 10 mM acetate buffer (pH 4.65).
184
es
po
ns
e 
(R
U
)
l im e  (s)
Figure 4.11: Immobilisation o f warfarin-BSA onto a CM-dextran chip surface:
(1) HBS running buffer is initially passed over the chip surface and a baseline 
measurement recorded.
(2) Following mixing a solution containing 0.05 M NHS and 0.2 M  EDC is passed 
over the chip surface to activate the chip, the large increase in SPR signal is due 
primarily to a bulk refractive index change.
(3) A small increase in baseline is recorded following activation o f the chip surface 
(-200RU).
(4) A solution containing 50 ¡ug/ml of warfarin-BSA in 10 mM acetate buffer (pH 4.65) 
is passed over the chip surface for a period o f 10 minutes.
(5) The amount o f bound ligand adsorbed is recorded whilst most o f the non- 
covalently bound protein has been eluted.
(6) Deactivation o f surface NHS-esters with 1M ethanolamine hydrochloride (pH 8.5), 
which also serves to elute non-covalently bound conjugate.
(7) One regeneration pulse with 25 mM HCl serves to remove any remaining non- 
covalently bound conjugate.
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4.2.3. Development o f  an Inhibition Immunoassay for Warfarin
A model assay system was developed in Hepes Buffered Saline (HBS) running buffer, to 
establish effective working range concentration parameters for the detection of warfarin and suitable 
regeneration conditions for dissociation of the antibody-antigen complex following the binding of 
antibody to the derivatised chip surface. The analytical validation parameters as outlined by Wong et 
al. (1997) were initially used to assess the overall performance characteristics of the immunoassay. 
These parameters include accuracy, precision and the stability of the immobilised ligand. The use of 
directly immobilised 4'-aminowarfarin and warfarin-BSA conjugate were compared to ascertain which 
drug surface provided the optimal ligand binding characteristics and stability.
4.2.3.1. Regeneration Conditions
Regeneration of the surface of the sensor chip is an important feature of real-time BIAcore 
applications as regeneration conditions affect the performance and life-time of the chip surface. 
Therefore, it is necessary to optimise conditions for analysis of large numbers of samples, to evaluate 
the reproducibility of each measurement and to reduce the cost of the assay. Ideally, it is desirable to 
have the ability to perform multiple measurements (>50) on a single derivatised chip surface, 
allowing for routine sample analysis. Wong et al. (1997) suggested that the ligand binding capacity be 
maintained within 20% of positive control values, and be routinely checked throughout the course of 
the assay to monitor the ligand-binding capacity.
The binding-capacity of both directly immobilised drug surfaces and conjugate immobilised 
drug surfaces were determined by a series of binding and surface regeneration sequences, to assess at 
which point the binding capacity deviated outside the desired performance range (<20%). Monoclonal 
antibody detection of warfarin regeneration cycles were compared on both immobilised surface types 
(directly immobilised 4'-aminowarfarin/warfarin-BSA conjugate). Protein-G purified monoclonal 
antibody samples were serially diluted in HBS running buffer as described in section 2.5.8.4. 
Antibody solutions (nominally a 1/100 dilution of each antibody preparation) were then repeatedly 
injected and the surface regenerated. Monoclonal antibodies could be dissociated using mild acid (10- 
25 mM HC1) pulses. Surface regeneration studies conducted demonstrated that the sensor chip 
surfaces to which the drug 4'-aminowarfarin was directly coupled were essentially ‘unlimited’ with 
respect to antibody-binding capacity, and demonstrated no decrease in antibody-binding capacity over 
the course of greater than 80 cycles (Figure 4.13). Such surfaces were in fact used for in excess of 
1,000 cycles (Fitzpatrick, 2001). The coefficient of variation of antibody binding over the course of 80
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cycles was 0.89 %. The binding capacity of warfarin-BSA surfaces was also assessed (70 cycles) 
using the monoclonal antibodies to warfarin. The conjugate surfaces displayed an initially relatively 
high decrease in binding capacity that began to plateau out after approximately 10 cycles (Figure 
4.12). Consequently, studies performed with such conjugate immobilised surfaces were exposed to at 
least 15 regeneration cycles prior to sample analysis. The monoclonal antibodies bound to the 4'- 
aminowarfarin immobilised chip surface demonstrated essentially no dissociation from the chip 
surfaces, which can be observed from the overlaid interaction curves at various antigen concentrations 
(Figure 4.15).
These results imply that directly immobilised drug molecules should be employed whenever 
target molecules with suitable reactive groups (e.g. the amine moiety on 4'-aminowarfarin) are 
available for direct coupling to the chip surface. In this instance such surfaces provided exceptional 
stability of the immobilised ligand (although, exposure to various pH extremes may affect the stability 
of the immobilised ligand molecule), and low coefficients of variation were observed over the course 
of binding studies (<4%). Clearly, the results generated demonstrate the use of drug-protein conjugates 
is applicable in many instances, provided the regeneration conditions maintain the binding capacity of 
the immobilised ligands. However, the use of drug-protein conjugates can be a limiting factor, 
particularly when trying to dissociate high affinity antibody and antigen interactions (Keating, 1998). 
The small molecular weight of warfarin (308 Da) is somewhat constrained in the type of immunoassay 
format available for the direct detection of analyte. Extremely high concentrations of IgG would need 
to be immobilised at the chip surface to attain any reasonable response for the direct detection of 
warfarin, which in turn would be reflected by a correspondingly large increase in the concentrations of 
analyte detectable. Direct chemical coupling of antibodies to the chip surface suffers from particular 
drawbacks; namely the regeneration conditions required too often result in significantly reduced 
surface binding capacity as a result of antibody denaturation. Secondly, direct immobilisation of 
antibodies does not afford any specific orientation of the antibody molecules for subsequent binding to 
antigen. The most reproducible assay condition for such assay formats has been to employ the use of 
suitable affinity-capture surfaces, typically those incorporating Protein A/G. Protein A-coated surfaces 
specifically bind (KD ~ 10 9 M) and orientates the antibody molecules through their Fc regions, and 
were shown to be capable of reproducibly being used for greater than 120 binding-regeneration cycles 
(Quinn et al., 1999). A notable feature of directly immobilised drug surfaces is the substantially 
reduced quantity (i.e. 10-fold) of antibody required for assay purposes, a direct result of the increased 
surface epitope concentration, which again can be an important parameter given the high cost of many 
commercial antibody preparations. The use of effective regeneration solutions such as guanidine 
hydrochloride and guanidine thiocyanate are routinely employed to dissociate bound antibody from
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Figure 4.12: 70 consecutive regeneration cycles o f a 4-minute binding o f monoclonal antibody (4-
2-25) to the warfarin-BSA drug surface. The surface was regenerated with one 30- 
second pulse o f 25 mM HCl. The binding response demonstrated a coefficient o f 
variation o f 1.86% over the course o f 70 cycles and no decrease in the measured 
binding response over the course o f the regeneration study (i.e. cycle 1= 297.9, cycle 
70 = 315.4).
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Figure 4.13: 80 consecutive regeneration cycles o f a 4-minute binding o f monoclonal antibody (4-
2-25) to the directly immobilised 4'-aminowarfarin drug surface. The surface was 
regenerated with one 30-second pulse o f 25 mM HCl. The binding response 
demonstrated a coefficient o f variation o f 0.89% over the course of 80 cycles and no 
decrease in the measured binding response over the course of the regeneration study 
(i.e. cycle 1= 345.1, cycle 80 = 343.0). Directly immobilised drug surfaces were 
essentially 'unlimited' with respect to antibody binding capacity and can be used for 
greater than 1,000 cycles (Fitzpatrick, 2001).
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Figure 4.14: Simultaneous injection o f 1/5 dilution monoclonal antibody (4-2-25) sample over 
immobilised warfarin-BSA, dextran and BSA surfaces. The negligible degree o f non-specific binding 
to BSA immobilised surface (1.1 RU) compared to the response recorded on the immobilised warfarin- 
BSA (225RU), can be attributed primarily to the particular immunoaffinity purification procedures 
employed.
4.2.3.3. Determination o f Working Range o f Model Inhibition Assay Range in PBS
Once the binding capacity and the degree of non-specific binding associated with the binding 
interactions was established, the working range of the biosensor assay for the monoclonal antibody 4-
2-25 could then be evaluated. The validation criteria described by Wong et al. (1997) in the 
development of a biosensor-based immunoassay regarding sensitivity, ligand-binding capacity, 
accuracy, and precision were assessed for the detection of warfarin by mAb on two immobilised (i.e. 
drug/drug-protein) surfaces. A brief description of the main definitions and terminology used in 
reference to bioanalytical methods is included in Appendix 1A.
For the determination of the working range of the inhibition immunoassay, dilutions of 
warfarin were firstly prepared in HBS buffer as described in section 2.5.8.6. Dilutions of warfarin 
were prepared in HBS buffer ranging from 0.03 to 5000 ng/ml for the monoclonal antibody inhibition 
assays. The protein-G purified anti-warfarin monoclonal antibody preparations were mixed with the 
corresponding dilution of warfarin using the autosampler, and allowed to equilibrate for a period of 5- 
10 minutes. The samples were then passed in random order, over the derivatised chip surface and
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regenerated using the appropriate predetermined regenerant. Typical antibody binding response curves 
are illustrated in Figure 4.15. The response measured following the binding of unliganded antibody 
from the equilibrium solution (warfarin¡antibody) could be thus determined. In order to obtain 
normalised binding responses (allowing for direct inter-assay comparison), the binding response at 
each antigen concentration (R) was subsequently divided by the antibody binding response determined 
in the presence of zero antigen concentration (R0).
These normalised (R/Ro) responses were then used to construct a calibration curve. It 
consisted of the normalised response plotted against the warfarin concentration (ng/ml) and a four- 
parameter logistic fit modelled to the data set using BIAevaluation™ 3.1 software (Section 2.5.8.6). 
The working range of the assay was calculated to be from 0.97-250 ng/ml. Examples of the calibration 
plots constructed for monoclonal antibody injected over either the 4'-aminowarfarin or warfarin-BSA 
chip surfaces are illustrated in Figures 4.16-4.19. In addition, the intra- (precision) and inter-assay 
(reproducibility) variability determined for the monoclonal antibody are displayed in Tables 4.3-4.6. 
The intra-assay variation (precision/repeatability) for the BIAcore-based inhibition assay was obtained 
by calculating the coefficient of variation between samples assayed during a single assay run. The 
inter-assay variation (reproducibility) for each antibody preparation was calculated by performing the 
assay on three separate days and calculating the precision, or coefficient of variation between batches.
In this context, based on the degrees of precision, reproducibility, sensitivity and accuracy 
recorded, a direct comparison could be made with respect to each immobilisation format and particular 
antibody preparation. The coefficients of variation for the assay were typically of the order of 4%, 
except as expected towards the asymptotes of the spline curves where the degree of precision 
decreased to ~9% at the higher limit of quantitation. The coefficients of variation for the complete 
curve including the lower limit of quantitation (LLOQ)(i.e. 0.97 ng/ml) are all well within the current 
recommended validation guidelines for immunoassay procedures (Findlay et al., 2000). From the 
inter- and intra-assay data (Tables 4.3-4.6), a direct comparison could be made between both 
immobilisation formats, based on degrees of precision, reproducibility, sensitivity and accuracy 
recorded. The coefficients of variation (CV’s) were determined to assess the precision of the analytical 
method, expressing standard deviation as a percentage function of the mean. For the immobilised 
warfarin-BSA conjugate chip the intra- and interday assay CV’s ranged from 0.12 -  9.21% and 0.58 -  
11.11% respectively. For the directly immobilised 4'-aminowarfarin chip the intra- and interday assay 
CV’s ranged from 0.10 -  4.53% and 0.16 -  5.86%. These values indicate that the assay performed on 
both chip surfaces have a good degree of precision. The percentage accuracy values obtained in the 
linear part of the interday assay indicate that the fitted four parameter curve provides an accurate
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representation of the measured response in the linear range of the assay. The % accuracy values for the 
warfarin-BSA conjugated chip and 4'-aminowarfarin chip ranged from 92 -  104% and 95 -  106%, 
respectively. It was concluded that the monoclonal antibody preparation 4-2-25 injected over a 
directly immobilised 4'-aminowarfarin drug surface performed with the highest degrees of accuracy, 
reproducibility and precision. Both surface types (warfarin-BSA and 4-aminowarfarin) were then 
selected for development of an inhibition biosensor assay for the detection of warfarin in urine.
Figure 4.15: Overlay interaction curves demonstrating the decrease in binding o f anti-warfarin mAb 
to the immobilised warfarin-BSA surface with increasing free warfarin concentrations in HBS. (A) 
shows the normalised baselines o f each sensorgram when HBS is injected over the chip surface. (B) 
shows the increasing binding offree antibody with decreasing free warfarin concentrations. (C) shows 
the baseline shift when HBS buffer is passed over the surface after sample injection. The 
concentration o f free warfarin used in each binding cycle is indicated beside each sensorgram. The 
measured binding response was used to calculate the normalised response values (R/Ro), which were 
subsequently used to construct the calibration curves. (D) The sensor chip could be easily regenerated 
using one 30 second pulse o f 25 mMHCl.
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Table 4.3: Intra-day Assay results (warfarin-BSA chip) for detecting warfarin in PBS. Coefficients o f 
variance (a quantitative measure o f precision) were calculated using the equation % CV= 
(S.D./Mean) x 100 where the standard deviation (S.D.) is computed from replicate (3 replicates) 
analyses within a single validation run. % Difference Accuracy is the difference between the actual 
warfarin concentration (AWC) o f the prepared warfarin standards and the mean back calculated 
warfarin concentration (MBCW) value obtained from the 4-parameter calibration curve: 
(A WC/MBCW) x 100
Actual Warfarin 
Concentration 
(ng/ml)
Mean Back Calculated 
Warfarin 
Concentration from 
calibration curve 
(ng/ml)
% C.V. % Accuracies
500.00 451.04 9.21 110.85
250.00 239.67 5.38 104.13
125.00 131.65 5.26 94.95
62.50 67.62 0.81 92.43
31.25 28.48 0.12 109.73
15.60 15.90 0.43 98.11
7.80 7.62 0.19 102.36
3.91 4.20 0.28 93.10
1.25 1.50 0.60 83.33
0.97 0.93 0.19 104.30
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Figure 4.16: Intra-day Assay calibration curve (watfarin-BSA chip) for the detection o f warfarin in 
PBS utilising an anti-warfarin mAb. A 4-parameter equation was fitted to the data set using 
BIAevaluation 3.1. software. The intraday means and coefficients o f variation are tabulated in Table
4.3. Each point on the curve is the mean o f three replicate measurements analysed within a single 
validation run. Residual plots for the calibration curves are included (for each calibration curve), 
which illustrate the 'goodness o f the fit' o f the applied 4-parameter equations and supports the % 
accuracy findings.
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Table 4.4: Inter-day Assay results (warfarin-BSA chip) for detecting warfarin in PBS. Coefficients o f 
variance (a quantitative measure o f precision) was calculated using the equation % CV= (S.D./Mean) 
x 100 where for interday studies the S.D. is computed from replicate (3 replicates) analyses over 3 
validation runs on 3 separate days. % Difference Accuracy is the difference between the actual 
warfarin concentration (AWC) o f the prepared warfarin standards and the mean back calculated 
warfarin concentration (MBCW) value obtained from the 4-parameter calibration curve: 
(AWC/MBCW) x 100
Actual Warfarin 
Concentration 
(ng/ml)
Mean Back Calculated 
Warfarin 
Concentration from 
calibration curve 
(ng/ml)
% C.V. % Accuracies
500.00 496.44 9.21 100.72
250.00 230.73 11.11 108.35
125.00 135.11 9.12 92.52
62.50 63.18 8.61 98.92
31.25 30.01 2.42 104.13
15.60 15.61 7.36 99.94
7.80 7.93 1.02 98.36
3.91 4.10 2.80 95.37
1.25 1.40 0.58 89.29
0.97 0.50 1.34 NA
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Figure 4.17: Inter-day Assay calibration curve (warfarin-BSA chip) for the detection o f warfarin in 
PBS utilising an anti-warfarin mAb. A 4-parameter equation was fitted to the data set using 
BIAevaluation 3.1 software. The interday means and coefficients o f variation are tabulated in Table
4.4. Each point on the curve is the mean o f three replicate measurements analysed over three days. 
Residual plots for the calibration curves are included (for each calibration curve), which illustrate the 
'goodness o f the fit ' o f the applied 4-parameter equations and supports the % accuracy findings.
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Table 4.5: Intra-day Assay results (directly immobilised 4 '-amino warfarin chip) for detecting 
warfarin in PBS. Coefficients o f variance (a quantitative measure ofprecision) were calculated using 
the equation % CV- (S.D./Mean) x 100 where the standard deviation (S.D.) is computed from 
replicate (3 replicates) analyses within a single validation run. % Difference Accuracy is the 
difference between the actual warfarin concentration (A WC) o f the prepared warfarin standards and 
the mean back calculated warfarin concentration (MBCW) value obtained from the 4-parameter 
calibration curve: (AWC/MBCW) x 100
Actual Warfarin 
Concentration 
(ng/ml)
Mean Back Calculated 
Warfarin 
Concentration from 
calibration curve 
(ng/ml)
%  c.v. % Accuracies
250.00 214.03 3.64 116.81
250.00 112.91 1.89 110.70
125.00 73.07 4.53 83.76
62.50 33.67 0.35 92.80
31.25 15.63 0.10 99.81
15.60 7.30 1.43 106.83
7.80 4.20 0.31 93.14
3.91 2.16 0.86 87.96
0.97 1.02 3.34 95.28
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Figure 4.18: Intra-day Assay calibration curve (4 ’-aminowarfarin chip) for the detection o f warfarin 
in PBS utilising an anti-warfarin mAb. A 4-parameter equation was fitted to the data set using 
BIAevaluation 3.1. Software. The intraday means and coefficients o f variation are tabulated in Table
4.5. Each point on the curve is the mean o f three replicate measurements analysed within a single 
validation run. Residual plots for the calibration curves are included (for each calibration curve), 
which illustrate the 'goodness o f the fit' o f the applied 4-parameter equations and supports the % 
accuracy findings.
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Table 4.6: Inter-day Assay results (directly immobilised 4 ’-amino warfarin chip) for detecting 
warfarin in PBS. Coefficients o f variance (a quantitative measure ofprecision) was calculated using 
the equation % CV= (S.D./Mean) x 100 where for interday studies the S.D. is computedfrom replicate 
(3 replicates) analyses over 3 validation runs on 3 separate days. % Difference Accuracy is the 
difference between the actual warfarin concentration (A WC) o f the prepared warfarin standards and 
the mean back calculated warfarin concentration (MBCW) value obtained from the 4-parameter 
calibration curve: (AWC/MBCW) x 100
Actual Warfarin 
Concentration 
(ng/ml)
Mean Back Calculated 
Warfarin 
Concentration from 
calibration curve 
(ng/ml)
% C.V. % Accuracies
250.00 209.00 3.45 119.62
125.00 105.22 5.86 118.80
61.20 72.75 4.49 84.12
31.25 33.79 2.48 92.48
15.60 15.66 0.65 99.62
7.80 7.30 0.60 106.85
3.91 4.10 0.37 95.37
1.90 2.10 0.16 90.48
0.97 0.96 1.05 101.04
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Figure 4.19: Inter-day Assay calibration curve (4 '-aminowarfarin chip) for the detection o f warfarin 
in PBS utilising an anti-warfarin mAb. A 4-parameter equation was fitted to the data set using 
BlAevaluation 3.1. software. The interday means and coefficients o f variation are tabulated in Table
4.6. Each point on the curve is the mean o f three replicate measurements analysed over three days. 
Residual plots for the calibration curves are included (for each calibration curve), which illustrate the 
'goodness o f the fit' o f the applied 4-parameter equations and supports the % accuracy findings.
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4.2.3.4. Determination o f Working Range o f Assay in Urine
The inhibition immunoassay was also used for the detection of warfarin in urine as described 
in section 2.5.8.6. The ionic composition of urine can demonstrate considerable variation depending 
on an individual’s liquid volume intake. The antibody sample was prepared in HBS of twice the 
normal ionic strength (i.e. 2 x [HBS]), in order to compensate for the potential of wide inter-individual 
variability in the salt composition of urine. A dilution step (i.e. 1 in 5 urine dilution) was also 
employed to reduce the potential effect on the measured binding response due to the altered salt 
composition. Warfarin dilutions were prepared for concentrations ranging between 0.97-500 ng/ml in 
the urine solution. Dilutions of antibody solution (i.e. nominally 1/100) were subsequently mixed with 
20 pi of warfarin-spiked urine of known warfarin concentration, and allowed to attain equilibrium for 
five minutes on the BIAcore autosampler. The equilibrium mixtures were then serially passed over 
either the 4'-aminowarfarin or warfarin-BSA-coated surface in random sequence, to ensure there was 
no bias in the recorded measurements. The normalised responses were then used to construct a 
calibration curve of the normalised response versus warfarin concentration (ng/ml) as explained in 
section 4.2.3.3. The working range of this assay was calculated to be from 0.97-250 ng/ml. Examples 
of the calibration plots constructed for monoclonal antibody injected over either the 4'-aminowarfarin 
or warfarin-BSA chip surfaces are illustrated in Figures 4.20-4.23. In addition, both the intraday and 
interday assay variabilities were determined and are displayed in Tables 4.7-4.10. The coefficients of 
variation for the assay were typically of the order of 2%, except as expected towards the asymptotes of 
the spline curves where the degree of precision decreased to ~9% at the higher limit of quantitation. 
The coefficients of variation for the complete curve including the lower limit of quantitation 
(LLOQ)(i.e. 0.97 ng/ml) are all well within the current recommended validation guidelines for 
immunoassay procedures (Findlay et al., 2000).
From the inter- and intra-assay data (Tables 4.7-4.10) a direct comparison could be made 
between both immobilisation formats based on degrees of precision, reproducibility, sensitivity and 
accuracy recorded. The coefficients of variation (CV’s) were determined to assess the precision of the 
analytical method, expressing standard deviation as a percentage function of the mean. For the 
immobilised warfarin-BSA conjugate chip the intra- and interday assay CV’s ranged from 0.8 -  8.33% 
and 4.53 -  15.16%, respectively. For the directly immobilised 4'-aminowarfarin chip the intra- and 
interday assay CV’s ranged from 0.13 -  7.17% and 0.16 -  11.80%. These values indicate that the 
assays performed on both chip surfaces have a high degree of precision. The percentage accuracy 
values obtained in the linear part of the interday assay indicates that the fitted four parameter curve 
provides an accurate representation of the measured response in the linear range of the assay. The %
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accuracy values for the warfarin-BSA conjugated chip and 4'-aminowarfarin chip ranged from 97.50 -  
105.93% and 95.71 -  103.59%, respectively. It was concluded that the monoclonal antibody 
preparation 4-2-25, on a directly immobilised 4'-aminowarfarin drug surface performed with the 
highest degrees of precision and reproducibility. This immunoassay format compares well to previous 
research data obtained using HPLC (Takahashi et al., 1997) and BIAcore analysis. Fitzpatrick & 
O’Kennedy (2001) utilised a panel of anti-warfarin monoclonal antibodies to establish a BIAcore 
detection method for warfarin in human plasma samples. The limit of detection was similar to the data 
presented in this thesis (L.O.D. = 0.97ng/ml). HPLC was utilised to detect warfarin in plasma samples, 
however, the L.O.D. = 5.0ng/ml which is not as sensitive as the BIAcore assays. Approximately 99% 
of warfarin present in plasma is protein-bound (Cai et al., 1994; Fitzpatrick & O’Kennedy, 2001; 
Bertucci & Cimitan, 2003). Therefore, initially there should be relatively little (1%) warfarin free in 
plasma and in urine. Hence, the BIAcore assay utilising anti-warfarin mAb is sufficient for the 
detection of warfarin in the concentration range 0.97 — 250ng/ml. If a higher range of detection is 
required (e.g. monitoring an increase in warfarin dose), anti-warfarin polyclonal antibodies can be 
utilised as the working range of a BIAcore assay for the detection of warfarin in urine was 
demonstrated to be from 10-5,000 ng/ml.
Proper patient compliance is tremendously important in the management of warfarin 
anticoagulation, as dosage modifications are made based on the pharmacological end-point of warfarin 
therapy (i.e. Prothrombin time measurements). Accordingly, any dosage adjustments made on the 
basis of improper patient compliance can have extremely serious consequences upon return of the 
patient to the recommended dosage regime. Therefore, the current system could be utilised as an 
immunoassay screening technique to guarantee adequate patient compliance prior to dosage 
adjustment. A comparable strategy could also be used in cases of suspected warfarin ingestion. George 
et al. (2000) described a similar approach for monitoring methadone compliance in patient urinaiy 
samples by immunoassay. These screening procedures could potentially be applied for rapid 
determination of substance abuse to a wide range of residues, by employing broad-spectrum 
antibodies (either poly-or monoclonal) capable of detecting particular classes of drugs of abuse (e.g. 
amphetamines). The BLAcore 3000 used in this work shows great promise in this area as different 
residues of illicit drugs and their metabolites can be immobilised on the available flow cells (1-4). 
Once this is accomplished, a single injection over the prepared surface of patient sample (e.g. urine, 
plasma or saliva) could be rapidly used to identify the presence of such illicit residues in minutes. 
Such rapid screening techniques are essential to allow for rapid identification of drugs so that an 
appropriate antidote may be administered.
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Table 4.7: Intra-day Assay coefficients o f variance (CV’s) and percentage accuracies for the anti- 
warfarin monoclonal antibody used for the detection o f warfarin in urine. Warfarin-BSA was 
immobilised onto the sensor chip surface. The standard deviation (S.D.) is computed from replicate (3 
replicates) analyses within a single validation run.
Actual Warfarin 
Concentration 
(ng/ml)
Mean Back Calculated 
Warfarin 
Concentration from 
calibration curve 
(ng/ml)
% C.V. % Accuracies
250.00 228.83 4.78 109.25
125.00 143.98 8.33 86.82
62.50 55.40 0.80 112.82
31.25 35.42 3.64 88.23
15.60 13.12 1.31 118.90
7.80 8.77 2.04 88.94
3.91 4.71 1.31 83.01
1.90 1.17 2.36 NA
0.97 0.62 1.92 NA
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Figure 4.20: Intra-day Assay calibration curve (warfarin-BSA chip) for the detection o f warfarin in 
urine utilising an anti-warfarin mAb. A 4-parameter equation was fitted to the data set using 
BIAevaluation 3.1 software. The intraday means and coefficients o f variation are tabulated in Table
4.7. Each point on the curve is the mean o f three replicate measurements analysed within a single 
validation run. Residual plots for the calibration curves are included (for each calibration curve), 
which illustrate the 'goodness o f the fit' o f the applied 4-parameter equations and supports the % 
accuracy findings.
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Table 4.8: Inter-day Assay coefficients o f variance (CV’s) and percentage accuracies for the anti­
warfarin monoclonal antibody used for the detection o f warfarin in urine. Warfarin-BSA was 
immobilised onto the sensor chip surface. The standard deviation (S.D.) is computed from replicate (.3 
replicates) analyses over 3 validation runs on 3 separate days.
Actual Warfarin 
Concentration 
(ng/ml)
Mean Back Calculated 
Warfarin 
Concentration from 
calibration curve 
(ng/ml)
% C.V. % Accuracies
250.00 256.40 5.40 97.50
125.00 118.00 6.77 105.93
62.50 63.40 11.05 98.58
31.25 32.10 13.87 97.35
15.60 15.65 15.16 99.68
7.80 7.51 11.69 103.86
3.91 3.65 4.53 107.12
1.90 1.74 7.27 109.20
0.97 1.20 10.32 80.83
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Figure 4.21: Inter-day Assay calibration curve (warfarin-BSA chip) for the detection o f warfarin in 
urine utilising an anti-warfarin mAb. A 4-parameter equation was fitted to the data set using 
BIAevaluation 3.1 software. The interday means and coefficients o f variation are tabulated in Table
4.8. Each point on the curve is the mean o f three replicate measurements analysed over three days. 
Residual plots for the calibration curves are included (for each calibration curve), which illustrate the 
'goodness o f the fit ' o f the applied 4-parameter equations and supports the % accuracy findings.
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Table 4.9: Intra-day Assay coefficients o f variance (CV's) and percentage accuracies for the anti­
warfarin monoclonal antibody used for the detection o f warfarin in urine. 4-aminowarfarin was 
immobilised onto the sensor chip surface. The standard deviation (S.D.) is computedfrom replicate (3 
replicates) analyses within a single validation run.
Actual Warfarin 
Concentration 
(ng/ml)
Mean Back Calculated 
Warfarin 
Concentration from 
calibration curve 
(ng/ml)
% C.V. % Accuracies
250.00 214.00 7.17 116.82
125.00 111.00 4.88 112.61
61.20 70.00 0.95 87.43
31.25 33.00 0.41 94.70
15.60 15.63 0.54 99.81
7.80 7.30 0.17 106.85
3.91 4.01 0.35 97.51
1.90 2.10 0.13 90.48
0.97 1.00 0.33 97.00
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Figure 4.22: Intra-day Assay calibration curve (4 ’-aminowarfarin chip) for the detection o f warfarin 
in urine utilising an anti-warfarin mAb. A 4-parameter equation was fitted to the data set using 
BIAevaluation 3.1 software. The intraday means and coefficients o f variation are tabulated in Table
4.9. Each point on the curve is the mean o f three replicate measurements analysed within a single 
validation run. Residual plots for the calibration curves are included (for each calibration curve), 
which illustrate the 'goodness o f the fit ' o f the applied 4-parameter equations and supports the % 
accuracy findings.
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Table 4.10: Inter-day Assay coefficients o f variance (CV’s) and percentage accuracies for the anti­
warfarin monoclonal antibody used for the detection o f warfarin in urine. 4-aminowarfarin was 
immobilised onto the sensor chip surface. The standard deviation (S.D.) is computed from replicate (3 
replicates) analyses over 3 validation runs on 3 separate days.
Actual Warfarin 
Concentration 
(ng/ml)
Mean Back Calculated 
Warfarin 
Concentration from 
calibration curve 
(ng/ml)
% C.V. % Accuracies
250.00 215.04 8.36 118.46
125.00 105.58 11.80 118.39
61.50 72.98 4.49 84.27
31.25 32.65 2.48 95.71
15.60 15.68 0.65 99.49
7.80 7.53 0.60 103.59
3.91 4.19 0.37 93.27
1.90 2.19 0.16 86.60
0.97 0.96 1.05 101.46
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Figure 4.23: Inter-day Assay calibration curve (4’-aminowarfarin chip) for the detection o f warfarin 
in urine utilising an anti-warfarin mAb. A 4-parameter equation was fitted to the data set using 
BIAevaluation 3.1. software. The interday means and coefficients o f variation are tabulated in Table
4.10. Each point on the curve is the mean o f three replicate measurements analysed over three days. 
Residual plots for the calibration curves are included (for each calibration curve), which illustrate the 
'goodness o f the fit' o f the applied 4-parameter equations and supports the % accuracy findings.
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4.2.3.5. Cross-Reactivity Studies
Cross reactivity studies with the monoclonal antibody 4-2-25 (defined in Section 3.2.4) were 
assessed utilising BlAcore. The procedure was similar to that performed for the ELISA cross­
reactivity studies. Three compounds (acenocoumarin, 6-hydroxywarfarin and 7-hydroxywarfarin) 
where chosen in order to determine their cross-reactivity with the anti-warfarin monoclonal antibody. 
In Section 3.2.4 percentage cross-reactivity was assessed for warfarin and several structurally similar 
compounds utilising ELISA. It was found that 7-hydroxycoumarin, 4-hydroxycoumarin, coumarin and 
7-hydroxycoumarin-4-acetic acid displayed negligible cross-reactivity (<0.1 %) with the anti-warfarin 
mAb. Therefore, it was decided to focus the BlAcore cross-reactivity studies on the compounds 
(acenocoumarin, 6- & 7-hydroxwarfarin), which displayed significant percentage cross-reactivity with 
the anti-warfarin mAb. Cross-reactivity was assessed by preparing serial dilutions of warfarin or one 
of the other compounds (Section 2.5.8.6.), using HBS as diluent. Protein-G purified monoclonal 
antibody was then mixed with the various antigen concentrations using the BlAcore autosampler 
(incubation time 5-10 mins). The equilibrium mixtures were then injected over the chip surface. The 
results obtained as explained in Section 2.5.8.6. and Section 3.2.4 were plotted and displayed as a 
single graph as in Figure 4.24. Formula X in section 3.2.4 was then used to calculate percentage cross 
reactivity of each compound. From the calculations it was determined as expected that acenocoumarin 
displayed the highest cross-reactivity with the anti-warfarin monoclonal antibody (-30%). 6- 
hydroxywarfarin displayed the next highest degree of cross-reactivity at approximately 18% and this 
was followed by 7-hydroxywarfarin at approximately 10%.
In terms of detecting warfarin in biological samples such as urine it is important to know 
whether the anti-warfarin monoclonal antibody can detect other metabolites present in biological 
samples besides warfarin. Warfarin is excreted in urine along with two major metabolites 6- and 7- 
hydroxywarfarin. From the results it is evident that the anti-warfarin monoclonal antibody will detect 
warfarin. Although both warfarin metabolites can be detected by the monoclonal antibody they need to 
be present at higher concentrations than warfarin (which is likely in biological samples where less than 
2% of warfarin is excreted as warfarin in urine). Acenocoumarin is also known as nitro-coumarin, 
which can be used as an anticoagulant to treat patients. Therapeutic plasma concentrations of 
acenocoumarin tend to be in the range of 30-100ng/ml. The binding of several warfarin derivatives 
(such as acenocoumarin) to HSA was previously characterized (Petitpas et ah, 2001). It is interesting 
to note that acenocoumarin binds more loosely to HSA than warfarin. Therefore, higher levels of free 
acenocoumarin are present in plasma and urine in comparison to warfarin. The weaker association of 
acenocoumarin probably occurs because the addition of an NQ2 group to the benzyl ring sterically
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hinders its accommodation in the hydrophobic compartment formed primarily by Phe-211, Trp-214, 
Leu-219, and Leu-238. It is possible that acenocoumarin if administered to patients at similar doses to 
warfarin could be detected by the anti-warfarin monoclonal antibody at a higher detection range than 
warfarin.
Drug Concentration (ng/'ml)
Figure 4.24: Overlay plot showing the cross reactivity o f the anti-warfarin monoclonal antibody with 
several warfarin analogues using the BIAcore 3000 system (Section 2.5.8.6).
4.2.3.6. Solution Phase Steady State Affinity Determinations
BIAcore technology was employed to determine and evaluate the dissociation constants 
obtained using ‘real-time’ biomolecular interaction with those determined using a well-based ELISA 
analysis for the interaction between anti-warfarin monoclonal antibodies and specific target antigens. 
The protocol employed utilises the same principle as that employed in the ELISA method of Friguet et 
al. (1985), but has several advantages over the ELISA technique. The continual flow of fresh 
equilibrium mixture over the warfarin-coated sensor chip and the short contact time of the 
antibody:antigen equilibrium mixture in the flow cell (compared to incubation step in the ELISA) 
limits the possibility of a re-equilibration of the antibodyrantigen mixture, and subsequent
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underestimation of the affinity constant. The method requires no additional labelling of the reagents, 
or the addition of secondary reagents, which may affect the intrinsic thermodynamic binding 
constants.
A known concentration of anti-warfarin antibodies were serially doubly diluted in HBS buffer 
and used to construct a calibration curve of free antibody concentration versus response as described 
in section 2.5.8.7. A known concentration of antibody (M) was then mixed with serial doubling 
dilutions of warfarin of known concentration and allowed to attain equilibrium. Each equilibrium 
mixture was then assayed for ‘free-unliganded’ anti-warfarin antibodies by passing the equilibrated 
mixtures over a warfarin-coated sensor chip surface. The concentration of free antibody at equilibrium 
was determined by reference to the standard curve (Figure 4.25.).
The model described below is used to calculate the solution equilibrium dissociation constant:
The equilibrium dissociation constant can be calculated by constructing a plot of free anti-warfarin 
antibodies versus warfarin concentration as shown in Figure 4.25. Equation (12) describing the model 
for solution phase affinity assumes that the antibodies are monovalently bound. The assay format 
utilised is capable of detecting free and monovalently bound antibody, and a correction similar to that 
applied to the ELISA measurements may be applied, so that the concentration of free antibody in the 
equilibrated antibody:antigen mixture is not overestimated giving an underestimated affinity constant. 
Piehler et al. (1997) amended the solution phase model based on the binomial distribution principle 
described by Stevens (1987), and expressed the ‘corrected’ concentration of free antibody with at least 
one antibody binding site free by the expression:
(12)
Where Bfree is the free concentration of anti-warfarin IgG. 
A is the total concentration of warfarin 
B is the total anti-warfarin IgG concentration 
Kd is the equilibrium dissociation constant.
Bfree — — 
2 2B 0 3 )
The symbols have the same meaning as described for equation (12).
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The model described in equation (13) assumes that the sensor responses for free and 
monovalently occupied antibody are similar. The assumption that the sensor responses measured 
would be similar for free and monovalently liganded antibodies particularly with larger target antigens 
is obviously incorrect, however with small molecules such as warfarin, the response measured for 
monovalently bound antibodies and free antibodies would be similar, given the small molecular 
weight of warfarin compared to an intact IgG molecule. The monovalent fit (Figure 4.26) appears to 
describe the interaction better between the antibody and the conjugate-immobilised drug surface 
(Kd=1.13 x 10'8 M). The data does not fit the bivalent model particularly well as seen in Figure 4.27, 
and the monovalent fit appears to describe the interaction better between the monoclonal antibody and 
the conjugate-immobilised drug surface.
Utilising BIAcore, affinity determinations were made by employing an immobilised 
monovalent ligand (warfarin-BSA) with a bivalent analyte (anti-warfarin monoclonal antibody) in 
solution, with the potential, of bivalent analyte binding. However, given the low epitope density and 
possible steric hindrance factors at the chip surface the probability of an antibody being bound to two 
immobilised conjugate-warfarin molecules simultaneously would be regarded as low. It is impossible 
to predict what conformation the protein (BSA)-bound warfarin molecules would assume when 
immobilised, given the inhomogenetity of the immobilised surface ligand (warfarin-BSA).
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Antibody Concentration (M)
Figure 4.25: Serial doubling dilutions o f anti-warfarin antibodies o f known concentration (M) were 
passed sequentially over a warfarin-coated (i.e. warfarin-BSA or 4'-aminowarfarin) sensor chip 
surface. A calibration plot was constructed o f anti-warfarin antibodies (M) versus response measured 
(RU). The calibration plot was then used to calculate the concentration o f free antibody at 
equilibrium. Results shown are the average o f triplicate measurements.
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W arfarin C oncentration (M )
Figure 4.26: Determination o f overall solution equilibrium affinity constant between mAb 4-2-25 and 
warfarin on a warfarin-BSA-coated chip surface. Warfarin concentrations were plotted against free 
anti-warfarin antibody concentration, determined by reference to a calibration plot o f anti-warfarin 
antibodies. A 1:1 interaction model was used to describe the interaction (equation 12) and fitted to 
the data set using BIAevaluation software, deriving an equilibrium dissociation constant o f KD=1.13 x 
I ff8 M, for the interaction between clone 4-2-25 and warfarin.
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Warfarin Concentration (M )
Figure 4.27: Solution phase affinity for warfarin and mAb 4-2-25 on warfarin-BSA -coated chip 
surface. The model describing bivalent binding was applied to the data set, giving an overall, 
equilibrium constant o f KD = 4.51 x 1(T9 M. The bivalent model described in equation (13) fitted to 
the data using BlAevaluation software, does not describe the interaction particularly well as seen 
from the plot.
4.2.3.7. Steady-State Affinity Determinations
Warfarin-BSA was immobilised at an adequately low surface concentration in order to 
provide a maximum response of approximately 200 RU on the sensor chip surface using conventional 
coupling chemistry. Direct immobilisation of 4'-aminowarfarin at a sufficiently low ligand density on 
the chip surface was difficult to manage, and consequently the warfarin-BSA conjugate was 
immobilised. A second flow cell was used to immobilise BSA at a similar surface concentration as 
the conjugate. Fortunately BIAcore 3000 is capable of on-line reference curve subtraction, thereby 
removing matrix effects, and baseline jumps due to sample injection and refractive index changes.
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Preferably, it would be ideal to immobilise the antibody to the chip surface by affinity capture using 
Protein A/G. However, direct immobilisation of the antibody would remove the complexity arising 
from a bivalent analyte binding to the drug surface, and possible avidity effects at the chip surface 
resulting in elevated affinity constant determinations. Previous work by Fitzpatrick (2001) 
demonstrated that the surface concentration of antibody required to achieve a quantifiable response 
signal following binding of warfarin to the affinity captured antibody proved to be a limiting factor 
and consequently the use of drug-protein conjugates was preferable. For example, affinity capture of 
10,000RU of anti-warfarin antibody via protein G, (which is difficult to accomplish in practice) results 
in a maximal saturation response of 41RU even when taking antibody bivalency into account given the 
ratio of the molecular weights of the antibody (~150,000Da), and warfarin (308Da). Given the large 
concentration of antibody needed to generate such a quantifiable signal, it is veiy time consuming to 
attain equilibrium and saturation of the surface
The steady state affinity for a surface interaction can be described by the expression:
Re <h,(C.V.«mK 
KaMCAl +1
Where n = Steric hindrance factor and represents the average number of ligand sites
occupied per analyte molecule.
Req = Response at equilibrium
(CA)i = Injected concentration of analyte (M)
Rmax = Maximal response
Ka = Equilibrium association constant
The value for steric hindrance factor, n, can be determined experimentally by calculating the 
fraction of the response measured versus the theoretical maximal response attainable given a specific 
immobilised ligand surface concentration. The value of n, could therefore not be calculated using drug 
protein conjugates and was set to 1, for the purposes of modelling experiments.
Serial dilutions of anti-warfarin antibody of known concentration were simultaneously 
injected over warfarin-BSA and BSA-coated surfaces at a flow rate of 2 pl/min for 40 minutes, using 
‘on-line’ reference curve subtraction as illustrated in Figures 4.28 and 4.29. A plot of the equilibrium 
response (Req) measured versus the injected antibody concentration was constructed (Figure 4.30). 
The steady state affinity model detailed in equation (14) was fitted to the plot deriving an association
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constant (KA) value of 1.10 x 107 ± 0.21 x 108 M'1 for the steady-state interaction between clone 4-2-25 
and warfarin.
The steady-state affinity model derives an association constant higher than that obtained for 
the solution phase constant using immobilised drug conjugates, but less than that obtained with 
directly immobilised drug surface. The solution phase affinity constant is expected to defer a slightly 
higher value for the association constant, provided that both interacting molecules (i.e. antibody and 
antigen) are free in solution. The possibility of bivalent analyte binding to the chip surface also exists 
which is similar to the solution phase assay. However, since a low surface ligand concentration of 
warfarin-BSA is employed, the probability of a monovalently bound antibody bound to the conjugate 
surface, encountering a second free ligand site would be particularly small, given also the saturating 
concentrations of antibody employed. In this situation, the restrictions enforced by the small molecular 
weight of the analyte and the use of the warfarin-BSA surface allows for approximations of overall 
association constants, provided that values for the steric hindrance factor, n, were impossible to 
calculate given the inconsistency of the conjugate on the surface.
Time (seconds)
Figure 4.28: Warfarin-BSA ( j and BSA (---- ) were immobilised onto (wo flow (Fc) celts o f a
sensor chip surface, namely Fc2 and Fcl, respectively. 80nM o f affinity-purified anti-warfarin 
antibodies were injected over the two sensor chip surfaces and monitored simultaneously using ‘on­
line’ reference curve subtraction (i.e. Fc2-Fcl).
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Figure 4.29: Serial dilutions o f anti-warfarin antibody o f known concentration were simultaneously 
injected over warfarin-BSA and BSA coated surfaces at a flow rate o f 2 pl/min for 40 minutes, using 
'on-line' reference curve subtraction. The interaction curve from Figure 4.26, following 'on-line' 
reference curve subtraction, is shown. The equilibrium binding response was measured at a variety of 
injected antibody concentration and used to plot a curve o f the binding response at equilibrium (Req) 
versus injected antibody concentration (Figure 4.28).
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Anti-warfarin antibody concentration (M)
Figure 4.30: The value obtained for Req was plotted against the molar concentration o f antibody 
injected. The steady state model was fitted to the data, and assuming a value o f n=l, the value for the 
association constant, KA, for the interaction between warfarin and affinity-purified antibodies from 
clone 4-2-25 was determined using BIAevaluation software to be 1.10 x 107 ±0.21 x l ( f  M l.
4.3. Conclusions
The results presented in this chapter describe the development and validation of an inhibition- 
based immunoassay for the detection of warfarin in biological samples. Both directly immobilised 
drug (4'-aminowarfarin) surfaces and the use of a drug-protein conjugate (warfarin-BSA) were utilised 
for ligand-binding capacity comparisons. In this instance it was demonstrated, that the directly 
immobilised drug surface offered considerably better binding reproducibility (% C.V. ~ 0.8%) over 
the binding-regeneration cycles studied (i.e. 80 cycles), which is primarily related to the exceptional 
stability of the immobilised drug molecule (4'-ammowarfarin) on the dextran surface. The use of 
hapten-protein conjugates offers an alternative when suitable reactive groups are not available for 
direct immobilisation of the drug. However, the use of hapten-protein conjugates can prove difficult 
particularly when trying to dissociate high affinity antibodyrantigen interactions, where the use of 
adequately harsh regeneration solutions to regenerate the sensor surface, too often results in 
denaturation of the immobilised ligand. Similarly, immobilisation of sufficiently high yields of 
conjugate for routine sample analysis can sometimes prove difficult using EDC/NHS chemistry, as
2 2 2
many hapten-protein conjugates are characterised by very acidic isoelectric points. Inhibition assays 
(in PBS or urine) generated calibration plots for both chip surfaces in order to determine the assay 
precision and reproducibility. The coefficients of variation for all the assays developed were well 
within the current recommended validation guidelines for immunoassay procedures.
Using BIAcore analysis affinity determinations were made using the warfarin-BSA conjugate 
surface. The dissociation plot fitted to the data generated on drug-protein conjugate surfaces appeared 
to conform to the fit of monovalent binding. The reality is that the dissociation fit lies somewhere 
between the modelled mono- and bivalent fit. The likelihood of an antibody being bound to two 
immobilised protein-bound warfarin molecules simultaneously would be small as a result of the lower 
epitope concentration and possible steric hindrance factors at the chip surface, giving slightly lower 
association constants. The lower dissociation constant values generally obtained using solution phase 
assays compared to steady state analysis, agrees with what one might have predicted. For solution 
phase assays, both interacting molecules (i.e. antibody and antigen) are free in solution and hence have 
an increased collision frequency, thus affecting the kinetic rate constants and the measured affinity 
constants, unlike steady state analysis where one of the interactants is immobilised. Ultimately, the 
method (solution phase/steady state analysis) of measuring antibody affinity should resemble the 
environment for their intended use (i.e. steady state analysis should be used for measuring antibody 
affinity to surface bound molecules and solution phase assays for situations where the antibody might 
encounter the antigen in solution).
It is evident from Section 4.3.2A. that anti-warfarin monoclonal antibodies can successfully 
detect warfarin in urine samples. In reality, most patients begin warfarin therapy by taking 5 mg per 
day. However, only less than 2% of the administered dose is excreted as warfarin (Kratochwil et al.,
2002). Therefore, in a regular setting anti-warfarin polyclonal antibodies are ideal as they have a 
broader range and cross-react with 6- and 7-hydroxywarfarin (warfarin metabolites). Warfarin dosing 
varies over time with some patients requiring lower or discontinued warfarin dosing. Monitoring 
warfarin levels at these times is very important to reduce the risk of thrombosis in patients. Both 
elderly patients and those with other medical complications (heart valves) require much lower doses 
than is regularly given (e.g. 0.5mg per day or lower) to patients. If surgery is required it may be 
recommended to discontinue warfarin therapy to prevent the risk of uncontrolled bleeding, however 
the patient is at risk from thrombosis prior to surgeiy. In this case, levels of warfarin in urine decrease 
to very low levels but can be monitored using anti-warfarin monoclonal antibodies, which have lower 
detection limits than anti-warfarin polyclonal antibodies (e.g. 0.9 ng/ml versus lOng/ml). If a patient 
requires medication for other medical conditions this can affect the levels of warfarin in blood plasma
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and in urine (Table 1.6.). When levels decrease below the detection range possible with polyclonal
antibodies it is better to utilise anti-warfarin monoclonal antibodies with lower detection limits.
The use of biosensors for monitoring ‘real-time’ interactions is proving to be a viable and 
useful alternative to currently existing techniques for drug detection and drug-biomolecule interaction 
studies. The advantages of using biosensors such as BlAcore include speed, versatility and 
amenability to automation. The detection and separation of enantiomers is a problem routinely 
encountered in pharmaceutical drug discoveiy and chemical synthesis. A host of different analytical 
techniques either alone (HPLC) or in conjunction (LC-MS) are employed to address the issue of drug 
detection. HPLC in combination with UV spectroscopy, mass spectrometry (MS) or fluorescence 
spectroscopy were utilised for the detection of various drug compounds and metabolites in human 
urine and plasma (Takahashi et al., 1997; Maurer & Arlt, 1998; Desta et al., 2000; Naidong et al.,
2001). However, the development of the majority of chromatographic assays requires individual 
manipulation of mobile phases, extraction schemes and detection techniques for the detection of 
particular drug molecules. Hence, in comparison to BlAcore assays these techniques can be laborious 
and time consuming. Previous work by Fitzpatrick (2001) demonstrated excellent correlation between 
the BlAcore inhibition assay and a HPLC technique for the detection of warfarin in human plasma. 
The limits of detection (Table 4.2) attainable with the developed inhibition immunoassay were more 
than an order of magnitude below those attainable using HPLC with UV detection (i.e. L.O.D. 
inhibition immunoassay = < 0.3 ng/ml, HPLC with UV-detection « 6ng/ml). The assay performance as 
measured by the conventional measures of analytical performance, namely precision, accuracy, 
reproducibility and robustness demonstrated that the assay performed comparably in every respect to 
the conventional chromatographic techniques. Several other studies involving HPLC analysis of 
warfarin also showed higher limits of detection, which ranged from 20-40 ng/ml down to 2.5-4.5 
ng/ml (Takahashi et al., 1997; Boppana et al., 2002). Gas chromatography-mass spectrometry was 
utilised by Maurer and Arlt (1998) for the detection of warfarin in urine with a limit of detection at 25 
ng/ml. The results presented in Section 4.2.3.4 demonstrate that the limit of detection (0.9 ng/ml) 
attainable with the inhibition immunoassay developed was lower than those obtained by conventional 
chromatographic methods (approx. 5 ng/ml).
The use of this inhibition BlAcore assay is amenable to the detection of a wide range of 
analytes in various matrices, as relatively facile manipulation of the experimental parameters (i.e. 
immobilised ligand, regeneration parameters and choice of antibody) can be achieved to tailor the 
assay for the detection of different analytes. Recent advances in genetic engineering with the 
development of phage-displayed libraries and various in-vitro affinity maturation techniques, has
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realised the potential o f  generating antibodies o f  extrem ely high affin ities (B rennan et al., 2003) to 
alm ost any m olecule. A llied with the sensitiv ity  o f  current SPR devices, the ability to accurately 
quantitate sub-picogram  quantities o f  analytes fo r detailed pharm acokinetic /  environm ental studies is 
now a reality.
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Chapter 5
The Effects of Benzopyrones on the 
Growth, Metabolism and Signalling Pathways 
of Human Tumour Cells
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5.1. Introduction to Chemosensitivity Testing
Cancer chemotherapy has witnessed a great deal of progress since the introduction of the 
nitrogen mustards in the 1940s. Unfortunately, chemotherapy today still faces the problem of 
determining which specific agent or agents are able to yield the desired clinical therapeutical effect for 
a particular tumour and patient. Attempts to individualise therapy have been the goal of oncologists 
since the 1950s. However, progress is delayed by the fact that cure rates are constrained not only by 
the limited range of agents currently available and their adverse side effects, but also by variations in 
individual responses (Clynes et al., 2003). Since the 1950s a number of in vitro assays have been 
developed to predict therapeutic outcome (chemosensitivity and chemoresistance) prior to the start of 
therapy. These tests are also used for screening potential novel drugs. Three groups of tests can be 
defined:
a) Cell viability tests e.g. the lactate dehydrogenase (LDH) assay.
b) Cellular metabolism tests e.g. the tetrazolium salt (MTT) assay.
c) Cellular proliferation tests e.g. in vitro proliferation assays.
Test time, tissue preparation, complexity of test performance, and correlation with the clinical 
progress of the disease are criteria used to judge how successful these tests are (Mestres-Ventura, 
2003). As outlined in Section 1.6.3, current cancer therapies, even combination therapies, offer limited 
success for cancer patients. Therefore, the harsh reality for scientists and clinicians alike is that new 
drugs with novel mechanisms of action and better treatment strategies are still required for the 
progression in the successful treatment of cancer. Hence, a vast program of screening for compounds 
(both natural and synthetic) was instigated by government and private institutions worldwide 
(Cardenas et ah, 1998; Kong et ah, 2001; Zhu, 2003). Drug resistance can occur at the onset of the 
disease or can be acquired after previous chemotherapy. It was determined that chemosensitivity 
testing invariably shows a predictive accuracy of over 90% to identify drugs that will not work 
(chemoresistance).
5.1.1. Current Chemosensitivity Tests
To select the most appropriate anti-cancer drugs and their optimal doses, various
chemosensitivity tests are now available. In examining the sensitivity of tumour cells (both biopsy and
cultured cell samples) to compounds, one can examine the effect of the compound on one of a number
of cellular mechanisms e.g. cellular proliferation, cellular metabolism and cell viability (Table 5.1). In
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recent years colorimetric assays based on an enzymatic reaction such as the MTT assay, were used in 
an attempt to replace the conventional isotopic assay for cell-mediated cytotoxicity. In conventional 
chromium (51Cr) release cytotoxicity assay there are problems with environmental pollution and poor 
labelling of some tumour cells. For these reasons, a variety of non-radioactive assays were developed 
as alternatives. These include flow cytometric analysis, time-resolved fluorometric assay, MTT 
colorimetric assay, the LDH assay and the AP assay. Among the colorimetric assays, the MTT assay is 
the most widely used (Niu, 2001). In order to better understand the most recent advances in 
chemosensitivity testing in cancer, a concise review of recent research follows.
The possibility of using the MTT assay as a substitute for the human tumour clonogenic assay 
(HTCA) was assessed in 5 human lung cancer cell lines. The results indicate that the MTT assay may 
be more convenient and less time-consuming in evaluating the effects of anticancer agents (Kawada et 
ah, 2002). This assay format has had further recent applications. Various malignant brain tumour cell 
lines were examined for their sensitivity to cisplatin, doxorubicin, etoposide and the antimitotic agents 
vincristine and paclitaxel by MTT-cytotoxicity assays. The tumour suppressor p33INGl has growth- 
inhibitory and pro-apoptotic effects recruiting p53 and it plays a role in DNA repair. p33INGl mRNA 
expression was determined by reverse transcriptase- polymerase chain reaction (RT-PCR) and these 
mRNA levels may be used to predict the chemosensitivity of brain tumour cells to vincristine (Tallen 
et ah, 2003). Another study was designed to determine whether this assay correlates with the clinical 
response. The effect of several compounds (cisplatin (CDDP), 5-fluorouracil (5-FU), mitomycin C, 
and adriamycin) on fresh human esophageal squamous cell carcinoma proliferation was investigated. 
The results suggest that the MTT assay may be useful in evaluating the optimum adjuvant 
chemotherapy for patients with regional lymph node positive (pNl) esophageal squamous cell 
carcinoma (Nakamori et ah, 2003).
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Table 5.1: Summary o f the current chemosensitivity tests available. These tests can be utilised for 
screening novel chemotherapeutic agents, for determining mechanisms o f action o f current and new 
drugs and for testing drug combinations with other chemotherapy drugs or radiation therapy.
Assay Reference Assay Description
C E LLU LA R  
PRO LIFERATIO N  
In Vitro Proliferation
BrdU Incorporation
Kenacid Blue 
Clonogenic Assays
Xenografts
CELLULAR METABOLISM 
M TT Assay
ATP Assay
C E LLU L A R  V IABILITY 
Dye Exclusion Assay
Fluorescent Assay
Lickiss et al. (1974) 
Brady et al. (2002) 
Gratzner, (1982) 
Huong et al. (1991) 
Hawker Jr, (2003) 
Clothier, (1985) 
Kowalska-Pylka et al. (2001)
Hamburger & Salmon, (1977) 
Kawada et al. (2002)
Tveit, (1983) 
Zembutsu et al, (2002)
Hansen et al. (1989) 
Chua et al. (2000)
Kangas et al. (1984) 
Kurbacher et al. (2003)
Weisenthal & Kem, (1991) 
Hartmann et al. (2003)
Meitner, (1988) 
Ivasenko & Shlyakhto, (2001)
Measures the total number of cells
Amount of BrdU incorporated
into viable cells is quantitated colorimeterical
Measures total cell protein
Measures colony formation capability of cells
Measures the change in size of human tumoui 
cells transplanted into immuno-compromised 
mice
Measures rate of reduction of tétrazolium salt 
(MTT) by mitochondrial dehydrogenases in 
metabolically active cells.
Measures intracellular ATP levels in cells 
(leaves decrease as cells die)
Measures ability of viable cells to exclude 
stains
Measures ability of viable cells to retain 
fluorescein.
LDH Assay Welder & Acosta, (1994) 
Putnam et al. (2002)
Measures release of intracellular enzyme 
(LDH) as a result of membrane damage
229
Currently, the ATP-based tumour chemosensitivity assay (ATP-TCA) can be regarded as the 
most sophisticated assay to investigate both solid samples and effusions derived from patients with 
various organ tumours. During the last 5 years, this assay has successfully revealed novel drug 
combinations for further clinical use in both ovarian and breast cancer such as mitoxantrone plus 
paclitaxel (NT) and treosulfan plus gemcitabine (TG), respectively (Sharma et al., 2003). In a recent 
phase II clinical trial performed in 59 patients with relapsed ovarian carcinoma, ATP-TCA-directed 
therapy was able to triple the response rate and to double the survival time, compared with published 
empirical chemotherapy regimes. Preliminary results with ATP-TCA-directed therapy in breast cancer 
also provided promising response rates. A phase III trial that is now actively recruiting patients with 
platinum-refractory ovarian cancer to verity the promising phase II studies may prove the further 
value of the ATP-TCA as a predictor applicable in routine clinical oncology (Kurbacher et al, 2003).
Collagen gel droplet embedded culture-drug sensitivity test (CD-DST) is a newly developed 
in vitro chemosensitivity test that has several advantages over the conventional tests. The clinical 
usefulness of this test in the prediction of response to chemotherapy in breast cancer patients was 
examined by Takamura and colleagues (2002). Their findings demonstrate that CD-DST can predict 
the response to CE (cyclophosphamide and epirubicin combination) and DOC (docetaxel) therapy 
with a high accuracy in breast cancer patients and seems to be superior to the conventional predictors. 
This chemosensitivity test has also been employed to determine the optimal chemotherapy regimens 
for patients with non-small cell lung cancer (NSCLC). An important advantage of this assay system is 
that it requires fewer cancer cells than conventional chemosensitivity tests and can be also used to 
assess cases of malignant effusion. The results suggest that the CD-DST is an effective method for 
chemosensitivity testing in unresectable NSCLC (Kawamura et al, 2002).
5.2. Drug Discovery
Discovering and developing new treatments for cancer is a lengthy and expensive process. 
Hence, therapeutics utilising the latest knowledge and the best technology are absolutely essential for 
the development of new and improved treatments for cancer patients. The total length of time from 
initial discovery to FDA approval averages around 15 years and only one in 5,000 compounds or 
fewer make it to FDA approval. However, only through this meticulously thorough process (outlined 
in Table 5.2) of drug discovery and development do the many cancer drugs (e.g. trastuzumab) coming 
out every year reach the patients whose survival is improved by them.
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Table 5.2: Overview o f the amount o f research and time that must be undertaken over the period from 
initial drug discovery to FDA approval o f the drug.
Research Stage Average Time Taken Procedures
Identification and 4.4 Years • 5000 compounds screened to identify
Preclinical Testing 250 for preclinical testing
• Laboratory/preclinical testing conducted
to assess safety & biological activity in
the laboratory and in animal models
• Investigational New Drug (IND)
application filed with Food & Drug
Administration (FDA)
Clinical Trials 8.6 Years • 5 of the 250 compounds advance to
clinical testing
• Phase I -  Determines safe dosage and
how treatment should be given
6 Phase II -  Evaluates effectiveness and
looks for side effects
• Phase III -  Determines whether the new
treatment or new use of a treatment is a
better alternative to the current standard
Post Clinical Trials 1.4 Years • New drug application or Biologies
Licence Application filed with FDA
• FDA approval for one new drug
5.2.1. In Vitro Testing
Human risk assessment of new pharmaceuticals, pesticides, food additives, cosmetics and 
other chemicals requires the submission of a large battery of in vivo toxicity data derived from tests 
utilising laboratory animals. Although fairly well proven for evaluating toxicity, the use of laboratory 
animals may have limited predictive values for human risk assessment because of differences in 
factors such as bioavailability, pharmacokinetics, metabolism, receptor sensitivity, and repair 
mechanisms (Cao et al., 1999). Ethical problems associated with the use of large numbers of 
laboratory animals for toxicity testing has also made the use of cell culture for measuring drug toxicity 
much more acceptable. Numerous organisations [e.g. the Fund for Replacement of Animals in 
Medical Experiments (FRAME), European Research Group for Alternate Testing (ERGAT), and the
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international Multicenter Evaluation of In Vitro Cytotoxicity (MEIC)] are encouraging the 
development of alternative testing protocols (Cao et al., 1999).
5.2.2. Benzopyrones in Cancer Therapy
The anti-cancer properties and mechanisms of action of the benzopyrones have been 
extensively researched and interest in these compounds arose as a result of the in vivo studies in 
patients with advanced malignancies (Section 1.6.1.3.).
5.2.2.1. In Vitro Testing o f  Coumarins
Chemosensitivity testing of coumarin and its chief human metabolite, 7-hydroxycoumarin, 
was accomplished by several investigators utilising in vitro cell proliferation-based methods. Total cell 
counts (Moran et al., 1993; Marshall et al., 1994) and MTT growth assays (Myers et al., 1994; Cooke 
& O’Kennedy, 1999) were successfully utilised to determine the inhibitory effects of these compounds 
on cell proliferation. In these studies, a time- and dose-dependent inhibition of cell growth was 
observed on exposure to 7-hydroxycoumarin and, in some cases, to coumarin. 7-hydroxycoumarin is a 
pro-drug and exerts a more potent inhibitory activity than coumarin. A variety of cell-lines were 
tested. Renal, prostate, breast, glioblastoma and leukaemic cell lines appear to be the most susceptible 
to the cytostatic effects of coumarin (Ebbinghaus et al., 1997). Several hydroxylated and/or 
methoxylated coumarin derivatives were tested for their relative cytotoxicity on four human tumour 
cell lines (oral squamous cell carcinoma HSC-2, HSC-3, melanoma A-375 and promyelocytic HL-60). 
Tumour cell-specific cytotoxicity was detected with all 6,7-dihydroxy-substituted coumarins only. The 
observations indicate that the tumour-specific cytotoxicity of the naturally occurring coumarin, 
esculetin, can be further enhanced by proper substitutions at 3- and/or 4-position(s) of the molecule. 
Agarose gel electrophoresis revealed that esculetin and its derivatives with tumour-specific 
cytotoxicity induce intemucleosomal DNA fragmentation in HL-60 cells (Kawase et al., 2003).
5.2.2.2. Other Coumarin Derivatives
A number of natural and synthetic coumarin derivatives have also been examined in vitro for 
their growth inhibitory activity. Egan et al. (1997) determined the in vitro activity of the synthesised 
derivative, 8-nitro-7-hydroxycoumarin. This compound displayed cytotoxic properties in two human 
cell lines (HL-60, promyelocystic leukaemia and K562, erythroleukaemia), inducing cell death by 
apoptosis. It also had a cytostatic effect on the three other cell lines (EJ, human bladder carcinoma;
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CH0K1 & CHrC5 Chinese hamster ovary cells) tested, exerted through a perturbation in their cell 
cycle (Egan et al., 1997). Kolodziej and co-workers (1997) evaluated the cytotoxicity of 22 simple 
coumarins on two human cell lines (colorectal and small cell lung carcinoma) using the MTT assay. 
While most compounds exhibited low toxicities on these cells lines over 96 hrs, they found the 
dihydroxy-compounds (6,7- and 6,8- dihydroxy-derivatives) acted as very potent anti-proliferative 
agents. A separate study involved four coumarin derivatives, theraphins A (1), B (2), C (3), and D (4), 
isolated from the bark of Kayea assamica (Clusiaceae). Theraphins A (1), B (2), and C (3) exhibited 
good cytotoxicity against Col2, KB, and LNCaP human cancer cell lines. Theraphin D (4) showed 
mild activity only against the KB cell line. The coumarins also exhibited mild antimalarial activities 
(Lee et al., 2004).
5.3. Introduction to the Cytosensor Microphysiometer
The cytosensor microphysiometer system, introduced in 1992, is a powerful tool that allows 
researchers to evaluate directly the effect of a wide variety of chemical compounds on li ving cells. The 
cytosensor system incorporates a patented Light-addressable Potentiometric Sensor (LAPS) 
technology into a unique system that monitors the metabolic state of living cells in ‘real-time’ without 
destroying the cells. Cellular metabolism is central for maintaining the viability of cells. Hence, in the 
following section, a brief overview of cellular metabolism and methods for its measurement are 
described.
5.3.1. Cellular Metabolism
Metabolism is defined as the overall biochemical process through which living systems 
acquire free energy from their environment, and utilise this free energy to maintain their normal 
functioning (Figure 5.1.). Central to this overall process is the ubiquitous cellular energy transmitter, 
adenosine triphosphate (ATP), the measurement of which is often used to assess the physiological 
state of the cell (Stryer, 1995). Cells take in nutrients (e.g. glucose) as part of their metabolic cycle, 
and break them down to produce useful energy, which is harnessed (via ATP), for use in cellular 
processes such as growth, motion, biosynthesis of complex molecules and active transport. The 
primary carbon sources used are sugars, amino acids and fatty acids, with glucose and glutamine of 
major importance in in vitro cell culture.
The primary waste products that are excreted are lactic acid and carbonic acid (carbon
dioxide). Glucose can be converted to lactic acid via glycolysis, or to C02 via respiration (glycolysis
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followed by the citric acid cycle and oxidative phosphorylation). Respiration is more proficient 
energetically than glycolysis, and also produces much less acid per ATP generated (compare 1 
H+/ATP and 0.167 H+/ATP, for glycolysis and respiration, respectively). However, although 
respiration is the predominant ATP source of cells in vivo, cells cultured in vitro utilise glycolysis as 
their major ATP-generating reaction. Glutamine metabolism has also been shown to contribute a 
proportion of ATP to mammalian cells in culture [estimated at 30-100% depending on cell type and 
culture medium composition] (Owicki & Parce, 1992).
The rate at which cells expel acids into their environment is strongly correlated to the rate at 
which they convert food to energy (e.g. metabolic rate). The cytosensor microphysiometer system 
measures the rate at which cells acidify their immediate environment. Cells respond to a particular 
stimulus, for example, a neurotransmitter binding to a cell-surface receptor, in complex ways that are 
reliably reflected in a change in the cells’ metabolism. Responses to stimuli can be transient or 
sustained, but the response to a particular stimulus is reproducible under constant conditions. The 
cytosensor monitors these metabolic changes as alterations in the acidification rate of the medium 
surrounding the population of cells. In this way, the system provides a ‘real-time’, non-invasive means 
of measuring cellular responses to a wide variety of agents (such as chemotherapeutics and 
antibiotics).
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Figure 5.1: Illustrative depiction o f cellular metabolism and its affiliation to cellular processes such 
as receptor activation. Glucose and oxygen are utilised in the production o f the cellular energy 
transmitter ATP, with the simultaneous manufacture o f acidic waste products (lactic acid and carbon 
dioxide). ATP is consumed by a variety o f cellular processes, e.g. growth, movement or receptor 
activation (as depicted in this diagram). In the Cytosensor Microphysiometer changes in metabolic 
rate, due to ATP, can be detected by measuring changes in the extracellular levels o f acidic waste 
products, using the pH-sensitive LAPS sensor.
5.3.2. The Cytosensor Microphysiometer Components
In the Cytosensor Microphysiometer, the cells are assembled into a disposable capsule, in 
such a way that they are sandwiched between two porous polycarbonate membranes. This assembly is 
then placed in a micro-flow chamber in aqueous diffusive contact with the silicon chip designed to 
function as an extremely sensitive pH detector. The chip is a light-addressable potentiometric sensor 
(LAPS), which serves as the bottom wall of the flow chamber (see Figure 5.2). The sensor chamber is 
the location at which all pH readings are taken. It is the heart of the instrument and with a volume of 
only 3(.il it allows for the acquisition of very precise and sensitive readings.
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Cytosensor Cell Capsule and Sensor Chamber
F lu id  In le t F lu id  outlet
Figure 5.2: Diagrammatic representation o f the Cytosensor cell capsule and sensor chamber
(Taken from Molecular Devices Users Manual).
A light emitting diode (LED) positioned below the sensor chamber in the chamber pad 
enables pH readings in a 2mm diameter circular region in the centre of the cell capsule. Figure 5.3, a 
schematic diagram showing how the major components of the cytosensor system work together. A 
constant flow of fresh low-buffered running media is pumped through the system, and introduced into 
this sensor chamber, providing the encased cells with fresh nutrients and removing any waste products 
from their immediate environment.
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Schem atic Diagram of the Cytosensor System
(Dual-Stream Configuration)
Reference
Electrode
Figure 5.3: Schematic diagram o f the major components o f the Cytosensor Microphysiometer
system (Taken from Molecular Devices Users Manual).
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\ ¿
Centrifuge tubes containing compound to 
be tested is attached to intake tubing
/&Zmp Peristaltic pump moves fluid through fluidpaths
Debubbler removes bubbles and reduces 
amount of dissolved gases
Valves used to switch between two 
different fluids
jr.1.____ «
£ a
Sensor chamber holds cell capsule and 
monitors pH  at sensor's surface
Reference electrode stabilises pH  
readings from sensor chamber
Computer controls acquisition, analysis 
and display of raw and rate data
Figure 5.4: Flow diagram describing what the major components contribute from start (fluid intake) 
to finish (display o f  raw & rate data) o f a cytosensor run.
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5.3.3. Measuring Acidification Rates
The pH of the sensor chamber remains constant once media is allowed to flow through it, as 
no build-up of acidic waste products can occur. The pH remains steady at approximately the pH of the 
running medium (pH 7.3-7.4). When the pump is stopped (typically for 10-40 seconds), acid 
metabolites begin to build up in the sensor chamber and the pH begins to drop, which can be detected 
by the LAPS sensor chip. The extremely small volume of the flow chamber in which the cells are 
contained ensures that a minute increase in acidic metabolites causes a detectable change in the 
chamber’s pH. When the pump is turned on again the flow sweeps out the acidic metabolites, 
returning the pH of the chamber to its original value, where it remains stabilised until the pump is 
stopped again. This pump on-off cycle generates data traces such as that shown in Figure 5.5.
The data obtained during the pump-off interval (also known as ‘the get rate period’) are fitted 
to a straight line, the slope [-pV/sec] of which is plotted as the acidification rate (Figure 5.5). If the 
metabolic rate of the cells changes in response to an effector agent (either stimulatory or inhibitory), 
the acidification rate data will reflect this change (Figure 5.5). The research in this thesis highlights the 
novel application of the microphysiometer for the analysis of the effects of benzopyrones on MCF-7 
cells and the elucidation of their mode of action.
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Figure 5.S: Raw Data (A) and Rate (B) data derived from an experiment in which A431 cells were 
exposed to 25ng/ml EGF for 12 mins (Time ofEGF exposure = 1:40:00). As can be seen from the raw 
data, a noticeable increase in the acidification rate during the pump-off cycle (highlighted in blue) 
denotes activation o f  the EGF-Receptor in these cells. This change in the cells metabolic rate is 
reflected in the Rate data (B). Molecular Devices Users Manual.
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5.3.4. Applications of the Cytosensor Microphysiometer
The cytosensor microphysiometer can be applied with mammalian cells (adherent and non- 
adherent cells, primary and established cell lines) yeast cells, prokaiyotic cells and insect cells. The 
main application is the analysis of cell membrane bound receptors but the system can also be used to 
study non-receptor mediated events on cell metabolism, for example, the effect of viral infection and 
toxicological effects (Hafner, 2000). A major attribute of the Cytosensor Microphysiometer is its 
flexibility: it accurately measures a general cellular event (extracellular acidification), and as such is 
applicable to a variety of biological disciplines (Table 5.3.).
Since this is an assay system that reliably measures cell surface receptor activation, with 
subsequent intracellular signalling events, the cytosensor has been principally applied to 
pharmacological investigations, being particularly advantageous over traditional methods for 
determining agonist/antagonist profiles of receptors (Lange/ al., 2001; McCall etal., 2002; Anderes et 
al., 2003). Recently, the cytosensor has featured in toxicological evaluations of anti-cancer 
compounds and has been shown to be suitable as an in vitro alternative microtitre plate assays such as 
the MTT assay (Cooke & O’Kennedy, 1999; Cai et al., 2002; Ekelund et al., 2002). Other areas that 
have benefited from the application of cytosensor technology include studies in immunology, cell 
biology and microbiology (Hoelscher et al., 2000; Sireci et al., 2001; Landwojtowicz et al., 2002).
Although general in its method of detection, the cytosensor can be used as a specific probe of 
signal transduction events in cells (Burvall et al., 2002; Lui et al., 2002). It has many advantages over 
traditional methods for examining signal transduction, as outlined in Table 5.4. In Section 5.4 signal 
transduction is introduced with the components of growth signalling pathways described.
241
Table 5.3: Examples o f the various research applications o f  the Cytosensor Microphysiometer in 
biological studies.
Discipline Application References
Pharmacology Receptor characterisation 
Signal transduction
Lang et al. (2001); Zambrano et al. (2002) 
McCall et al. (2002); Anderes et al. (2003) 
Burvall et al. (2002); Lui et al. (2002)
Toxicology Compound cytotoxicity 
Tumour cytotoxicity
Hepatotoxicity
Cao et al. (1999)
Liminga et al. (1999); Ekelund et al. (2000) 
Ekelund et al. (2001)
Cao etal. (1998)
Cell Biology Kinetics
Na+/H+ antiport studies 
Metabolic studies
Lanwojtowicz et al. (2002),
Wada et al. (1993); Fischer et al. (1999) 
Fan et al. (2002)
Immunology T-cell activation 
Inflammatory Studies 
Macrophage/monocyte studies
Wada et al. (1994); Sireci et al. (2001) 
Burvall et al. (2002)
Romano et al. (1996); DeVries et al. (1998)
Oncology Chemotherapeutic efficacy 
Apoptosis
Wada e ta l  (1992); Ekelund et al. (2002) 
Kuo et al. (1994); Cai et al. (2002)
M icrobiology Antibiotic susceptibility assays 
Anti-viral studies 
Ion channel studies
Libby et al. (1998); Hoelscher et al. (2000) 
Wada et al. (1992)
Hahnenberger et al. (1996)
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Table 5.4: Advantages of the Cytosensor Microphysiometer for research applications
Advantages of the Cytosensor Microphysiometer 
Non-Invasive - Internal controls, Examine recovery.
Real-time M easurement -  No need to do multiple assays for time course points
Rapid Results -  Quicker than traditional assays (Ca2+ mobilisation, IP3 assays)
High Reproducibility 
Flexibility 
No Radioactivity  
Reduced Animal Usage
Reversibility studies -  Efficient system 
Increased Sensitivity -  in comparison to MTT assay
5.4. Introduction to Signal Transduction and Cell Cycle 
Regulation
Signal transduction at the cellular level refers to the movement of signals from outside the cell 
to inside. Cell-surface receptors recognising and responding to extracellular stimuli are the key 
components required for the survival of any living organism (Bai, 2003). If cellular proliferation is 
desirable-for instance in wound healing, growth factors are generated which act as messengers for the 
cells wounded area stimulating them to proliferate. Growth factors are peptides or steroid hormones, 
which are recognised by specific cellular receptors. Binding of the growth factor to the receptor 
initiates a cascade of cell signalling events (Grunicke, 1995). The principal function of cell signalling 
is to co-ordinate the behaviour of different cells in order to achieve maximal benefits for the whole 
organism. The primary cellular mechanism for reception of a specific response commences with the 
binding of a ligand to its receptor, which in turn transmits a signal designed to express certain genes in 
a controlled manner (Helleday, 1998). These signalling pathways within cells are composed of chains
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of interconnecting proteins. Each protein element in a pathway consolidates signals from activators 
upstream to itself, and passes these signals onto downstream effector proteins, this whole process 
being termed signal transduction (Hardie, 1991).
The significance of growth factors and the signalling pathways initiated by them to regulate 
cell cycle progression in eukaryotes has been identified as an important component of their function. 
Several studies have shown that cell signalling pathways determine cell growth as well as inhibition 
through cell cycle regulation (Agarwal, 2000). In the cell cycle of eukaryotes, DNA is replicated 
during S (synthesis) phase, and the replicated chromosomes are segregated into daughter nuclei during 
the M (mitosis) phase. A gap phase Gi intervenes between mitosis and DNA synthesis, and another 
gap, G2, occurs between DNA synthesis and mitosis. The two key decisions are when to enter S phase 
and subsequently, the M phase. Mitosis only begins after DNA synthesis has been completed and 
requires major changes in cell architecture (Stryer, 1995).
In order to stimulate a normal quiescent cell in G0 to proliferate, the cell has to be exposed to 
growth factors, which can be recognised by corresponding cellular receptors. These growth factors 
have been classified as competence and progression factors. Combined activities of competence and 
progression factors lead to progression in G! until the restriction point is reached. The progression 
through Gi phase of the cell cycle and the preparation for DNA replication requires the continuous 
signalling of progression factors, which are essential until the restriction point in G] is reached. EGF is 
an example of a competence factor needed for advancement of quiescent cells into G, phase. Beyond 
the restriction point, no further exogenous growth factors are required for the completion of the cell 
cycle (Grunicke, 1995).
Research in the area of signal transduction and cell cycle regulation has been stimulated by the 
belief that an understanding of signalling pathways interacting with cell cycle regulators responsible 
for cell growth in normal cells will provide an understanding into uncontrolled growth observed in 
cancer. In the remainder of the introduction to this chapter, the main elements of proliferative 
signalling pathways, as determined to date, will be reviewed. A detailed account of the cell cycle in 
normal cells is given so that comparisons can be made to cell cycle dysregulation leading to cancerous 
growth. The main focus of this work is with regard to breast cancer with particular emphasis on 
studies relating to the estrogen-positive MCF-7 cell line. Therefore, signal transduction and cell cycle 
regulation in breast cancer cells are discussed in detail.
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5.5. Components of Growth Signalling Pathways
5.5.1. Introduction to Phosphorylation in Signalling Pathways
Receptor-ligand interactions launch downstream signalling cascades through intermediate 
cellular proteins, with the eventual effect of nuclear transcription. Stimulation of receptors by ligands 
can be of an autocrine, paracine or endocrine manner. It has been determined that phosphorylation 
reactions are the central mechanism for the progression of these growth signals from membrane to 
nucleus. Phosphorylation is one of the most common forms of protein modification. The most frequent 
targets for protein phosphorylation in eukaryotes are serine, threonine and tyrosine residues (Steen et 
al., 2002). Receptor phosphorylation provides a pathway for cross-talk between responses initiated by 
steroid hormones, polypeptide growth factors, cyclic AMP, PKC or calmodulin (Strobl et al., 1995).
Tyrosine phosphorylation plays an important role in the regulation of cell proliferation, 
differentiation, signal transduction and cell cycle progression. Induced tyrosine phosphorylation is 
mediated by activation of protein tyrosine kinases and/or inhibition of protein tyrosine phosphatases 
(Qian et al., 2003). Phosphatases and protein kinases are enzymes that respectively remove or add 
phosphate residues, on either serine/threonine or tyrosine residues of proteins. ATP is utilised as a 
phosphate source. The signal transduction pathways in mammalian cells are being found to involve an 
increasing number of receptors and intracellular signals. However, many of these receptors and 
pathways can be grouped into superfamilies exhibiting high levels of identity at the protein level and 
similarities in the mechanism by which the signal is transmitted into the cell (Helleday, 1998).
5.5.2. Receptor Classes
The various growth factor receptor subtypes employ different mechanisms for post-receptor 
signalling. In order to understand the biological consequences of abnormal signal transducing 
elements in cancer, the various signal transmission pathways have to be briefly discussed (Grunicke, 
1995). In this work, it is the importance of tyrosine phosphorylation in growth control and its 
deregulation in cancer that is addressed. Three distinct classes of receptors exist which use tyrosine 
phosphorylation to propagate proliferate signals. They are as follows:
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1. Receptor Tyrosine Kinase (RTK) Family whose members have receptors with intrinsic
intracellular tyrosine kinase domains, activated upon ligand binding. Downstream 
phosphorylation of proteins on tyrosine residues transduces the extracellular signal to the 
nucleus, e.g. EGF to EGF receptor.
2. Binary Receptor Tyrosine Kinase Family whose members do not possess an intracellular 
tyrosine kinase domain. They can only signal by association with a cytoplasmic tyrosine 
kinase molecule. This leads to a cascade of phosphorylation reactions, resulting in propagation 
of the external signal to the nucleus, e.g. IL-2.
3. G-protein-coupled Receptors cause activation of a number of signalling intermediates with
eventual downstream activation of cytoplasmic kinases.
Tight regulation of RTK signalling is crucial for eliciting an appropriate type and level of 
response to external stimuli and they are the most important receptor subtype in proliferative 
signalling pathways (Chiarugi & Cirri, 2003). Therefore, the Receptor Tyrosine Kinase family shall 
now be discussed in more detail.
5.5.3. Receptor Tyrosine Kinases (RTKs) and Their Substrates
The Receptor Tyrosine Kinase (RTK) family of receptors consists of a group of cell-surface 
proteins, all members of which possess a large glycosylated extracellular ligand-binding domain, a 
single transmembrane domain, and an intracellular cytoplasm domain that contains a tyrosine kinase 
catalytic region. They are activated upon either ligand binding or receptor cross-linking (Qian et a!.,
2003). Many subclasses of RTKs have been described based on sequence similarity and structural 
function, and the characteristics of the five principal subclasses are represented in Figure 5.6.
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Figure 5.6: Schematic representation o f the five principal Receptor Tyrosine Kinase subclasses. The 
family members include Epidermal growth factor-receptor (EGF-R), Platelet derived growth factor- 
receptor (PDGF-R), Insulin-receptor (INS-R), Nerve growth factor-receptor (NGF-F) and Fibroblast 
growth factor-receptor (FGF-R).
Many growth factors mediate their actions by binding to their cognate receptors e.g. the 
binding of epidermal growth factor (EGF) to the epidermal growth factor receptor (EGF-R). This 
causes activation of the intrinsic tyrosine kinase activity, which leads to the intracellular transmission 
and amplification of the extra cellular signal (Weiss & Schlessinger, 1998). Binding of the growth 
factor to the extracellular domain of the corresponding receptors activates the tyrosine kinase in the 
cytoplasmic domain and mediates a conformational change of the extra cellular domains, which 
induces receptor oligomerisation, usually dimérisation (Figure 5.7). Receptor dimérisation stabilises 
interactions between adjacent cytoplasmic domains, which in turn permits cross-phosphorylation of 
tyrosyl residues of the cytoplasmic domains. This process is termed autophosphoiylation.
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Figure 5.7: Diagram illustrating the events, which occur following ligand (e.g. EGF) -  receptor 
interaction. The EGF-Receptor dimerises with a neighbouring receptor, allowing autophosphorylation 
o f receptor tyrosine residues. Molecules containing SH2 domains (either adaptor e.g. GRB-2 or 
effector proteins e.g. PI3-K) can bind to tyrosine phosphorylated (P-Tyr) residues, leading to 
transduction o f the binding signal towards the nucleus.
Receptor autophosphorylation enables the activated kinase to phosphorylate cytoplasmic 
molecules at tyrosine residues, thus initiating the cascade of signals downstream towards the nucleus. 
The phosphorylated tyrosyl moieties now serve as recognition signals for a variety of signalling 
molecules (substrates), which recognise specific autophosphorylated residues via their SH2 domains 
(domains homologous to a non-catalytic region of the src proto-oncogene) and bind only to these. The 
Src protein is a tyrosine kinase first identified as a transforming protein in Rous sarcoma virus. 
Subsequently, a cellular homologue was identified as c-Src. A number of RTK substrates have been 
identified to date. These include phosphatidylinositol-3-kinase (PI3-K), phospholipase Cy(PLCy), 
members of the nonreceptor Src family of tyrosine kinases, phosphatases and peptides. They consist 
almost entirely of SH2 and SH3 (responsible for accurate docking of appropriate downstream target) 
domains like growth factor receptor binding protein-2 (Grb-2). The latter links signalling molecules, 
including Ras, to tyrosine phosphorylated receptors (Grunicke, 1995). It was ascertained that certain 
molecules like Grb-2 contain only SH2 and SH3 domains, with no other functional domains. It is 
believed that these molecules function only as adaptor molecules to couple the activated receptor to 
other signalling intermediates. With regard to proliferative signal transduction, the SH3 domains 
couple with the Ras signalling pathway.
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5.5.4. Ras Activation Pathway
Binding of ligand to its membrane receptor initiates a common sequence of events. The 
adaptor protein She binds to its peptide hormone receptor and becomes phosphorylated. She exists in 
three isoforms of 66, 52, and 46kDa and has three docking sites: an SH2, a phosphotyrosine binding 
domain (PTB) and a collagen homology (CH) site. She may be phosphorylated by the peptide receptor 
itself, by one of the SRC family kinases, or by other kinases (Santen et al., 2002).
The receptor-Shc complex then further complexes with the adapter protein Grb-2. The 
guanine nucleotide release factor (GRF) SOS (mammalian homologue of “son of sevenless” genes in 
drosophila) is bound to activated receptor tyrosine kinases via the adapter protein Grb-2 (Santen et al.,
2002). Grb-2 is composed of one SH2 domain and two SH3 domains. The two SH3 domains bind to 
the carboxy-terminal proline-rich region of SOS, whereas the SH2 domain binds to the tyrosine 
phosphorylated sites in other proteins (Grunicke, 1995). When SOS enters the complex it is then able 
to catalyse the conversion of GDP to GTP-Ras.
The Ras protein has been assumed to act as a key regulator of cell growth and other functions. 
Ras is a 21kDa guanine nucleotide-binding protein whose biological activity is determined by the 
bound nucleotide. Activated protein contains bound GTP, while the inactive state binds GDP. 
Activation of Ras proteins is a key step in signal transduction process. Central to the activation of Ras 
is a family of GRFs, e.g. SOS. They are responsible for the release of bound GDP from the Ras 
protein, thereby enabling its activation. Deactivation of Ras occurs by hydrolysis of GTP to GDP, a 
reaction dramatically hastened by GTPase activating proteins (GAPs). Therefore, the relative activities 
of GRFs and GAPs acting on Ras at any instant determines its activation state (Figure 5.8.). Processed 
Ras proteins that have localised to the inner surface of the plasma membrane, function as a molecular 
switch that cycles between an inactive and active form (Caponigro, 2002). In transformed cells, 
however, the Ras protein usually has diminished GTPase activity, (as a result of mutations in the 
amino acids important for guanine nucleotide co-ordination), causing prolonged signalling periods 
since Ras can not switch from the active to inactive form to stop cell signalling when required.
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Figure 5.8: Schematic representation o f the activation/deactivation cycle o f Ras. Inactive Ras binds 
GDP, while active Ras contains bound GTP. Two molecule types, the Guanine-nucleotide Releasing 
Factors (e.g. SOS) and the GTPase Activating Proteins (e.g. 120-GAP) control the activation state o f 
Ras, with their relative activities at any instant, deciding its state o f activation. The GRFs cause the 
release o f bound GDP from Ras, enabling its activation. The deactivation of Ras occurs by hydrolysis 
o f GTP to GDP, catalysed by GAPs.
The GAP proteins do not account for all signals emanating from Ras. Activated GTP-Ras
interacts with Raf-1 kinase. Raf-1 is a 70-75kDa protein, which is divided into three functional
domains. The amino orN-terminal CR1 contains the domain responsible for interaction with Ras. CR2
contains the negative-regulatory domain. This domain regulates the kinase domain contained in CR3
that is located at the carboxyl-end of the protein. The fact that Ras has to be activated in order to
associate with Raf-1 and that the binding of Raf-1 occurs through the Ras effector domain emphasizes
the biological significance of this interaction. GTP-Ras binds to a site located at amino-acids 51-131
in the N-terminal region of Raf-1, which phosphorylates and activates the kinase properties of this
peptide. Crystal structure analysis reveals that the Ras binding domain (RBD) of Raf involves direct
contact of Ras with Gin 66, Arg 67, Lys 84, Arg 59, Gin 64, and Thr 68. GTP-Ras binds to this RBD
with 100-fold higher affinity than GDP-Ras. Another Ras-binding domain for Raf was located in the
cysteine-rich domain, which binds phosphatidylserine. There are two important steps involved in the
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activation of Raf-1. Firstly, Ras interacts with Raf-1 and stimulates the translocation of Raf-1 to the 
plasma membrane. This facilitates further interaction with additional activators (Figure 5.9.). Secondly 
Raf-1 is phosphorylated on tyrosine and/or serine/threonine residues. When activated in this manner, 
Raf-1 in turn phosphorylates a second kinase, MEK kinase. This enzyme controls a third family of 
enzymes, the MAPK, again through phosphorylation on both the tyrosine and threonine residues 
(Santen etal., 2002).
Figure 5.9: Components o f the RTK ^  MAP Kinase pathway. Ligand binding to its cognate receptor 
at the membrane surface results in signal cascades towards the nucleus via the Ras/MAP Kinase 
pathway, with eventual nuclear phosphorylation o f transcription factors (precise details in text).
5.5.5. Role o f  Mitogen Activating Protein Kinase (MAPK) in Breast 
Cancer
Mitogen-activated protein kinase (MAP kinase) cascades transmit and amplify signals 
involved in cell proliferation as well as cell death. Three major MAP kinase pathways exist in human 
tissues:
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a) Peptide growth factors acting through tyrosine kinase containing receptors are the 
major regulators of (extracellular-regulated kinase) ERK-1 and -2,
e.g. EGF and EGF-R.
b) Estradiol, progesterone and other steroid hormones can act non-genomically via 
membrane-associated receptors to activate MAP kinase.
c) Various other ligands can activate MAP kinase by acting through heterotrimeric G 
protein receptors.
In this work the pathways of importance involve both the EGF and Estradiol stimulation of 
MAP kinase. Highly specific factors activate the MAP kinase pathway, usually through receptor- 
ligand interactions. Amplification of the signal then results from activation of a sequence of three or 
more linked kinase reactions. A small amount of active enzyme in the first kinase reaction acts upon a 
larger amount of substrate in the second and subsequent kinase reactions. The kinase sequence cascade 
usually involves three analogous proteins, a MAP kinase kinase kinase (MAPKKK), a MAP kinase 
kinase (MAPKK), and a MAP kinase (MAPK). One of the major mammalian MAP kinase cascades 
involves Raf-1 as the initial kinase in the sequence (i.e. MAPKKK); MAP/ERK kinase (MEK-1 and - 
2) as the second (i.e. MAPKK), and ERK-1 and -2 as the third sequential kinase (MAPK). It should be 
noted that MAP kinase is also called ERK and exists in the ERK-1 and -2 isoforms which are 85% 
homologous and have molecular weights of42-44kDa, respectively (Santen et al., 2002).
Since the work referred to in this section involves the estrogen receptor positive cell line 
MCF-7, emphasis shall be placed on the role of MAP kinase in breast cancer. Estrogen receptors (ER) 
belong to the steroid receptor gene superfamily, the members of which share some structural and 
functional similarities. The first estrogen receptor, now named ERa, was cloned in 1986, more than 20 
years after it was identified by its affinity for 17P-estradiol. In 1996, the second ER, ERp was reported 
(Weihua et al., 2003). Clinical and experimental data have established that the leading cause of 
sporadic female breast cancer is exposure to estrogens, predominantly the steroid hormone 17(3- 
estradiol (Foster et al., 2001). Estradiol (E2) was established as the pre-eminent breast epithelial cell 
mitogen in the development of human breast cancer and the polypeptide growth factors e.g. EGF also 
stimulate breast cancer growth in tissue culture. E2 target tissues can be divided into two groups, the 
classical and non- classical E2 target tissues, respectively. The classical targets are the uterus, 
mammary gland, placenta, liver, central nervous system (CNS), cardiovascular system and bone. 
These tissues have a high ERa content and respond to E2 challenge with increases in transcription of 
certain E2 responsive genes. The non-classical target tissues include prostate, testis, ovary, pineal 
gland and thyroid gland among others. In these tissues ERa expression is either veiy low or not
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measurable. In the breast, E2 stimulates growth and the estrogen receptor antagonist tamoxifen has 
been the most effective treatment for ERa-positive breast cancer (Weihua et al., 2003).
Cell lines and breast tumour biopsies with high ER levels characteristically exhibit low or 
nonexistent EGF-R (170kDa). The inverse relationship between ER levels and receptors for epidermal 
growth factor is a clinically important observation. The ER+/EGF-R negative tumour types are better 
differentiated, whereas the ER-negative/EGF-R + types are associated with metastasis and shorter 
survival times. The down-regulation of ER levels by EGF observed in some tissue culture cell lines 
might provide a partial mechanism for the inverse relationship. Over expression or activation of 
receptor tyrosine kinase such as EGF-R is a poor prognostic indicator for breast cancer. The MCF-7 
cell line contains high levels of ER with low levels of EGF-R (Strobl et al, 1995).
Peptide growth factors utilising tyrosine kinase containing membrane receptors are the major 
regulators of ERK-1 and -2. However, numerous other receptor-ligand pathways can also stimulate 
ERK-1 and -2. For breast cancer estrogen can activate MAP kinase through interaction with ER, 
which co-opts the growth factor signalling pathway to activate MAP kinase (Santen et al., 2002). ERa 
constantly shuttles between the cytoplasm and the cell nucleus, where it progressively stabilises, 
leading to an apparent permanent nuclear localisation (Seo et al., 2003). Strong evidence now exists 
for the presence and importance of plasma membrane ERs in a variety of cells that are targets for 
steroid action. It is important to know the physical structure of the receptor and where it resides within 
the lipid bilayer, in order to better understand the function of the membrane ER. Signalling by growth 
factor receptor and non-growth factor tyrosine kinases as well as G protein receptors occurs at least in 
part after localisation to plasma membrane microstructures, known as caveolae (Levin, 2002).
Newly synthesised ER enters a phosphoiylation/dephosphorylation process, continuously 
trafficking between cell compartments to achieve its physiological role before its final shipment into 
the proteosome (Seo et al., 2003). The cell biologic roles of the two receptor pools may be quite 
complementary even though ER in the membrane and nuclear compartments appear to act by very 
different mechanisms (signalling versus transcriptional transactivation). It is possible that membrane 
kinase signalling can rapidly activate transcription, which can then be sustained by the nuclear 
receptor. The latter’s action is probably facilitated by the phosphorylation of the co-activator proteins, 
and this could result from ER signalling from the membrane. Signalling from the membrane may also 
amplify the actions of the nuclear receptor. Furthermore, signalling appears to play an important role 
in the post-translational modification of proteins that can be upregulated in their synthesis via the 
nuclear receptor (Levin, 2002).
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In MCF-7 breast cancer cells, estradiol binds to the membrane ER, which induces the 
phosphorylation of She and the binding of She to the ER. She proteins are substrates of activated 
tyrosine kinases and are involved in the cascade that leads to Ras activation and mitogenesis (Figure 
5.10.) Both the SH2 and the phosphotyrosine binding (PTB) domains appear necessary for the 
interactions between She and the ER. Following She phosphorylation She binds to GRB-2 and SOS 
which in-tum activates the Ras pathway as described in Section 5.5.4. Once Raf-1 is activated in Ras 
signalling pathway it can phosphorylate MEK and activates its kinase activity by nearly 7000 fold. 
MEK exists in two molecular weight forms called MEK-1 and -2. Activated MEK then phosphorylates 
the tyrosinel85 and threoninel83 residues in the activation loop of ERK-1 and -2. This 
phosphorylation step increases the activity of MAP kinase by 1000-fold. ERK-1 and -2 then stimulate 
downstream events involved in gene regulation (Santen et al., 2002). The MAP kinase pathway 
regulates the transcription of c-fos and c-jun two early response genes, which together dimerise to 
become the AP-1 nuclear transcription factor (Figure 5.10.).
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Figure 5.10: Estrogen-activated MAP Kinase pathway. Estrogen may activate pathways, which utilise 
a membrane-associated ER or via nuclear ER. In breast cancer cells estradiol can bind to estrogen 
receptor-a (ER-a) molecules in the peri-membrane region which in turn initiates a cascade o f protein 
reactions similar to Figure 5.8 involving She, GRB-2 and SOS to activate MAP kinase (Pathway 1). 
Estradiol can also initiate transcriptional events in the nucleus (Pathway 2).
5.5.5.I. Events Downstream o f  M AP Kinase
The precise downstream events initiated by MAP kinase, which result in cell proliferation are
still under investigation. Activation of other protein kinases such as the RSK proteins (RSK1, 2 and 3)
is stimulated by MAP kinase. This occurs by MAP kinase mediated phosphorylation of serine 363 on
the RSK protein. Once activated the RSK proteins can phosphorylate down stream targets involved in
transcriptional activation such as cAMP response element binding protein (CREB), c-Fos and the
estrogen receptor (Santen et al„ 2002). RSK proteins can enter the nucleus and phosphorylate the
transcription factor c-fos, thus stimulating the transcription of genes under AP-1 control. Activated
ERK-1 and -2 can elicit direct effects on transcription factors within the nucleus. It has been shown
that phosphorylation of ERK-2 is necessary for its nuclear translocation. This nuclear translocation is
important, as experiments have shown that when ERK2 was sequestered in the cytoplasm there was a
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strong inhibition of cell cycle re-entry. Once ERK has been translocated to the nucleus it can directly 
phosphorylate c-Jun and c-Fos. It also has the ability to directly catalyse the phosphorylation of serine 
118 of the ER and increase its transcriptional efficiency. RSK can also phosphorylate the ER at serine 
167, which also increases its transcriptional efficiency (Figure 5.11.). Therefore it is true to say, MAP 
kinase is a key regulatory enzyme involved in mediating cell proliferation through phosphorylation of 
a number of important factors (Pan et al., 2003).
Figure 5.11: Schematic diagram illustrating in detail the events downstream o f MAP Kinase. Once 
ERK has been translocated to the nucleus it can directly phosphorylate c-Jun and c-Fos. Activated 
ERK-1 and -2 can elicit direct effects on transcription factors within the nucleus. Activation o f other 
protein kinases (by serine phosphorylation) such as the RSK proteins (RSK1, 2 and 3) is stimulated by 
MAP kinase. Once activated the RSK proteins can phosphorylate downstream targets involved in 
transcriptional activation and can enter the nucleus and phosphorylate the transcription factor c-fos, 
thus stimulating the transcription o f genes under AP-1 control. [PS depicted on RAS molecule is 
phosphatidylserine, which binds to a RAS binding domain (RBD-2) on RAF-1 molecule. This 
interaction is explained in Section 5.5.4.]
5.5.6. PI3-K Signal Transduction Pathway
Since its discovery in 1988 the activity of PI3-K has been associated with the actions of 
mitogenic growth factors (Corvera, 2001). It is one of the intracellular signalling pathways that are
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frequently activated in cancer cells (Van de Sande et al., 2002). PI3-K heterodimer is an important 
mediator, of survival factors, protecting many cell types from multiple apoptosis-inducing stimuli 
(Barragan et al, 2002). Growth factor receptor activation causes receptor autophosphorylation of 
tyrosine residues, which recruits the SH2 domain containing p85 regulatory subunit coupled to the 
pi 10 catalytic subunit of PI3-K (Dangi et al., 2003). PI3-K catalyses the formation of the 3- 
phosphoinositides, phosphatidylinositol 3,4-diphosphate and phosphatidylinositol 3,4,5-triphosphate. 
Increases in 3-phosphoinositides lead to transmembrane translocation of downstream effectors such as 
the serine/threonine protein kinase AKT (also known as protein kinase B). On translocation, AKT is 
phosphorylated and activated, ultimately resulting in stimulation of cell growth and survival (Van de 
Sande et al., 2002). AKT is fully activated by phosphorylation at two sites, Thr308 and Ser473. In 
breast cancer cells activated AKT phosphorylates a serine residue on glycogen synthase kinase -3 
(GSK-3) resulting in GSK-3 inactivation. Subsequently, inactive GSK-3 is unable to inhibit cyclin D1 
expression (Figure 5.45). Cyclin D1 is an essential cell cycle regulator important in Gi phase 
progression, which is discussed in more detail in Section 5.6. Activation of AKT is responsible for 
increasing and maintaining high levels of cyclin Dl, resulting in the promotion of cell division and 
proliferation (West et al., 2003).
Recently it has been reported that E2 stimulates the phosphatidylinositol-3-kinase (PI3- 
K/AKT) pathway in MCF-7 cells. Interestingly, in these cells activation of Src and the PI3-K- 
dependent pathways is simultaneous and mediated by direct interactions of the two kinases with 
ERa. The sex steroid hormone signalling pathway activation in MCF-7 cells has been shown to lead 
to DNA synthesis and cell growth. E2 treatment of MCF-7 cells activates the Src-Shc-Ras-Raf-MEK- 
1-Erk pathway as well as the PI3-K pathway. Activation of the two pathways is simultaneous and each 
item is required to trigger the S-phase entry of the cells. E2 stimulates PI3-K/AKT pathway under the 
Src control and increases the transcriptional activity of the cyclin Dl promotor. This is of major 
importance as it is the first time that it has been found that E2 controls expression of a cell cycle 
regulator through signalling pathway activation. As stated above, E2 stimulation of S-phase entry of 
MCF-7 cells requires both MEK-1 and PI3-K activity. However, whereas MEK-1 activity is important 
at the beginning of hormone treatment, PI3-K is necessary for at least 3 hours. These findings indicate 
important differences between the action of the two pathways, although both converge on DNA 
synthesis (Migliaccio et al., 2003).
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5.6. Cell Cycle Regulation
Significant advances have been made towards understanding the eukaryotic cell cycle in the 
last twenty years. The cell cycle is divided into Gj phase, S phase, G2 phase and M phase. Eukaryotic 
cells have evolved signalling pathways to coordinate cell cycle transitions and ensure faithful 
replication of the genome before mitosis (Stewart et al., 2003). Cell cycle progression requires the 
sequential activation of different cyclin-dependent kinases (CDKs), which are positively regulated by 
cyclins and negatively regulated by CDK inhibitors (CDKIs) (Barboule et al., 1999). Cyclins are key 
components of the cell cycle progression machinery. They activate their partners, CDKs, which 
phosphorylate sequentially critical substrates that regulate the progression of the cell cycle. Normal, 
non-tumour cells express cyclin proteins in an orderly, scheduled fashion, at a given phase of the cell 
cycle. There are four types of cyclin important throughout the cell cycle. Cyclins D are expressed 
early in Gj phase, and are degraded prior to entrance to S phase. Synthesis of cyclin E begins in mid­
phase Gi and its expression peaks at the Gi/S transition. It is degraded during the S phase. Synthesis of 
cyclin A starts in S phase, it peaks at S/G2 transition and decreases stepwise during the latter part of 
the G2 phase. Synthesis of cyclin B starts at the end of S phase, peaks as the cell enters M phase and 
breaks down at the transition to anaphase (Jimenez-Orozco el al., 2001).
In the cell cycle there are 3 CDKs of importance, which are CDK4/6, CDK2 and CDK1. 
Activation of CDK4/6 by growth stimuli appears to govern exit from Go and entry into early Gi, 
activation of CDK2 occurs mid-to-late Gi and regulates transition into, and passage through S phase, 
whereas late G2 and completion of mitosis is regulated by CDK1. Normal cells do not progress from 
one phase to the next unless the events of the proceeding phase have been correctly completed (Foster 
et al., 2001). The complexes cyclin-D-CDK4, cyclin-D-CDK6, cyclin-E-CDK2 and cyclin-A-CDK2 
regulate the progression from Gi phase to S phase (Stewart et al., 2003). To prevent abnormal 
proliferation, cyclin-CDK complexes are precisely regulated by two families of CDKIs that block their 
catalytic activity. The first class of inhibitors includes the INK4a proteins (e.g. pl6INK4A) that bind 
only CDK4-CDK6 kinases and not to cyclins and are, therefore, specific for early Gi phase. By 
forming dimers with CDK4 or CDK6 they can inhibit kinase activation by preventing the formation of 
complexes with members of the D-cyclin family. The second family of inhibitors is composed of 
CIP/KIP proteins (e.g. p21cn>1 and p27fapl), that inhibit all cyclin-CDK complexes and are not specific 
for a particular phase (Coqueret, 2003). These proteins form trimeric complexes with CDK2 bound to 
cyclin E or A and inactivate enzyme activity. Interaction of these proteins with CDK4/6 is, however, 
more complex, because at physiological concentrations, both p21cn>1 and p27KIP1 promote the 
formation of active D cyclin-CDK4/6 complexes (Foster et al., 2001). Both p21cn>1 and p27KIP1 act as
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a bridge between cyclin D and CDK4 to promote their association. Therefore, cyclin D-CDK4 
complexes function to sequester p21CIP1/p27KIPI away from cyclin E-CDK2 complexes, facilitating 
their activation and Gi/S transition (Figure 5.12.).
The retinoblastoma protein (pRB) is a crucial substrate of activated cyclin-CDK complexes in 
the Gi phase. pRB is sequentially phosphorylated by cyclin D-CDK4 and cyclin E-CDK2 during Gi 
phase progression, and either represses or activates transcription, depending on its phosphorylation 
state and associated proteins. Hypophosphoiylated pRB binds to and inactivates members of the E2F 
family of transcription factors. Because E2F family members mediate transcription of genes required 
for DNA synthesis, binding of hypophosphorylated pRB to E2F arrests cells in the Gi phase. During 
G,-phase progression, CDK-mediated hyperphosphorylation of pRB results in the dissociation of pRB 
and E2F and entry into the S phase (Stewart et al., 2003).
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Figure 5.12: Simplified scheme for cell cycle regulation in mammalian cells. The four phases Gj ,
S, Gj and M  phase, reflect stages in cell cycle progression where DNA synthesis and replication (S 
phase) and mitosis (M) occur in a temporally regulated fashion, separated by two gap phases (Gt and 
G2). The restriction point (R-Point) is a point o f control which determines when a cell becomes 
committed to cell cycle progression. The cyclin D1-CDK4 and cyclin E-CDK2 complexes 
phosphorylate pRB, which releases transcription factor E2F, resulting in progression through R-Point 
and entry into S-phase. Synthesis o f cyclin A begins in S phase and complexes with CDK2 to regulate 
S phase progression. Cyclin B synthesis starts at the end of S phase and complexes with CDK1 in G2 
to help regulate late G2 progression and completion o f mitosis.
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5.6.1. Estrogens and Cell Cycle Regulation in Breast Cancer
Over the past thirty years, many groups have studied the effects of E2 and estrogens on breast 
cancer cells in culture. Characterisation of the mammalian cell cycle has progressed rapidly in recent 
years. A considerable body of evidence indicates that, compared with normal ductal cells, cyclin Dl 
(mRNA and protein) is over expressed in nearly 50% of breast cancer cells. Overproduction of cyclin 
D 1 protein and mRNA correlates strongly with ER synthesis in tumour tissues, and relates inversely to 
the level of cyclin E. In accordance with these results, cyclin Dl is a well-defined target of E2 action in 
MCF-7 cells (Foster el al., 2001). Through stimulation of cyclin Dl, E2 activates cyclinDl-CDK4 and 
this complex appears essential for E2 action. Anti-estrogens are able to block the proliferative effect of 
E2 on breast cancer cells. Treatment of MCF-7 cells with anti-estrogens elicits G] phase cell cycle 
arrest with a decrease in cyclin Dl expression and elevated expression of both p21CIPI and p27K1P1 
(Strobl et al., 1995). Estrogens and, to the lesser extent, anti-estrogens, as well as protein kinase 
activators and growth factors increase phosphorylation of the ER and possibly other proteins in the 
ER-specific response pathway, suggesting that changes in cellular phosphorylation state will be 
important in determining the biological activity of the ER and the effectiveness of anti-estrogens as 
estrogen antagonists (Katzenellenbogen, 1996).
5.7. Breast Cancer Research and Treatment
Breast cancer is the second most common cancer among women in the world. In developed 
countries, it is the most common. What separates a malignant from a normal cell? This question has 
occupied scientists for decades. Although a simple answer remains elusive, several hallmarks of 
malignancy have been identified. These include evasion of apoptosis, lack of senescence and invasion 
and metastasis. Oncologists typically thought of systemic therapies for breast cancer as belonging to 
one of two categories: either cytotoxic chemotherapy or hormonal therapy. The growing complexity of 
cancer treatment, and more particularly of the biological basis underlying these therapies, suggest we 
re-consider our conceptual approach to the treatment of breast, and indeed all cancer (Sledge & Miller,
2003).
During normal growth and differentiation, cell proliferation is rigidly controlled. Cancer cells 
escape normal growth controls via mutations that result in over expression of differentially regulated 
growth factors or their receptors. Targeting self-sufficiency in growth signals in breast cancer has had 
profound effects. The biological underpinnings for hormonal therapy remained unexplained until the 
identification of the ER in the 1960s. The ER remains arguably the most important growth factor
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receptor identified for breast cancer. The question remains, can other aspects of growth self- 
sufficiency be targeted in breast cancer? Leaving aside the introduction of new agents for old targets, 
an increased understanding of signalling pathways and the identification of other growth factors point 
to novel opportunities for therapy. Current efforts are underway to target downstream mediators of cell 
surface receptors (e.g. ras, MAP kinase and PI3-K pathways). Intact EGF-R is present in 
approximately 40% of breast cancers. Research has brought about the development of many inhibitors 
including the EGF-R kinase inhibitor Iressa/gefitinib (ZD 1839) (Liem et al, 2002). Initial clinical 
trials of EGF-R blocking agents have proven disappointing with few responding patients. It is possible 
that inhibition of EGF-R alone is insufficient to limit self-sufficient growth as alternate pathways may 
come into play at this stage (Section 5.8.). In order to create more effective drugs, better understanding 
of this signalling pathway is essential (Sledge & Miller, 2003).
In human cancer, not only are the positive stimulators overactive: the negative controls fail to 
function properly. Altered expression of cyclins, CDKs and CDKIs are frequently found in 
malignancy. A considerable body of evidence indicates that in comparison with normal cells, cyclin 
D1 (mRNA and protein) is overexpressed in nearly 50% of breast cancer cells (Prall et al., 1998; 
Foster et al., 2001; Foster et al., 2001a). Cyclin D1 is expressed relatively early in breast 
carcinogenesis. Overexpression of cyclins and related CDKs is associated with poor prognosis in 
breast cancer. Similarly, lack of expression of CDKIs (p21 and p27) also leads to a poor prognosis for 
breast cancer patients. Together these data suggest the importance of insensitivity to inhibitory signals 
in breast cancer.
Other important hallmarks of breast cancer beyond the scope of this work include, evasion of 
apoptosis, limitless replicative potential, invasion and metastasis, sustained angiogenesis and genomic 
instability. The ability to apply the hallmarks of cancer to clinical practice has been limited by the 
insufficiency of both available testing methods and knowledge of breast cancer biology. Today’s 
research and treatment of cancer is fuelled by a host of technologies that analyse and manipulate 
genetic material at the molecular level. The first harvest of these technologies is now coming into 
focus. Genomic analysis of human breast cancers, using cDNA microarraiys ‘gene-chips’, reveals that 
breast cancer based on morphology in fact consists of several distinct subtypes. These subtypes have 
different ‘tool-kits’: for instance, different mechanisms of growth signal sufficiency. Due to the fact 
that the cancer ‘tool-kit’ is a finite package, and because cancer cells rely heavily on this limited 
repertoire for their survival, cancer should ultimately represent a calculable problem. In the future it is 
hoped that instead of stamping someone with the generic diagnosis “breast cancer,” the patients illness 
will be treated according to which genes are mutated. Such a distinction could go a long way to
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explaining why some cancers respond to certain drugs and others do not. It is also likely to change the 
way drugs will be designed and tested (Kahn, 2003).
5.8. Signal Transduction Therapy
Research in the area of signal transduction has always been stimulated by the belief that an 
understanding of signalling pathways responsible for cell growth in normal cells, will provide an 
understanding into the uncontrolled growth observed in cancer (Cooke, 1999). It is well known now 
that there is an important relationship between genes controlling normal cell growth, and those capable 
of inducing cell transformation. The genes that control normal cell growth, proliferation and 
differentiation, are known as proto-oncogenes and they are responsible for encoding proteins that are 
components of signalling pathways. Many oncogenes (cancer-causing genes) are altered versions of 
normal proto-oncogenes. The concept to employ elements of mitogenic signal transduction as targets 
for cancer chemotherapy originated as a result of increasing knowledge of the mechanism of 
transformation by oncogenes (Grunicke et al., 1996). Signal transduction therapy involves utilising 
novel agents specifically designed to block signalling pathways or their components. Any component 
of the signalling pathway can be targeted. Inhibition of these pathways can be achieved by a variety of 
reagents. These include, small molecules such as peptides, antibodies, anti-estrogens, tyrosine kinase 
inhibitors, antisense oligodeoxynucleotides and target-specific RNA ribozymes (Levitzki, 1996). 
These inhibitors target different areas along the signalling cascade starting with the receptor and 
ending with transcription factors.
5.8.1. Signal Transduction Targets
5.8.1.1. Growth Factor Receptors
Proliferation, differentiation, and cell death are co-ordinated processes that help maintain 
homeostasis among diverse cell types in higher organisms. Growth factors play an important role in 
the control of these processes. They exert their function by triggering signal transduction cascades 
upon binding to their cognate membrane receptors. The varying efficacy and toxicity of traditional 
cancer therapies has driven the development of novel target-based agents. In particular, the EGF-R 
superfamily is an attractive therapeutic target because it is commonly overexpressed in malignant 
disease. Several selective inhibitors of this family of receptors are currently being evaluated in a 
number of cancers (Arteaga, 2003). EGF responsiveness has been reported in a variety of solid
tumours, including breast, pancreatic, oesophageal, colon and prostate. There are at least 15 EGF-like
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ligands, including transforming growth factor (TGF-a), heparin-binding, EGF-like growth factor, 
betacullin and epiregulin. For tumour cells, the final effects of signal transduction sequence are 
survival, proliferation, and blockage of differentiation, as opposed to apoptosis and senescence. 
Therefore, understanding the molecular interactions that occur from receptor occupation to induction 
of gene transcription will allow the rational design of chemotherapeutic drugs (Weinstein- 
Oppenheimer et al., 2000). Several strategies have been developed to antagonise EGF-R family 
members and they will be discussed in the next paragraph.
Table 5.5: Inhibitors o f EGF-R-mediated MAP kinase pathway activation, which may prove useful as 
a single agent or combination treatment (radiation or chemotherapy) in cancer patients.
INHIBITOR NAME REFERENCE
Anti-EG F-R  m A b Erbitux, Cetuximab, Huang et al., 2003.
Trastuzumab Sridhar et a l, 2003
Tyrosine K inase Inhibitor Erlotinib, Herbst, 2003
Gefitinib, Grunwald & Hidalgo, 2003
OSI-774 Seymour, 2003
Fusion  Protein EGF-Genistein Uckun et al., 1998
Im m unoconjugate Mab806, Y 10 Sridhar SS et al., 2003
A nti-E G F V accin e YMB2000 Sridhar SS et al., 2003
Recently Yang and co-workers (1999) generated a fully humanised monoclonal antibody
(E7.6.3) to EGF-R. This mAb prevented engraftment of A431 xenografts in athymic mice. As a result
eradication of pre-existing tumours was observed. This work was performed without the use of
additional chemotherapy. These observations are encouraging to the development of humanised mAb,
which should exhibit minimal immunogenicity and a longer half-life. Combination therapy is showing
promise as illustrated by pancreatic cancer research performed by Huang and colleagues (2003).
Pancreatic cancer remains a devastating disease, with 95% of all patients diagnosed with the disease
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dying within 2 years. The combined therapy using an anti-EGF-R mAb (Erbitux), gemcitabine 
chemotherapy, and radiation caused complete tumour regression using a nude mouse model inoculated 
with pancreatic MiaPaCa-2 cells. Proliferation assays indicated that prolonged exposure to Erbitux 
increased the sensitivity of pancreatic cells to gemcitabine and radiation therapy. Research regarding 
drug resistance and the effect of Erbitux on signal transduction was also investigated. The results 
showed association of GRB-2 to EGF-R induced by EGF in the presence of Erbitux. This indicates an 
alternate pathway of Ras-MAPK activation, which may be related with tumour resistance to treatment.
The design of inhibitors to the tyrosine kinase activity of the EGF-R is an active area of 
research. Erlotinib (also known as OSI-774 or CP-358,774) is a small molecule selective inhibitor of 
the EGF-R tyrosine kinase that competes with ATP for binding with the intracellular catalytic domain 
of EGF-R tyrosine kinase, inhibiting phosphorylation. In preclinical studies, this compound inhibited 
the phosphorylation of the EGF-R in a dose-dependent and concentration dependent manner resulting 
in cell cycle arrest and induction of apoptosis in various human tumour xenografts alone and in 
combination with chemotherapeutic drugs. Both Phase I and II (monotherapy trial) data from patients 
with advanced NSCLC, ovarian cancer and head and neck squamous cell cancer showed erlotinib was 
well tolerated with favorable activity compared with single-agent chemotherapy in similar patient 
populations. Phase III trials with erlotinib in NSCLC and pancreatic cancer are in progress, as are a 
range of studies to optimise the use of erlotinib alone and in combination with chemotherapy, 
radiotherapy, and other targeted agents (Herbst, 2003). There is a definite need to opimise these trials 
as there has been some disappointing results from gefitinab phase III clinical trials (Seymour, 2003). 
While results from phase III trials with other agents such as erlotinib and cetuximab (monoclonal 
antibody studied as an anticancer drug) will be reported in the next 12 to 18 months, the early results 
indicate that present and future research efforts need to be directed towards the selection of patients 
with EGF-R-dependent tumours, identification of differences among the various classes of agents, and 
new clinical development strategies. Early data suggest a number of potential roles for these agents in 
the modulation of resistance and in combination with other inhibitors of signal transduction. The 
erlotinib clinical trials illustrate its potential as a novel inhibitor of EGF-R tyrosine kinase and is 
presently undergoing full development as an anti-cancer drug (Grunwald & Hidalgo, 2003). Uckun 
and co-workers (1998) have developed a fusion protein called EGF-Gen. Genistein is a tyrosine kinase 
inhibitor which is bound to the EGF to form a fusion protein. In vitro studies have shown the fusion 
protein caused apoptosis of EGF-R-expressing breast cancer cell lines.
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5.8.1.2. Ras Protein
In 1993, a signal transduction cascade, starting from the membrane-anchored activated Ras 
protein and ending in nuclear gene transcription was first described. Ras proteins are present in every 
cell, with the highest levels in proliferating cells. Therefore, it is not surprising that Ras was 
implicated in the development of tumours that circumvent both the effects of therapy and the immune 
response. The MCF-7 cell line, transfected with an inducible Harvey- Ras (H-Ras) gene, showed 
increased resistance to cisplatin and mitomycin C (Fan et al., 1997) Ras oncogenes (K-, H-, N-ras) are 
known to be involved in signal transduction pathways regulating cell growth and differentiation in 
many human cancers (Dempke, 2003). Ras was one of the first oncogenes targeted by pharmaceutical 
companies to develop anticancer drugs (Prendergast & Gibbs, 1994). Interruption of the Ras signalling 
pathway can be basically achieved in three ways, i.e. inhibition of Ras protein expression through 
antisense oligonucleotides, prevention of Ras membrane localisation and inhibition of Ras 
downstream effectors (Caponigro, 2002). The high incidence of mutated, transforming ras genes in 
human cancer and the restricted number of sites within the ras genes where transforming mutations 
occur spontaneously made these oncogenes attractive candidates for antisense technology.
Inhibition of Ras function is an alternative strategy for the interference with Ras controlled 
malignant growth. Ras activation requires its association with the plasma membrane. This process is 
initiated by the attachment of a famesyl (15-C isoprenyl) group to the protein and is catalysed by the 
famesyl transferase (Dempke, 2003). Famesyl transferase inhibitors (FTIs) are a novel class of anti­
cancer agents that competitively inhibit famesyl protein transferase (FPT), and are currently being 
developed and tested across a wide range of human cancers (Lancet & Karp, 2003). These studies 
include both single-agent and combination (e.g. chemotherapy) clinical trials in pancreatic cancer, 
acute myeloid lymphoma, colon cancer, liver cancer and breast cancer (Caponigro, 2002; Gana-Weisz 
et al., 2002; Dempke, 2003; Mazzocca et al., 2003).
Both R-l 15777 and SCH-66336, are orally active heterocyclic FTIs undergoing research in 
phase III studies in patients with advanced pancreatic cancers. It is expected that these studies will 
determine the extent of clinical activity and whether these agents can be used as single agents or have 
to be used in combination with other cytostatic drugs. In addition, it remains to be clarified whether 
FTIs may sensitise drug-resistant cancers following conventional chemotherapy (Dempke, 2003). 
However other researchers have been able to shed light on this area. Recent studies by Gana-Weisz 
and co-workers (2002) demonstrated that treatment with S-trans, trans-famesylthiosalycyclic acid 
(FTS) led to a marked increase in sensitivity to gemcitabine of the formerly resistant SW480 colon
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cancer cells and a 100-fold increase in sensitivity to gemcitabine of Pane-1 pancreatic cancer cells. 
Their previous studies have shown that FTS disrupts Ras membrane anchorage, which contributes to 
inhibition of tumour growth and cell transformation. Most tumour cells develop resistance to 
anticancer agents. It was shown that Panc-1 pancreatic cancer cells and SW480 colon cancer cells 
exposed to FTS do not escape FTS-induced growth inhibition and do not develop drug resistance.
Phase I clinical trials using FTIs in acute myelogenous leukaemia (AML) and other myeloid 
malignancies have been performed, demonstrating enzyme target inhibition, low toxicity and 
promising response rates. These findings have prompted further development in phase II trials. It is 
anticipated that such information will ultimately define the optimal roles of FTIs in patients with AML 
and other myeloid disorders, facilitate the incorporation of FTIs into current therapeutic strategies for 
myeloid malignancies, and provide insight into effective methods of combining FTIs with other signal 
transduction inhibitors (Lancet & Karp, 2003). One aspect of FTI biology that is poorly understood is 
the ability of these drugs to induce cancer cell growth arrest at the G2/M phase of cell cycle. The 
effects of FTI-277 on two human liver cancer cell lines (HepG2 & Huh7) were investigated by 
Mazzocca and colleagues (2003). It was shown that FTI-277 induced up-regulation of CDKI p27KIPI 
without affecting the cellular levels of p53 and p21. This event correlated with reduced activity of 
CDK-2 and CDK-1. Increased expression of Bcl-2 protein was observed in both cell lines treated with 
FTI-277. Taken together, these results show that increased expression of p27 and Bcl-2 is concomitant 
with altered association between Ras, Raf-1 and Bcl-2 and suggests that this is responsible for the 
growth-inhibitory properties of FTI-277.
Nonsteroidal anti-inflammatory drugs (NSAIDs) have also been shown to inhibit Ras. The 
NSAID Sulindac is used in the therapy and treatment of tumours in patients with the inherited cancer 
predisposition familial adenomatous polyposis. Sulindac binds to Ras and inhibits activation of 
downstream Raf. It also inhibits the activation of the nucleotide exchange activating protein. However, 
the major limitation of these results was that they were performed at high doses of sulindac (Herrmann 
et al., 1998). Vaccination with mutated Ras has been another approach to block Ras signalling. 
Peptides that correspond to mutated Ras were studied in a phase I vaccine trial. The response was 
modest, 3 out of 10 patients with advanced cancer showing cytotoxic T lymphocytes responses that 
were specific for the mutated Ras (Khleif et al., 1999). Human reovirus therapy has become a novel 
approach to combat tumours expressing activated Ras (Coffey et al., 1998).
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5.8.L3. Raf-1
Mutated forms of the Raf oncogenes have been observed in diverse neoplasias, including 
breast, cervical, renal, hepatocellular and small cell lung carcinomas. Raf-1 is the most extensively 
studied member of the Raf family. It was shown that for Raf-1 synergistic activation occurs with 
oncogenic Ras and activated tyrosine kinases. Certain residues are important in the regulation of Raf 
activity. Amino acids 340 and 341 of Raf-1 are both tyrosine phosphorylated which results in the 
activation of Raf-1 activity. The involvement of the different Raf oncogenes in various cancers is 
important to determine since they have different capacities to induce downstream signalling proteins. 
This may indicate that the development of inhibitors to the different Raf proteins will be complex. 
Inhibitors to each kinase may have to be developed, as they may have opposing roles in either 
stimulating or preventing cell cycle progression.
Until quite recently, the benzoquinone ansamycin antibiotic, geldanamycin (GA), was the 
only compound reported to inhibit Raf activity. It was demonstrated that this compound binds to the 
heat shock protein (hsp)90 and disrupts the Raf-l-hsp90 multimolecular complex, which prevents Raf- 
1 protein maturation. Other proteins are degraded in the presence of geldanamycin e.g. c-ErbB-2, 
EGF-R and ER components. c-ErbB-2 down-regulation is a desirable effect since this is a gene that is 
frequently mutated in tumours such as breast and non-small cell lung cancer. Kim and co-workers 
(2003) have shown that GA exhibits potent anti-tumour activity in certain cancer cell lines by 
destabilising important signal transduction proteins (e.g., Raf-1 and AKT). The purpose of the study 
was to determine whether GA alters the expression of Raf-1 and AKT, shown to be critical for 
neuronal cell survival, and induce apoptosis of neuroblastoma cells. It was determined that GA 
decreases cell viability and induces apoptosis in human neuroblastoma cells. These findings suggest 
that GA may be a novel therapeutic agent, which may be effective in treatment of neuroblastomas. A 
separate study utilised antisense oligonucleotides to antagonise Raf activity. A 20-base 
phosphorothioate oligonucleotide complementary to c-raf-1 mRNA (ISIS 5132) specifically 
suppresses Raf-1 expression both in vitro and in vivo. However, further development and optimisation 
is necessary before ISIS 5132 be properly evaluated as novel therapeutics (Barnard et al., 1998; Rudin 
et al., 2001).
5.8.1.4. Src Family o f  Tyrosine Kinases
The Src family of non-receptor protein tyrosine kinases plays critical roles in a variety of 
cellular signal transduction pathways, regulating such diverse processes as cell division, motility,
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adhesion, angiogenesis and survival. Src family kinases are frequently overexpressed and/or aberrantly 
activated in a variety of epithelial and non-epithelial cancers. Activation is very common in colorectal 
and breast cancers. Exactly how Src family kinases contribute to individual tumours remains to be 
defined completely, however, they appear to be important for multiple aspects of tumour progression, 
including proliferation, disruption of cell/cell contacts, invasiveness, apoptosis resistance and 
angiogenesis. Given the ability of Src and its family members to participate in so many aspects of 
tumour progression and metastasis, Src family kinases are attractive targets for future anti-cancer 
therapeutics (Summy & Gallick, 2003). N-myristoylated peptides have been reported as src inhibitors. 
These modified peptides showed an improved potency compared with the original peptides (Ramdas 
et al., 1999). 6-Aiyl-pyrido-[2,3-d]pyramiding (PD089828) inhibits EGF-R and Src tyrosine kinase 
activity. This broad-spectrum tyrosine kinase inhibitor may be a valuable inhibitor of Raf activation, 
mediated by tyrosine phosphorylation (Oppenheimer-Weinstein et al, 2000).
5.8.L5. MAP/ERK Kinase (MEK)
The MEK pathway has been associated with a variety of neoplasias, including breast cancer 
renal cell carcinoma and hepatocellular carcinoma. MEK-2 is the most potent ERK-1 activator, 
followed by MEK-1, which is approximately 7 times less active in activating ERK-1 than MEK-2. In 
cells expressing normal MEK-1, the kinase appears as a 45kDa protein. The amino terminal end of the 
kinase has a negative regulatory domain, as deletion of these residues results in the constitutive 
activation of MEK-1. The catalytic activity is localised in the carboxyl terminus of the protein. Raf-1 
activation of MEK-1 requires the phosphorylation of S residues 218 and 222. MEK activity can be 
blocked with the use of specific inhibitors. These kind of drugs, which inhibit MEK activity, show 
promise in turning off this pathway in rapidly proliferating malignant cells. One such inhibitor 
recently identified is l,4-diamino-2,3-dicyano-l,4-bis[2-aminophenylthio] butadiene (U0126). This 
compound is selective for MEK-1 and MEK-2 (Favata et al., 1998). The effects of U0126 on the 
growth of eight human breast cancer cell lines have been examined by Fukazawa and colleagues 
(2002). The results indicated that concurrent inhibition of MEK-ERK and S6K pathways induces 
apoptosis when cells are deprived of anchorage but not when anchored. These inhibitors may provide 
a therapeutic strategy to selectively target neoplasms proliferating at ectopic locations, with acceptable 
effects on normal cells in their proper tissue context. The effect of MEK inhibitor PD98059 on the 
growth of human pancreatic cancer was also investigated. Although tumour growth was not reduced 
by the MEK inhibitor, the findings suggest that the Ras signalling pathways are potential targets for 
manipulation of radiosensitivity, and that induction of an alternative pathway may enhance 
radiosensitivity of pancreatic cancer (Matsui et al, 2003).
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5.8.1.6. Extracellular Regulated Kinase (ERK)
ERK activity has been detected in increased levels in breast, colon, ovary and kidney cancer 
cel 1-lines. ERK mRNA expression was shown to be elevated in mammary adenocarcinoma cell lines 
with higher metastatic potential. In most solid tumours, a positive correlation has been found between 
Ras-activating mutations and ERK activation. In haematopoietic cells the situation seems different as 
it has been shown that 50% of patient with primary acute myeloid leukaemia exhibit constitutive ERK 
activation. However, leukaemia cells that exhibited the N-Ras mutations showed no signs of ERK 
activation. These observations are a reflection of the complexity of the signalling process and 
underscore the necessity to study different cell systems to avoid erroneous generalisations.
The role of nuclear translocation of ERK was demonstrated by sequestering both ERK-1 and- 
2 in the cytoplasm of the cell. Both Elk-1-dependent gene transcription and cell cycle re-entry were 
strongly inhibited (Brunet et al., 1999). This research illustrates the potential for targets of ERK 
nuclear translocation.
5.9. Benzopyrones in Signalling Processes & Cell Cycle 
Regulation
Interest in the study of benzopyrones has originated in the clinical observation of its efficacy 
in cancer patients. Much presented work has shown that both coumarin and 7-hydroxycoumarin 
inhibit the in vitro growth of a range of cell lines in a dose-and time-dependent manner, with some cell 
lines more sensitive than others to these effects (Bogan et al, 1996; Egan et al., 1997; Cooke & 
O’Kennedy, 1999). In all cases 7-hydroxycoumarin was more potent than its parent compound. In 
order to exploit the effects of any drug optimally, it is essential to locate its precise cellular or 
molecular target. Recent advances made in both signal transduction and cell cycle research involving 
the use of benzopyrones will now be reviewed.
The central role of the Ras protein in growth signalling pathways was highlighted in Section 
5.5.4. Recent research by Pan and colleagues (2003) has involved investigation into the inhibitory 
effects of esculetin on vascular smooth muscle cell (VSMC) proliferation and intimal hyperplasia by 
balloon angioplasty in the rat. Three predominant signalling pathways were found to be inhibited by 
esculetin:
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a) Activation of MAP kinase and downstream effectors of c-fos and c-jun immediate 
early genes.
b) Activation of nuclear factor-KB and AP-1
c) Activation of PI-3K and cell cycle progression
Using western blot RT-PCR they found that esculetin inhibits serum-induced MAP kinase 
phosphorylation, expression of c-fos and c-jun mRNA and the DNA binding activity of AP-1. 
Furthermore, esculetin also inhibits Ras activation, a shared upstream event of these signalling 
cascades. It was recently suggested that PI-3K-mediated pathways play a key role in cyclin D1 
expression and in turn effects progression of the cell cycle into S phase (Section 5.6.). Through these 
investigations it has been demonstrated that esculetin profoundly reduced cyclin D1 expression in the 
VSMC tested. Taken together it is clear from these results that esculetin inhibits the serum-induced 
events such as MAP kinase and PI-3K activation. It is likely that the cardinal target of esculetin is 
before these events. They concluded that esculetin inhibits VSMC proliferation via an upstream 
effector of Ras and downstream events such as MAPK and PI-3K activation.
The effect of esculetin, coumarin and 7-hydroxycoumarin on the cell cycle and its regulatory 
molecules have been investigated. Wang et al. (2002) have presented evidence that esculetin affected 
phosphoiylation of pRB thus inducing Gi arrest of human leukaemia HL-60 cells. The results 
demonstrated that the treatment with esculetin resulted in an accumulation of hypophosphorylated 
pRB in HL-60 cells along with reductions of both cyclin D1 and E. This induced the arrest of the cell 
cycle at the Gi phase. Among the released proteins, the E2F family of transcription factor has central 
position. Not only does E2F induce gene expression necessary for DNA synthesis, it also contributes 
to the regulation of the cyclin D1 and E genes. Esculetin treatment also induced enhanced expression 
of the CDKI p27 and a reduced expression of CDK-4, thus inhibiting pRB phosphorylation (Wang et 
al., 2002). A separate study set out to clarify mechanisms of action of 7-hydroxycoumarin and 
coumarin were studied with regard to their effects on cell cycle progression of human adenocarcinoma 
cell line A427. These cells are pRB positive and have homozygous deletions at the gene of pl6mK4A. 
The results showed that 7-hydroxycoumarin had greater cytostatic activity than coumarin. The 
inhibition of the cell-cycle at transition Gi/S is consistent with the cytostatic effect of 7- 
hydroxycoumarin. Furthermore, the decrease in the percentage of cells expressing cyclin D1 indicates 
that the action of 7-hydroxycoumarin involves early events in phase Gt. Absence of changes in the 
level of cyclin D1 mRNA suggests a post-transcriptional effect of 7-hydroxycoumarin. A pathway 
which regulates post-transcriptionally the levels of cyclin D1 is the PI-3K/AKT pathway (Section
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5.6.). If this pathway is inhibited it cannot inhibit phosphorylation of GSK-3 which leads to cyclin 
degradation (Jimenez-Orozco et al., 2001).
Flavonoid compounds in food items of plant origins (such as soybean), including isoflavone 
genistein, are known to have a wide spectrum of biological activities (Hua et al., 2003). A very 
important biological activity of genistein regards its ability to inhibit cancer cell proliferation in vitro 
(Tanos et al., 2002). It is also a well-known tyrosine kinase inhibitor and therefore many studies have 
been performed in order to better understand its mechanism of action in inhibiting cancer cell 
proliferation. The purpose of a study by Akimoto and colleagues (2001) was to test the potential 
effects of genistein on enhancement of radio-sensitivity as a therapeutic agent and to explore the 
molecular mechanism in human esophageal cancer cell lines. The investigations revealed that growth 
factor receptor-mediated signal transduction pathways play an important role in determining cellular 
response to radiation or other stresses. In this study, radiation activated both survival signals p42/p44 
ERK and AKT/PKB. However, incubation with genistein for 9 hours greatly enhanced radio­
sensitivity in the cell lines examined. In TE-2 esophageal cancer cells, there was a slight decrease in 
expression of (anti-apoptotic) Bcl-2 protein and an increase in (pro-apoptotic) Bax expression.
An earlier signal transduction study also demonstrated that genistein inactivates bcl-2 
expression via phosphorylation. This compound can delay the G2/M Phase of the cell cycle and induce 
apoptosis of MCF-7 breast cancer cells. Substantial changes in bcl-2 phosphorylation were detected 
following treatment with genistein. These changes involved increased bcl-2 phosphorylation, which 
was evident within 30 mins after genistein exposure. It was proposed that bcl-2 protects cells from 
apoptosis by forming heterodimer with bax and reducing the number of bax homodimers. 
Phosphorylated bcl-2 is incapable of forming heterodimer with bax, and it loses its anti-apoptotic 
potential. In genistein-treated MCF-7 cells, bcl-2 protein expression was down regulated and this was 
evident 48hrs after treatment. These results strongly suggest that an integral and independent early 
component of the apoptotic signalling is bcl-2 inactivation through phosphorylation. The combination 
of DNA targeting agents with protein tyrosine kinase inhibitors may prove especially beneficial in the 
treatment of breast cancer (Constantinou et al., 1998).
It is evident from the above discussion, that the benzopyrones exert a number of effects on 
important components of cell signalling pathways. To further the investigation of the effects of the 
benzopyrones on signalling components and pathways it was decided to investigate the effect of 
esculetin and warfarin on tyrosine phosphorylation within cells as this type of phosphorylation is 
important to the accurate regulation of growth control.
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5.10. Summary of Research Described in This Chapter
The effect of five benzopyrone compounds (warfarin, 4-hydroxycoumarin, 7- 
hydroxycoumarin, genistein, and esculetin) on proliferation in cultured human tumour cell-lines 
(MCF-7 and A549) was examined. Previous observations by Kolodziej and colleagues (1997) and 
Cooke & O’Kennedy (1999) indicated that a dihydroxy-fiinction, in either an ortho- or meta-form of 
coumarin, was an extremely potent chemical structure for toxicity in human tumour cell lines. In the 
present study it was decided to concentrate on esculetin (6,7-dihydroxycoumarin), and 7- 
hydroxycoumarin in order to confirm the increased potency of esculetin in comparison to 7- 
hydroxycoumarin on the two tumour cell-lines examined. Previous clinical trials suggest warfarin may 
be more useful as an aid to the management and control of tumour growth rather than its eradication 
(Zacharski et al., 1984; Zacharski, 1992). Therefore, as part of this research it was necessary to 
investigate the effect of warfarin on cell proliferation and draw comparisons with the antiproliferative 
effects of the other coumarins examined. Genistein has shown great promise in previous toxicity 
studies (Papazisis, 2000; Ratna, 2002; Tanos et al., 2002). Determination of the effects of the 
benzopyrones on cell proliferation and metabolism was accomplished by performing in vitro 
proliferation assays, three microtitre format assays [Lactate Dehydrogenase assay, Tetrazolium Salt 
assay (MTT), Acid Phosphatase assay] and cytosensor studies. Signal transduction studies focused on 
the mechanism of action of esculetin, warfarin and genistein in MCF-7 cells. Investigation of the 
inhibitory effects of these compounds on tyrosine phosphorylation of the stimulated EGF-R was 
performed using ELISA. The cytosensor microphysiometer was utilised to determine the effect on 
tyrosine kinase activity of MCF-7 cells pre-exposed to benzopyrones. Finally, a BrdU ELISA was 
used to determine the effect of all the compounds on DNA synthesis of exposed MCF-7 cells.
5.11. Results and Discussion
5.11.1. In Vitro Proliferation Assays
Previous investigators have used cell proliferation-based assays in their chemosensitivity 
assessment of coumarin compounds (Myers et al., 1994: Cooke, 1999). Recently a murine xenograft 
in vitro proliferation assay was utilised to determine the antitumour activities of SP500263, a novel 
next-generation selective estrogen receptor modulator (SERM), tamoxifen, and raloxifene in an in 
vitro and in vivo MCF-7 breast cancer model (Brady et al., 2002). The insensitivity of many human 
tumour cell lines previously tested to growth inhibition by coumarin, seems to confirm the generally
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held belief that coumarin is not responsible for the observed in vivo effects, but is a pro-drug for other 
active metabolites. Therefore, in our research we chose initially to examine three benzopyrone 
compounds, namely warfarin, esculetin, and genistein under similar assay procedures, for the MCF-7 
cell line and the A549 cell line (Table 5.6.). The cell line was exposed to each of the three compounds 
for 96 hours as outlined in Section 2.5.4.2. In general, cells were exposed to drug concentrations in the 
range 0-25pg/ml for warfarin, 0-20pg/ml for esculetin, and 0-13.5pg/ml for genistein. Following 
exposure, cell counts were performed, and the decrease in cell number for drug-treated cells was 
expressed as a percentage of the increase for solvent-treated control cells, and growth curves were 
constructed from this data.
Figure 5.13. shows proliferation curves for cells exposed to the three benzopyrone 
compounds, for the cell line tested -  MCF-7, a breast carcinoma cell line. Preliminary studies showed 
this cell line to be quite sensitive to all compounds and thus exposure to the three compounds is 
illustrated in the range 0-25pg/ml drug. As shown, all three compounds caused a significant cytostatic 
effect over the 96 hour exposure period, with genistein illustrating the most potent effect, followed by 
esculetin, and warfarin, in decreasing order of potency. Figure 5.14. illustrates the effect the three 
compounds tested have on A549 cells exposed to drug over 96 hours. As with the MCF-7 cell line, 
warfarin showed the least inhibitory effect over the drug range tested. At the highest concentration of 
warfarin tested (lOOpg/ml) there was only ~ 15% decrease in cell proliferation in comparison to 
control cells. Esculetin was far more potent at inhibiting cell proliferation in these cells, as at the 
highest concentration (20f^g/ml) there was a decrease in cell proliferation by over 80%. For genistein 
there was a similar decrease of over 80% in cell proliferation at its highest concentration value of 
13.5pg/ml. Although genistein at its highest concentration of 13.5|xg/ml is just as effective as an 
inhibitor of cell proliferation as esculetin at the higher concentration of 20pg/ml, the IC50 is 
misleading, as esculetin appears to be a more effective inhibitor of proliferation than genistein. This 
illustrates the inadequacy of the in vitro proliferation assay to accurately determine the effects of drugs 
on cell proliferation. These results can only be guidelines for further assay development as can be seen 
in Sections 5.11.2.1 -5.11.2.4.
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Drug Concentration (ug/ml)
Figure 5.13: In Vitro Cell Proliferation Assay following exposure o f MCF-7 cells to 3 benzopyrone 
compounds for 96 hours. All experiments were conducted in duplicate on three separate occasions. 
The decrease in cell number for drug-treated cells was expressed as a percentage o f the untreated 
control cells and plotted versus the appropriate drug concentration. Each experiment was carried out 
in duplicate on three separate occasions (n=3), and the mean IC50 value (± standard deviation) for 
these experiments determined and tabulated (Table 5.6).
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Figure 5.14: In Vitro Proliferation Assay following exposure o f A549 cells to 3 benzopyrone 
compounds for 96 hoars. All experiments were conducted in duplicate on three separate occasions. 
The decrease in cell number for drug-treated cells was expressed as a percentage o f the untreated 
control cells and plotted versus the appropriate drug concentration. Each experiment was carried out 
in duplicate on three separate occasions (n=3), and the mean IC50 value (± standard deviation) for 
these experiments determined and tabulated (Table 5.6).
The proliferation curves in the above Figure 5.14 were utilised to obtain IC50 values (IC50 
value defined as the concentration of drug that causes a 50% inhibition of growth in drug-treated cells 
as compared to untreated control cells). The most evident trend from the proliferation curves and table 
of 1C50 values (Table 5.6.) is the sensitivity of MCF-7 cells tested, to growth inhibition by esculetin 
(6,7-dihydroxycoumarin). Previous studies by Cooke (1999) have shown that this compound is 10-100 
times more inhibitory to cell proliferation than the parent coumarin compound. This reflects well the 
previous observation by Kolodziej and colleagues (1997), that a dihydroxy-function in either an ortho- 
or meta-format, was an extremely potent chemical structure for toxicity in two human tumour cell 
lines, as ascertained by the MTT assay. Since this potency was not evident in either of the single- 
hydroxycoumarin compounds, the added potency must be due to the existence of a double hydroxy- 
function on the coumarin ring (Kawase et al., 2003).
Previous studies by Tanos et al., (2002) have shown that genistein inhibits cancer cell 
proliferation in vitro. This effect has been attributed to a competitive inhibition by occupying the
276
estrogen receptor (ER) of the cell or to inhibition of several key enzymes, especially tyrosine kinases, 
which are thought to be involved in the control of cell proliferation, carcinogenesis and are associated 
with oncogene expression in breast cancer (Tanos, 2002). From Figure 5.13 - 5.14 and Table 5.6. it 
can be seen that genistein is more potent inhibitor to cell proliferation than esculetin.
Cell Line IC50 Warfarin ICS0 Esculetin ICS0 Genistein
(jjg/ml) (M/ml) (P R /m l)
A549 > 150 3.0 + 0.68 5.9+ 0.10
MCF-7 5.8 + 0.73 2.0 ±0.28 0.5 ± 0.04
Table 5.6: IC50 values determined for the exposure o f 2 cell lines to benzopyrones. The ICS0 value is 
defined as the concentration that causes a 50% inhibition o f growth in drug-treated cells, as 
compared to untreated control cells. Each experiment was carried out in duplicate on three separate 
occasions (n=3), and the mean IC50 value (±_ S.D.) for these experiments determined and tabulated 
above.
5.11.2. Further Chemosensitivity Testing
As outlined in Section 5.1, cell proliferation assays are only one of a number of 
chemosensitivity tests, which can be used to examine the response of cells to chemical agents. 
Therefore, as part of our study into the effects of benzopyrones on cultured cells, it was decided not to 
limit this investigation solely to the anti-proliferative effects of these agents, as many investigators in 
the past have done, but to also examine the effect of these compounds on other cellular mechanisms. 
In order to increase the number of assay formats performed and include signal transduction studies it 
was decided to limit this investigation to two human cell lines, the MCF-7 breast carcinoma and A549 
a lung carcinoma cell line. The MCF-7 cell line was chosen for the presence of its estrogen receptor. 
Cellular proliferation is induced (Section 5.6.1) when this receptor is stimulated by estrogen or 
estradiol. Previous studies (Section 1.8.1.2.) have shown that genistein is a phytoestrogen. For cells 
possessing the estrogen receptor exposure to low doses (0.1-10pM) of genistein results in increased 
cellular proliferation due to the “estrogen-like” stimulation of the estrogen receptor. A549 cells do not 
possess the estrogen receptor. Hence, no estrogen receptor-induced cell proliferation should be 
observed when these cells are exposed to genistein. The microtitre assays described in the following 
sections were utilised to determine what effect genistein and the other benzopyrones had on the 
cellular proliferation of both cell lines.
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5.11.2.1. Lactate Dehydrogenase (LDH) Assay
Cytotoxicity studies with culture systems provide useful information for understanding the 
effects of compounds on human tumour cell lines. Use of the LDH assay along with other types of 
assays (MTT, AP) can yield this information.
Although the LDH assay gives a rapid and simple quantification of cellular damage, one 
disadvantage of the assay is the possibility that the test compound may inhibit the LDH enzyme 
activity, causing underestimation of membrane damage. The test compound may also react with other 
assay components causing interference, which may lead to inaccurate results. Therefore, it is essential 
when assessing membrane damage with the LDH assay, that these two possible interferences are 
excluded. Inhibition of LDH activity is tested by incubating a standard LDH solution with various 
drug concentrations, and determining the activity of the enzyme in the presence of these drug 
concentrations. The second interference can be discounted by incubating the drug in culture media 
with the LDH Assay reagents and detecting whether presence of the drug gives rise to an increased 
absorbance at 492nm (assay absorbance wavelength) compared to drug-free culture medium. This 
interference testing was accomplished for all four coumarin compounds under investigation (esculetin, 
warfarin, 7-hydroxycoumarin, and 4-hydroxycoumarin as shown in Figure 5.15. This diagram 
illustrates that none of the four compounds are inhibitors of the enzyme activity (top), or react with the 
assay components yielding interfering species (bottom).
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Figure 5.15: Control tests confirming that coumarin compounds (0.25-250ug/ml) do not 
interfere with LDH Assay reagents. Results (A ^nJ for drug solutions are expressed as a percentage 
o f control absorbance (A0) at 492nm. The coumarins when incubated with an LDH standard (0.1 U/ml) 
did not inhibit this LDH activity (top). A0 for LDH standard (O.lU/ml) = 0.354 ±  0.024. The 
coumarins when incubated with culture medium alone did not interfere significantly with other LDH 
reagents (bottom). Ao for control medium = 1.376 ±  0.021
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Different cell types may contain different amounts of LDH. Therefore, it was necessary to 
determine the optimum cell concentration for both cell lines used in this experiment. This cell 
concentration (5 X 104 cells/well) was determined from graphs (Figure 5.16) in which the difference 
between the low (spontaneous LDH release) and high (maximal LDH release) control is at a maximum 
and this cell concentration was used in all subsequent assays.
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Figure 5.16: Determination o f the optimal target cell concentration for both MCF-7 (A) and A549 (B) 
cell lines.
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Having excluded interferences, both cell lines were incubated with the four coumarins (range 
0.25-250^g/ml) for 24 hours and the culture supernatants assessed for enzyme release using the LDH 
assay as outlined in section 2.5.4.3. A 1% (v/v) Triton X-100 solution in culture medium was used as a 
positive control representing 100% membrane damage. The absorbances at 492nm for cells exposed to 
Triton X-100 were normalised at 100% and absorbances of cells exposed to the various drug 
concentrations expressed as a percentage of this positive control (Figure 5.17 and 5.18.). It is evident 
from the graphs that 24 hour exposure of both cell lines to 4-hydroxycoumarin warfarin and 7- 
hydroxycoumarin caused no significant membrane damage when compared to untreated cells. 
However, A549 cells (Figure 5.17) appeared to be sensitive to the effects of esculetin (25-250 p.g/ml) 
as there was 30-40% LDH release indicating the occurrence of membrane damage to the cells. The 
MCF-7 cells did not appear to be as sensitive to the effects of esculetin (Figure 5.18). At the highest 
concentration (250 fAg/ml) there was -25% LDH release indicating slight membrane damage in 
comparison to control treated cells.
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Figure 5.17: LDH Assay o f culture supernatants ofA549 cells exposed to coumarins (0-250pg/ml) for 
24 hours. Results (A492nm) for coumarin-treated cells are expressed as a percentage o f A492nm of 
positive control (Triton X-100) cells (Abs=1.93±_ 0.019). Each drug was tested in five separate 
wells/plate, and the experiment was carried out on three separate occasions (n~3).
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24hr Exposure to Coumarins: LDH Assay
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Figure 5.18: LDH Assay o f culture supernatants ofMCF-7 cells exposed to coumarins (0-250pg/ml) 
for 24 hours. Results (A492nm) for coumarin-treated cells are expressed as a percentage o f A492nm 
ofpositive control (Triton X-100) cells (Abs=1.823 ±  0.031). Each drug was tested in five separate 
wells/plate, and the experiment was carried out on three separate occasions (n=3).
5.11.2.2. M TT Assay
The MTT Assay is a well-established colourimetric assay, which can be used to detect the 
effects of agents on cellular metabolism. The assay is based on the cleavage of the yellow tétrazolium 
salt, MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide), to purple formazan crystals 
by mitochondrial dehydrogenases. Therefore, cells must not only be alive, but also metabolically 
active for this reaction to occur (Cooke, 1999). The assay can be used in either a long- (96hr) or short­
term (24hr) drug-exposure format, to assess the effects of a drug on cellular growth or metabolism, 
respectively. Previously, the MTT assay has been used to assess the anti-proliferative effects of 
coumarins (Kumi-Diaka, 2002; Krebs et al., 2002).
The assay was carried out as outlined in Section 2.5.4.4. Prior to determining the effects of the 
benzopyrone compounds on cellular metabolism in MCF-7 cells and A549 cells, optimisation of cell 
seeding density (Figure 5.19) and interference testing (Figure 5.20) were necessary. Optimum seeding
density of both cell lines was found to be 5 X 105 cells/ml, and this was used in all subsequent assays.
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Incubating the MTT reagents with drug concentrations in the absence of cells (Figure 5.20) tested 
interference effects of the coumarins. Warfarin, 7-hydroxycoumarin and genistein did not interfere 
with the tetrazolium salt. However, esculetin reacts mildly with the tetrazolium salt in the 
concentration range 0-10p.g/ml, but intensely at concentrations >10fxg/ml. Therefore, all subsequent 
MTT assays were conducted with an esculetin concentration range of 0-25|j.g/ml and absorbance 
values were corrected for the interference effects. The significance of any reduction in cellular 
viability was determined using a paired Student’s t-test with confidence limits set at 95%. A 
probability of 0.05 (P<0.05) or less was deemed statistically significant.
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Optimisation of Seeding Density for MTT Assay
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Figure 5.19: Optimisation o f seeding density ofA549 (top) and MCF-7 (bottom) cells for MTT assay. 
5 x 10s cells/ml was chosen as the optimum density for both cell lines as it gave a high A560nm value 
at a pre-plateau point on the curve.
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Figure 5.20: Examination o f the interference ofbenzopyrone compounds with MTT tetrazolium salt in 
the absence o f cells. Neither warfarin, 7-hydroxycoumarin nor genistein interfere, but esculetin reacts 
intensely with the MTT salt especially at concentrations > 10pg/ml.
MTT assays were conducted on both cell lines for warfarin and 7-hydroxycoumarin in the 
concentration range 0-250^g/ml, esculetin concentration range 0-25(ig/ml and genistein concentration 
range O-lOOfxM, with 24hr drug exposure. The results were plotted as A/Ao, where A represents the 
absorbance value at a given drug concentration (e.g. lOOpg/ml esculetin) and Ao represents the 
absorbance value at Ofig/ml drug exposure. Therefore, the AJAo value for cells exposed to Opg/ml of 
drug should equal 1.0 or 100 when expressed as a percentage value. Figures 5.21 to 5.24 show the 
results for these experiments. From Figure 5.21 (A549 cells) and Figure 5.23 (MCF-7 cells) it can be 
seen that neither 7-hydroxycoumarin nor warfarin exerted any significant adverse effect on the 
metabolic activity of mitochondrial dehydrogenases in cells exposed to these drugs for 24hrs. 
Exposure of both cell lines to genistein (Figure 5.22 & Figure 5.24) indicates there is a slight decrease 
in mitochondrial dehydrogenase activity up to lOpM. From 25-100(jM genistein there is an 
underestimation of the growth inhibitory effects of the drug, which is explained in Section 5.12. 
Esculetin was the only compound to show a significant decrease in mitochondrial dehydrogenase 
activity throughout the concentration range (0-25pg/ml) for both cell lines. Although interference 
effects were compensated for, these results require comparison with other assay formats (e.g. 
cytosensor and acid phosphatase assay) where interference effects are not a problem. Comparison to 
the Cytosensor microphysiometer shows that the MTT assay results are not as reliable as the
Cytosensor results over 24 hours (Section 5.11.2.4.).
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24hr Exposure to 7-Hydroxycoumarin: MTT
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Figure 5.21: MTT assay results determining the effect o f 24hr exposure o f benzopyrones on the 
metabolic activity o f A549 cells. The above graphs represent 24hr exposure to 7-hydroxycoumarin 
(top) and warfarin (bottom) in the concentration range 0-250pg/ml. All drug concentrations were 
tested in five separate wells/plate on three separate occasions. All absorbances (550nm) o f test wells 
were expressed as a percentage o f control well absorbances (Ao).Aofor 7-hydroxycoumarin = 0.770 
±  0.024; Ao for warfarin = 0.790 ±  0.018. It is evident from Table 5.7 that both compounds have no 
significant effect on metabolic activity (formazan formation).
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Figure 5.22: MTT assay results determining the effect o f 24hr exposure o f benzopyrones on the 
metabolic activity o f A549 cells. The above graphs represent 24hr exposure to genistein (top) and 
esculetin (bottom) in the concentration range 0-100pM and 0-250jug/ml respectively. All drug 
concentrations were tested in five separate wells/plate on three separate occasions. All absorbances 
(550nm) o f test wells were expressed as a percentage o f control well absorbances (Ao). Ao for 
genistein = 0.750 ±  0.021; Ao for esculetin = 0.832 + 0.023. An explanation for the increase in 
absorbance as genistein concentration (25-100ug/ml) increases, is explained in Section 5.12.
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Figure 5.23: MTT assay results determining the effect o f 24hr exposure o f benzopyrones on the 
metabolic activity o f MCF-7 cells. The above graphs represent 24hr exposure to 7-hydroxycoumarin 
(top) and warfarin (bottom) in the concentration range 0-250/ug/ml. All drug concentrations were 
tested in five separate wells/plate on three separate occasions. All absorbances (550nm) o f test wells 
were expressed as a percentage o f control well absorbances (Ao). Ao for 7-hydroxycoumarin = 0.826
0.016; Ao for warfarin = 0.850 ±  0.017. There is slight decrease (5-10%) in formazan production 
and hence metabolic activity for both compounds (0-5/ig/ml. At the higher concentrations (25- 
250/j.g/ml) there is an increase in absorbance values (overestimation), which may be due to cell cycle 
perturbations, or formazan production in lethally damaged cells.
288
24hr Exposure to Genestein: MITT Assay
160
10 25 50 100
Concentration of Drug (uM)
24hr Exposure to Esculetin: MTT Assay
120
0 0.063 0.125 0.25 0.5 2.5 5
Concentration of Drug (ug/ml)
Figure 5.24: MTT assay results determining the effect o f 24hr exposure o f benzopyrones on the 
metabolic activity o f MCF-7 cells. The above graphs represent 24hr exposure to genistein (top) and 
esculetin (bottom) in the concentration range 0-100pM  and 0-250pg/ml respectively. All drug 
concentrations were tested in five separate wells/plate on three separate occasions. All absorbances 
(550nm) o f test wells were expressed as a percentage o f control well absorbances (Ao). Ao for 
genistein = 0.848 ±  0.015; Ao for esculetin = 0.865 + 0.028.
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Table 5.7: Significance o f the reduction in cellular viability. A probability o f 0.05 (P<0.05) or less 
was deemed statistically significant.
Compound MCF-7 Significance 
P Value
A 549 Significance 
P Value
Warfarin (fjg/ml)
0.25 >0.05 >0.05
0.5 <0.01 >0.05
2.5 <0.05 >0.05
5 <0.01 >0.05
25 >0.05 >0.05
50 <0.01 <0.01
250 <0.0001 <0.01
7-OHC (fJg/ml)
0.25 <0.01 >0.05
0.5 <0.0001 >0.05
2.5 <0.0001 <0.05
5 <0.0001 >0.05
25 <0.01 >0.05
50 <0.01 >0.05
250 <0.01 >0.05
Esculetin (fjg/ml)
0.063 <0.01 >0.05
0.125 <0.01 <0.01
0.25 <0.0001 <0.01
0.5 <0.0001 <0.0001
2.5 0.0001 <0.01
5 >0.05 0.01
25 <0.0001 <0.0001
Genistein (fjM)
0.01 0.01 >0.05
0.1 <0.0001 <0.05
1 <0.0001 >0.05
10 <0.01 <0.01
25 <0.01 >0.05
50 <0.0001 <0.0001
100 <0.0001 <0.0001
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5.11.2.3. Acid Phosphatase Assay
The acid phosphatase assay can quantitate cells in culture by determination of intracellular 
enzyme activity (acid phosphatase). This assay was used as a different microtitre assay format (to 
yield benzopyrone cell proliferation inhibitory effects data) for comparison to the MTT microtitre 
assay results (Section 5.11.2.2). Following the removal of the growth medium from cells grown in 96- 
well culture plates, cells are lysed in buffer containing the detergent Triton X-100 and the phosphatase 
substrate p-nitrophenyl phosphate (pNPP). After two hours at 37°C, the reaction is stopped with 
sodium hydroxide, and colour development is determined using a rapid multiwell plate reader. In a 
paper by Connolly et al. (1986), linear activity of the enzyme was demonstrated for cell numbers over 
the range 100 to 10,000 endothelial cells per well. This miniaturised, semiautomated, colorimetric 
assay was used to determine growth curves for endothelial cells in the presence and absence of 
endothelial growth factor from bovine hypothalmus and to monitor fractions during purification of 
growth factors. In the work described in this thesis, the assay was applied to cytotoxicity testing 
(Martin, 1992).
Both 7-hydroxycoumarin and warfarin do not have a significant adverse effect on A549 cells 
over 96 hours in the range 0-50(ig/ml. However, there is a decrease (approximately 50%) in 
proliferation at a concentration of 250|ag/ml for both compounds (Figure 5.25.). There was a gradual 
decrease in proliferation in the A549 cell line when exposed to esculetin (range 0-25fig/ml). At the 
highest drug concentration there was approximately a 70% decrease in cell proliferation when 
compared to control cells with no drug present in the media. Genistein seems to be the most potent of 
all the compounds on A549 cells (Figure 5.26.). There was a significant decrease in cell proliferation 
(approx. 80%) at the highest concentration (100^M) of genistein.
Results were slightly different for MCF-7 cells due to the stimulation of the estrogen receptor 
(ER) present in this cell line by the compounds. Stimulation of the ER promotes cell proliferation and 
is evident with low dose levels of genistein exposed MCF-7 cells. 7-hydroxycoumarin has a 
detrimental effect on proliferation (-55%), which is most apparent in the concentration range 25- 
250fig/ml (Figure 5.27.). Warfarin has a slightly more effective inhibition (-60% decrease in 
proliferation) on MCF-7 cells than A549 cells. This compound may stimulate the estrogen receptor 
(ER) between 0.5 and 2.5|jg/ml (Figure 5.27). However, it inhibits cell proliferation from 5-250pg/ml. 
Esculetin has a similar effect on MCF-7 cells as it did on A549 cells. It is evident from the graph in 
Figure 5.28. that there is approximately 70% decrease in proliferation of MCF-7 cells exposed to 
esculetin. Similar to previous studies (Hsieh et al., 1998; Clarke et al, 2001), it was expected that
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genistein would act like estrogen at low concentrations (0.01 to ljxM). Figure 5.17 illustrates that in 
this concentration range there is a maximum increase of 30% in cell proliferation as compared to 
control cells. At higher concentrations (lO-lOOpM) genistein inhibits cell proliferation by up to 75% 
in comparison to control cells (0 p.g/ml genistein exposure). The significance of any reduction in 
cellular viability was determined using a paired Student’s t-test with confidence limits set at 95%. A 
probability of 0.05 (P<0.05) or less was deemed statistically significant.
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Figure 5.25: Acid phosphatase assay results determining the effect o f 96hr exposure ofbenzopyrones 
on the metabolic activity o f A549 cells. The above graphs represent 96hr exposure to 7- 
hydroxycoumarin (top) and warfarin (bottom) in the concentration range 0-250ng/ml. All drug 
concentrations were tested in five separate wells/plate on three separate occasions. All absorbances 
(405nm) o f test wells were expressed as a percentage o f control well absorbances (Ao). Ao for 7- 
hydroxycoumarin = 0.929 ±  0.027; Ao for warfarin = 0.905 ±  0.023. Only at 250fig/ml exposure to 
both drugs is there a significant decrease in A/Ao values (-50%) indicating a decrease cell 
proliferation due to drug exposure.
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Figure 5.26: Acid phosphatase assay results determining the effect o f 96hr exposure ofbenzopyrones 
on the metabolic activity o f A549 cells. The above graphs represent 96hr exposure to genistein (top) 
and esculetin (bottom) in the concentration range 0-100pM and 0-25fig/ml, respectively. All drug 
concentrations were tested in five separate wells/plate on three separate occasions. All absorbances 
(405nm) o f test wells were expressed as a percentage o f control well absorbances (Ao). Ao for 
genistein = 1.089 ±  0.029; Ao for esculetin = 1.012 ±  0.025.
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Figure 5.27: Acid phosphatase assay results determining the effect o f 96hr exposure o f benzopyrones 
on the metabolic activity o f MCF-7 cells. The above graphs represent 96hr exposure to 7- 
hydroxycoumarin (top) and warfarin (bottom) in the concentration range 0-250jug/ml. All drug 
concentrations were tested in five separate wells/plate on three separate occasions. All absorbances 
(405nm) o f test wells were expressed as a percentage o f control well absorbances (Ao). Ao for 7- 
hydroxycoumarin = 0.852 ±0.031; Ao for warfarin = 0.869 ±_ 0.028.
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Figure 5.28: Acid phosphatase assay results determining the effect o f 96hr exposure o f benzopyrones 
on the metabolic activity o f MCF-7 cells. The above graphs represent 96hr exposure to genistein (top) 
and esculetin (bottom) in the concentration range 0-100pM and 0-250pg/ml, respectively. All drug 
concentrations were tested in five separate wells/plate on three separate occasions. All absorbances 
(405nm) o f test wells were expressed as a percentage o f control well absorbances (Ao). Ao for 
genistein = 0.962 + 0.018; Ao for esculetin = 0.951 ±  0.022. The Biphasic effect o f genistein is 
explained in Section 5.12 and esculetin has a similar effect on MCF-7 cells as is evident on A549 cells 
(Figure 5.26).
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Table 5.8: Significance of the reduction in cellular viability. A probability of 0.05 (P<0.05) or less
was deemed statistically significant.
Compound MCF-7  Significance 
P  Values
A549 Significance 
P  Values
Warfarin (/Jg/ml)
0.25 >0.05 >0.05
0.5 >0.05 >0.05
2.5 >0.05 <0.01
5 >0.05 <0.01
25 <0.01 <0.01
50 <0.01 <0.01
250 <0.01 <0.0001
7-OHC (fig/ml)
0.25 >0.05 >0.05
0.5 <0.05 >0.05
2.5 >0.05 <0.01
5 >0.05 <0.0001
25 <0.01 <0.01
50 <0.01 <0.0001
250 <0.0001 <0.0001
Esculetin (fJg/ml)
0.063 >0.05 <0.01
0.125 >0.05 <0.01
0.25 <0.05 <0.01
0.5 >0.05 <0.05
2.5 <0.0001 >0.05
5 <0.0001 <0.05
25 <0.0001 <0.01
Genistein (fjM)
0.01 >0.05 >0.05
0.1 <0.01 >0.05
1 <0.0001 >0.05
10 <0.0001 >0.05
25 >0.05 <0.0001
50 <0.0001 <0.0001
100 <0.0001 <0.0001
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5.11.2.4. Cytosensor Microphysiometer
An alternative method was used to evaluate the effect of coumarins on cellular metabolism. 
As described in detail in Section 5.3.2, this biosensing instrument determines the extracellular 
acidification rate of cells, which is closely coupled to their basal metabolic rate. Monitoring of cellular 
metabolism is achieved using a pH-sensitive sensor, in ‘real-time’, which offers distinct advantages 
over the end-point nature of the MTT assay, when examining the effect of chemical agents on cellular 
metabolism (Cooke, 1999). The effect of 24hr exposure ofMCF-7 cells to two coumarin compounds 
(warfarin and esculetin) was examined using this technique (Figures 5.29.-5.31.). In these experiments 
the basal metabolic rate of the cells was determined prior to drug-exposure, and this value was 
normalised as 100%. This was achieved for each of the four separate sensor chambers in the 
Cytosensor. Following drug exposure all subsequent metabolic rates were expressed as a percentage of 
the basal rate of the particular sensor chamber, ensuring each chamber with its encased cells acted as 
its own internal control.
Figure 5.29 illustrates the dose-dependent depression of metabolism in MCF-7 cells, on 
exposure of the cells to warfarin over 24hrs. Concentrations required to achieve this were high when 
compared to levels of esculetin (Figure 5.30.). Initially, during the first 4 hours of exposure, 
concentrations of 25 and 50jj.g/ml caused a slight increase in the metabolic rate of the cells, (maximum 
10% and 8%, respectively). This was followed by suppression of metabolism over the 24hrs 
monitored. The metabolic rate of the cells also declined steadily after 2hrs exposure to 1OOpg/ml 
warfarin, and attained a metabolic rate approximately 50% of the basal rate after 24hrs. Figure 5.30. 
illustrates the exposure of MCF-7 cells to a range of esculetin concentrations and the consequent 
depression of basal cellular metabolism as a result. It is obvious from this figure that esculetin 
concentrations greater than 20pg/ml severely damaged the metabolic functioning of cells over a 24hr 
exposure period -  at these concentrations, the metabolism of cells 24hrs post-exposure was only in the 
region of 20% of the basal metabolic rate. At 50 and 100pg/ml the principal damage to the cells 
metabolism occurred within the first ten hours of exposure. At lower concentrations, damage was 
dose- and time-dependent.
In Figure 5.31. the effects of genistein on MCF-7 cells over 24hrs are illustrated. As expected 
from previous results (Section 5.11.2.3.), at the lower concentration range between 0.1-1 (iM, genistein 
acted as a phytoestrogen and increased the metabolic rate above the baseline values throughout the 
24hr exposure. At 0.1 pM genistein the metabolic rate peaked to 50% above normalised baseline 
values between 2-4hrs after exposure to the drug. After this time values leveled off to 20% above the
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baseline values for the remainder of the 24 hr exposure time. At l.OfiM genistein the metabolic rate 
peaked to a higher point of 80% above baseline values over the same time period of between 2-4 
hours. Again levels dropped to 60% above baseline values for the remainder of the 24 hr exposure. 
From the 10-100|xM concentration range, genistein acted as a potent inhibitor of the metabolic rate in 
comparison to control cells. Cells exposed to lOpM genistein showed no significant decrease in 
metabolic rate for the first 10 hrs, after this time the metabolic rate decreased by 30%. For 25|iM 
genistein there was a decrease in metabolic rate by 30% over the 24 hr drug exposure time. Both 
50pM and 1 OOp,M genistein concentrations show similar inhibitory effects on metabolic rate with no 
significant effects observed in the first 12 hrs. From 12 to 24 hours genistein exposure for both 
concentrations there is a sharp decline to nearly 100% inhibition of metabolic rate of the MCF-7 cells 
exposed to genistein.
One of the findings of major importance from the data collected indicated that the cytosensor 
microphysiometer was more sensitive to the effects of the benzopyrones on cellular metabolism than 
the MTT assay. For example, the MTT assay detected a decrease in cellular metabolism of 
approximately 30% when MCF-7 cells were exposed to 20p.g/ml esculetin for 24hrs (Figure 5.32.). 
The cytosensor results indicate that the cellular metabolism in cells exposed to 20|jg/ml esculetin 
decreased by approximately 60% over this time period (Figure 5.32). Experimental data collected to 
determine the effect of genistein on MCF-7 cells over 24hrs confirms the superior sensitivity of the 
cytosensor over the MTT assay format. Genistein is a phytoestrogen and, therefore, one would expect 
to see a biphasic effect on the metabolic rate. The MTT results show very little variation of metabolic 
rate in comparison to control cells over the entire drug range (0-1 OOfiM). However, it is evident from 
Figure 5.32. that the cytosensor illustrates the biphasic result well, resulting in a metabolic rate 
increase in the range of O.l-l.OjxM genistein. At this concentration range the MTT assays indicate a 
mitochondrial dehydrogenase activity decrease, whereas, the cytosensor reveals up to a 60% increase 
in metabolic rate over this drug range. At the higher concentration range (10-100pM) there is a decline 
in metabolic rate to nearly 100% inhibition. This is not apparent from MTT values over the same drug 
range. MTT values show less than 20% decrease in mitochondrial dehydrogenase activity at the 
highest concentration whereas cytosensor values show almost complete inhibition of metabolic rate at 
the same concentration of genistein (Figure 5.32.). The MCF-7 cells exposed to warfarin also show 
differences in values obtained for both the MTT assay and the cytosensor (Figure 5.33). The MTT 
assay results indicate that there is no major suppression of metabolic mitochondrial activity in these 
exposed cells as there is only approximately 20% decrease in metabolism in comparison to control 
cells at 50(^g/ml warfarin. The cytosensor results suggest there is a much higher (than MTT results)
suppression of metabolic rate in comparison to the basal rate as at a concentration of between 50-
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1 OOpg/ml there is approximately 50% decrease in the metabolic rate of exposed cells. It would appear 
from these findings that the cytosensor microphysiometer is a much more sensitive predictor of 
metabolic inhibition (Table 5.9). These results concur with the findings of Cooke (1999) with regard 
to the cell line A431 and further backup the importance of utilising several different assay types when 
investigating the effects of a particular compound on any cell type.
- Ougfrrd Warfarin
- 25ug/ml Warfarin
- 5Qug/ml Warfarin
- 100ug/rtil Warfarin
24 hr Exposure to Warfarin: Cytosensor studies
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Figure 5.29: Exposure ofMCF-7 cells to various concentrations o f warfarin for 24hrs. The above plot 
shows mean o f three experiments conducted on the Cytosensor Microphysiometer, to determine the 
effects o f the drug on cellular metabolism (Section 2.5.5). The cellular acidification rate for each 
sensor chamber was determined prior to drug exposure, using a 4 min pump cycle, with the 
acidification rate measured in the final 30secs. o f this cycle. This rate was normalised at 100% and all 
subsequent acidification rates during drug-exposure expressed as a percentage o f this normalised 
value. These values o f metabolic rate (mean of three experiments) were plotted vs time in the above 
graph.
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Figure 5.30: Exposure ofMCF-7 cells to various concentrations o f esculetin for 24hrs. The above plot 
shows mean o f three experiments conducted on the Cytosensor Microphysiometer, to determine the 
effects o f the drug on cellular metabolism (Section 2.5.5). The cellular acidification rate for each 
sensor chamber was determined prior to drug exposure, using a 4 min pump cycle, with the 
acidification rate measured in the final 30secs. o f this cycle. This rate was normalised at 100% and all 
subsequent acidification rates during drug-exposure expressed as a percentage o f this normalised 
value. These values o f metabolic rate (mean o f three experiments) were plotted vs time in the above 
graph.
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Figure 5.31: Exposure o f MCF-7 cells to various concentrations o f genistein for 24hrs. The above 
plot shows mean o f three experiments conducted on the Cytosensor Microphysiometer, to determine 
the effects o f the drug on cellular metabolism (Section 2.5.5). The cellular acidification rate for each 
sensor chamber was determined prior to drug exposure, using a 4 min pump cycle, with the 
acidification rate measured in the final 30secs. o f this cycle. This rate was normalised at 100% and all 
subsequent acidification rates during drug-exposure expressed as a percentage o f this normalised 
value. These values o f metabolic rate (mean o f three experiments) were plotted vs time in the above 
graph.
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Comparison of 241ir MTT and Cytosensor Values 
following exposure to Esculetin
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Comparison of 241ir MTT and Cytosensor Values 
following exposure to Genistein
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Figure 5.32: Comparison o f values obtainedfrom MTT Assays and Cytosensor Studies on metabolism 
suppression in MCF-7 cells by esculetin (top), and genistein (bottom) following 24hr exposures. This 
is clearly evident in the genistein exposure graph where a metabolic rate increase in the range o f 0.1- 
1.0¡jM  genistein is depicted (cytosensor results-red bars). This estrogenic effect that enhances 
metabolism o f MCF-7 cells due to the presence o f the estrogen receptor is not evident from the MTT 
assay results (blue bars) where cells were exposed to the same concentration range (0.1-1.0/iM 
genistein).
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Comparison of 24hr MTT and Cytosensor Values 
following exposure to Warfarin
1 2 0  n
I MTT - Warfarin 
I Cytosensor - W arfarin
25 50
Concentration of Warfarin (ug/ml)
Figure 5.33: Comparison o f values obtained from MTT Assays and Cytosensor Studies on metabolism 
suppression in MCF-7 cells by warfarin, following 24hr exposures. The Cytosensor studies are more 
sensitive in the prediction o f metabolism perturbations (Table 5.9). Section 4.12 explains the cell 
proliferation overestimation evident at the highest warfarin concentration (MTT results).
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Table 5.9: Significance o f difference in sensitivity between the cytosensor microphysiometer and MTT 
assay. A probability o f 0.05 (P<0.05) or less was deemed statistically significant.
Compound MCF-7 Significance 
P Value
Warfarin (fjg/ml)
25 <0.05
50 <0.01
100 <0.01
Esculetin (pg/ml)
2 <0.01
5 <0.01
10 0.01
20 <0.01
50 <0.01
100 <0.01
Genistein (¡jM)
0.1 0.01
1 <0.01
10 <0.05
25 <0.05
50 <0.0001
100 <0.01
5.11.3. Reversibility Studies with the Cytosensor Microphysiometer
Previous reversibility studies of the effects of the benzopyrones on cultured cells have utilised 
proliferative-based assessments to determine whether cells could recover from exposure to these 
compounds (Egan et al., 1997; Finn et al., 2002). In most instances, this type of experiment entailed a 
period of drug exposure, followed by a drug-free recovery growth period for a subpopulation of the 
original exposed cells. This introduces an element of selection into the reversibility study, i.e.- 
outgrowth of a subpopulation of drug-resistant cells could account for the appearance of a “reversible 
effect”.
It is, therefore more desirable to assess the recovery of cells exposed to benzopyrones using an 
alternative method, preferably internally controlled, to avoid the above problems of subpopulation 
selection. The cytosensor is an ideal instrument for such an experiment- each sensor chamber, with its
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encased cells, acts as its own internal control. During exposure of cells to a compound, the metabolic 
rate of the cells is compared to the metabolic rate of the same sample of cells prior to exposure; during 
a recovery period the same complete sample of exposed cells, not a subpopulation, are allowed to 
recover, and again their metabolic rate during recovery is compared to the original metabolic rate. This 
allows for the complete and valid assessment of the reversibility of the effects of a compound on the 
cells metabolism.
Reversibility studies were completed for esculetin, warfarin and genistein. Various exposure / 
recovery periods were assessed, the results of which are shown in Figures 5.34-5.39. The recovery of 
MCF-7 cells from exposure to warfarin was assessed following both 4hr and 24hr (Figure 5.34. & 
5.37.) periods. The effects of warfarin on cellular metabolism have been described in Section 5.11.2.2. 
and were not as significantly inhibitory in comparison to esculetin and genistein even at the high 
concentrations used. MCF-7 cells were exposed to warfarin at various concentrations (O-lOOpg/ml) for 
4hrs, after this time the cells were allowed to recover by exposure to normal running media with out 
warfarin for a further 4hrs. At the highest concentration (100|ig/ml) there was a slight drop in 
metabolic rate (approximately 5%), however once the drug-containing media was removed there was 
no sign of recovery over the following 4hrs. When cells were exposed to 50 i^g/ml warfarin for 4hrs 
there was a slight decrease in metabolic rate to approximately 4% (the same was evident for 20|j.g/ml 
exposure over 4hrs). After drug-containing media was removed the cells recovered to their pre­
exposure levels, for both 50ng/ml and 20pg/ml pre-exposed MCF-7 cells. Cells were then exposed to 
warfarin for 24hrs and this was followed by a 24hr recovery period where cells were exposed to drug- 
free media. The metabolic rate of the cells declined steadily after 24hrs exposure to 100^g/ml 
warfarin, and attained a metabolic rate approximately 40% below the basal rate. Exposure to 50(xg/ml 
warfarin has similar inhibitory effect on the metabolic rate after 24hrs (Figure 5.37.). However, during 
the following 24hr recovery period there is significant recovery of metabolic rate (to basal metabolic 
levels) for cells pre-exposed to 50(J.g/ml warfarin but not to 100(j.g/ml warfarin where the metabolic 
rate continues to drop to approximately 60% below the basal metabolic rate. Recovery of metabolic 
rate is also apparent in cells pre-exposed to 20pg/ml warfarin with metabolic rate reaching levels that 
are slightly higher (a maximum of 10%) than the basal metabolic rate. It is therefore, evident that 
recovery of MCF-7 cells from warfarin exposure is both dose-and time-dependent.
Reversibility studies were also completed for MCF-7 cells exposed to esculetin at various
concentrations (O-lOOjag/ml) over 4hrs and 24hrs (Figure 5.35. & 5.38. respectively). 4hr exposure to
esculetin concentrations in the range 20-100fig/ml caused a suppression of cellular metabolism that
was both dose-dependent and reversible as illustrated in Figure 5.35. However, following 24hrs of
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esculetin exposure, the ability to recover from such severe metabolic suppression (e.g. approx. 80% 
decrease in metabolic rate in comparison to basal levels) was lost by the cells at all concentrations 
tested (2-100pg/ml). Data obtained from reversibility studies accomplished with genistein and MCF-7 
cells are shown in Figures 5.36. & 5.39. 4 hr exposure of cells to genistein in the range (50-100pM) 
caused approximately 10% decrease in metabolic rate in comparison to the basal metabolic rate. 
However, it is evident from Figure 5.36. that no significant recovery took place once the cells were 
exposed to drug-free media. As expected at the lowest concentration of l.O^M genistein there was an 
increase in metabolic rate as genistein exerted its estrogen like effect on the estrogen responsive MCF- 
7 cell line. Exposure of these cells to drug-free media caused a slight decrease in metabolic rate as the 
estrogen receptor is no longer stimulated by genistein. Following 24hrs of genistein exposure (50- 
100pM) the results are similar to esculetin in that the cells lost their ability to fully recover from 
severe metabolic suppression. Again when cells are exposed to l.OpM genistein there is an increase in 
metabolic rate by ~ 60% and like 4hr exposure when cells are introduced to drug-free media there is a 
decrease in metabolic rate close to basal metabolic levels due to lack of ER stimulation.
The results obtained in these cytosensor studies indicate that the suppression of cellular 
metabolism in MCF-7 cells exposed to benzopyrones such as esculetin and genistein is not fully 
reversible following prolonged (24hr) exposure. In previous studies by Cooke, (1999) esculetin was 
found to irreversibly suppress metabolism in A431 cells over 24hrs. These findings correlate well with 
the results presented in this study with MCF-7 cells. Since warfarin does not significantly suppress the 
metabolism of exposed cells over 4hrs there is no significant difference in metabolic rate during 
warfarin exposure or recovery. Over 24hrs warfarin has an effect on the metabolism of exposed cells 
(Figure 5.37.), however, only the highest concentration (lOOpg/ml) irreversibly suppresses the 
metabolism of the MCF-7 cells tested.
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4hr Reversibility Studies with Warfarin
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Figure 5.34: Exposure o f MCF-7 cells to various concentrations o f warfarin for 4hrs, followed by a 
further 4hrs period o f recovery in drug-free medium. The above plot shows the mean of three 
experiments conducted on the Cytosensor Microphysiometer, to determine the reversibility o f the 
effects o f the drug on cellular metabolism. In individual experiments, the cellular acidification rate for 
each sensor chamber was determined prior to drug exposure, using a 4 min pump cycle, with the 
acidification rate measured in the final 30secs. o f this cycle. This rate was normalised at 100% and all 
subsequent acidification rates during exposure and recovery periods were expressed as a percentage 
of this normalised value. These values o f metabolic rate (mean o f three experiments) were plotted vs 
time in the above graph (same conditions for all experiments Figure 5.33-5.38). At the highest 
concentration (lOOjug/ml) there was a minor decline in metabolic rate (~5%). However, once the drug 
media was removed there was no sign o f recovery over the following 4hrs. When cells were exposed to 
20- 50fjg/ml warfarin for 4hrs there was a slight decrease in metabolic rate to ~4%. After drug media 
was removed the cells recovered to their pre-exposure levels, for both 50/j.g/ml and 20/j.g/ml pre­
exposed MCF-7 cells.
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Figure 5.35: Exposure o f MCF-7 cells to various concentrations o f esculetin for 4hrs, followed by a 
further 4hrs period o f recovery in drug-free medium. The above plot shows the mean o f three 
experiments conducted on the Cytosensor Microphysiometer, to determine the reversibility o f the 
effects o f the drug on cellular metabolism. 4hr exposure to esculetin concentrations in the range 20- 
100fig/ml caused a suppression o f cellular metabolism that was both dose-dependent and reversible 
as illustrated in the above graph.
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4hr Reversibility Studies with Genistein
Time (hours)
Figure 5.36: Exposure o f MCF-7 cells to various concentrations o f genistein for 4hrs, followed by a 
further 4hrs period o f recovery in drug-free medium. The above plot shows the mean o f three 
experiments conducted on the Cytosensor Microphysiometer, to determine the reversibility o f the 
effects o f the drug on cellular metabolism. 4 hr exposure o f cells to genistein in the range (50-100pM) 
caused -10% decrease in metabolic rate in comparison to the basal metabolic rate. However, it is 
evident from the above graph that no significant recovery took place once the cells were exposed to 
drug-free media. As expected at the lowest concentration o f 1.0pM genistein there was an increase in 
metabolic rate as genistein exerted its estrogenic effect on the estrogen-responsive MCF-7 cell line. 
Exposure o f these cells to drug-free media caused a slight decrease in metabolic rate as the estrogen 
receptor is no longer stimulated by genistein.
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Figure 5.37: Exposure o f MCF-7 cells to various concentrations o f warfarin for 24hrs, followed by a 
further 24hrs period o f recovery in drug-free medium. The above plot shows the mean of three 
experiments conducted on the Cytosensor Microphysiometer, to determine the reversibility o f the 
effects o f the drug on cellular metabolism. The metabolic rate o f the cells declined steadily after 24hrs 
exposure to 100fig/ml warfarin, and attained a metabolic rate — 40% below the basal rate. Exposure 
to 50jig/ml warfarin had a similar inhibitory effect on the metabolic rate after 24hrs. However, during 
the following 24hr recovery period there is significant recovery o f metabolic rate (to basal metabolic 
levels) for cells pre-exposed to 50fig/ml warfarin but not to 100fig/ml warfarin where the metabolic 
rate continues to drop to -60% below the basal metabolic rate. Recovery o f metabolic rate is also 
apparent in cells pre-exposed to 20/jg/ml warfarin with metabolic rate reaching levels that are slightly 
higher (a maximum -10%) than the basal metabolic rate. It is evident that recovery of MCF-7 cells 
from warfarin exposure is both dose-and time-dependent. During the subsequent 10 hours after the 
initial 24 hour exposure to warfarin there is a sharp increase followed by a steady decrease in 
metabolic rate. This increase may represent activation o f an ATP-coupled transporter protein e.g. the 
P-glycoprotein, which results in the efflux o f drug from the intracellular environment. Prolonged 
exposure to high drug concentrations overcomes this efflux mechanism
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Figure 5.38: Exposure o f MCF-7 cells to various concentrations o f esculetin for 24hrs, followed by a 
further 24hrs period o f recovery in drug-free medium. The above plot shows the mean o f three 
experiments conducted on the Cytosensor Microphysiometer, to determine the reversibility o f the 
effects o f the drug on cellular metabolism. Following 24hrs o f esculetin exposure, the ability to 
recover from such severe metabolic suppression (e.g. -80% decrease in metabolic rate in comparison 
to basal levels) was lost by the cells at all concentrations tested (2-100pg/ml).
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Figure 5.39: Exposure o f MCF-7 cells to various concentrations o f genistein for 24hrs, followed by a 
further 24hrs period of recovery in drug-free medium. The above plot shows the mean o f three 
experiments conducted on the Cytosensor Microphysiometer, to determine the reversibility o f the 
effects o f the drug on cellular metabolism. Following 24hrs o f genistein exposure (50-100pM) the 
results are comparable to esculetin as the cells lost their ability to fully recover from severe metabolic 
suppression. When cells are exposed to 1.0pM genistein there is an increase in metabolic rate by 
approximately 60%. Similar to the results illustrated in Figure 5.35 there is a decrease in metabolic 
rate (due to lack o f ER stimulation.) close to basal metabolic levels as cells are introduced to drug- 
free media.
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5.11.4. ELISA-Detection o f Tyrosine Phosphorylation inM CF-7 Cells
As outlined in Section 5.9. it was decided to examine the effect of esculetin and warfarin, on 
total tyrosine phosphorylation in intact MCF-7 cells. An ELISA-based system was used to achieve 
this. The ELISA used was adapted from the method of Cooke (1999), where it had been used to 
determine the effect of 7-hydroxycoumarin and esculetin on tyrosine phosphorylation in A431 cells. 
This cell line is known to over express the EGF-R. When serum-starved A431 cells are exposed to 
EGF, their signalling pathways become activated, and the overall levels of phosphorylated tyrosine (P- 
Tyr) within the cells increase. Although the MCF-7 cell line does not over express the EGF-R it is 
present at lower levels than the ER. Therefore, an increase in P-Tyr levels was expected to be evident 
for MCF-7 cells stimulated with EGF, like the A431 cells. The phosphorylated tyrosines can be 
detected in an ELISA-system using anti-phosphotyrosine antibodies. If the cells are exposed to 
tyrosine kinase inhibitors, and then stimulated with EGF, the increase in P-Tyr should be diminished 
in inhibitor-treated cells compared to control cells.
Initial experiments were necessary as a number of parameters needed to be optimised (e.g. 
Cell seeding density, EGF concentration). The optimised ELISA parameters are shown in Table 5.10. 
The effect of esculetin and warfarin on growth factor stimulated tyrosine phosphorylation was then 
determined, following pre-exposure periods of 1 and 6 hours. Genistein a well-known tyrosine kinase 
inhibitor was used as a positive control in this experiment. In all experiments, increases in P-Tyr levels 
in drug-treated cells were compared to P-tyr increases in control cells, with diminished increases 
illustrating tyrosine kinase inhibition. The results of these experiments are shown in Tables 5.11.-5.16. 
and Figures 5.40.-5.45. Tables 5.15-5.16 and Figures 5.44-5.45. illustrates the results for genistein the 
positive control. After 1 hour pre-exposure, genistein caused a slight inhibition of tyrosine 
phosphorylation EGF stimulated MCF-7 cells, with 18% inhibition at the highest concentration tested 
(100|ig/ml). Increasing the genistein pre-exposure time to 6 hours caused a major augmentation of this 
effect, with approximately 40% inhibition of P-Tyr levels at the highest concentration (100pg/ml).
Tables 5.13.-5.14 and Figure 5.42.-5.43 illustrates the results following stimulation of P-Tyr 
in MCF-7 cells pre-exposed to warfarin. 1 hour pre-exposure to warfarin lead to little or no difference 
in P-Tyr levels as a 2% decrease at the highest concentration (100pg/ml) is not significant in 
comparison to control cells. 6 hour pre-exposure of cells to warfarin lead to a slight decrease (approx. 
6% at 100jig/ml ) of P-Tyr levels. Tables 5.11.-5.12 and Figure 5.40.-5.41 illustrate the results for 
esculetin. 1 hour pre-exposure of MCF-7 cells to esculetin followed by stimulation with EGF did not 
affect cellular tyrosine phosphorylation levels as even at the highest concentration there was only a
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slight decrease of ~ 8% at 100|xg/ml. However, increasing esculetin pre-exposure time to 6 hours, 
caused a decrease in P-Tyr levels up to 20% inhibition at the highest concentration tested (100(j.g/ml).
These results indicate that only esculetin inhibits growth factor-stimulated tyrosine 
phosphorylation by up to 20%. Warfarin is a less potent inhibitor of cell proliferation and metabolic 
activity than esculetin (Section 5.11.1, Section 5.11.2.2. & 5.11.2.4.) and this maybe partly due to the 
fact that it shows no significant tyrosine phosphorylation inhibition in comparison to both esculetin 
and genistein. Neither esculetin nor warfarin prevented phosphorylation with the efficiency of 
genistein the positive control (maximal effect 40% inhibition at 100|ig/ml, following 6 hour pre­
exposure). The ELISA-based system yielded no information on the effects of the compounds on 
tyrosine kinase activity. Therefore, the cytosensor microphysiometer was employed for this research. 
Experimental details are described in Section 2.5.6.2. and involve pre-exposure of MCF-7 cells to 
either warfarin or esculetin (0-20pg/ml) for either 1 or 6 hours prior to EGF (200ng/ml) stimulation. If 
either warfarin or esculetin inhibit the signal transduction of metabolically active MCF-7 cells a 
decrease in EGF stimulated metabolic rate should be evident (Figure 5.44-5.45).
Table 5.10: Optimised parameters for the ELISA-based assessment o f tyrosine phosphorylation in 
EGF-stimulatedMCF-7 cells.
Variable Examined Optimal Conditions
Cell Seeding Density 5 X 104 cells/well
EGF Concentration 200ng/ml. 15 mins.
ELISA Blocking Conditions 1.5 hrs @ 37°C, 10%FCS,
0.2% Tween-20 in Tris-Buffered Saline.
Primary Ab (Anti-Phosphotyrosine Exposure 1/750 Dilution 
Ihr @ 37°C
Secondary Ab (AP-labelled Anti-Mouse IgG) 1/1500 Dilution
Exposure Ihr @ 37°C
The significance of any inhibition (by esculetin, warfarin or genistein) of growth factor- 
stimulated tyrosine phosphorylation was determined using a paired Student’s t-test with confidence 
limits set at 95%. A probability of 0.05 (P<0.05) or less was deemed statistically significant.
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Table 5.11: ELISA results: Esculetin inhibition of tyrosine phosphorylation in MCF-7 cells
Concentration of 
Esculetin (jig/ml)
lhr Drug Pre-exposure Significance 
P Value
0 100.00 ±  1.35 -
2 98.18 ± 1.90 >0.05
10 92.04 + 0.75 <0.01
20 93.57 + 0.92 0.01
50 94.29 ±0.87 0.01
100 91.14 ± 1.84 <0.01
0 2 10 20 50 100
Drug Concentration (ug/ml)
Figure 5.40: Bar Chart illustrating the inhibition o f tyrosine phosphorylation in EGF-stimulated 
MCF-7 cells by esculetin (lhr pre-exposure) All experiments involved drug samples replicated four 
times (n=4), and were carried out on three separate occasions (Section 2.2.6.3). The drug-treated 
cells absorbance values were normalised vs absorbances o f untreated control cells. Control 
absorbance (0 pg/ml Drug/no drug pre-exposure) = 0.896 ±  0.035.
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Table 5.12: ELISA results: Esculetin inhibition of tyrosine phosphorylation in MCF-7 cells
Concentration of 
Esculetin (|ig/ml)
6h r D ru g  P re-exp osu re Significance 
P Value
0
2
10
20
50
100
1 0 0 . 0 0 +  1.48 
9 1 . 0 7 +  1.21
84.38 + 0.98 
8 8 . 3 9 +  1.76
84.38 ±  1.39 
83.48 + 1.05
<0.01
<0.0001
<0.0001
<0.0001
<0.0001
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Figure 5.41: Bar Chart illustrating the inhibition o f tyrosine phosphorylation in EGF-stimulated 
MCF-7 cells by esculetin (6hr pre-exposure) All experiments involved drug samples replicated four 
times (n=4), and were carried out on three separate occasions (Section 2.2.6.3). The drug-treated 
cells absorbance values were normalised vs absorbances o f untreated control cells. Control 
absorbance = 0.848 ±0.041.
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Table 5.13: ELISA results: Warfarin inhibition of tyrosine phosphorylation in MCF-7 cells
Concentration of 
Warfarin (jig/ml)
lhr Drug Pre-exposure Significance 
P Value
0 1 0 0 . 0 0 +  1.08 -
2 100.30 + 2.57 >0.05
10 9 4 . 5 0 +  1.61 <0.05
20 101.67 ± 2 . 7 7 >0.05
50 99.93 + 1.68 >0.05
100 98.32 ±  1.26 >0.05
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Figure 5.42: Bar Chart illustrating the inhibition o f tyrosine phosphorylation in EGF-stimulated 
MCF-7 cells by warfarin (lhr pre-exposure) All experiments involved drug samples replicated four 
times (n=4), and were carried out on three separate occasions (Section 2.2.6.3). The drug-treated 
cells absorbance values were normalised vs absorbances o f untreated control cells. Control 
absorbance = 1.225 + 0.027.
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Table 5.14: ELISA results: Warfarin inhibition of tyrosine phosphorylation in MCF-7 cells
Concentration of 
Warfarin (fig/ml)
6hr Drug Pre-exposure Significance 
P Value
0 100.00 + 2.51 -
2 100.25 + 2.49 >0.05
10 102.30 + 2.93 >0.05
20 99.50 + 2.74 >0.05
50 96.80+ 1.87 <0.05
100 94.65 ± 1.03 <0.05
2 10 20 50
Drug Concentration (ug/ml)
100
Figure 5.43: Bar Chart illustrating the inhibition o f tyrosine phosphorylation in EGF-stimulated 
MCF-7 cells by warfarin (6hr pre-exposure) All experiments involved drug samples replicated four 
times (n=4), and were carried out on three separate occasions (Section 2.2.6.3). The drug-treated 
cells absorbance values were normalised vs absorbances o f untreated control cells. Control 
absorbance = 0.985 + 0.03.
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Table 5.15: ELISA results: Genistein inhibition of tyrosine phosphorylation in MCF-7 cells
Concentration of 
Genistein (¿ig/ml)
lhr Drug Pre-exposure Significance 
P Value
0 100.00 ± 2 . 3 1 -
2 82.09 ± 3 . 1 5 <0.0001
10 76.60 ± 2 . 5 4 <0.0001
20 87.14 ±  1.05 <0.0001
50 85.83 ±  1.89 <0.0001
100 82.41 ±  1.83 <0.0001
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Figure 5.44: Bar Chart illustrating the inhibition o f tyrosine phosphorylation in EGF-stimulated 
MCF-7 cells by genistein (lhr pre-exposure) All experiments involved drug samples replicated four 
times (n=4), and were carried out on three separate occasions (Section 2.2.6.3). The drug-treated 
cells absorbance values were normalised vs absorbances o f untreated control cells. Control 
absorbance = 0.741 + 0.034.
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Table 5.16: ELISA results: Genistein inhibition of tyrosine phosphorylation in MCF-7 cells
Concentration of Genistein 
(Ug/ml)
6hr Drug Pre-exposure Significance 
P Value
0 100.00 ±02.48 -
2 54.21 ±0.38 <0.0001
10 51.64 ±0.65 <0.0001
20 65.36 ±0.96 <0.0001
50 67.86 ±0.68 <0.0001
100 60.79 ±0.59 <0.0001
1 1 1 1 1
2 10 20 50 100
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Figure 5.45: Bar Chart illustrating the inhibition o f tyrosine phosphorylation in EGF-stimulated 
MCF-7 cells by genistein (6hr pre-exposure) All experiments involved drug samples replicated four 
times (n=4), and were carried out on three separate occasions (Section 2.2.6.3). The drug-treated 
cells absorbance values were normalised vs absorbances o f untreated control cells. Control 
absorbance = 0.919 + 0.037.
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The Cytosensor Microphysiometer system has proven to be a powerful tool for receptor 
discovery and characterisation and can rapidly and reliably measure cell surface receptor activation. 
The flexibility of this system is due to its measurement of the extracellular acidification rate (ECAR). 
Fluctuation in cellular acid excretion is a physiological consequence of receptor activation for all 
classes of cell surface receptors examined so far. A major advantage of this system is the ability to 
examine receptor interactions using intact, viable cells, which is an essential condition for evaluating 
drugs directed at intracellular targets. The cytosensor microphysiometer has been used in the past to 
dissect various cellular signalling pathways e.g. research stimulation of proton efflux from 
chondrocytic cells by EGF. The cytosensor has also been used to examine signal transduction of 
neurohormones. Therefore, we chose to use this instrument to examine the effect of esculetin and 
warfarin on EGF-stimulated pathways in MCF-7 cells. The cytosensor is an attractive method for 
examining inhibition of EGF-RTK in MCF-7 cells for two reasons:
1. The study was carried out in intact cells, thereby eliminating worries about receptor stability.
2. Downstream signalling events could be observed concurrently, thereby yielding more information 
per experiment.
The EGF-stimulation of EGF-RTK in serum-starved MCF-7 cells had to be optimised, as a 
higher concentration of EGF was required to stimulate these cells than A431 cells. This is due to the 
fact that the EGF-R although present in MCF-7 cells it is found in low amounts as there are higher 
levels of ER present (Section 5.5.5.). Maximal stimulation of the cells was with 200ng/ml EGF and 
this concentration was used in all subsequent experiments. As illustrated in Figure 5.46. exposure of 
MCF-7 cells to 200ng/ml of EGF caused an increase in the acidification rate of the cells, to a peak of 
25% above baseline values. This peak in acidification rate was transient and acidification rate dropped 
to approximately 5% below baseline values. The initial rise in acidification rate is principally due to 
the activation of the EGF-Receptor-associated tyrosine kinase activity, as it can be blocked by pre­
exposure of cells to the tyrosine kinase inhibitor genistein, for 1 hour or 6 hours, respectively.
Figure 5.46. portrays the activation of EGF-RTK in cells pre-exposed to esculetin for 1 or 6 
hours. Pre-exposure of MCF-7 cells to 20pg/ml esculetin prior to EGF stimulation, caused a slight 
decrease (approx. 10%) in the peak activation of EGF-RTK. However the metabolic rate continued to 
drop to approximately 15 % below baseline levels and this may indicate a block in the signalling
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5.11.5. Cytosensor Microphysiometer Studies into Tyrosine Kinase
Inhibition
pathway downstream of the EGF-RTK. 6 hours pre-exposure of the cells to 20fig/ml esculetin prior to 
EGF stimulation, caused a decrease (approx. 15%) in the peak activation of EGF-RTK. Again, the 
esculetin-treated cells metabolic rate continued to drop to 20 % below baseline levels suggesting a 
downstream block of EGF-stimulated signalling pathway.
As shown in Figure 5.47, lhr pre-exposure of cells to 20fig/ml warfarin did not block 
activation of the EGF-RTK. However, warfarin results were similar to esculetin 1 hr pre-exposure, as 
there was a continued drop in metabolic rate to approximately 15% below baseline values. After 6 
hour pre-exposure to warfarin there was approximately 5% decrease in peak activation of EGF-RTK. 
The observed results correlate well with the ELISA-TK results of Section 5.11.4. Both sets of results 
show that esculetin has the ability to inhibit both tyrosine phosphorylation and its kinase activity, 
whereas warfarin shows no ability to block tyrosine phosphorylation or inhibit its kinase activity. 
Although the results show some similarity to the work carried out by Cooke (1999) there are some 
significant differences. This is most likely due to the different cell lines used. The A431 cell line over­
expressed the EGF-R and due to this the peak acidification rates (although transient like in MCF-7 
cells) were much higher, stimulation of cells with 100ng/ml EGF gave a peak rate of approximately 
80% above the baseline values. The cells maintained a higher metabolic rate of approximately 30% 
above the baseline in A431 cells whereas MCF-7 cells metabolic rate dropped below the base line. In 
MCF-7 cells the main mitogenic receptor of importance is the ER, which is at much higher levels than 
EGF-R. In this experiment MCF-7 cells were not exposed to E2 a well-known mitogenic activator of 
the ER. Therefore MCF-7 cells stimulated by EGF could indirectly activate the nuclear ER by 
phosphorylation of Ser 118 through MAP-K and PI3-K pathways. However from the results it seems 
that by blocking EGF-R phosphorylation the cross-talk between the EGF-R and ER is also blocked. 
This could explain why there is a drop in metabolic rate after the peak has been reached because the 
cross-talk is necessary to maintain the basal metabolic rate. Signal transduction through ERK may 
indirectly influence cell biologic functions via the transactivation of target genes. This was thought to 
be the exclusive function of the nuclear ER (Glass et al., 1997; Halachmi et al., 1994), but examples 
are emerging that signalling from the membrane has a similar role. One established mechanism is that 
growth factor receptors for EGF or IGF can stimulate ERK, leading to the phosphorylation of Ser 118 
of the nuclear ER (Bunone et al., 1996). This provides a means by which growth factor signalling 
transactivates genes, via ER in the absence of E2 and defines the importance of cross-talk between 
EGF-R and ER. As stated above, the decrease may be due to downstream block in signalling pathway, 
which is most likely ERK and nuclear ER phosphorylation in MCF-7 cells. A431 cells do not have the 
ER present and, therefore, there is no cross talk and metabolic rates remain higher than those of MCF-
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7 cells. The rates may also be higher due to the higher levels of EGF-R in A431 cells than MCF-7 
cells.
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Figure 5.46: Exposure o f MCF-7 cells to esculetin for different time periods, prior to stimulation with 
200ng/ml EGF. The above plot shows the experiment conducted on the Cytosensor Microphysiometer 
to determine the effect o f esculetin exposure on the activation o f the EGF-RTK in MCF-7 cells. 
Genistein was included as a positive tyrosine kinase inhibitor control. In individual experiments, the 
cellular acidification rate for each sensor chamber was determined prior to EGF exposure, using a 2 
min cycle, with the acidification rate measured in the final 30 secs, o f this cycle. This rate was 
normalised at 100% and all subsequent acidification rates during and following EGF exposure were 
expressed as a percentage o f this normalised value. These values o f metabolic rate (mean o f three 
experiments) were plotted vs time in the above graph.
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Figure 5.47: Exposure o f MCF-7 cells to warfarin for different time periods, prior to stimulation with 
200ng/ml EGF. The above plot shows the experiment conducted on the Cytosensor Microphysiometer 
to determine the effect o f warfarin exposure on the activation o f the EGF-RTK in MCF-7 cells. 
Genistein was included as a positive tyrosine kinase inhibitor control. In individual experiments, the 
cellular acidification rate for each sensor chamber was determined prior to EGF exposure, using a 2 
min cycle, with the acidification rate measured in the final 30 secs, o f this cycle. This rate was 
normalised at 100% and all subsequent acidification rates during and following EGF exposure were 
expressed as a percentage o f this normalised value. These values o f metabolic rate (mean o f three 
experiments) were plotted vs time in the above graph.
5.11.6. DNA Synthesis Studies
Incorporation of radioactive thymidine is a widely used method to quantify initiation of DNA
synthesis by exogenous growth factors, hormones, drugs or other agents in cell culture. Measurement
of DNA synthesis with the [3H]-thymidine assay is considered as the ‘gold standard’ for the
assessment of cell growth. Unfortunately this assay has several disadvantages, which have prompted
the development of viable non-radioactive alternatives to measure DNA synthesis or cell proliferation
in cultured cells. An important development has been the replacement of the [3H]-thymidine assay by
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the BrdU ELISA. This assay technique is based on the incorporation of the pyrimidine analogue BrdU 
instead of thymidine into the DNA of proliferating cells. In other words BrdU has the ability to label 
cell in the S-phase of the cell cycle. After its incorporation into DNA, BrdU is detected by ELISA. 
Finn et al., (2002) have shown that DNA synthesis is decreased in human renal carcinoma cells 
exposed to 6-nitro-7-hydroxycoumarin and 7,8-dihydroxycoumarin. BrdU incorporation assays 
showed that both agents had a concentration-dependent inhibitory effect on DNA synthesis.
It can be seen from Figure 5.48. that all compounds tested seem to affect DNA synthesis of 
MCF-7 cells. These cells were exposed to warfarin, esculetin or genistein over 96 hours. The 
microtitre assays for determining the effect of the benzopyrones on proliferation and metabolism 
indicated that warfarin has the least inhibitory effect on both cell lines examined. Therefore, as 
expected, warfarin had the least inhibitory effect on DNA synthesis. At the highest concentration of 
lOOpg/ml there was approximately 20% decrease in DNA synthesis levels compared to control cells. 
Both esculetin and genistein showed time and dose-dependent inhibitory effects on DNA synthesis. At 
the highest concentration of esculetin there was approximately 80% inhibition of DNA synthesis in 
MCF-7 cells. There was a sharp decrease in DNA synthesis between 1-lOp.g/ml esculetin. Genistein 
(as anticipated) at the lower concentration range (upwards to ~1 ng/ml) yielded a slight increase in 
DNA synthesis. This is due to the fact that genistein is a phytoestrogen (Section 5.12.) and can 
stimulate the ER in MCF-7 cells at low concentrations. At the higher concentration range between 1- 
13.5pg/ml there is a sharp decline in DNA synthesis with an inhibition of approximately 75-80% at 
the highest concentration tested (13.5p.g/ml).
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Figure 5.48: Exposure ofMCF-7 cells to various concentrations o f genistein, warfarin and esculetin 
for 96 hrs. This time period was chosen for the reasons outlined in Section 5.12. Optimal assay 
duration for human cell lines should be a minimum o f 4 days to allow for cell death and loss of 
intracellular activities. The MTT assay was the only microtitre assay performed with drug exposure 
over 24hrs in order for direct comparison to the 24hr cytosensor assays (Section 5.11.2.4; Figure 
5.32-5.33).
5.12. Conclusions
In this chapter the effect of benzopyrones (warfarin, 7-hydroxycoumarin, esculetin, and 
genistein) on the growth and metabolism of human tumour cells (MCF-7 & A549) was examined. 
Signal transduction studies were also performed in order to obtain information regarding the 
mechanism of action of warfarin, esculetin and genistein on MCF-7 cells. Signalling studies focused 
on this cell line due to its possession of the ER, which can be stimulated by mitogens such as EGF and 
estradiol (E2).
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Proliferation assays yielded some interesting information on growth inhibition by 
benzopyrones:
1. The potency of growth inhibition by genistein was greater than esculetin, which, in turn was 
greater than warfarin.
2. MCF-7 cells tested were quite sensitive to the effects of all three compounds.
3. A549 cells did not seem to be as sensitive to the effects of all three compounds in comparison 
to MCF-7 cells. However both genistein and esculetin displayed significant inhibitory effects 
on A549 cells.
Assessment of leakage of a wide variety of enzymes has been used for cytotoxicity testing 
endpoints. Lactate dehydrogenase (LDH) is a convenient marker because of the stability of the 
enzyme activity in the culture system (Martin, 1992). In this study none of the four compounds tested 
(warfarin, 4-hydroxywarfarin, esculetin and 7-hydroxycoumarin) caused significant membrane 
damage in both cell lines (MCF-7 and A549) assessed by LDH assay. There are some drawbacks that 
should be noted when using the LDH assay. If serum contaminates the system with endogenous 
enzymes they can mask low levels of leached enzymes, which leads to underestimation of LDH 
present. The main drawback of this assay however, is its reliance on the premise that membrane 
integrity and cellular viability are closely linked. This is not always the case, at least in the early stages 
of cell death; so these assays may not always be true / sensitive indicators of viability. Therefore, other 
assays (MTT, AP) must be performed in order to obtain a complete picture of the effects of 
benzopyrones on cells under investigation.
The effects of four compounds (warfarin, 7-hydroxycoumarin, esculetin, and genistein) on 
cellular metabolism was examined using the MTT assay and the cytosensor (where only warfarin and 
esculetin have been tested on MCF-7 cells). However, the cytosensor method proved to be more useful 
than the MTT assay.
An important result evident from the data collected, was the fact that the Cytosensor 
Microphysiometer was more sensitive to the effects of the benzopyrones on cellular metabolism than 
the MTT assay. For example, the MTT assay detected a decrease in cellular metabolism of ~ 30% 
when MCF-7 cells were exposed to 20pg/ml esculetin for 24hrs (Figure 5.32.). According to the 
cytosensor results, the cellular metabolism in cells exposed to 20(ig/ml esculetin decreased by 
approximately 60% over this time period. In fact it would appear from comparing the MTT and 
Cytosensor results for warfarin, esculetin and genistein (Figure 5.32 & 5.33), that the Cytosensor
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Microphysiometer is a much more sensitive predictor of metabolic inhibition. These results support 
previous indications that the cytosensor possesses superior sensitivity in comparison to the MTT assay 
(Cooke & O’Kennedy, 1999).
The reason for this is unclear but may be coupled to the fact that the MTT assay relies on the 
activity of just one group of mitochondrial enzymes to predict adverse effects on metabolism, and in 
doing so may underestimate metabolic effects. The MTT assay has been shown to underestimate the 
growth inhibitory effects of interferons (IFNs) in the past (Jabbar et al., 1989). Formazan production 
can also be induced by drugs that cause perturbations of the cell cycle (Supino, 1985). Cells have also 
been observed to metabolise the tetrazolium dye when lethally damaged and have lost the ability to 
exclude vital dyes (Maehara et al., 1987). It should be noted that previous studies have shown optimal 
assay duration for human cell lines is a minimum of four days to allow for cell death and loss of 
dehydrogenase activity, with a maximum of seven days to obviate the necessity for refeeding cultures 
(Martin. 1992). The MTT assay was performed over 24 hrs (necessary for direct comparison to the 
24hr cytosensor assay) and can only give an indication of the effects of drug exposure to cells (the 
results on their own cannot be conclusive). However, the data produced from this assay format can be 
assessed in conjunction with the other 96-well microtitre plate assays to determine the overall effect of 
the benzopyrones on cell proliferation and metabolism.
Apart from the increased sensitivity of prediction, the Cytosensor has several other advantages 
over the MTT assay for the detection of metabolic suppression. As mentioned before, the ‘real-time’ 
aspect of detection with the cytosensor yields large amounts of information on the nature of the 
metabolic suppression (e.g. time of detrimental effects, etc.), per experiment. To attain this 
information with an end-point system such as the MTT Assay would require multiple, kinetic end­
point assays. In addition, the exposure set-up of the Cytosensor (flow-through, perfusive) mimics the 
in vivo drug delivery/exposure more than the static exposure set-up of the MTT Assay. Finally, the 
Cytosensor Microphysiometer allows for reversibility studies to be performed on drug-treated cells to 
assess their recovery, an experiment difficult, if not impossible to achieve with cells following the 
MTT Assay. The tested benzopyrones (warfarin, esculetin and genistein on cytosensor) all displayed a 
dose- and time-dependent effect on cellular metabolism, with genistein followed by esculetin 
displaying the most potent effects. For warfarin, only the highest concentration (lOOpg/ml) 
irreversibly suppressed the metabolism of the MCF-7 cells tested.
The acid phosphatase (AP) assay is based on hydrolysis of pNPP by intracellular AP in viable 
cells to produce /»-nitrophenol. In comparison to [3H] thymidine incorporation, AP assay has similar
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sensitivity but a wider linear response range. The method also shows higher sensitivity and 
reproducibility in comparison to cell proliferation assays based on reduction of tetrazolium salts (e.g. 
MTT assay). Due to its ease of use, sensitivity and low cost the AP assay method is especially suited 
to applications where a large number of samples are assayed (Yang, et al., 1996; Si, et al., 1999). 
Results obtained for AP assays carried out on both cell lines showed that all compounds tested (same 
as MTT assay) had a detrimental effect on cell proliferation with esculetin and genistein being the 
most potent. Genistein had a proliferative effect at low concentrations only in MCF-7 cells, which was 
expected and correlates well with previous studies (Hsieh, 1998). Overall the AP assay was found to 
offer the best combination of sensitivity, linearity, flexibility, ease of performance, reproducibility and 
precision, of all the 96-well culture plate assays.
The investigation of how esculetin and warfarin affect the signal transduction cascade and cell 
cycle progression in MCF-7 cells was performed using three different assay formats. An ELISA for 
detection of tyrosine phosphorylation in whole cells was used in order to determine whether the agents 
tested inhibit tyrosine phosphorylation of growth factor stimulated EGF-R in MCF-7 cells. The 
cytosensor microphysiometer was utilised to determine whether esculetin or warfarin inhibit tyrosine 
kinase activity in EGF stimulated MCF-7 cells. The final assay again utilised the ELISA format, 
however this time it determined to what extent the agents inhibited DNA synthesis in MCF-7 cells. 
Previous studies have investigated the effects of E2 on ER stimulation and signal transduction (Kelly 
& Wagner, 1999; Migliaccio et al., 1996; Aronica et al., 1994). However, breast cancer cells can be 
stimulated to proliferate with growth factors in the absence of added estrogen or progesterone. MAP 
kinase activation increases in response to stimuli such as EGF and IGF-1. Urokinase type plasminogen 
activator, FGF-2 and insulin activate MAP kinase in MCF-7 cells (Nguyen el al., 2000; Vercoutter- 
Edouart et al., 2000; Albas et al., 1998). Therefore, it was possible in this study to successfully 
stimulate the EGF-R in serum-starved MCF-7 cells with EGF and in turn activate the MAP kinase 
pathway in the absence of E2.
The regulation of activated MAP kinase in MCF-7 cells involves inhibitory (TNF-a) as well 
as stimulatory (EGF) pathways. Research has shown that EGF stimulates activated MAP kinase within 
1-2 minutes in MCF-7 cells. Maximal stimulation occurs at 6-8 minutes with a decrease in MAP 
kinase stimulation after this time period (Flury et al., 1997). The cytosensor results reflect this 
stimulation pattern as after the transient maximal stimulation of EGF-R (which will also transiently 
stimulate downstream MAP kinase activation), there is a decline in stimulation after a short time 
period of -10 minutes. It was important to determine for this study that the EGF-R is tyrosine 
phosphorylated in MCF-7 cells. This has been demonstrated and tyrosine kinase activity was also
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detected in Western blots of whole-cell protein extracts from the MCF-7 cell line probed with a 
phosphotyrosine antibody (Mueller et al., 1994). Therefore, when MCF-7 cells were pre-exposed to 
either esculetin or warfarin it was possible to determine whether these agents inhibited tyrosine 
phosphorylation or not.
Esculetin is known to be a cytostatic drug and the inhibition of the cell-cycle at transition G,/S 
is consistent with the cytostatic effect of both 7-hydroxycoumarin and esculetin. It is also evident from 
previous studies that esculetin primarily effects/inhibits events in the Gi phase of the cell cycle 
(Jimenez-Orozco et al., 2001; Wang et al., 2002). If cells are arrested in Gi phase before S phase 
progression there would be a significant decrease in DNA synthesis expected in these arrested cells. 
Therefore, the results illustrated in Figure 5.45. indicates there is a significant decrease in DNA 
synthesis in MCF-7 cells treated with either esculetin or genistein but not warfarin. It is possible that 
the decrease in DNA synthesis in esculetin-treated MCF-7 cells is due to the agent’s ability to induce 
Gj arrest with no progression to S phase where DNA synthesis occurs. Genistein seems to affect cell 
cycle progression differently to esculetin. Figure 5.44. shows that the decline in DNA synthesis occurs 
at a higher concentration than esculetin and this may be due to the fact that genistein does not arrest 
cells at G| phase. Genistein has been shown to inhibit progression later at G2/M phase transition 
(Constantinou et al., 1998; Fioravanti et al., 1998; Papazisis et al., 2000). This is after S phase and 
therefore, some DNA synthesis may occur. However, this stop in G2/M phase usually is followed by 
apoptosis and not progression into mitosis as would happen in normal cycling cells. This leads to a 
decrease in DNA synthesis as cells die off due to apoptosis.
Taken together the signal transduction and cell cycle regulation results indicate what the 
possible target of esculetin in MCF-7 cells is and how it affects components of the activated MAP 
kinase pathway. This is illustrated in Figure 5.49. It is shown in this diagram that (backed up by results 
in Section 5.11.4.) esculetin can inhibit tyrosine phosphorylation of the stimulated EGF-R. This 
inhibition affects downstream molecules (e.g. Ras, ERK, Myc and Nuclear ER) with important roles 
in MAP kinase cascade (Pan et al., 2003). Therefore, esculetin can inhibit the receptor tyrosine kinase 
activity of growth factor receptors such as EGF-R and ER. This in turn will prevent growth signals 
reaching other signalling intermediates such as Ras, or activation of transcription factors such as Myc. 
Another signal transduction pathway involves phosphatidylinositol-3-kinase (PI3-K) heterodimer, 
which is an important mediator of survival factors, protecting many cell types from multiple 
apoptosis-inducing stimuli. If PI3-K is inhibited (by esculetin inhibiting phosphorylation) the 
signalling pathway is interrupted and the cell is unable to progress into the S phase of the cell cycle.
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Figure 5.49: Proposed mechanism o f action o f esculetin in MCF-7 cells. Esculetin may function by 
inhibiting the RTK activity ofgrowth factor receptors. This will prevent growth signals reaching other 
signalling intermediates such as Ras, or activation o f transcription factors such as Myc. Alternatively, 
PI3-K may be a target, i f  inhibited (by inhibiting phosphorylation) it cannot inhibit GSK-3 which is 
free to degrade cyclin D1 which inhibits cell cycle progression.
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Given the importance of signalling anomalies in cancer cells, it was of interest to determine if 
the cellular target of esculetin or warfarin was a signalling pathway component. Since tyrosine 
phosphorylation is essential to the emanation of growth signals, and esculetin was previously reported 
to inhibit cellular tyrosine kinases, it was decided to concentrate on this aspect of signalling. The work 
presented in this chapter outlines the fact that the activity of the EGF-Receptor, tyrosine kinase, is 
affected adversely by exposure to esculetin but not by warfarin. The downregulation of RTK-induced 
tyrosine phosphorylation is important for the downstream growth factor signalling, and if inhibited, 
causes gross perturbation and downregulation of its signalling targets (particularly at the mRNA 
level). This might explain previous reports of downregulation of ras and c-myc, in 7-hydroxycoumarin 
and esculetin-treated cells (Seliger & Pettersson, 1994b; Lu et al., 1996; Pan et al, 2002). Regardless 
of whether they directly or indirectly inhibit the EGF-RTK, the decrease in tyrosine phosphorylation 
effected by coumarin compounds such as esculetin may offer an explanation for the precise mode of 
their anti-tumour action. Anomalies in tyrosine phosphorylation are extremely prevalent in tumour 
cells, and are responsible for persistent growth signalling in these cells. Interruption/disruption of this 
persistent signalling suppresses this abnormal proliferation, and therefore any compound, which 
decreases tyrosine phosphorylation, has anti-proliferative properties and potential clinical applications.
i
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Chapter 6 
Overall Conclusions
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6.1 Overall Conclusions
The aim of the research performed was to study toxicological and immunological aspects of 
the benzopyrones. The immunological studies involved the characterisation of an anti-warfarin 
monoclonal antibody from clone 4-2-25 which was then used for the development of antibody-based 
assay systems for the detection of warfarin in biological fluids. The purpose of the toxicological 
studies was to examine the anti-cancer properties of benzopyrone compounds at a cellular level, in 
order to comprehend the observed clinical properties of these compounds.
Chapter 3 describes the characterisation of the anti-warfarin monoclonal antibody. The 
antibody was purified using a protein-G column and then utilised for the development of a competitive 
ELISA for the detection of warfarin in PBS and urine. Intra- and interday variability studies were 
performed to determine the precision and reproducibility of the assay. The assay proved to be accurate 
and reproducible with intra- and interday CVs of typically less than 10%. Cross reactivity studies 
demonstrated that the anti-warfarin mAb shared a common epitope with 4-hydroxycoumarin ring 
structure and the carbonyl substituent. Acenocoumarin showed the highest degree of cross-reactivity 
(18%) due to its structural similarities to warfarin. Both 6-hydroxywarfarin and 7-hydroxywarfarin 
show degrees of cross-reactivity of 8 & 1%, respectively. The method of Friguet et al., (1985) was 
utilised to measure the affinity of the anti-warfarin mAb, which exhibited excellent specificity towards 
the parent molecule (warfarin) over structurally-related analogues (acenocoumarin, 6- and 7- 
hydroxywarfarin). This is evident from the resulting KD values where the anti-warfarin mAb showed a 
higher affinity for warfarin (KD = 2.0 xlO'8) than for any of the hydroxy metabolites assayed (KD = 2.0 
xlO'6 -  4.0 xlO'7).
Chapter 4 involves the use of the anti-warfarin mAb (described in chapter 3) for the 
development of a BIAcore-based inhibition immunoassay for the detection of warfarin in biological 
fluids. Two sensor chip surfaces, the warfarin-BSA conjugated immobilised surface and the directly 
immobilised 4'-aminowarfarin chip surface were utilised. Decreasing concentrations of free warfarin 
was incubated with anti-warfarin mAb and allowed to equilibrate for 5-10 minutes. The samples were 
then passed in random order, over the derivatised chip surface. The biosensor-based assay system 
developed for the detection of warfarin in urine utilised a chip surface to which 4'-aminowarfarin was 
covalently coupled. Such surfaces demonstrated exceptional stability and reproducibility (% C.V. less 
than 12%) and were capable of being used for greater than 1,000 assays. In the clinical setting, 
economics is becoming increasingly more important and the use of such regenerable assay formats
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offers a very attractive alternative to current high consumable-based alternatives (i.e. ELISA 
(immunoplates) and HPLC (solvent waste)).
The initial work in chapter 5, examined the toxicological effects of selected benzopyrones on 
the growth and metabolism of the two human tumour cell lines (MCF-7 & A549). From the assays 
performed (MTT, AP, LDH and cytosensor studies) it was evident that both genistein and esculetin 
exhibit the most potent anti-proliferative effects. Warfarin possessed weaker anti-proliferative effects 
in comparison to genistein and esculetin. Cell signalling studies are of interest with regard to the 
search for novel cancer chemotherapeutic agents. Knowledge of the effects of anti-cancer agents on 
signal transduction and cell cycle of cancer cells may prove useful in controlling the spread of cancer. 
Given the importance of signalling irregularities in cancer cells, it was of interest to determine if the 
cellular target of esculetin or warfarin was a signalling pathway component. Tyrosine phosphorylation 
is essential for the emanation of growth signals, and, since esculetin was previously reported to inhibit 
cellular tyrosine kinases, it was decided to concentrate on this aspect of signalling. The results 
presented in chapter 5 indicate that the tyrosine kinase activity of the EGF-Receptor in MCF-7 cells is 
affected adversely by pre-exposure to esculetin but not by warfarin. Therefore, it was possible to 
elucidate esculetin’s mechanism of action on MCF-7 cells (Figure 5.49), from the results obtained in 
sections 5.11.4 - 5.11.5.
It is evident that the benzopyrones are a therapeutically interesting group of compounds with 
many clinically beneficial properties ranging from anti-coagulation (e.g. warfarin) to anti-proliferative 
effects (e.g. esculetin, genistein). It is apparent from this research that monoclonal antibodies can be 
produced to successfully detect these compounds (e.g. warfarin) in biological matrices. This thesis 
illustrates the current and potential clinical benefits of the benzopyrones. Clearly, the benzopyrones 
deserve further immunological and toxicological studies to facilitate better understanding of their 
mode of action and how they can be therapeutically applied in the future.
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Appendix 1A
1A.1. Glossary o f  Terms and Definitions Commonly Employed in 
Bioanalytical Validation Procedures:
The terms listed below are commonly referred to in bioanalytical validation procedures and the criteria 
which they can be defined under have been extensively reviewed (Findlay et al., 2000).
Mean
Describes the average of replicate (x) measurements, (i.e. nj+n2+ nx/x)
Accuracy
Is defined as the closeness of agreement between a measured test result and its expected true reference 
value.
Precision
Is defined as the closeness of agreement, or variance between independent test results of multiple 
measurements of the same sample obtained under a set of specified analytical test conditions. It is 
normally expressed in terms of the relative standard deviation (% R.S.D.), or the coefficient of 
variation (% C. V.) of the determined concentration of a replicate number of assays. The degree of 
precision assessed between replicates (i.e. % C.V.) performed during a single assay batch, is 
commonly referred to as the intra-assay variation (also referred to as repeatability). The term inter­
assay variation (also referred to as reproducibility) is used to describe the precision between assays 
when related to multiple batches.
Limit of Detection (L.O.D.)
Defines the lowest concentration of analyte that the analytical technique can differentiate from 
background.
Lower Limit of Quantitation (L.O.Q.):
The lowest concentration of analyte that can be measured from the calibration curve with acceptable
levels of precision and accuracy.
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Robustness:
Is a term used to describe the ability of an analytical technique to withstand fluctuations in the 
described analytical test conditions. For immunoassay procedures the term could be used to describe 
changes in the ionic strength of the matrix, as well as pH and temperature changes.
Standard Curve:
This describes the relationship between the measured analyte response (i.e. absorbance, response 
units) and the analyte concentration.
Coefficient of Variation (% C. V.)
A quantitative measure of the precision of an analytical measurement expressed as a percent function 
of the mean value, also referred to as the Relative Standard Deviation (% R.S.D.).
% C.V. = [S.D./Mean value] x 100
Batch/Run:
Refers to a single set of samples (standards) analysed together as a single sample set using the same 
analytical technique.
Residual:
Describes the difference between the value described by the equation model and the true value. 
Precision profile:
A quantitative measure of the variation between measurements, usually the coefficient of variation 
versus the nominal concentration of analyte in the sample.
Normalised Response Values:
The response recorded in response units (R) at each particular antigen concentration divided by the 
response recorded in the presence of zero antigen (R/Ro).
Normalised Response = Response measured at particular antigen concentration
Response measured at zero antigen concentration
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Normalised Absorbance Values:
The absorbance recorded (A) at each particular antigen concentration divided by the absorbance 
recorded in the presence of zero antigen (A/Ao).
Normalised Absorbance = Absorbance measured at particular antigen concentration
Absorbance measured at zero antigen concentration
Appendix IB
1B.1. 'Student's't Test (For Paired Samples)
"Student" (real name: W. S. Gossett [1876-1937]) developed statistical methods to solve problems 
stemming from his employment in Guinness’s brewery. Student's t-test deals with the problems 
associated with inference based on "small" samples: the calculated mean (Xavg) and standard deviation 
((7) may by chance deviate from the "real" mean and standard deviation (i.e., what one would measure 
if many more data items were available: a "large" sample).
Definition: It is the statistical test used to evaluate if two groups are significatively different according 
to their means.
Example using EXCEL
t-Test: Paired Two Sample for Means
Variable 1 Variable 2
Mean 0.6393 0.5537
Variance 0.000492 0.001044
Observations 10 10
Pearson Correlation 0.216921
Hypothesized Mean Difference 0
df 9
t Stat 7.734238
P(T<=t) one-tail 1.45E-05
t Critical one-tail 1.833114
P(T<=t) two-tail 2.90E-05
t Critical two-tail 2.262159
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